# Patent

## Title
Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity

## Abstract

The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.

## Background
This Non-Provisional Patent Application claims priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/807,063 filed Jul. 11, 2006, which is hereby incorporated by reference in its entirety.


All patents and publications cited in this application are hereby incorporated by reference in their entirety.
The ability of Clostridial toxins, such as, e.g., Botulinum neurotoxins (BoNTs), BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F and BoNT/G, and Tetanus neurotoxin (TeNT), to inhibit neuronal transmission are being exploited in a wide variety of therapeutic and cosmetic applications, see e.g., William J. Lipham, COSMETIC AND CLINICAL APPLICATIONS OF BOTULINUM TOXIN (Slack, Inc., 2004). Clostridial toxins commercially available as pharmaceutical compositions include, BoNT/A preparations, such as, e.g., BOTOX® (Allergan, Inc., Irvine, Calif.), Dysport®/Reloxin®, (Beaufour Ipsen, Porton Down, England), Linurase® (Prollenium, Inc., Ontario, Canada), Neuronox® (Medy-Tox, Inc., Ochang-myeon, South Korea) BTX-A (Lanzhou Institute Biological Products, China) and Xeomin® (Merz Pharmaceuticals, GmbH, Frankfurt, Germany); and BoNT/B preparations, such as, e.g., MyoBlocTM/NeuroBlocTM (Elan Pharmaceuticals, San Francisco, Calif.). As an example, BOTOX® is currently approved in one or more countries for the following indications: achalasia, adult spasticity, anal fissure, back pain, blepharospasm, bruxism, cervical dystonia, essential tremor, glabellar lines or hyperkinetic facial lines, headache, hemifacial spasm, hyperactivity of bladder, hyperhidrosis, juvenile cerebral palsy, multiple sclerosis, myoclonic disorders, nasal labial lines, spasmodic dysphonia, strabismus and VII nerve disorder.
Clostridial toxin therapies are successfully used for many indications. Generally, administration of a Clostridial toxin treatment is well tolerated. However, toxin administration in some applications can be challenging because of the larger doses required to achieve a beneficial effect. First, larger doses can increase the likelihood that the toxin may move through the interstitial fluids and the circulatory systems, such as, e.g., the cardiovascular system and the lymphatic system, of the body, resulting in the undesirable dispersal of the toxin to areas not targeted for toxin treatment. Such dispersal can lead to undesirable side effects, such as, e.g., inhibition of neurotransmitter release in neurons not targeted for treatment or paralysis of a muscle not targeted for treatment. For example, a patient administered a therapeutically effective amount of a BoNT/A treatment into the neck muscles for torticollis may develop dysphagia because of dispersal of the toxin into the oropharynx. Thus, there remains a need for improved Clostridial toxins that are effective at the site of treatment, but have negligible to minimal effects in areas not targeted for a toxin treatment.
Second, larger doses of a Clostridial toxin treatment may elicit an antibody response against the toxin. While a potent and effective treatment, the inhibition of neurotransmitter release and the resulting neuromuscular paralysis elicited by Clostridial toxin therapies is not permanent. The reversible nature of these paralytic effects requires periodic treatments in order to maintain the therapeutic benefits from this toxin. As a consequence of this repeated exposure, an immune response against a Clostridial toxin can occur in some patients which reduce or completely prevent the individual's responsiveness to further treatments, see, e.g., Joseph Jankovic, Botulinum toxin: Clinical Implications of Antigenicity and Immunoresistance, (SCIENTIFIC AND THERAPEUTIC ASPECTS OF BOTULINUM TOXIN, 409-415, Mitchell F. Brin et al., eds., Lippincott Williams & Wilkins, 2002); Dirk Dressler, Clinical Presentation and Management of Antibody-induced Failure of Botulinum Toxin Therapy, 19(Suppl. 8) MOV. DISORD. S92-S100 (2004); M. Zouhair Atassi, Basic Immunological Aspects of Botulinum Toxin Therapy, 19(Suppl. 8) MOV. DISORD. S68-S84, (2004). Thus, there remains a need for improved Clostridial toxins that maintain effective therapeutic benefits, but have reduced ability to evoke an immunogenic response against itself.
The growing clinical, therapeutic and cosmetic use of Clostridial toxins in therapies requiring larger doses necessitates the pharmaceutical industry to develop modified Clostridial toxins that are effective at the target site of the application, but reduce or prevent the undesirable side-effects associated with the dispersal of the toxins to unwanted locations and reduce or prevent an unwanted immunogenic response. One approach involves modifying a Clostridial toxin so that the modified toxin has an enhanced cell binding activity for a naturally-occurring Clostridial toxin receptor. This enhanced binding activity is achieved by modifying the endogenous targeting domain of a naturally-occurring Clostridial toxin in order to enhance a cell binding activity of the toxin for its naturally-occurring receptor. Such modifications to a targeting domain result in, e.g., a enhanced cell binding activity that increases binding affinity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell; an enhanced cell binding activity that increases binding specificity for a subgroup of endogenous Clostridial toxin receptors present on a naturally-occurring Clostridial toxin target cell; or an enhanced cell binding activity that increases both binding affinity and binding specificity. An added advantage is achieved when the targeting domain is derived from a human targeting domain polypeptide as these polypeptides as less likely to elicit an immunogenic response in a patient. A modified Clostridial toxin with an enhanced binding activity can bind to a receptor, translocate into the cytoplasm, and exert its proteolytic effect on the SNARE complex of the Clostridial toxin target cell.
Non-limiting examples of modified Clostridial toxins an enhanced cell binding activity for a naturally-occurring Clostridial toxin receptor are described in, e.g., Lance E. Steward, et al., Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptors, International Patent Application No. 2006/008956 (Mar. 14, 2006). This enhanced binding activity for a naturally occurring Clostridial toxin receptor allows for lower effective doses of a modified Clostridial toxin to be administered to an individual because more toxins will be delivered to the target cell. Thus, modified Clostridial toxins with an enhanced cell binding activity for a Clostridial toxin receptor will reduce the undesirable dispersal of the toxin to areas not targeted for treatment, thereby reducing or preventing the undesirable side-effects associated with diffusion of a Clostridial toxin to an unwanted location.
The present invention provides novel modified Clostridial toxins that reduce or prevent unwanted side-effects associated with toxin dispersal into non-targeted areas. These modified Clostridial toxins comprise, in part, a translocation facilitator domain that enhances the process by which a light chain from a modified toxin translocates into the cytoplasm of a target cell and enzymatically modify its target SNARE substrate. Thus modified Clostridial toxins with enhanced cell binding activity for its naturally-occurring receptor, such as, e.g., those disclosed in Steward, supra, (2006), comprising a translocation facilitator domain disclosed in the present specification, exhibit increased potency at the Clostridial toxin target cell and a concomitant reduction of unwanted side-effects associated with toxin dispersal into non-targeted areas. These and related advantages are useful for various clinical, therapeutic and cosmetic applications, such as, e.g., the treatment of neuromuscular disorders, neuropathic disorders, eye disorders, pain, muscle injuries, headache, cardiovascular diseases, neuropsychiatric disorders, endocrine disorders, cancers, otic disorders and hyperkinetic facial lines, as well as, other disorders where administration of a modified Clostridial toxin with enhanced cell binding activity for a Clostridial toxin receptor to an individual can produce a beneficial effect.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a schematic of the current paradigm of neurotransmitter release and Clostridial toxin intoxication in a central and peripheral neuron. FIG. 1A shows a schematic for the neurotransmitter release mechanism of a central and peripheral neuron. The release process can be described as comprising two steps: 1) vesicle docking, where the vesicle-bound SNARE protein of a vesicle containing neurotransmitter molecules associates with the membrane-bound SNARE proteins located at the plasma membrane; and 2) neurotransmitter release, where the vesicle fuses with the plasma membrane and the neurotransmitter molecules are exocytosed. FIG. 1B shows a schematic of the intoxication mechanism for tetanus and botulinum toxin activity in a central and peripheral neuron. This intoxication process can be described as comprising four steps: 1) receptor binding, where a Clostridial toxin binds to a Clostridial receptor and initiates the intoxication process; 2) complex internalization, where after toxin binding, a vesicle containing the toxin/receptor complex is endocytosed into the cell; 3) light chain translocation, where multiple events result in the release of the active light chain into the cytoplasm; and 4) enzymatic target modification, where the active light chain of Clostridial toxin proteolytically cleaves its target SNARE substrate, such as, e.g., SNAP-25, VAMP or Syntaxin, thereby preventing vesicle docking and neurotransmitter release.
FIG. 2 shows the domain organization of naturally-occurring Clostridial toxins. The single chain form depicts the amino to carboxyl linear organization comprising an enzymatic domain, a translocation domain, a HCN translocation facilitating domain and a HCC targeting domain. The di-chain loop region located between the translocation and enzymatic domains is depicted by the double SS bracket. This region comprises an endogenous di-chain loop protease cleavage site that upon proteolytic cleavage with a naturally-occurring protease, such as, e.g., an endogenous Clostridial toxin protease or a naturally-occurring protease produced in the environment, converts the single chain form of the toxin into the di-chain form. As depicted above the single-chain form, the HCC targeting domain comprises the β-trefoil domain which comprises in an amino to carboxyl linear organization of an α-fold, a β4/β5 hairpin turn, a β-fold, a β8/β9 hairpin turn and a γ-fold.
FIG. 3 shows a ribbon diagram of BoNT/A illustrating the modular three-dimensional structure of the light chain (LC) comprising the enzymatic domain, the heavy chain HN domain comprising the translocation domain, the heavy chain HCN domain comprising the translocation facilitating domain and the heavy chain HCC domain comprising the targeting domain.
FIG. 4 shows modified Clostridial toxins with an enhanced translocation capability and an enhanced targeting activity located at the amino terminus of the modified toxin. FIG. 4A depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising an enhanced targeting domain, a translocation domain, a translocation facilitating domain and an enzymatic domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the translocation facilitating and enzymatic domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the targeting and translocation domains, the translocation and translocation facilitating domains, translocation facilitating and enzymatic domains or any combination thereof. FIG. 4B depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising an enhanced targeting domain, an enzymatic domain, a translocation domain and a translocation facilitating domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the enzymatic and translocation domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the targeting and enzymatic domains, the enzymatic and translocation domains, translocation and translocation facilitating domains or any combination thereof.
FIG. 5 shows modified Clostridial toxins with an enhanced translocation capability and an enhanced targeting activity located between the two other domains. FIG. 5A depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising an enzymatic domain, an enhanced targeting domain, a translocation domain and a translocation facilitating domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the enzymatic and targeting domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the enzymatic and targeting domains, the targeting and translocation domains, the translocation and translocation facilitating domains or any combination thereof. FIG. 5B depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising a translocation domain, a translocation facilitating domain, an enhanced targeting domain and an enzymatic domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the translocation facilitating and targeting domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the translocation and translocation facilitating domains, the translocation facilitating and targeting domains, the targeting and enzymatic domains or any combination thereof.
FIG. 6 shows modified Clostridial toxins with an enhanced translocation capability and an enhanced targeting activity located at the carboxyl terminus of the modified toxin. FIG. 6A depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising an enzymatic domain, a translocation domain, a translocation facilitating domain and an enhanced targeting domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the enzymatic and translocation domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the enzymatic and translocation domains, the translocation and translocation facilitating domains, the translocation facilitating and targeting domains or any combination thereof. FIG. 6B depicts the single polypeptide form of a modified Clostridial toxin with an amino to carboxyl linear organization comprising a translocation domain, a translocation facilitating domain, an enzymatic domain and an enhanced targeting domain, with the di-chain loop region depicted by the double SS bracket. A proteolytic cleavage site (P) within a di-chain loop region is located between the translocation facilitating and enzymatic domains. Upon proteolytic cleavage with a P protease, the single chain form of the toxin is converted to the di-chain form. The P protease site can be a Clostridial toxin endogenous protease cleavage site or a non-Clostridial toxin exogenous protease cleavage site. Spacers can be placed between the translocation and translocation facilitating domains, the translocation facilitating and enzymatic domains, the enzymatic and targeting domains or any combination thereof.
FIG. 7 shows a ribbon diagram of BoNT/A illustrating the boundary regions of the HCN domain comprising the translocation facilitating domain. FIG. 7A depicts the amino-terminal boundary region. FIG. 7B depicts the carboxyl-terminal boundary region.



DETAILED DESCRIPTION
Clostridia toxins produced by Clostridium botulinum, Clostridium tetani, Clostridium baratii and Clostridium butyricum are the most widely used in therapeutic and cosmetic treatments of humans and other mammals. Strains of C. botulinum produce seven antigenically-distinct types of Botulinum toxins (BoNTs), which have been identified by investigating botulism outbreaks in man (BoNT/A, /B, /E and /F), animals (BoNT/C1 and /D), or isolated from soil (BoNT/G). While all seven botulinum toxins (BoNT) serotypes have similar structure and pharmacological properties, each also displays heterogeneous bacteriological characteristics. In contrast, tetanus toxin (TeNT) is produced by a uniform group of C. tetani. Two other species of Clostridia, C. baratii and C. butyricum, also produce toxins similar to BoNT/F and BoNT/E, respectively.
Clostridia toxins possess approximately 35% amino acid identity with each other and share the same functional domain organization and overall structural architecture. Clostridial toxins are each translated as a single chain polypeptide of approximately 150 kDa that is subsequently cleaved by proteolytic scission within a disulfide loop by a naturally-occurring protease, such as, e.g., an endogenous Clostridial toxin protease or a naturally-occurring protease produced in the environment (FIG. 2). This posttranslational processing yields a di-chain molecule comprising an approximately 50 kDa light chain (LC) and an approximately 100 kDa heavy chain (HC) held together by a single disulfide bond and noncovalent interactions. It is widely held that the mature di-chain molecule comprises three functionally distinct domains: 1) an enzymatic domain located in the LC that includes a metalloprotease region containing a zinc-dependent endopeptidase activity which specifically targets core components of the neurotransmitter release apparatus (Table 1); 2) a translocation domain contained within the amino-terminal half of the heavy chain (HN domain) that facilitates release of the LC from intracellular vesicles into the cytoplasm of the target cell (Table 1); and 3) a binding domain found within the carboxyl-terminal half of the heavy chain (HC domain) that determines the binding activity and binding specificity of the toxin to the receptor complex located at the surface of the target cell (Table 1), see, e.g., Kathryn Turton et al., Botulinum and Tetanus Neurotoxins: Structure, Function and Therapeutic Utility, 27(11) Trends Biochem. Sci. 552-558. (2002); John A. Chaddock and P. M. H. Marks, Clostridial Neurotoxins: Structure-Function Led Design of New Therapeutics, 63(5) Cell. Mol. Life. Sci. 540-551 (2006); and Keith Foster et al., Re-engineering the Target Specificity of Clostridial Neurotoxins—A Route To Novel Therapeutics, 9(2-3) Neurotox Res. 101-107 (2006).







TABLE 1







Clostridial Toxin Reference Sequences and Regions












SEQ 


HC












Toxin
ID NO:
LC
HN
HCN
HCC





BoNT/A
1
M1-K448
A449-I873
I874-P1110
Y1111-L1296


BoNT/B
2
M1-K441
A442-I860
L861-E1097
Y1098-E1291


BoNT/C1
3
M1-K449
T450-I868
N869-E1111
Y1112-E1291


BoNT/D
4
M1-R445
D446-I864
N865-E1098
Y1099-E1276


B0NT/E
5
M1-R422
K423-I847
K848-E1085
Y1086-K1252


B0NT/F
6
M1-K439
A440-I866
K867-K1105
Y1106-E1274


BoNT/G
7
M1-K446
S447-I865
S866-Q1105
Y1106-E1297


TeNT
8
M1-A457
S458-L881
K882-E1127
Y1128-D1315









The binding, translocation and enzymatic activities of a Clostridial toxin are all necessary to execute the overall cellular intoxication mechanism whereby Clostridial toxins enter a neuron and inhibit neurotransmitter release is similar, regardless of serotype or subtype. The current paradigm describes the intoxication mechanism as comprising at least four steps: 1) receptor binding, 2) complex internalization, 3) light chain translocation, and 4) enzymatic target modification (see FIG. 1). The process is initiated when the HC domain of a Clostridial toxin binds to a toxin-specific receptor located on the plasma membrane surface of a target cell. The binding specificity of a receptor complex is thought to be achieved, in part, by specific combinations of gangliosides and protein receptors that appear to distinctly comprise each Clostridial toxin receptor complex. Once bound, the toxin/receptor complexes are internalized by endocytosis and the internalized vesicles are sorted to specific intracellular routes. The translocation step, now thought to be mediated by the HN domain and further facilitated by the HCN domain, appears to be triggered by the acidification of the vesicle compartment. This process seems to initiate two important pH-dependent structural rearrangements that increase hydrophobicity and promote separation of the light chain from the heavy chain of the toxin. Once activated, light chain endopeptidase of the toxin is released from the intracellular vesicle into the cytosol where it appears to specifically target one of three known core components of the neurotransmitter release apparatus. These core proteins, vesicle-associated membrane protein (VAMP)/synaptobrevin, synaptosomal-associated protein of 25 kDa (SNAP-25) and Syntaxin, are necessary for synaptic vesicle docking and fusion at the nerve terminal and constitute members of the soluble N-ethylmaleimide-sensitive factor-attachment protein-receptor (SNARE) family. BoNT/A and BoNT/E cleave SNAP-25 in the carboxyl-terminal region, releasing a nine or twenty-six amino acid segment, respectively, and BoNT/C1 also cleaves SNAP-25 near the carboxyl-terminus. The botulinum serotypes BoNT/B, BoNT/D, BoNT/F and BoNT/G, and tetanus toxin, act on the conserved central portion of VAMP, and release the amino-terminal portion of VAMP into the cytosol. BoNT/C1 cleaves syntaxin at a single site near the cytosolic membrane surface. The selective proteolysis of synaptic SNAREs accounts for the block of neurotransmitter release caused by Clostridial toxins in vivo. The SNARE protein targets of Clostridial toxins are common to exocytosis in a variety of non-neuronal types; in these cells, as in neurons, light chain peptidase activity inhibits exocytosis, see, e.g., Yann Humeau et al., How Botulinum and Tetanus Neurotoxins Block Neurotransmitter Release, 82(5) Biochimie. 427-446 (2000); and Giovanna Lalli et al., The Journey of Tetanus and Botulinum Neurotoxins in Neurons, 11(9) Trends Microbiol. 431-437, (2003).
The three-dimensional crystal structures of BoNT/A, BoNT/B and the HC domain of TeNT indicate that the three functional domains of Clostridial neurotoxins are structurally distinct. The HEXXH consensus motif of the light chain forms the tetrahedral zinc binding pocket of the catalytic site located in a deep cleft on the protein surface that is accessible by a channel. The structure of the HN and HC domains consists primarily of β-sheet topologies that are linked by a single α-helix. The cylindrical-shaped HN domain comprises two long amphipathic α-helices that resemble the coiled-coil motif found in some viral proteins. The HN domain also forms a long unstructured loop called the ‘translocation belt,’ which wraps around a large negatively charged cleft of the light chain that blocks access of the zinc atom to the catalytic-binding pocket of active site. The HC domain comprises two distinct structural features of roughly equal size that indicate function. The first, designated the HCN domain, is located in the amino half of the HC domain. The HCN domain forms a β-barrel, jelly-roll fold. The HCC domain is the second domain that comprises the HC domain. This carboxyl-terminal domain comprises a modified β-trefoil domain which forms three distinct carbohydrate binding regions that resembles the carbohydrate binding moiety found in many sugar-binding proteins, such as, e.g., serum amyloid P, sialidase, cryia, insecticidal ∂-endotoxin and lectins. Biochemical studies indicate that the β-trefoil domain structure of the HCC domain appears to mediate the binding to specific carbohydrate containing components of the Clostridial toxin receptor on the cell surface, see, e.g., Krzysztof Ginalski et al., Structure-based Sequence Alignment for the Beta-Trefoil Subdomain of the Clostridial Neurotoxin Family Provides Residue Level Information About the Putative Ganglioside Binding Site, 482(1-2) FEBS Lett. 119-124 (2000). The HC domain tilts away from the HN domain exposing the surface loops and making them accessible for binding. No contacts occur between the light chain and the HC domain.
We know that only the HCC domain participates in receptor binding because the β-trefoil domains are restricted to this domain. Proteins containing the structural β-trefoil domain represents a diverse group of proteins organized into at least eight superfamilies including the cytokines, MIR domain proteins, Ricin B-like lectins, agglutinins, Soybean trypsin inhibitor like proteins, Actin-crosslinking proteins, LAG-1 proteins and AbfB domain proteins, see, e.g., C. A. Orengo et al., Protein Superfamilies and Domain Superfolds, 372 Nature 631-634 (1994); and Alexey G. Murzin et al., SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures, 247(4) J. Mol. Biol. 536-540 (1995). While having diverse cellular roles, members of these superfamilies mechanistically function via protein-protein associations through the β-trefoil domain. Of particular interest is the fact that many of these members are specifically involved in receptor interactions, including, e.g., the cytokine superfamily members Fibroblast Growth Factors (FGFs) and the Interleukin-1s (IL-1s); the Ricin B-like lectins; the agglutinins; and STI-like members the Kunitz inhibitors and Clostridium neurotoxins. That only the HCC domain alone mediates the cell binding step of intoxication is further supported by the finding that mutations that disrupt the receptor binding activity of Clostridial toxins have been confined to the HCC domain, see, e.g., Andreas Rummel et al., The HCC-Domain of Botulinum Neurotoxins A and B Exhibits a Singular Ganglioside Binding Site Displaying Serotype Specific Carbohydrate Interaction, 51(3) Mol. Microbiol. 631-643 (2004).
Because the HCC domain appears not only necessary, but sufficient for selective binding of a Clostridial toxin to its receptor, we have deduced that the primary function of the HCN domain of Clostridial toxins is involved in the translocation step of the intoxication process, and not in the cell binding step, because the lack of HCN domain appears to reduce intoxication efficiency. For example, a modified BoNT/A comprising a Substance P targeting domain was inefficient in intoxicating its corresponding target cells. In this modified toxin, the entire BoNT/A HC domain, comprising both the BoNT/A HCC domain and the BoNT/A HCN domain, was replaced by the Substance P targeting domain. Likewise, we have determined that several other modified Clostridial toxins that have replaced the entire BoNT/A HC domain with an exogenous targeting domain have exhibited reduced intoxication capabilities. Thus, the HCN domain possess a translocation facilitating function because 1) HCC domain primarily mediates the receptor binding step of the intoxication process; 2) modified Clostridial toxins lacking the HCN domain exhibit a reduced ability to translocate into the cytoplasm as evident by such modified toxins exhibiting decreased proteolysis of their SNARE substrates; and 3) the LC domain mediates the enzymatic activity of the toxin. While the exact translocation facilitating mechanism of the HCN domain is currently not understood, the HCN domain may 1) participate in the formation of an endosomal pore; 2) mediate the insertion of the pore into a vesicle membrane; 3) assist in the delivery of LC across the endosomal membrane and/or 4) serve as a structural scaffold or spacer that facilitates the appropriate orientation a the targeting domain in relationship to the translocation domain. In this last point, the HCN domain would serve to orient the translocation domain to facilitate the proper presentation of the translocation domain for insertion into the membrane following binding of the ligand by the receptor. This novel role of the HCN domain in the translocation step is contrary to the widely accepted view that the Clostridial toxin HCN domain played an integral role in the cell binding step of the intoxication process.
Thus, the present invention discloses modified Clostridial toxins that exhibit 1) an enhanced translocation capability; and 2) an enhanced targeting capability for a naturally-occurring Clostridial toxin receptor. The enhanced translocation capability is mediated by a translocation facilitating domain comprising, e.g., a HCN region of Clostridial toxins. The HCN domain enhances the process by which the HN domain mediates the release of the light chain from internalized intracellular vesicles into the cytoplasm of the target cell during the translocation step. Enhanced translocation capability is obtained by including or maintaining a Clostridial toxin HCN domain in a modified Clostridial toxin disclosed in the present specification. The enhanced targeting capability for a naturally-occurring Clostridial toxin receptor is mediated by an enhanced targeting domain comprising a modified HCC targeting domain of Clostridial toxins. The HCC domain primarily determines the binding activity and binding specificity of the toxin to the receptor complex located at the surface of the target cell. Enhanced binding activity is achieved by replacing the endogenous HCC targeting domain of a Clostridial toxin with a targeting domain showing enhanced binding activity for a Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell.
Both the enhanced translocation and enhanced targeting activity should allow lower effective doses of a modified Clostridial toxin to be administered to an individual because more toxin will be delivered to a target cell. Thus modified Clostridial toxins with enhanced translocation and binding capabilities will reduce the undesirable dispersal of the toxin to areas not targeted for treatment, thereby reducing or preventing the undesirable side-effects associated with diffusion of a Clostridial toxin to an unwanted location.
Thus, aspects of the present invention provide modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain, wherein the modified Clostridial toxin exhibits an enhanced targeting activity for a Clostridial toxin receptor as compared to a naturally-occurring Clostridial toxin. It is envisioned that any translocation facilitating domain capable of further facilitating the translocation step of the intoxication process where the light chain is released from intracellular vesicles into the cytoplasm of the target cell will be useful to practice aspects of the present invention, including, without limitation, a Clostridial toxin translocation facilitating domain and an enveloped virus fusogenic peptide domain. Likewise, a multitude of enhanced targeting domains are envisioned, including, without limitation, a modified Clostridial toxin targeting domain with enhanced binding activity, such as, e.g., a BoNT/A targeting domain with enhanced binding activity, a BoNT/B targeting domain with enhanced binding activity, a BoNT/C1 targeting domain with enhanced binding activity, a BoNT/D targeting domain with enhanced binding activity, a BoNT/E targeting domain with enhanced binding activity, a BoNT/F targeting domain with enhanced binding activity, a BoNT/G targeting domain with enhanced binding activity, a TeNT targeting domain with enhanced binding activity, or active fragment thereof; a Clostridial NAP, such as, e.g., a Clostridial botulinum serotype A HA-33, a Clostridial botulinum serotype B HA-33, a Clostridial botulinum serotype C1 HA-33, a Clostridial botulinum serotype D HA-33, a Clostridial botulinum serotype A HA-17, a Clostridial botulinum serotype B HA-17, a Clostridial botulinum serotype C1 HA-17, a Clostridial botulinum serotype D HA-17, a Clostridial botulinum serotype A NTNH, a Clostridial botulinum serotype B NTNH, a Clostridial botulinum serotype C1 NTNH, a Clostridial botulinum serotype D NTNH, a Clostridial botulinum serotype E NTNH, a Clostridial botulinum serotype F NTNH and a Clostridial botulinum serotype G NTNH; and a FGF, such as, e.g., a FGF-1, a FGF-2, a FGF-4, a FGF-8, a FGF-9, a FGF-17 and a FGF-18. It is also envisioned that the location of the enhanced targeting domain in the modified Clostridial toxins of the present specification can be located at the amino terminus of the toxin, between the enzymatic and translocation domains or at the carboxyl terminus of the toxin. Thus, a modified Clostridial toxins disclosed in the present specification can comprise an amino to carboxyl domain arrangement of, e.g., an enhanced targeting domain, a Clostridial toxin translocation domain, a translocation facilitating domain and a Clostridial toxin enzymatic domain; an enhanced targeting domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a translocation facilitating domain; a Clostridial toxin enzymatic domain, an enhanced targeting domain, a Clostridial toxin translocation domain and a translocation facilitating domain; a Clostridial toxin translocation domain, a translocation facilitating domain, an enhanced targeting domain and a Clostridial toxin enzymatic domain; a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; and a Clostridial toxin translocation domain, a translocation facilitating domain, a Clostridial toxin enzymatic domain and an enhanced targeting domain.
Other aspects of the present invention provide polynucleotide molecules encoding modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain, wherein the modified Clostridial toxin exhibits an enhanced targeting activity for a Clostridial toxin receptor as compared to a naturally-occurring Clostridial toxin. It is envisioned that the location of the enhanced targeting domain of the modified Clostridial toxins encoded by polynucleotide molecules of the present specification can be located at the amino terminus of the toxin, between the enzymatic and translocation domains or at the carboxyl terminus of the toxin.
Other aspects of the present invention provide methods of producing a modified Clostridial toxin disclosed in the present specification, the method comprising the step of expressing in a cell a polynucleotide molecule encoding a modified Clostridial toxin comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain, wherein the modified Clostridial toxin exhibits an enhanced targeting activity for a Clostridial toxin receptor as compared to a naturally-occurring Clostridial toxin. Other aspects of the present invention provide methods of producing a modified Clostridial toxin disclosed in the present specification, the method comprising the steps of introducing in a cell an expression construct comprising a polynucleotide molecule encoding a modified Clostridial toxin comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain, wherein the modified Clostridial toxin exhibits an enhanced targeting activity for a Clostridial toxin receptor as compared to a naturally-occurring Clostridial toxin and expressing the expression construct in the cell.
Aspects of the present invention provide, in part, a modified Clostridial toxin. As used herein, the term “modified Clostridial toxin” means any polypeptide that can execute the overall cellular mechanism whereby a Clostridial toxin enters a neuron and inhibits neurotransmitter release and encompasses the binding of a Clostridial toxin to a low or high affinity receptor complex, the internalization of the toxin, the translocation of the Clostridial toxin light chain into the cytoplasm and the enzymatic modification of a Clostridial toxin substrate. A modified Clostridial toxin disclosed in the present specification is distinguished from a naturally-occurring Clostridial toxin by the fact that a modified Clostridial toxin comprises a translocation facilitating domain that enhances the process by which a light chain from a modified toxin translocates into the cytoplasm of a target cell and a modified Clostridial toxin lacks the cell binding activity of a naturally-occurring binding domain found in a Clostridial toxin. Instead, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain that determines the binding activity of the modified Clostridial toxin to an endogenous Clostridial toxin receptor located at the surface of the target cell. By definition, a naturally-occurring Clostridial toxin lacks an enhanced targeting domain. Examples of modified Clostridial toxin are described in, e.g., Lance E. Steward, et al., Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems, International Patent Application No. 2006/008956 (Mar. 14, 2006). Any of the modified Clostridial toxins described in, e.g., Steward, supra, (Mar. 14, 2006), can be further modified to include a translocation facilitating domain as disclosed in the present specification.
Aspects of the present invention provide, in part, a Clostridial toxin enzymatic domain. As used herein, the term “Clostridial toxin enzymatic domain” means any Clostridial toxin polypeptide that can execute the enzymatic target modification step of the intoxication process. Thus, a Clostridial toxin enzymatic domain specifically targets a Clostridial toxin substrate and encompasses the proteolytic cleavage of a Clostridial toxin substrate, such as, e.g., SNARE proteins like a SNAP-25 substrate, a VAMP substrate and a Syntaxin substrate. Non-limiting examples of a Clostridial toxin enzymatic domain include, e.g., a Clostridial toxin light chain region such as, e.g., a BoNT/A light chain region, a BoNT/B light chain region, a BoNT/C1 light chain region, a BoNT/D light chain region, a BoNT/E light chain region, a BoNT/F light chain region, a BoNT/G light chain region, and a TeNT light chain region.
A Clostridial toxin enzymatic domain includes, without limitation, naturally occurring Clostridial toxin light chain variants, such as, e.g., Clostridial toxin light chain isoforms and Clostridial toxin light chain subtypes; non-naturally occurring Clostridial toxin light chain variants, such as, e.g., conservative Clostridial toxin light chain variants, non-conservative Clostridial toxin light chain variants, Clostridial toxin light chain chimerics, active Clostridial toxin light chain fragments thereof, or any combination thereof.
As used herein, the term “Clostridial toxin light chain variant,” whether naturally-occurring or non-naturally-occurring, means a Clostridial toxin light chain that has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 1) and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all Clostridial toxin light chain variants disclosed in the present specification are capable of executing the enzymatic target modification step of the intoxication process. As non-limiting examples, a BoNT/A light chain variant comprising amino acids 1-448 of SEQ ID NO: 1 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-448 of SEQ ID NO: 1; a BoNT/B light chain variant comprising amino acids 1-441 of SEQ ID NO: 2 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-441 of SEQ ID NO: 2; a BoNT/C1 light chain variant comprising amino acids 1-449 of SEQ ID NO: 3 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-449 of SEQ ID NO: 3; a BoNT/D light chain variant comprising amino acids 1-445 of SEQ ID NO: 4 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-445 of SEQ ID NO: 4; a BoNT/E light chain variant comprising amino acids 1-422 of SEQ ID NO: 5 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-422 of SEQ ID NO: 5; a BoNT/F light chain variant comprising amino acids 1-439 of SEQ ID NO: 6 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-439 of SEQ ID NO: 6; a BoNT/G light chain variant comprising amino acids 1-446 of SEQ ID NO: 7 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-446 of SEQ ID NO: 7; and a TeNT light chain variant comprising amino acids 1-457 of SEQ ID NO: 8 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1-457 of SEQ ID NO: 8.
It is recognized by those of skill in the art that within each serotype of Clostridial toxin there can be naturally occurring Clostridial toxin light chain variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, there are presently four BoNT/A subtypes, BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4, with specific light chain subtypes showing approximately 95% amino acid identity when compared to another BoNT/A light chain subtype. As used herein, the term “naturally occurring Clostridial toxin light chain variant” means any Clostridial toxin light chain produced by a naturally-occurring process, including, without limitation, Clostridial toxin light chain isoforms produced from alternatively-spliced transcripts, Clostridial toxin light chain isoforms produced by spontaneous mutation and Clostridial toxin light chain subtypes. A naturally occurring Clostridial toxin light chain variant can function in substantially the same manner as the reference Clostridial toxin light chain on which the naturally occurring Clostridial toxin light chain variant is based, and can be substituted for the reference Clostridial toxin light chain in any aspect of the present invention. A naturally occurring Clostridial toxin light chain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial toxin light chain on which the naturally occurring Clostridial toxin light chain variant is based. A naturally occurring Clostridial toxin light chain variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin light chain on which the naturally occurring Clostridial toxin light chain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin light chain on which the naturally occurring Clostridial toxin light chain variant is based.
A non-limiting examples of a naturally occurring Clostridial toxin light chain variant is a Clostridial toxin light chain isoform such as, e.g., a BoNT/A light chain isoform, a BoNT/B light chain isoform, a BoNT/C1 light chain isoform, a BoNT/D light chain isoform, a BoNT/E light chain isoform, a BoNT/F light chain isoform, a BoNT/G light chain isoform, and a TeNT light chain isoform. A Clostridial toxin light chain isoform can function in substantially the same manner as the reference Clostridial toxin light chain on which the Clostridial toxin light chain isoform is based, and can be substituted for the reference Clostridial toxin light chain in any aspect of the present invention.
Another non-limiting examples of a naturally occurring Clostridial toxin light chain variant is a Clostridial toxin light chain subtype such as, e.g., a light chain from subtype BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4; a light chain from subtype BoNT/B1, BoNT/B2, BoNT/B bivalent and BoNT/B nonproteolytic; a light chain from subtype BoNT/C1-1 and BoNT/C1-2; a light chain from subtype BoNT/E1, BoNT/E2 and BoNT/E3; and a light chain from subtype BoNT/F1, BoNT/F2, BoNT/F3 and BoNT/F4. A Clostridial toxin light chain subtype can function in substantially the same manner as the reference Clostridial toxin light chain on which the Clostridial toxin light chain subtype is based, and can be substituted for the reference Clostridial toxin light chain in any aspect of the present invention.
As used herein, the term “non-naturally occurring Clostridial toxin light chain variant” means any Clostridial toxin light chain produced with the aid of human manipulation, including, without limitation, Clostridial toxin light chains produced by genetic engineering using random mutagenesis or rational design and Clostridial toxin light chains produced by chemical synthesis. Non-limiting examples of non-naturally occurring Clostridial toxin light chain variants include, e.g., conservative Clostridial toxin light chain variants, non-conservative Clostridial toxin light chain variants, Clostridial toxin light chain chimeric variants and active Clostridial toxin light chain fragments.
As used herein, the term “conservative Clostridial toxin light chain variant” means a Clostridial toxin light chain that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference Clostridial toxin light chain sequence (Table 1). Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative Clostridial toxin light chain variant can function in substantially the same manner as the reference Clostridial toxin light chain on which the conservative Clostridial toxin light chain variant is based, and can be substituted for the reference Clostridial toxin light chain in any aspect of the present invention. A conservative Clostridial toxin light chain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids, 100 or more amino acids or 200 or more amino acids from the reference Clostridial toxin light chain on which the conservative Clostridial toxin light chain variant is based. A conservative Clostridial toxin light chain variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin light chain on which the conservative Clostridial toxin light chain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin light chain on which the conservative Clostridial toxin light chain variant is based. Non-limiting examples of a conservative Clostridial toxin light chain variant include, e.g., conservative BoNT/A light chain variants, conservative BoNT/B light chain variants, conservative BoNT/C1 light chain variants, conservative BoNT/D light chain variants, conservative BoNT/E light chain variants, conservative BoNT/F light chain variants, conservative BoNT/G light chain variants, and conservative TeNT light chain variants.
As used herein, the term “non-conservative Clostridial toxin light chain variant” means a Clostridial toxin light chain in which 1) at least one amino acid is deleted from the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based; 2) at least one amino acid added to the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference Clostridial toxin light chain sequence (Table 1). A non-conservative Clostridial toxin light chain variant can function in substantially the same manner as the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based, and can be substituted for the reference Clostridial toxin light chain in any aspect of the present invention. A non-conservative Clostridial toxin light chain variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids from the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based. A non-conservative Clostridial toxin light chain variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids to the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based. A non-conservative Clostridial toxin light chain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids, 100 or more amino acids or 200 or more amino acids from the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based. A non-conservative Clostridial toxin light chain variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin light chain on which the non-conservative Clostridial toxin light chain variant is based. Non-limiting examples of a non-conservative Clostridial toxin light chain variant include, e.g., non-conservative BoNT/A light chain variants, non-conservative BoNT/B light chain variants, non-conservative BoNT/C1 light chain variants, non-conservative BoNT/D light chain variants, non-conservative BoNT/E light chain variants, non-conservative BoNT/F light chain variants, non-conservative BoNT/G light chain variants, and non-conservative TeNT light chain variants.
As used herein, the term “Clostridial toxin light chain chimeric” means a polypeptide comprising at least a portion of a Clostridial toxin light chain and at least a portion of at least one other polypeptide to form a toxin light chain with at least one property different from the reference Clostridial toxin light chains of Table 1, with the proviso that this Clostridial toxin light chain chimeric is still capable of specifically targeting the core components of the neurotransmitter release apparatus and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate. Such Clostridial toxin light chain chimerics are described in, e.g., Lance E. Steward et al., Leucine-based Motif and Clostridial Toxins, U.S. Patent Publication 2003/0027752 (Feb. 6, 2003); Lance E. Steward et al., Clostridial Neurotoxin Compositions and Modified Clostridial Neurotoxins, U.S. Patent Publication 2003/0219462 (Nov. 27, 2003); and Lance E. Steward et al., Clostridial Neurotoxin Compositions and Modified Clostridial Neurotoxins, U.S. Patent Publication 2004/0220386 (Nov. 4, 2004).
As used herein, the term “active Clostridial toxin light chain fragment” means any of a variety of Clostridial toxin fragments comprising the light chain can be useful in aspects of the present invention with the proviso that these light chain fragments can specifically target the core components of the neurotransmitter release apparatus and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate. The light chains of Clostridial toxins are approximately 420-460 amino acids in length and comprise an enzymatic domain (Table 1). Research has shown that the entire length of a Clostridial toxin light chain is not necessary for the enzymatic activity of the enzymatic domain. As a non-limiting example, the first eight amino acids of the BoNT/A light chain (residues 1-8 of SEQ ID NO: 1) are not required for enzymatic activity. As another non-limiting example, the first eight amino acids of the TeNT light chain (residues 1-8 of SEQ ID NO: 8) are not required for enzymatic activity. Likewise, the carboxyl-terminus of the light chain is not necessary for activity. As a non-limiting example, the last 32 amino acids of the BoNT/A light chain (residues 417-448 of SEQ ID NO: 1) are not required for enzymatic activity. As another non-limiting example, the last 31 amino acids of the TeNT light chain (residues 427-457 of SEQ ID NO: 8) are not required for enzymatic activity. Thus, aspects of this embodiment can include Clostridial toxin light chains comprising an enzymatic domain having a length of, e.g., at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, at least 425 amino acids and at least 450 amino acids. Other aspects of this embodiment can include Clostridial toxin light chains comprising an enzymatic domain having a length of, e.g., at most 350 amino acids, at most 375 amino acids, at most 400 amino acids, at most 425 amino acids and at most 450 amino acids.
Any of a variety of sequence alignment methods can be used to determine percent identity of naturally-occurring Clostridial toxin light chain variants and non-naturally-occurring Clostridial toxin light chain variants, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Global methods align sequences from the beginning to the end of the molecule and determine the best alignment by adding up scores of individual residue pairs and by imposing gap penalties. Non-limiting methods include, e.g., CLUSTAL W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement, see, e.g., Osamu Gotoh, Significant Improvement in Accuracy of Multiple Protein Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. Mol. Biol. 823-838 (1996).
Local methods align sequences by identifying one or more conserved motifs shared by all of the input sequences. Non-limiting methods include, e.g., Match-box, see, e.g., Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501-509 (1992); Gibbs sampling, see, e.g., C. E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262(5131) Science 208-214 (1993); Align-M, see, e.g., Ivo Van Walle et al., Align-M—A New Algorithm for Multiple Alignment of Highly Divergent Sequences, 20(9) Bioinformatics: 1428-1435 (2004).
Hybrid methods combine functional aspects of both global and local alignment methods. Non-limiting methods include, e.g., segment-to-segment comparison, see, e.g., Burkhard Morgenstern et al., Multiple DNA and Protein Sequence Alignment Based 0n Segment-To-Segment Comparison, 93(22) Proc. Natl. Acad. Sci. U.S.A. 12098-12103 (1996); T-Coffee, see, e.g., Cédric Notredame et al., T-Coffee: A Novel Algorithm for Multiple Sequence Alignment, 302(1) J. Mol. Biol. 205-217 (2000); MUSCLE, see, e.g., Robert C. Edgar, MUSCLE: Multiple Sequence Alignment With High Score Accuracy and High Throughput, 32(5) Nucleic Acids Res. 1792-1797 (2004); and DIALIGN-T, see, e.g., Amarendran R Subramanian et al., DIALIGN-T: An Improved Algorithm for Segment-Based Multiple Sequence Alignment, 6(1) BMC Bioinformatics 66 (2005).
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises a Clostridial toxin enzymatic domain. In an aspect of this embodiment, a Clostridial toxin enzymatic domain comprises a naturally occurring Clostridial toxin light chain variant, such as, e.g., a Clostridial toxin light chain isoform or a Clostridial toxin light chain subtype. In another aspect of this embodiment, a Clostridial toxin enzymatic domain comprises a non-naturally occurring Clostridial toxin light chain variant, such as, e.g., a conservative Clostridial toxin light chain variant, a non-conservative Clostridial toxin light chain variant, a Clostridial toxin chimeric light chain, an active Clostridial toxin light chain fragment, or any combination thereof.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/A light chain. In an aspect of this embodiment, a BoNT/A light chain comprises amino acids 1-448 of SEQ ID NO: 1. In another aspect of this embodiment, a BoNT/A light chain comprises a naturally occurring BoNT/A light chain variant, such as, e.g., a light chain from a BoNT/A isoform or a light chain from a BoNT/A subtype. In another aspect of this embodiment, a BoNT/A light chain comprises amino acids 1-448 of a naturally occurring BoNT/A light chain variant of SEQ ID NO: 1, such as, e.g., amino acids 1-448 of a BoNT/A isoform of SEQ ID NO: 1 or amino acids 1-448 of a BoNT/A subtype of SEQ ID NO: 1. In still another aspect of this embodiment, a BoNT/A light chain comprises a non-naturally occurring BoNT/A light chain variant, such as, e.g., a conservative BoNT/A light chain variant, a non-conservative BoNT/A light chain variant, a BoNT/A chimeric light chain, an active BoNT/A light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/A light chain comprises amino acids 1-448 of a non-naturally occurring BoNT/A light chain variant of SEQ ID NO: 1, such as, e.g., amino acids 1-448 of a conservative BoNT/A light chain variant of SEQ ID NO: 1, amino acids 1-448 of a non-conservative BoNT/A light chain variant of SEQ ID NO: 1, amino acids 1-448 of an active BoNT/A light chain fragment of SEQ ID NO: 1, or any combination thereof.
In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at least 75% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at least 80% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at least 85% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at least 90% amino acid identity with amino acids 1-448 of SEQ ID NO: 1 or at least 95% amino acid identity with amino acids 1-448 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at most 75% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at most 80% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at most 85% amino acid identity with amino acids 1-448 of SEQ ID NO: 1, at most 90% amino acid identity with amino acids 1-448 of SEQ ID NO: 1 or at most 95% amino acid identity with amino acids 1-448 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-448 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-448 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-448 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-448 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-448 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-448 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-448 of SEQ ID NO: 1.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/B light chain. In an aspect of this embodiment, a BoNT/B light chain comprises amino acids 1-441 of SEQ ID NO: 2. In another aspect of this embodiment, a BoNT/B light chain comprises a naturally occurring BoNT/B light chain variant, such as, e.g., a light chain from a BoNT/B isoform or a light chain from a BoNT/B subtype. In another aspect of this embodiment, a BoNT/B light chain comprises amino acids 1-441 of a naturally occurring BoNT/B light chain variant of SEQ ID NO: 2, such as, e.g., amino acids 1-441 of a BoNT/B isoform of SEQ ID NO: 2 or amino acids 1-441 of a BoNT/B subtype of SEQ ID NO: 2. In still another aspect of this embodiment, a BoNT/B light chain comprises a non-naturally occurring BoNT/B light chain variant, such as, e.g., a conservative BoNT/B light chain variant, a non-conservative BoNT/B light chain variant, a BoNT/B chimeric light chain, an active BoNT/B light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/B light chain comprises amino acids 1-441 of a non-naturally occurring BoNT/B light chain variant of SEQ ID NO: 2, such as, e.g., amino acids 1-441 of a conservative BoNT/B light chain variant of SEQ ID NO: 2, amino acids 1-441 of a non-conservative BoNT/B light chain variant of SEQ ID NO: 2, amino acids 1-441 of an active BoNT/B light chain fragment of SEQ ID NO: 2, or any combination thereof.
In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at least 75% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at least 80% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at least 85% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at least 90% amino acid identity with amino acids 1-441 of SEQ ID NO: 2 or at least 95% amino acid identity with amino acids 1-441 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at most 75% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at most 80% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at most 85% amino acid identity with amino acids 1-441 of SEQ ID NO: 2, at most 90% amino acid identity with amino acids 1-441 of SEQ ID NO: 2 or at most 95% amino acid identity with amino acids 1-441 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-441 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-441 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-441 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-441 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-441 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-441 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-441 of SEQ ID NO: 2.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/C1 light chain. In an aspect of this embodiment, a BoNT/C1 light chain comprises amino acids 1-449 of SEQ ID NO: 3. In another aspect of this embodiment, a BoNT/C1 light chain comprises a naturally occurring BoNT/C1 light chain variant, such as, e.g., a light chain from a BoNT/C1 isoform or a light chain from a BoNT/C1 subtype. In another aspect of this embodiment, a BoNT/C1 light chain comprises amino acids 1-449 of a naturally occurring BoNT/C1 light chain variant of SEQ ID NO: 3, such as, e.g., amino acids 1-449 of a BoNT/C1 isoform of SEQ ID NO: 3 or amino acids 1-449 of a BoNT/C1 subtype of SEQ ID NO: 3. In still another aspect of this embodiment, a BoNT/C1 light chain comprises a non-naturally occurring BoNT/C1 light chain variant, such as, e.g., a conservative BoNT/C1 light chain variant, a non-conservative BoNT/C1 light chain variant, a BoNT/C1 chimeric light chain, an active BoNT/C1 light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/C1 light chain comprises amino acids 1-449 of a non-naturally occurring BoNT/C1 light chain variant of SEQ ID NO: 3, such as, e.g., amino acids 1-449 of a conservative BoNT/C1 light chain variant of SEQ ID NO: 3, amino acids 1-449 of a non-conservative BoNT/C1 light chain variant of SEQ ID NO: 3, amino acids 1-449 of an active BoNT/C1 light chain fragment of SEQ ID NO: 3, or any combination thereof.
In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at least 75% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at least 80% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at least 85% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at least 90% amino acid identity with amino acids 1-449 of SEQ ID NO: 3 or at least 95% amino acid identity with amino acids 1-449 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at most 75% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at most 80% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at most 85% amino acid identity with amino acids 1-449 of SEQ ID NO: 3, at most 90% amino acid identity with amino acids 1-449 of SEQ ID NO: 3 or at most 95% amino acid identity with amino acids 1-449 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-449 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-449 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-449 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-449 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-449 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-449 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-449 of SEQ ID NO: 3.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/D light chain. In an aspect of this embodiment, a BoNT/D light chain comprises amino acids 1-445 of SEQ ID NO: 4. In another aspect of this embodiment, a BoNT/D light chain comprises a naturally occurring BoNT/D light chain variant, such as, e.g., a light chain from a BoNT/D isoform or a light chain from a BoNT/D subtype. In another aspect of this embodiment, a BoNT/D light chain comprises amino acids 1-445 of a naturally occurring BoNT/D light chain variant of SEQ ID NO: 4, such as, e.g., amino acids 1-445 of a BoNT/D isoform of SEQ ID NO: 4 or amino acids 1-445 of a BoNT/D subtype of SEQ ID NO: 4. In still another aspect of this embodiment, a BoNT/D light chain comprises a non-naturally occurring BoNT/D light chain variant, such as, e.g., a conservative BoNT/D light chain variant, a non-conservative BoNT/D light chain variant, a BoNT/D chimeric light chain, an active BoNT/D light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/D light chain comprises amino acids 1-445 of a non-naturally occurring BoNT/D light chain variant of SEQ ID NO: 4, such as, e.g., amino acids 1-445 of a conservative BoNT/D light chain variant of SEQ ID NO: 4, amino acids 1-445 of a non-conservative BoNT/D light chain variant of SEQ ID NO: 4, amino acids 1-445 of an active BoNT/D light chain fragment of SEQ ID NO: 4, or any combination thereof.
In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at least 75% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at least 80% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at least 85% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at least 90% amino acid identity with amino acids 1-445 of SEQ ID NO: 4 or at least 95% amino acid identity with amino acids 1-445 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at most 75% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at most 80% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at most 85% amino acid identity with amino acids 1-445 of SEQ ID NO: 4, at most 90% amino acid identity with amino acids 1-445 of SEQ ID NO: 4 or at most 95% amino acid identity with amino acids 1-445 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-445 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-445 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-445 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-445 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-445 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-445 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-445 of SEQ ID NO: 4.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/E light chain. In an aspect of this embodiment, a BoNT/E light chain comprises amino acids 1-422 of SEQ ID NO: 5. In another aspect of this embodiment, a BoNT/E light chain comprises a naturally occurring BoNT/E light chain variant, such as, e.g., a light chain from a BoNT/E isoform or a light chain from a BoNT/E subtype. In another aspect of this embodiment, a BoNT/E light chain comprises amino acids 1-422 of a naturally occurring BoNT/E light chain variant of SEQ ID NO: 5, such as, e.g., amino acids 1-422 of a BoNT/E isoform of SEQ ID NO: 5 or amino acids 1-422 of a BoNT/E subtype of SEQ ID NO: 5. In still another aspect of this embodiment, a BoNT/E light chain comprises a non-naturally occurring BoNT/E light chain variant, such as, e.g., a conservative BoNT/E light chain variant, a non-conservative BoNT/E light chain variant, a BoNT/E chimeric light chain, an active BoNT/E light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/E light chain comprises amino acids 1-422 of a non-naturally occurring BoNT/E light chain variant of SEQ ID NO: 5, such as, e.g., amino acids 1-422 of a conservative BoNT/E light chain variant of SEQ ID NO: 5, amino acids 1-422 of a non-conservative BoNT/E light chain variant of SEQ ID NO: 5, amino acids 1-422 of an active BoNT/E light chain fragment of SEQ ID NO: 5, or any combination thereof.
In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at least 75% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at least 80% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at least 85% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at least 90% amino acid identity with amino acids 1-422 of SEQ ID NO: 5 or at least 95% amino acid identity with amino acids 1-422 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at most 75% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at most 80% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at most 85% amino acid identity with amino acids 1-422 of SEQ ID NO: 5, at most 90% amino acid identity with amino acids 1-422 of SEQ ID NO: 5 or at most 95% amino acid identity with amino acids 1-422 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-422 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-422 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-422 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-422 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-422 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-422 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-422 of SEQ ID NO: 5.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/F light chain. In an aspect of this embodiment, a BoNT/F light chain comprises amino acids 1-439 of SEQ ID NO: 6. In another aspect of this embodiment, a BoNT/F light chain comprises a naturally occurring BoNT/F light chain variant, such as, e.g., a light chain from a BoNT/F isoform or a light chain from a BoNT/F subtype. In another aspect of this embodiment, a BoNT/F light chain comprises amino acids 1-439 of a naturally occurring BoNT/F light chain variant of SEQ ID NO: 6, such as, e.g., amino acids 1-439 of a BoNT/F isoform of SEQ ID NO: 6 or amino acids 1-439 of a BoNT/F subtype of SEQ ID NO: 6. In still another aspect of this embodiment, a BoNT/F light chain comprises a non-naturally occurring BoNT/F light chain variant, such as, e.g., a conservative BoNT/F light chain variant, a non-conservative BoNT/F light chain variant, a BoNT/F chimeric light chain, an active BoNT/F light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/F light chain comprises amino acids 1-439 of a non-naturally occurring BoNT/F light chain variant of SEQ ID NO: 6, such as, e.g., amino acids 1-439 of a conservative BoNT/F light chain variant of SEQ ID NO: 6, amino acids 1-439 of a non-conservative BoNT/F light chain variant of SEQ ID NO: 6, amino acids 1-439 of an active BoNT/F light chain fragment of SEQ ID NO: 6, or any combination thereof.
In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at least 75% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at least 80% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at least 85% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at least 90% amino acid identity with amino acids 1-439 of SEQ ID NO: 6 or at least 95% amino acid identity with amino acids 1-439 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at most 75% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at most 80% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at most 85% amino acid identity with amino acids 1-439 of SEQ ID NO: 6, at most 90% amino acid identity with amino acids 1-439 of SEQ ID NO: 6 or at most 95% amino acid identity with amino acids 1-439 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-439 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-439 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-439 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-439 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-439 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-439 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-439 of SEQ ID NO: 6.
In another embodiment, a Clostridial toxin enzymatic domain comprises a BoNT/G light chain. In an aspect of this embodiment, a BoNT/G light chain comprises amino acids 1-446 of SEQ ID NO: 7. In another aspect of this embodiment, a BoNT/G light chain comprises a naturally occurring BoNT/G light chain variant, such as, e.g., a light chain from a BoNT/G isoform or a light chain from a BoNT/G subtype. In another aspect of this embodiment, a BoNT/G light chain comprises amino acids 1-446 of a naturally occurring BoNT/G light chain variant of SEQ ID NO: 7, such as, e.g., amino acids 1-446 of a BoNT/G isoform of SEQ ID NO: 7 or amino acids 1-446 of a BoNT/G subtype of SEQ ID NO: 7. In still another aspect of this embodiment, a BoNT/G light chain comprises a non-naturally occurring BoNT/G light chain variant, such as, e.g., a conservative BoNT/G light chain variant, a non-conservative BoNT/G light chain variant, a BoNT/G chimeric light chain, an active BoNT/G light chain fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/G light chain comprises amino acids 1-446 of a non-naturally occurring BoNT/G light chain variant of SEQ ID NO: 7, such as, e.g., amino acids 1-446 of a conservative BoNT/G light chain variant of SEQ ID NO: 7, amino acids 1-446 of a non-conservative BoNT/G light chain variant of SEQ ID NO: 7, amino acids 1-446 of an active BoNT/G light chain fragment of SEQ ID NO: 7, or any combination thereof.
In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at least 75% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at least 80% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at least 85% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at least 90% amino acid identity with amino acids 1-446 of SEQ ID NO: 7 or at least 95% amino acid identity with amino acids 1-446 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at most 75% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at most 80% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at most 85% amino acid identity with amino acids 1-446 of SEQ ID NO: 7, at most 90% amino acid identity with amino acids 1-446 of SEQ ID NO: 7 or at most 95% amino acid identity with amino acids 1-446 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-446 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-446 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-446 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-446 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-446 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-446 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-446 of SEQ ID NO: 7.
In another embodiment, a Clostridial toxin enzymatic domain comprises a TeNT light chain. In an aspect of this embodiment, a TeNT light chain comprises amino acids 1-457 of SEQ ID NO: 8. In another aspect of this embodiment, a TeNT light chain comprises a naturally occurring TeNT light chain variant, such as, e.g., a light chain from a TeNT isoform or a light chain from a TeNT subtype. In another aspect of this embodiment, a TeNT light chain comprises amino acids 1-457 of a naturally occurring TeNT light chain variant of SEQ ID NO: 8, such as, e.g., amino acids 1-457 of a TeNT isoform of SEQ ID NO: 8 or amino acids 1-457 of a TeNT subtype of SEQ ID NO: 8. In still another aspect of this embodiment, a TeNT light chain comprises a non-naturally occurring TeNT light chain variant, such as, e.g., a conservative TeNT light chain variant, a non-conservative TeNT light chain variant, a TeNT chimeric light chain, an active TeNT light chain fragment, or any combination thereof. In still another aspect of this embodiment, a TeNT light chain comprises amino acids 1-457 of a non-naturally occurring TeNT light chain variant of SEQ ID NO: 8, such as, e.g., amino acids 1-457 of a conservative TeNT light chain variant of SEQ ID NO: 8, amino acids 1-457 of a non-conservative TeNT light chain variant of SEQ ID NO: 8, amino acids 1-457 of an active TeNT light chain fragment of SEQ ID NO: 8, or any combination thereof.
In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at least 75% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at least 80% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at least 85% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at least 90% amino acid identity with amino acids 1-457 of SEQ ID NO: 8 or at least 95% amino acid identity with amino acids 1-457 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at most 75% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at most 80% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at most 85% amino acid identity with amino acids 1-457 of SEQ ID NO: 8, at most 90% amino acid identity with amino acids 1-457 of SEQ ID NO: 8 or at most 95% amino acid identity with amino acids 1-457 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 1-457 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 1-457 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 1-457 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 1-457 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 1-457 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-457 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT light chain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 1-457 of SEQ ID NO: 8.
Aspects of the present invention provide, in part, a Clostridial toxin translocation domain. As used herein, the term “Clostridial toxin translocation domain” means any Clostridial toxin polypeptide that can execute the translocation step of the intoxication process that mediates Clostridial toxin light chain translocation. Thus, a Clostridial toxin translocation domain facilitates the movement of a Clostridial toxin light chain across a membrane and encompasses the movement of a Clostridial toxin light chain through the membrane an intracellular vesicle into the cytoplasm of a cell. Non-limiting examples of a Clostridial toxin translocation domain include, e.g., a Clostridial toxin HN region such as, e.g., a BoNT/A HN region, a BoNT/B HN region, a BoNT/C1 HN region, a BoNT/D HN region, a BoNT/E HN region, a BoNT/F HN region, a BoNT/G HN region, and a TeNT HN region.
A Clostridial toxin translocation domain includes, without limitation, naturally occurring Clostridial toxin HN region variants, such as, e.g., Clostridial toxin HN region isoforms and Clostridial toxin HN region subtypes; non-naturally occurring Clostridial toxin HN region variants, such as, e.g., conservative Clostridial toxin HN region variants, non-conservative Clostridial toxin HN region variants, Clostridial toxin HN region chimerics, active Clostridial toxin HN region fragments thereof, or any combination thereof.
As used herein, the term “Clostridial toxin HN region variant,” whether naturally-occurring or non-naturally-occurring, means a Clostridial toxin HN region that has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 1) and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all Clostridial toxin HN region variants disclosed in the present specification are capable of executing the translocation step of the intoxication process that mediates Clostridial toxin light chain translocation. As non-limiting examples, a BoNT/A HN region variant comprising amino acids 449-873 of SEQ ID NO: 1 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 449-873 of SEQ ID NO: 1; a BoNT/B HN region variant comprising amino acids 442-860 of SEQ ID NO: 2 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 442-860 of SEQ ID NO: 2; a BoNT/C1 HN region variant comprising amino acids 450-868 of SEQ ID NO: 3 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 450-868 of SEQ ID NO: 3; a BoNT/D HN region variant comprising amino acids 446-864 of SEQ ID NO: 4 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 446-864 of SEQ ID NO: 4; a BoNT/E HN region variant comprising amino acids 423-847 of SEQ ID NO: 5 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 423-847 of SEQ ID NO: 5; a BoNT/F HN region variant comprising amino acids 440-866 of SEQ ID NO: 6 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 440-866 of SEQ ID NO: 6; a BoNT/G HN region variant comprising amino acids 447-865 of SEQ ID NO: 7 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 447-865 of SEQ ID NO: 7; and a TeNT HN region variant comprising amino acids 458-881 of SEQ ID NO: 8 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 458-881 of SEQ ID NO: 8.
It is recognized by those of skill in the art that within each serotype of Clostridial toxin there can be naturally occurring Clostridial toxin HN region variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, there are presently four BoNT/A subtypes, BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4, with specific HN region subtypes showing approximately 87% amino acid identity when compared to another BoNT/A HN region subtype. As used herein, the term “naturally occurring Clostridial toxin HN region variant” means any Clostridial toxin HN region produced by a naturally-occurring process, including, without limitation, Clostridial toxin HN region isoforms produced from alternatively-spliced transcripts, Clostridial toxin HN region isoforms produced by spontaneous mutation and Clostridial toxin HN region subtypes. A naturally occurring Clostridial toxin HN region variant can function in substantially the same manner as the reference Clostridial toxin HN region on which the naturally occurring Clostridial toxin HN region variant is based, and can be substituted for the reference Clostridial toxin HN region in any aspect of the present invention. A naturally occurring Clostridial toxin HN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial toxin HN region on which the naturally occurring Clostridial toxin HN region variant is based. A naturally occurring Clostridial toxin HN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HN region on which the naturally occurring Clostridial toxin HN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HN region on which the naturally occurring Clostridial toxin HN region variant is based.
A non-limiting examples of a naturally occurring Clostridial toxin HN region variant is a Clostridial toxin HN region isoform such as, e.g., a BoNT/A HN region isoform, a BoNT/B HN region isoform, a BoNT/C1 HN region isoform, a BoNT/D HN region isoform, a BoNT/E HN region isoform, a BoNT/F HN region isoform, a BoNT/G HN region isoform, and a TeNT HN region isoform. A Clostridial toxin HN region isoform can function in substantially the same manner as the reference Clostridial toxin HN region on which the Clostridial toxin HN region isoform is based, and can be substituted for the reference Clostridial toxin HN region in any aspect of the present invention.
Another non-limiting examples of a naturally occurring Clostridial toxin HN region variant is a Clostridial toxin HN region subtype such as, e.g., a HN region from subtype BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4; a HN region from subtype BoNT/B1, BoNT/B2, BoNT/B bivalent and BoNT/B nonproteolytic; a HN region from subtype BoNT/C1-1 and BoNT/C1-2; a HN region from subtype BoNT/E1, BoNT/E2 and BoNT/E3; and a HN region from subtype BoNT/F1, BoNT/F2, BoNT/F3 and BoNT/F4. A Clostridial toxin HN region subtype can function in substantially the same manner as the reference Clostridial toxin HN region on which the Clostridial toxin HN region subtype is based, and can be substituted for the reference Clostridial toxin HN region in any aspect of the present invention.
As used herein, the term “non-naturally occurring Clostridial toxin HN region variant” means any Clostridial toxin HN region produced with the aid of human manipulation, including, without limitation, Clostridial toxin HN regions produced by genetic engineering using random mutagenesis or rational design and Clostridial toxin HN regions produced by chemical synthesis. Non-limiting examples of non-naturally occurring Clostridial toxin HN region variants include, e.g., conservative Clostridial toxin HN region variants, non-conservative Clostridial toxin HN region variants, Clostridial toxin HN region chimeric variants and active Clostridial toxin HN region fragments.
As used herein, the term “conservative Clostridial toxin HN region variant” means a Clostridial toxin HN region that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference Clostridial toxin HN region sequence (Table 1). Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative Clostridial toxin HN region variant can function in substantially the same manner as the reference Clostridial toxin HN region on which the conservative Clostridial toxin HN region variant is based, and can be substituted for the reference Clostridial toxin HN region in any aspect of the present invention. A conservative Clostridial toxin HN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids, 100 or more amino acids or 200 or more amino acids from the reference Clostridial toxin HN region on which the conservative Clostridial toxin HN region variant is based. A conservative Clostridial toxin HN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HN region on which the conservative Clostridial toxin HN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HN region on which the conservative Clostridial toxin HN region variant is based. Non-limiting examples of a conservative Clostridial toxin HN region variant include, e.g., conservative BoNT/A HN region variants, conservative BoNT/B HN region variants, conservative BoNT/C1 HN region variants, conservative BoNT/D HN region variants, conservative BoNT/E HN region variants, conservative BoNT/F HN region variants, conservative BoNT/G HN region variants, and conservative TeNT HN region variants.
As used herein, the term “non-conservative Clostridial toxin HN region variant” means a Clostridial toxin HN region in which 1) at least one amino acid is deleted from the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based; 2) at least one amino acid added to the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference Clostridial toxin HN region sequence (Table 1). A non-conservative Clostridial toxin HN region variant can function in substantially the same manner as the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based, and can be substituted for the reference Clostridial toxin HN region in any aspect of the present invention. A non-conservative Clostridial toxin HN region variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids from the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based. A non-conservative Clostridial toxin HN region variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids to the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based. A non-conservative Clostridial toxin HN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids, 100 or more amino acids or 200 or more amino acids from the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based. A non-conservative Clostridial toxin HN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HN region on which the non-conservative Clostridial toxin HN region variant is based. Non-limiting examples of a non-conservative Clostridial toxin HN region variant include, e.g., non-conservative BoNT/A HN region variants, non-conservative BoNT/B HN region variants, non-conservative BoNT/C1 HN region variants, non-conservative BoNT/D HN region variants, non-conservative BoNT/E HN region variants, non-conservative BoNT/F HN region variants, non-conservative BoNT/G HN region variants, and non-conservative TeNT HN region variants.
As used herein, the term “Clostridial toxin HN region chimeric” means a polypeptide comprising at least a portion of a Clostridial toxin HN region and at least a portion of at least one other polypeptide to form a toxin HN region with at least one property different from the reference Clostridial toxin HN regions of Table 1, with the proviso that this Clostridial toxin HN region chimeric is still capable of facilitating the release of the LC from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
As used herein, the term “active Clostridial toxin HN region fragment” means any of a variety of Clostridial toxin fragments comprising the HN region can be useful in aspects of the present invention with the proviso that these active fragments can facilitate the release of the LC from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate. The HN regions from the heavy chains of Clostridial toxins are approximately 410-430 amino acids in length and comprise a translocation domain (Table 1). Research has shown that the entire length of a HN region from a Clostridial toxin heavy chain is not necessary for the translocating activity of the translocation domain. Thus, aspects of this embodiment can include Clostridial toxin HN regions comprising a translocation domain having a length of, e.g., at least 350 amino acids, at least 375 amino acids, at least 400 amino acids and at least 425 amino acids. Other aspects of this embodiment can include Clostridial toxin HN regions comprising translocation domain having a length of, e.g., at most 350 amino acids, at most 375 amino acids, at most 400 amino acids and at most 425 amino acids.
Any of a variety of sequence alignment methods can be used to determine percent identity of naturally-occurring Clostridial toxin HN region variants and non-naturally-occurring Clostridial toxin HN region variants, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises a Clostridial toxin translocation domain. In an aspect of this embodiment, a Clostridial toxin translocation domain comprises a naturally occurring Clostridial toxin HN region variant, such as, e.g., a Clostridial toxin HN region isoform or a Clostridial toxin HN region subtype. In another aspect of this embodiment, a Clostridial toxin translocation domain comprises a non-naturally occurring Clostridial toxin HN region variant, such as, e.g., a conservative Clostridial toxin HN region variant, a non-conservative Clostridial toxin HN region variant, a Clostridial toxin chimeric HN region, an active Clostridial toxin HN region fragment, or any combination thereof.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/A HN region. In an aspect of this embodiment, a BoNT/A HN region comprises amino acids 449-873 of SEQ ID NO: 1. In another aspect of this embodiment, a BoNT/A HN region comprises a naturally occurring BoNT/A HN region variant, such as, e.g., a HN region from a BoNT/A isoform or a HN region from a BoNT/A subtype. In another aspect of this embodiment, a BoNT/A HN region comprises amino acids 449-873 of a naturally occurring BoNT/A HN region variant of SEQ ID NO: 1, such as, e.g., amino acids 449-873 of a BoNT/A isoform of SEQ ID NO: 1 or amino acids 449-873 of a BoNT/A subtype of SEQ ID NO: 1. In still another aspect of this embodiment, a BoNT/A HN region comprises a non-naturally occurring BoNT/A HN region variant, such as, e.g., a conservative BoNT/A HN region variant, a non-conservative BoNT/A HN region variant, a BoNT/A chimeric HN region, an active BoNT/A HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/A HN region comprises amino acids 449-873 of a non-naturally occurring BoNT/A HN region variant of SEQ ID NO: 1, such as, e.g., amino acids 449-873 of a conservative BoNT/A HN region variant of SEQ ID NO: 1, amino acids 449-873 of a non-conservative BoNT/A HN region variant of SEQ ID NO: 1, amino acids 449-873 of an active BoNT/A HN region fragment of SEQ ID NO: 1, or any combination thereof.
In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at least 75% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at least 80% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at least 85% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at least 90% amino acid identity with amino acids 449-873 of SEQ ID NO: 1 or at least 95% amino acid identity with amino acids 449-873 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at most 75% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at most 80% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at most 85% amino acid identity with amino acids 449-873 of SEQ ID NO: 1, at most 90% amino acid identity with amino acids 449-873 of SEQ ID NO: 1 or at most 95% amino acid identity with amino acids 449-873 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 449-873 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 449-873 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 449-873 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 449-873 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 449-873 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 449-873 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 449-873 of SEQ ID NO: 1.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/B HN region. In an aspect of this embodiment, a BoNT/B HN region comprises amino acids 442-860 of SEQ ID NO: 2. In another aspect of this embodiment, a BoNT/B HN region comprises a naturally occurring BoNT/B HN region variant, such as, e.g., a HN region from a BoNT/B isoform or a HN region from a BoNT/B subtype. In another aspect of this embodiment, a BoNT/B HN region comprises amino acids 442-860 of a naturally occurring BoNT/B HN region variant of SEQ ID NO: 2, such as, e.g., amino acids 442-860 of a BoNT/B isoform of SEQ ID NO: 2 or amino acids 442-860 of a BoNT/B subtype of SEQ ID NO: 2. In still another aspect of this embodiment, a BoNT/B HN region comprises a non-naturally occurring BoNT/B HN region variant, such as, e.g., a conservative BoNT/B HN region variant, a non-conservative BoNT/B HN region variant, a BoNT/B chimeric HN region, an active BoNT/B HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/B HN region comprises amino acids 442-860 of a non-naturally occurring BoNT/B HN region variant of SEQ ID NO: 2, such as, e.g., amino acids 442-860 of a conservative BoNT/B HN region variant of SEQ ID NO: 2, amino acids 442-860 of a non-conservative BoNT/B HN region variant of SEQ ID NO: 2, amino acids 442-860 of an active BoNT/B HN region fragment of SEQ ID NO: 2, or any combination thereof.
In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at least 75% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at least 80% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at least 85% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at least 90% amino acid identity with amino acids 442-860 of SEQ ID NO: 2 or at least 95% amino acid identity with amino acids 442-860 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at most 75% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at most 80% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at most 85% amino acid identity with amino acids 442-860 of SEQ ID NO: 2, at most 90% amino acid identity with amino acids 442-860 of SEQ ID NO: 2 or at most 95% amino acid identity with amino acids 442-860 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 442-860 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 442-860 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 442-860 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 442-860 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 442-860 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 442-860 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 442-860 of SEQ ID NO: 2.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/C1 HN region. In an aspect of this embodiment, a BoNT/C1 HN region comprises amino acids 450-868 of SEQ ID NO: 3. In another aspect of this embodiment, a BoNT/C1 HN region comprises a naturally occurring BoNT/C1 HN region variant, such as, e.g., a HN region from a BoNT/C1 isoform or a HN region from a BoNT/C1 subtype. In another aspect of this embodiment, a BoNT/C1 HN region comprises amino acids 450-868 of a naturally occurring BoNT/C1 HN region variant of SEQ ID NO: 3, such as, e.g., amino acids 450-868 of a BoNT/C1 isoform of SEQ ID NO: 3 or amino acids 450-868 of a BoNT/C1 subtype of SEQ ID NO: 3. In still another aspect of this embodiment, a BoNT/C1 HN region comprises a non-naturally occurring BoNT/C1 HN region variant, such as, e.g., a conservative BoNT/C1 HN region variant, a non-conservative BoNT/C1 HN region variant, a BoNT/C1 chimeric HN region, an active BoNT/C1 HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/C1 HN region comprises amino acids 450-868 of a non-naturally occurring BoNT/C1 HN region variant of SEQ ID NO: 3, such as, e.g., amino acids 450-868 of a conservative BoNT/C1 HN region variant of SEQ ID NO: 3, amino acids 450-868 of a non-conservative BoNT/C1 HN region variant of SEQ ID NO: 3, amino acids 450-868 of an active BoNT/C1 HN region fragment of SEQ ID NO: 3, or any combination thereof.
In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at least 75% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at least 80% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at least 85% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at least 90% amino acid identity with amino acids 450-868 of SEQ ID NO: 3 or at least 95% amino acid identity with amino acids 450-868 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at most 75% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at most 80% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at most 85% amino acid identity with amino acids 450-868 of SEQ ID NO: 3, at most 90% amino acid identity with amino acids 450-868 of SEQ ID NO: 3 or at most 95% amino acid identity with amino acids 450-868 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 450-868 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 450-868 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 450-868 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 450-868 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 450-868 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 450-868 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 450-868 of SEQ ID NO: 3.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/D HN region. In an aspect of this embodiment, a BoNT/D HN region comprises amino acids 446-864 of SEQ ID NO: 4. In another aspect of this embodiment, a BoNT/D HN region comprises a naturally occurring BoNT/D HN region variant, such as, e.g., a HN region from a BoNT/D isoform or a HN region from a BoNT/D subtype. In another aspect of this embodiment, a BoNT/D HN region comprises amino acids 446-864 of a naturally occurring BoNT/D HN region variant of SEQ ID NO: 4, such as, e.g., amino acids 446-864 of a BoNT/D isoform of SEQ ID NO: 4 or amino acids 446-864 of a BoNT/D subtype of SEQ ID NO: 4. In still another aspect of this embodiment, a BoNT/D HN region comprises a non-naturally occurring BoNT/D HN region variant, such as, e.g., a conservative BoNT/D HN region variant, a non-conservative BoNT/D HN region variant, a BoNT/D chimeric HN region, an active BoNT/D HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/D HN region comprises amino acids 446-864 of a non-naturally occurring BoNT/D HN region variant of SEQ ID NO: 4, such as, e.g., amino acids 446-864 of a conservative BoNT/D HN region variant of SEQ ID NO: 4, amino acids 446-864 of a non-conservative BoNT/D HN region variant of SEQ ID NO: 4, amino acids 446-864 of an active BoNT/D HN region fragment of SEQ ID NO: 4, or any combination thereof.
In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at least 75% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at least 80% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at least 85% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at least 90% amino acid identity with amino acids 446-864 of SEQ ID NO: 4 or at least 95% amino acid identity with amino acids 446-864 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at most 75% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at most 80% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at most 85% amino acid identity with amino acids 446-864 of SEQ ID NO: 4, at most 90% amino acid identity with amino acids 446-864 of SEQ ID NO: 4 or at most 95% amino acid identity with amino acids 446-864 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 446-864 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 446-864 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 446-864 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 446-864 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 446-864 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 446-864 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 446-864 of SEQ ID NO: 4.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/E HN region. In an aspect of this embodiment, a BoNT/E HN region comprises amino acids 423-847 of SEQ ID NO: 5. In another aspect of this embodiment, a BoNT/E HN region comprises a naturally occurring BoNT/E HN region variant, such as, e.g., a HN region from a BoNT/E isoform or a HN region from a BoNT/E subtype. In another aspect of this embodiment, a BoNT/E HN region comprises amino acids 423-847 of a naturally occurring BoNT/E HN region variant of SEQ ID NO: 5, such as, e.g., amino acids 423-847 of a BoNT/E isoform of SEQ ID NO: 5 or amino acids 423-847 of a BoNT/E subtype of SEQ ID NO: 5. In still another aspect of this embodiment, a BoNT/E HN region comprises a non-naturally occurring BoNT/E HN region variant, such as, e.g., a conservative BoNT/E HN region variant, a non-conservative BoNT/E HN region variant, a BoNT/E chimeric HN region, an active BoNT/E HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/E HN region comprises amino acids 423-847 of a non-naturally occurring BoNT/E HN region variant of SEQ ID NO: 5, such as, e.g., amino acids 423-847 of a conservative BoNT/E HN region variant of SEQ ID NO: 5, amino acids 423-847 of a non-conservative BoNT/E HN region variant of SEQ ID NO: 5, amino acids 423-847 of an active BoNT/E HN region fragment of SEQ ID NO: 5, or any combination thereof.
In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at least 75% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at least 80% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at least 85% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at least 90% amino acid identity with amino acids 423-847 of SEQ ID NO: 5 or at least 95% amino acid identity with amino acids 423-847 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at most 75% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at most 80% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at most 85% amino acid identity with amino acids 423-847 of SEQ ID NO: 5, at most 90% amino acid identity with amino acids 423-847 of SEQ ID NO: 5 or at most 95% amino acid identity with amino acids 423-847 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 423-847 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 423-847 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 423-847 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 423-847 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 423-847 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 423-847 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 423-847 of SEQ ID NO: 5.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/F HN region. In an aspect of this embodiment, a BoNT/F HN region comprises amino acids 440-866 of SEQ ID NO: 6. In another aspect of this embodiment, a BoNT/F HN region comprises a naturally occurring BoNT/F HN region variant, such as, e.g., a HN region from a BoNT/F isoform or a HN region from a BoNT/F subtype. In another aspect of this embodiment, a BoNT/F HN region comprises amino acids 440-866 of a naturally occurring BoNT/F HN region variant of SEQ ID NO: 6, such as, e.g., amino acids 440-866 of a BoNT/F isoform of SEQ ID NO: 6 or amino acids 440-866 of a BoNT/F subtype of SEQ ID NO: 6. In still another aspect of this embodiment, a BoNT/F HN region comprises a non-naturally occurring BoNT/F HN region variant, such as, e.g., a conservative BoNT/F HN region variant, a non-conservative BoNT/F HN region variant, a BoNT/F chimeric HN region, an active BoNT/F HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/F HN region comprises amino acids 440-866 of a non-naturally occurring BoNT/F HN region variant of SEQ ID NO: 6, such as, e.g., amino acids 440-866 of a conservative BoNT/F HN region variant of SEQ ID NO: 6, amino acids 440-866 of a non-conservative BoNT/F HN region variant of SEQ ID NO: 6, amino acids 440-866 of an active BoNT/F HN region fragment of SEQ ID NO: 6, or any combination thereof.
In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at least 75% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at least 80% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at least 85% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at least 90% amino acid identity with amino acids 440-866 of SEQ ID NO: 6 or at least 95% amino acid identity with amino acids 440-866 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at most 75% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at most 80% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at most 85% amino acid identity with amino acids 440-866 of SEQ ID NO: 6, at most 90% amino acid identity with amino acids 440-866 of SEQ ID NO: 6 or at most 95% amino acid identity with amino acids 440-866 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 440-866 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 440-866 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 440-866 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 440-866 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 440-866 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 440-866 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 440-866 of SEQ ID NO: 6.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/G HN region. In an aspect of this embodiment, a BoNT/G HN region comprises amino acids 447-865 of SEQ ID NO: 7. In another aspect of this embodiment, a BoNT/G HN region comprises a naturally occurring BoNT/G HN region variant, such as, e.g., a HN region from a BoNT/G isoform or a HN region from a BoNT/G subtype. In another aspect of this embodiment, a BoNT/G HN region comprises amino acids 447-865 of a naturally occurring BoNT/G HN region variant of SEQ ID NO: 7, such as, e.g., amino acids 447-865 of a BoNT/G isoform of SEQ ID NO: 7 or amino acids 447-865 of a BoNT/G subtype of SEQ ID NO: 7. In still another aspect of this embodiment, a BoNT/G HN region comprises a non-naturally occurring BoNT/G HN region variant, such as, e.g., a conservative BoNT/G HN region variant, a non-conservative BoNT/G HN region variant, a BoNT/G chimeric HN region, an active BoNT/G HN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/G HN region comprises amino acids 447-865 of a non-naturally occurring BoNT/G HN region variant of SEQ ID NO: 7, such as, e.g., amino acids 447-865 of a conservative BoNT/G HN region variant of SEQ ID NO: 7, amino acids 447-865 of a non-conservative BoNT/G HN region variant of SEQ ID NO: 7, amino acids 447-865 of an active BoNT/G HN region fragment of SEQ ID NO: 7, or any combination thereof.
In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at least 75% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at least 80% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at least 85% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at least 90% amino acid identity with amino acids 447-865 of SEQ ID NO: 7 or at least 95% amino acid identity with amino acids 447-865 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at most 75% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at most 80% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at most 85% amino acid identity with amino acids 447-865 of SEQ ID NO: 7, at most 90% amino acid identity with amino acids 447-865 of SEQ ID NO: 7 or at most 95% amino acid identity with amino acids 447-865 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 447-865 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 447-865 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 447-865 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 447-865 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 447-865 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 447-865 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 447-865 of SEQ ID NO: 7.
In another embodiment, a Clostridial toxin translocation domain comprises a TeNT HN region. In an aspect of this embodiment, a TeNT HN region comprises amino acids 458-881 of SEQ ID NO: 8. In another aspect of this embodiment, a TeNT HN region comprises a naturally occurring TeNT HN region variant, such as, e.g., a HN region from a TeNT isoform or a HN region from a TeNT subtype. In another aspect of this embodiment, a TeNT HN region comprises amino acids 458-881 of a naturally occurring TeNT HN region variant of SEQ ID NO: 8, such as, e.g., amino acids 458-881 of a TeNT isoform of SEQ ID NO: 8 or amino acids 458-881 of a TeNT subtype of SEQ ID NO: 8. In still another aspect of this embodiment, a TeNT HN region comprises a non-naturally occurring TeNT HN region variant, such as, e.g., a conservative TeNT HN region variant, a non-conservative TeNT HN region variant, a TeNT chimeric HN region, an active TeNT HN region fragment, or any combination thereof. In still another aspect of this embodiment, a TeNT HN region comprises amino acids 458-881 of a non-naturally occurring TeNT HN region variant of SEQ ID NO: 8, such as, e.g., amino acids 458-881 of a conservative TeNT HN region variant of SEQ ID NO: 8, amino acids 458-881 of a non-conservative TeNT HN region variant of SEQ ID NO: 8, amino acids 458-881 of an active TeNT HN region fragment of SEQ ID NO: 8, or any combination thereof.
In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at least 75% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at least 80% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at least 85% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at least 90% amino acid identity with amino acids 458-881 of SEQ ID NO: 8 or at least 95% amino acid identity with amino acids 458-881 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at most 75% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at most 80% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at most 85% amino acid identity with amino acids 458-881 of SEQ ID NO: 8, at most 90% amino acid identity with amino acids 458-881 of SEQ ID NO: 8 or at most 95% amino acid identity with amino acids 458-881 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid substitutions relative to amino acids 458-881 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid deletions relative to amino acids 458-881 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 non-contiguous amino acid additions relative to amino acids 458-881 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid substitutions relative to amino acids 458-881 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid deletions relative to amino acids 458-881 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 458-881 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100 or 200 contiguous amino acid additions relative to amino acids 458-881 of SEQ ID NO: 8.
Aspects of the present invention provide, in part, a translocation facilitating domain. As used herein, the term “translocation facilitating domain” means any polypeptide that can further facilitate the translocation step of the intoxication process that mediates Clostridial toxin light chain translocation. Thus, a translocation facilitating domain assists the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane and encompasses the movement of a Clostridial toxin light chain through the membrane of an intracellular vesicle into the cytoplasm of a cell. A non-limiting example of a translocation facilitating domain is a Clostridial toxin translocation facilitating domain, such as, e.g., a Clostridial toxin HCN region such as, e.g., a BoNT/A HCN region, a BoNT/B HCN region, a BoNT/C1 HCN region, a BoNT/D HCN region, a BoNT/E HCN region, a BoNT/F HCN region, a BoNT/G HCN region, and a TeNT HCN region. Another non-limiting example of a translocation facilitating domain is a viral fusogenic peptide domain found in an enveloped virus, such as, e.g., an influenzavirus, an alphavirus, a vesiculovirus, a respirovirus, a morbillivirus, an avulavirus, a henipavirus, a metapneumovirus and a foamy virus.
Thus, in an embodiment, a translocation facilitating domain facilitates the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane. In aspects of this embodiment, a translocation facilitating domain facilitates the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane by increasing the amount of Clostridial toxin light chain in the cytoplasm by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%. In other aspects of this embodiment, a translocation facilitating domain facilitates the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane by increasing the amount of Clostridial toxin light chain in the cytoplasm by, e.g., at least two-fold, at least three-fold, at least four-fold, at least five-fold, at least ten-fold or at least twenty-fold. In yet other aspects of this embodiment, a translocation facilitating domain facilitates the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane by increasing the amount of Clostridial toxin light chain in the cytoplasm by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%. In other aspects of this embodiment, a translocation facilitating domain facilitates the Clostridial toxin translocation domain in the movement of a Clostridial toxin light chain across a membrane by increasing the amount of Clostridial toxin light chain in the cytoplasm by, e.g., at most two-fold, at most three-fold, at most four-fold, at most five-fold, at most ten-fold or at most twenty-fold.
A Clostridial toxin “translocation facilitating domain includes, without limitation, naturally occurring Clostridial toxin HCN region variants, such as, e.g., Clostridial toxin HCN region isoforms and Clostridial toxin HCN region subtypes; non-naturally occurring Clostridial toxin HCN region variants, such as, e.g., conservative Clostridial toxin HCN region variants, non-conservative Clostridial toxin HCN region variants, Clostridial toxin HCN region chimerics, active Clostridial toxin HCN region fragments thereof, or any combination thereof.
As used herein, the term “Clostridial toxin HCN region variant,” whether naturally-occurring or non-naturally-occurring, means a Clostridial toxin HCN region that has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 1) and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all Clostridial toxin HCN region variants disclosed in the present specification are capable of further facilitating the translocation step of the intoxication process that mediates Clostridial toxin light chain translocation. As non-limiting examples, a BoNT/A HCN region variant comprising amino acids 874-1110 of SEQ ID NO: 1 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 874-1110 of SEQ ID NO: 1; a BoNT/B HCN region variant comprising amino acids 861-1097 of SEQ ID NO: 2 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 861-1097 of SEQ ID NO: 2; a BoNT/C1 HCN region variant comprising amino acids 869-1111 of SEQ ID NO: 3 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 869-1111 of SEQ ID NO: 3; a BoNT/D HCN region variant comprising amino acids 865-1098 of SEQ ID NO: 4 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 865-1098 of SEQ ID NO: 4; a BoNT/E HCN region variant comprising amino acids 848-1085 of SEQ ID NO: 5 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 848-1085 of SEQ ID NO: 5; a BoNT/F HCN region variant comprising amino acids 867-1105 of SEQ ID NO: 6 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 867-1105 of SEQ ID NO: 6; a BoNT/G HCN region variant comprising amino acids 866-1105 of SEQ ID NO: 7 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 866-1105 of SEQ ID NO: 7; and a TeNT HCN region variant comprising amino acids 882-1127 of SEQ ID NO: 8 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 882-1127 of SEQ ID NO: 8.
It is recognized by those of skill in the art that within each serotype of Clostridial toxin there can be naturally occurring Clostridial toxin HCN region variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, there are presently four BoNT/A subtypes, BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4, with specific HCN region subtypes showing approximately 87% amino acid identity when compared to another BoNT/A HCN region subtype. As used herein, the term “naturally occurring Clostridial toxin HCN region variant” means any Clostridial toxin HCN region produced by a naturally-occurring process, including, without limitation, Clostridial toxin HCN region isoforms produced from alternatively-spliced transcripts, Clostridial toxin HCN region isoforms produced by spontaneous mutation and Clostridial toxin HCN region subtypes. A naturally occurring Clostridial toxin HCN region variant can function in substantially the same manner as the reference Clostridial toxin HCN region on which the naturally occurring Clostridial toxin HCN region variant is based, and can be substituted for the reference Clostridial toxin HCN region in any aspect of the present invention. A naturally occurring Clostridial toxin HCN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids or 50 or more amino acids from the reference Clostridial toxin HCN region on which the naturally occurring Clostridial toxin HCN region variant is based. A naturally occurring Clostridial toxin HCN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HCN region on which the naturally occurring Clostridial toxin HCN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HCN region on which the naturally occurring Clostridial toxin HCN region variant is based.
A non-limiting examples of a naturally occurring Clostridial toxin HCN region variant is a Clostridial toxin HCN region isoform such as, e.g., a BoNT/A HCN region isoform, a BoNT/B HCN region isoform, a BoNT/C1 HCN region isoform, a BoNT/D HCN region isoform, a BoNT/E HCN region isoform, a BoNT/F HCN region isoform, a BoNT/G HCN region isoform, and a TeNT HCN region isoform. A Clostridial toxin HCN region isoform can function in substantially the same manner as the reference Clostridial toxin HCN region on which the Clostridial toxin HCN region isoform is based, and can be substituted for the reference Clostridial toxin HCN region in any aspect of the present invention.
Another non-limiting examples of a naturally occurring Clostridial toxin HCN region variant is a Clostridial toxin HCN region subtype such as, e.g., a HCN region from subtype BoNT/A1, BoNT/A2, BoNT/A3 and BoNT/A4; a HCN region from subtype BoNT/B1, BoNT/B2, BoNT/B bivalent and BoNT/B nonproteolytic; a HCN region from subtype BoNT/C1-1 and BoNT/C1-2; a HCN region from subtype BoNT/E1, BoNT/E2 and BoNT/E3; and a HCN region from subtype BoNT/F1, BoNT/F2, BoNT/F3 and BoNT/F4. A Clostridial toxin HCN region subtype can function in substantially the same manner as the reference Clostridial toxin HCN region on which the Clostridial toxin HCN region subtype is based, and can be substituted for the reference Clostridial toxin HCN region in any aspect of the present invention.
As used herein, the term “non-naturally occurring Clostridial toxin HCN region variant” means any Clostridial toxin HCN region produced with the aid of human manipulation, including, without limitation, Clostridial toxin HCN regions produced by genetic engineering using random mutagenesis or rational design and Clostridial toxin HCN regions produced by chemical synthesis. Non-limiting examples of non-naturally occurring Clostridial toxin HCN region variants include, e.g., conservative Clostridial toxin HCN region variants, non-conservative Clostridial toxin HCN region variants, Clostridial toxin HCN region chimeric variants and active Clostridial toxin HCN region fragments.
As used herein, the term “conservative Clostridial toxin HCN region variant” means a Clostridial toxin HCN region that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference Clostridial toxin HCN region sequence (Table 1). Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative Clostridial toxin HCN region variant can function in substantially the same manner as the reference Clostridial toxin HCN region on which the conservative Clostridial toxin HCN region variant is based, and can be substituted for the reference Clostridial toxin HCN region in any aspect of the present invention. A conservative Clostridial toxin HCN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial toxin HCN region on which the conservative Clostridial toxin HCN region variant is based. A conservative Clostridial toxin HCN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HCN region on which the conservative Clostridial toxin HCN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HCN region on which the conservative Clostridial toxin HCN region variant is based. Non-limiting examples of a conservative Clostridial toxin HCN region variant include, e.g., conservative BoNT/A HCN region variants, conservative BoNT/B HCN region variants, conservative BoNT/C1 HCN region variants, conservative BoNT/D HCN region variants, conservative BoNT/E HCN region variants, conservative BoNT/F HCN region variants, conservative BoNT/G HCN region variants, and conservative TeNT HCN region variants.
As used herein, the term “non-conservative Clostridial toxin HCN region variant” means a Clostridial toxin HCN region in which 1) at least one amino acid is deleted from the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based; 2) at least one amino acid added to the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference Clostridial toxin HCN region sequence (Table 1). A non-conservative Clostridial toxin HCN region variant can function in substantially the same manner as the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based, and can be substituted for the reference Clostridial toxin HCN region in any aspect of the present invention. A non-conservative Clostridial toxin HCN region variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids from the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based. A non-conservative Clostridial toxin HCN region variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids to the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based. A non-conservative Clostridial toxin HCN region variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based. A non-conservative Clostridial toxin HCN region variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial toxin HCN region on which the non-conservative Clostridial toxin HCN region variant is based. Non-limiting examples of a non-conservative Clostridial toxin HCN region variant include, e.g., non-conservative BoNT/A HCN region variants, non-conservative BoNT/B HCN region variants, non-conservative BoNT/C1 HCN region variants, non-conservative BoNT/D HCN region variants, non-conservative BoNT/E HCN region variants, non-conservative BoNT/F HCN region variants, non-conservative BoNT/G HCN region variants, and non-conservative TeNT HCN region variants.
As used herein, the term “Clostridial toxin HCN region chimeric” means a polypeptide comprising at least a portion of a Clostridial toxin HCN region and at least a portion of at least one other polypeptide to form a toxin HCN region with at least one property different from the reference Clostridial toxin HCN regions of Table 1, with the proviso that this Clostridial toxin HCN region chimeric is still capable of further facilitating the translocation step of the intoxication process where the LC is released from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
As used herein, the term “active Clostridial toxin HCN region fragment” means any of a variety of Clostridial toxin fragments comprising the HCN region can be useful in aspects of the present invention with the proviso that these active fragments can further facilitate the translocation step of the intoxication process where the LC is released from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate. The HCN regions from the heavy chains of Clostridial toxins are approximately 230-250 amino acids in length and comprise a translocation domain (Table 1). Additionally, while a specific amino acid positions have been identified to delineate the boundaries of the Clostridial toxin HCN region (Table 1), it is well known in the art that the functional boundaries are not definitive. For example, amino-terminus of the HCN domain for all naturally-occurring Clostridial toxins is the HN domain (translocation domain). In examining the structure for BoNT/A, a random coil linker region forms a boundary between the HN and HCN domains (see FIG. 7A). The BoNT/A HN domain appears to end with an α-helix comprising amino acids N859 to I873. Following the α-helix there is a random coil (I873 to I878) that leads into the HCN domain where a β-sheet begins at position I878. The above residues define boundaries at the beginning or end of defined secondary structures and do not imply that there are not significant interactions (i.e., hydrophobic, H-bond, etc.) between residues in the random coil region and one or both of the domains that it links together. Thus, minimally an amino acid that defines the amino-terminal boundary of the BoNT/A HCN domain comprises can be any amino acid present in the amino acid region Y869 to L879. Similar analysis indicates that minimally, the amino acid that defines the amino-terminal boundary of the BoNT/B HCN domain can be any amino acid present in the amino acid region Y856 to L866; the amino acid that defines the amino-terminal boundary of the BoNT/C1 HCN domain can be any amino acid present in the amino acid region Y864 to L874; the amino acid that defines the amino-terminal boundary of the BoNT/D HCN domain can be any amino acid present in the amino acid region Y860 to L870; the amino acid that defines the amino-terminal boundary of the BoNT/E HCN domain can be any amino acid present in the amino acid region F843 to L853; the amino acid that defines the amino-terminal boundary of the BoNT/F HCN domain can be any amino acid present in the amino acid region L862 to L872; the amino acid that defines the amino-terminal boundary of the BoNT/G HCN domain can be any amino acid present in the amino acid region Y861 to L871; and the amino acid that defines the amino-terminal boundary of the TeNT HCN domain can be any amino acid present in the amino acid region I877 to L887.
Similarly, the carboxyl-terminal portion of the HCN domain (i.e., the fusion point between the HCN and HCC domains) all naturally-occurring Clostridial toxins comprises a range of amino acids. In defining the boundary of the BoNT/A HCN domain as the beginning or the end of ordered secondary structure, the HCN domain could end at Q1091 of an α-helix and the HCC domain could begin at K1109 of a β-strand (see FIG. 7B). The intervening amino acid sequence between these two domains comprises a longer random coil but, this does not imply that the random coil is not structurally important. In fact, this random coil has a great deal of interaction with both the HCN and HCC domains (i.e., hydrophobic and H-bonding). Thus, minimally an amino acid that defines the carboxyl-terminal boundary of the BoNT/A HCN domain comprises can be any amino acid present in the amino acid region D1089 to Y1111. Similar analysis indicates that minimally, the amino acid that defines the carboxyl-terminal boundary of the BoNT/B HCN domain can be any amino acid present in the amino acid region K1076 to Y1098; the amino acid that defines the carboxyl-terminal boundary of the BoNT/C1 HCN domain can be any amino acid present in the amino acid region N1090 to Y1112; the amino acid that defines the carboxyl-terminal boundary of the BoNT/D HCN domain can be any amino acid present in the amino acid region E1077 to Y1099; the amino acid that defines the carboxyl-terminal boundary of the BoNT/E HCN domain can be any amino acid present in the amino acid region S1064 to Y1086; the amino acid that defines the carboxyl-terminal boundary of the BoNT/F HCN domain can be any amino acid present in the amino acid region S1084 to Y1106; the amino acid that defines the carboxyl-terminal boundary of the BoNT/G HCN domain can be any amino acid present in the amino acid region W1084 to Y1106; and the amino acid that defines the carboxyl-terminal boundary of the TeNT HCN domain can be any amino acid present in the amino acid region T1106 to Y1128.
Thus, aspects of this embodiment can include Clostridial toxin HCN regions comprising a translocation facilitating domain having a length of, e.g., at least 200 amino acids, at least 225 amino acids, at least 250 amino acids and at least 275 amino acids. Other aspects of this embodiment can include Clostridial toxin HCN regions comprising translocation facilitating domain having a length of, e.g., at most 200 amino acids, at most 225 amino acids, at most 250 amino acids and at most 275 amino acids.
Any of a variety of sequence alignment methods can be used to determine percent identity of naturally-occurring Clostridial toxin HCN region variants and non-naturally-occurring Clostridial toxin HCN region variants, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises a Clostridial toxin translocation domain. In an aspect of this embodiment, a Clostridial toxin translocation domain comprises a naturally occurring Clostridial toxin HCN region variant, such as, e.g., a Clostridial toxin HCN region isoform or a Clostridial toxin HCN region subtype. In another aspect of this embodiment, a Clostridial toxin translocation domain comprises a non-naturally occurring Clostridial toxin HCN region variant, such as, e.g., a conservative Clostridial toxin HCN region variant, a non-conservative Clostridial toxin HCN region variant, a Clostridial toxin chimeric HCN region, an active Clostridial toxin HCN region fragment, or any combination thereof.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/A HCN region. In an aspect of this embodiment, a BoNT/A HCN region comprises amino acids 874-1110 of SEQ ID NO: 1. In another aspect of this embodiment, a BoNT/A HCN region comprises a naturally occurring BoNT/A HCN region variant, such as, e.g., a HCN region from a BoNT/A isoform or a HCN region from a BoNT/A subtype. In another aspect of this embodiment, a BoNT/A HCN region comprises amino acids 874-1110 of a naturally occurring BoNT/A HCN region variant of SEQ ID NO: 1, such as, e.g., amino acids 874-1110 of a BoNT/A isoform of SEQ ID NO: 1 or amino acids 874-1110 of a BoNT/A subtype of SEQ ID NO: 1. In still another aspect of this embodiment, a BoNT/A HCN region comprises a non-naturally occurring BoNT/A HCN region variant, such as, e.g., a conservative BoNT/A HCN region variant, a non-conservative BoNT/A HCN region variant, a BoNT/A chimeric HCN region, an active BoNT/A HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/A HCN region comprises amino acids 874-1110 of a non-naturally occurring BoNT/A HCN region variant of SEQ ID NO: 1, such as, e.g., amino acids 874-1110 of a conservative BoNT/A HCN region variant of SEQ ID NO: 1, amino acids 874-1110 of a non-conservative BoNT/A HCN region variant of SEQ ID NO: 1, amino acids 874-1110 of an active BoNT/A HCN region fragment of SEQ ID NO: 1, or any combination thereof.
In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at least 75% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at least 80% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at least 85% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at least 90% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1 or at least 95% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at most 75% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at most 80% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at most 85% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1, at most 90% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1 or at most 95% amino acid identity with amino acids 874-1110 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 874-1110 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 874-1110 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 874-1110 of SEQ ID NO: 1.
In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 874-1110 of SEQ ID NO: 1. In yet other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 874-1110 of SEQ ID NO: 1. In still other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 874-1110 of SEQ ID NO: 1. In other aspects of this embodiment, a BoNT/A HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 874-1110 of SEQ ID NO: 1.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/B HCN region. In an aspect of this embodiment, a BoNT/B HCN region comprises amino acids 861-1097 of SEQ ID NO: 2. In another aspect of this embodiment, a BoNT/B HCN region comprises a naturally occurring BoNT/B HCN region variant, such as, e.g., a HCN region from a BoNT/B isoform or a HCN region from a BoNT/B subtype. In another aspect of this embodiment, a BoNT/B HCN region comprises amino acids 861-1097 of a naturally occurring BoNT/B HCN region variant of SEQ ID NO: 2, such as, e.g., amino acids 861-1097 of a BoNT/B isoform of SEQ ID NO: 2 or amino acids 861-1097 of a BoNT/B subtype of SEQ ID NO: 2. In still another aspect of this embodiment, a BoNT/B HCN region comprises a non-naturally occurring BoNT/B HCN region variant, such as, e.g., a conservative BoNT/B HCN region variant, a non-conservative BoNT/B HCN region variant, a BoNT/B chimeric HCN region, an active BoNT/B HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/B HCN region comprises amino acids 861-1097 of a non-naturally occurring BoNT/B HCN region variant of SEQ ID NO: 2, such as, e.g., amino acids 861-1097 of a conservative BoNT/B HCN region variant of SEQ ID NO: 2, amino acids 861-1097 of a non-conservative BoNT/B HCN region variant of SEQ ID NO: 2, amino acids 861-1097 of an active BoNT/B HCN region fragment of SEQ ID NO: 2, or any combination thereof.
In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at least 75% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at least 80% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at least 85% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at least 90% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2 or at least 95% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at most 75% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at most 80% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at most 85% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2, at most 90% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2 or at most 95% amino acid identity with amino acids 861-1097 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 861-1097 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 861-1097 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 861-1097 of SEQ ID NO: 2.
In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 861-1097 of SEQ ID NO: 2. In yet other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 861-1097 of SEQ ID NO: 2. In still other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 861-1097 of SEQ ID NO: 2. In other aspects of this embodiment, a BoNT/B HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 861-1097 of SEQ ID NO: 2.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/C1 HCN region. In an aspect of this embodiment, a BoNT/C1 HCN region comprises amino acids 869-1111 of SEQ ID NO: 3. In another aspect of this embodiment, a BoNT/C1 HCN region comprises a naturally occurring BoNT/C1 HCN region variant, such as, e.g., a HCN region from a BoNT/C1 isoform or a HCN region from a BoNT/C1 subtype. In another aspect of this embodiment, a BoNT/C1 HCN region comprises amino acids 869-1111 of a naturally occurring BoNT/C1 HCN region variant of SEQ ID NO: 3, such as, e.g., amino acids 869-1111 of a BoNT/C1 isoform of SEQ ID NO: 3 or amino acids 869-1111 of a BoNT/C1 subtype of SEQ ID NO: 3. In still another aspect of this embodiment, a BoNT/C1 HCN region comprises a non-naturally occurring BoNT/C1 HCN region variant, such as, e.g., a conservative BoNT/C1 HCN region variant, a non-conservative BoNT/C1 HCN region variant, a BoNT/C1 chimeric HCN region, an active BoNT/C1 HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/C1 HCN region comprises amino acids 869-1111 of a non-naturally occurring BoNT/C1 HCN region variant of SEQ ID NO: 3, such as, e.g., amino acids 869-1111 of a conservative BoNT/C1 HCN region variant of SEQ ID NO: 3, amino acids 869-1111 of a non-conservative BoNT/C1 HCN region variant of SEQ ID NO: 3, amino acids 869-1111 of an active BoNT/C1 HCN region fragment of SEQ ID NO: 3, or any combination thereof.
In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at least 75% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at least 80% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at least 85% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at least 90% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3 or at least 95% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at most 75% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at most 80% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at most 85% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3, at most 90% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3 or at most 95% amino acid identity with amino acids 869-1111 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 869-1111 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 869-1111 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 869-1111 of SEQ ID NO: 3.
In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 869-1111 of SEQ ID NO: 3. In yet other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 869-1111 of SEQ ID NO: 3. In still other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 869-1111 of SEQ ID NO: 3. In other aspects of this embodiment, a BoNT/C1 HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 869-1111 of SEQ ID NO: 3.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/D HCN region. In an aspect of this embodiment, a BoNT/D HCN region comprises amino acids 865-1098 of SEQ ID NO: 4. In another aspect of this embodiment, a BoNT/D HCN region comprises a naturally occurring BoNT/D HCN region variant, such as, e.g., a HCN region from a BoNT/D isoform or a HCN region from a BoNT/D subtype. In another aspect of this embodiment, a BoNT/D HCN region comprises amino acids 865-1098 of a naturally occurring BoNT/D HCN region variant of SEQ ID NO: 4, such as, e.g., amino acids 865-1098 of a BoNT/D isoform of SEQ ID NO: 4 or amino acids 865-1098 of a BoNT/D subtype of SEQ ID NO: 4. In still another aspect of this embodiment, a BoNT/D HCN region comprises a non-naturally occurring BoNT/D HCN region variant, such as, e.g., a conservative BoNT/D HCN region variant, a non-conservative BoNT/D HCN region variant, a BoNT/D chimeric HCN region, an active BoNT/D HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/D HCN region comprises amino acids 865-1098 of a non-naturally occurring BoNT/D HCN region variant of SEQ ID NO: 4, such as, e.g., amino acids 865-1098 of a conservative BoNT/D HCN region variant of SEQ ID NO: 4, amino acids 865-1098 of a non-conservative BoNT/D HCN region variant of SEQ ID NO: 4, amino acids 865-1098 of an active BoNT/D HCN region fragment of SEQ ID NO: 4, or any combination thereof.
In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at least 75% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at least 80% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at least 85% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at least 90% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4 or at least 95% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at most 75% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at most 80% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at most 85% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4, at most 90% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4 or at most 95% amino acid identity with amino acids 865-1098 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 865-1098 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 865-1098 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 865-1098 of SEQ ID NO: 4.
In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 865-1098 of SEQ ID NO: 4. In yet other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 865-1098 of SEQ ID NO: 4. In still other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 865-1098 of SEQ ID NO: 4. In other aspects of this embodiment, a BoNT/D HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 865-1098 of SEQ ID NO: 4.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/E HCN region. In an aspect of this embodiment, a BoNT/E HCN region comprises amino acids 848-1085 of SEQ ID NO: 5. In another aspect of this embodiment, a BoNT/E HCN region comprises a naturally occurring BoNT/E HCN region variant, such as, e.g., a HCN region from a BoNT/E isoform or a HCN region from a BoNT/E subtype. In another aspect of this embodiment, a BoNT/E HCN region comprises amino acids 848-1085 of a naturally occurring BoNT/E HCN region variant of SEQ ID NO: 5, such as, e.g., amino acids 848-1085 of a BoNT/E isoform of SEQ ID NO: 5 or amino acids 848-1085 of a BoNT/E subtype of SEQ ID NO: 5. In still another aspect of this embodiment, a BoNT/E HCN region comprises a non-naturally occurring BoNT/E HCN region variant, such as, e.g., a conservative BoNT/E HCN region variant, a non-conservative BoNT/E HCN region variant, a BoNT/E chimeric HCN region, an active BoNT/E HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/E HCN region comprises amino acids 848-1085 of a non-naturally occurring BoNT/E HCN region variant of SEQ ID NO: 5, such as, e.g., amino acids 848-1085 of a conservative BoNT/E HCN region variant of SEQ ID NO: 5, amino acids 848-1085 of a non-conservative BoNT/E HCN region variant of SEQ ID NO: 5, amino acids 848-1085 of an active BoNT/E HCN region fragment of SEQ ID NO: 5, or any combination thereof.
In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at least 75% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at least 80% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at least 85% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at least 90% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5 or at least 95% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at most 75% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at most 80% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at most 85% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5, at most 90% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5 or at most 95% amino acid identity with amino acids 848-1085 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 848-1085 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 848-1085 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 848-1085 of SEQ ID NO: 5.
In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 848-1085 of SEQ ID NO: 5. In yet other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 848-1085 of SEQ ID NO: 5. In still other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 848-1085 of SEQ ID NO: 5. In other aspects of this embodiment, a BoNT/E HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 848-1085 of SEQ ID NO: 5.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/F HCN region. In an aspect of this embodiment, a BoNT/F HCN region comprises amino acids 867-1105 of SEQ ID NO: 6. In another aspect of this embodiment, a BoNT/F HCN region comprises a naturally occurring BoNT/F HCN region variant, such as, e.g., a HCN region from a BoNT/F isoform or a HCN region from a BoNT/F subtype. In another aspect of this embodiment, a BoNT/F HCN region comprises amino acids 867-1105 of a naturally occurring BoNT/F HCN region variant of SEQ ID NO: 6, such as, e.g., amino acids 867-1105 of a BoNT/F isoform of SEQ ID NO: 6 or amino acids 867-1105 of a BoNT/F subtype of SEQ ID NO: 6. In still another aspect of this embodiment, a BoNT/F HCN region comprises a non-naturally occurring BoNT/F HCN region variant, such as, e.g., a conservative BoNT/F HCN region variant, a non-conservative BoNT/F HCN region variant, a BoNT/F chimeric HCN region, an active BoNT/F HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/F HCN region comprises amino acids 867-1105 of a non-naturally occurring BoNT/F HCN region variant of SEQ ID NO: 6, such as, e.g., amino acids 867-1105 of a conservative BoNT/F HCN region variant of SEQ ID NO: 6, amino acids 867-1105 of a non-conservative BoNT/F HCN region variant of SEQ ID NO: 6, amino acids 867-1105 of an active BoNT/F HCN region fragment of SEQ ID NO: 6, or any combination thereof.
In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at least 75% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at least 80% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at least 85% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at least 90% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6 or at least 95% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at most 75% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at most 80% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at most 85% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6, at most 90% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6 or at most 95% amino acid identity with amino acids 867-1105 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 867-1105 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 867-1105 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 867-1105 of SEQ ID NO: 6.
In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 867-1105 of SEQ ID NO: 6. In yet other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 867-1105 of SEQ ID NO: 6. In still other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 867-1105 of SEQ ID NO: 6. In other aspects of this embodiment, a BoNT/F HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 867-1105 of SEQ ID NO: 6.
In another embodiment, a Clostridial toxin translocation domain comprises a BoNT/G HCN region. In an aspect of this embodiment, a BoNT/G HCN region comprises amino acids 866-1105 of SEQ ID NO: 7. In another aspect of this embodiment, a BoNT/G HCN region comprises a naturally occurring BoNT/G HCN region variant, such as, e.g., a HCN region from a BoNT/G isoform or a HCN region from a BoNT/G subtype. In another aspect of this embodiment, a BoNT/G HCN region comprises amino acids 866-1105 of a naturally occurring BoNT/G HCN region variant of SEQ ID NO: 7, such as, e.g., amino acids 866-1105 of a BoNT/G isoform of SEQ ID NO: 7 or amino acids 866-1105 of a BoNT/G subtype of SEQ ID NO: 7. In still another aspect of this embodiment, a BoNT/G HCN region comprises a non-naturally occurring BoNT/G HCN region variant, such as, e.g., a conservative BoNT/G HCN region variant, a non-conservative BoNT/G HCN region variant, a BoNT/G chimeric HCN region, an active BoNT/G HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a BoNT/G HCN region comprises amino acids 866-1105 of a non-naturally occurring BoNT/G HCN region variant of SEQ ID NO: 7, such as, e.g., amino acids 866-1105 of a conservative BoNT/G HCN region variant of SEQ ID NO: 7, amino acids 866-1105 of a non-conservative BoNT/G HCN region variant of SEQ ID NO: 7, amino acids 866-1105 of an active BoNT/G HCN region fragment of SEQ ID NO: 7, or any combination thereof.
In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at least 75% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at least 80% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at least 85% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at least 90% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7 or at least 95% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at most 75% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at most 80% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at most 85% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7, at most 90% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7 or at most 95% amino acid identity with amino acids 866-1105 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 866-1105 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 866-1105 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 866-1105 of SEQ ID NO: 7.
In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 866-1105 of SEQ ID NO: 7. In yet other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 866-1105 of SEQ ID NO: 7. In still other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 866-1105 of SEQ ID NO: 7. In other aspects of this embodiment, a BoNT/G HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 866-1105 of SEQ ID NO: 7.
In another embodiment, a Clostridial toxin translocation domain comprises a TeNT HCN region. In an aspect of this embodiment, a TeNT HCN region comprises amino acids 882-1127 of SEQ ID NO: 8. In another aspect of this embodiment, a TeNT HCN region comprises a naturally occurring TeNT HCN region variant, such as, e.g., a HCN region from a TeNT isoform or a HCN region from a TeNT subtype. In another aspect of this embodiment, a TeNT HCN region comprises amino acids 882-1127 of a naturally occurring TeNT HCN region variant of SEQ ID NO: 8, such as, e.g., amino acids 882-1127 of a TeNT isoform of SEQ ID NO: 8 or amino acids 882-1127 of a TeNT subtype of SEQ ID NO: 8. In still another aspect of this embodiment, a TeNT HCN region comprises a non-naturally occurring TeNT HCN region variant, such as, e.g., a conservative TeNT HCN region variant, a non-conservative TeNT HCN region variant, a TeNT chimeric HCN region, an active TeNT HCN region fragment, or any combination thereof. In still another aspect of this embodiment, a TeNT HCN region comprises amino acids 882-1127 of a non-naturally occurring TeNT HCN region variant of SEQ ID NO: 8, such as, e.g., amino acids 882-1127 of a conservative TeNT HCN region variant of SEQ ID NO: 8, amino acids 882-1127 of a non-conservative TeNT HCN region variant of SEQ ID NO: 8, amino acids 882-1127 of an active TeNT HCN region fragment of SEQ ID NO: 8, or any combination thereof.
In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at least 75% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at least 80% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at least 85% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at least 90% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8 or at least 95% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at most 75% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at most 80% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at most 85% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8, at most 90% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8 or at most 95% amino acid identity with amino acids 882-1127 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50, 100, or 200 non-contiguous amino acid substitutions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid substitutions relative to amino acids 882-1127 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid deletions relative to amino acids 882-1127 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 non-contiguous amino acid additions relative to amino acids 882-1127 of SEQ ID NO: 8.
In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid substitutions relative to amino acids 882-1127 of SEQ ID NO: 8. In yet other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid deletions relative to amino acids 882-1127 of SEQ ID NO: 8. In still other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 882-1127 of SEQ ID NO: 8. In other aspects of this embodiment, a TeNT HCN region comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10, 20, 30, 40, 50 or 100 contiguous amino acid additions relative to amino acids 882-1127 of SEQ ID NO: 8.
The fusion of the membrane of enveloped viruses to a cellular membrane is an essential step in the release of the viral capsule into the cytoplasm of the host cell. This fusion event is mediated by a fusogenic peptide segment present in viral glycoproteins located on the viral membrane and involves either a pH-dependent or pH-independent process, see, e.g., Frederick M. Hughson, Structural Characterization of Viral Fusion Proteins, 5(3) Curr. Biol. 158-274 (1128); Trudy G. Morrison, Structure and Function of a Paramyxovirus Fusion Protein, 1304(1) Biochim. Biophys. Acta. 73-84; David J. Schibli and Winfried Weissenhorn, Class I and Class II Viral Fusion Protein Structures Reveal Similar Principles in Membrane Fusion, 21(6) Mol. Membr. Biol. 361-371 (1137). The fusogenic peptide domain comprises a hydrophobic, glycine-rich peptide of approximately 20-30 amino acids that assist in the insertion of the viral capsule into a cellular membrane. Thus, an enveloped virus fusogenic peptide domain can be useful as a translocation facilitating domain.
An enveloped virus fusogenic peptide domain includes, without limitation, naturally occurring enveloped virus fusogenic peptide domain variants, such as, e.g., enveloped virus fusogenic peptide domain isoforms and enveloped virus fusogenic peptide domain subtypes; non-naturally occurring enveloped virus fusogenic peptide domain variants, such as, e.g., conservative enveloped virus fusogenic peptide domain variants, non-conservative enveloped virus fusogenic peptide domain variants, enveloped virus fusogenic peptide domain chimerics, active enveloped virus fusogenic peptide domain fragments thereof, or any combination thereof.
As used herein, the term “enveloped virus fusogenic peptide domain variant,” whether naturally-occurring or non-naturally-occurring, means an enveloped virus fusogenic peptide domain that has at least one amino acid change from the corresponding region of the disclosed reference sequences and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all Clostridial toxin HCN region variants disclosed in the present specification are capable of further facilitating the translocation step of the intoxication process that mediates Clostridial toxin light chain translocation. As non-limiting examples, an Influenza virus A fusogenic peptide domain variant comprising SEQ ID NO: 87 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 87; a Semliki Forest virus fusogenic peptide domain variant comprising SEQ ID NO: 92 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 92; an Eastern equine encephalitis virus fusogenic peptide domain variant comprising SEQ ID NO: 94 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 94; a Venezuelan equine encephalitis virus fusogenic peptide domain variant comprising SEQ ID NO: 102 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 102; a Vesicular stomatitis virus fusogenic peptide domain variant comprising SEQ ID NO: 119 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 119; a Sendai virus fusogenic peptide domain variant comprising SEQ ID NO: 130 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 130; a Canine distemper virus fusogenic peptide domain variant comprising SEQ ID NO: 137 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 137; a Newcastle disease virus fusogenic peptide domain variant comprising SEQ ID NO: 147 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 147; and a Hendra virus fusogenic peptide domain variant comprising SEQ ID NO: 160 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to SEQ ID NO: 160.
It is recognized by those of skill in the art that for each enveloped virus there can be naturally occurring fusogenic peptide domain variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, at least five naturally-occurring variants of the fusogenic peptide domain present in the Influenza A virus haemagglutinin are known (SEQ ID NO: 87 to SEQ ID NO: 91); at least six naturally-occurring variants of the fusogenic peptide domain present in the Eastern equine encephalitis virus E1 protein are known (SEQ ID NO: 94 to SEQ ID NO: 99); at least eight naturally-occurring variants of the fusogenic peptide domain present in the Venezuelan equine encephalitis virus E1 protein are known (SEQ ID NO: 102 to SEQ ID NO: 109); at least seven naturally-occurring variants of the fusogenic peptide domain present in the Vesicular stomatitis virus (VSV) glycoprotein G are known (SEQ ID NO: 119 to SEQ ID NO: 125); and at least eleven naturally-occurring variants of the fusogenic peptide domain present in the Newcastle disease virus F protein are known (SEQ ID NO: 147 to SEQ ID NO: 157). As used herein, the term “enveloped virus fusogenic peptide domain variant” means any enveloped virus fusogenic peptide domain produced by a naturally-occurring process, including, without limitation, enveloped virus fusogenic peptide domain isoforms produced from alternatively-spliced transcripts, enveloped virus fusogenic peptide domain isoforms produced by spontaneous mutation and enveloped virus fusogenic peptide domain subtypes. A naturally occurring enveloped virus fusogenic peptide domain variant can function in substantially the same manner as the reference enveloped virus fusogenic peptide domain on which the naturally occurring enveloped virus fusogenic peptide domain variant is based, and can be substituted for the reference enveloped virus fusogenic peptide domain in any aspect of the present invention. A naturally occurring enveloped virus fusogenic peptide domain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids or ten or more amino acids from the reference enveloped virus fusogenic peptide domain on which the naturally occurring enveloped virus fusogenic peptide domain is based. A naturally occurring enveloped virus fusogenic peptide domain variant can also substitute at least 2 contiguous amino acids, at least 3 contiguous amino acids, at least 4 contiguous amino acids or at least 5 contiguous amino acids from the reference enveloped virus fusogenic peptide domain on which the naturally occurring enveloped virus fusogenic peptide domain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference enveloped virus fusogenic peptide domain on which the naturally occurring enveloped virus fusogenic peptide domain variant is based.
A non-limiting examples of a naturally occurring enveloped virus fusogenic peptide domain variant is a enveloped virus fusogenic peptide domain isoform such as, e.g., an influenzavirus fusogenic peptide domain isoform, an alphavirus fusogenic peptide domain isoform, a vesiculovirus fusogenic peptide domain isoform, a respirovirus fusogenic peptide domain isoform, a morbillivirus fusogenic peptide domain isoform, an avulavirus fusogenic peptide domain isoform, a henipavirus fusogenic peptide domain isoform, a metapneumovirus fusogenic peptide domain isoform and a foamy virus fusogenic peptide domain isoform. An enveloped virus fusogenic peptide domain isoform can function in substantially the same manner as the reference enveloped virus fusogenic peptide domain on which the enveloped virus fusogenic peptide domain isoform is based, and can be substituted for the reference enveloped virus fusogenic peptide domain in any aspect of the present invention.
A non-limiting examples of a naturally occurring enveloped virus fusogenic peptide domain variant is a enveloped virus fusogenic peptide domain subtype such as, e.g., an influenzavirus fusogenic peptide domain subtype, an alphavirus fusogenic peptide domain subtype, a vesiculovirus fusogenic peptide domain subtype, a respirovirus fusogenic peptide domain subtype, a morbillivirus fusogenic peptide domain subtype, an avulavirus fusogenic peptide domain subtype, a henipavirus fusogenic peptide domain subtype, a metapneumovirus fusogenic peptide domain subtype and a foamy virus fusogenic peptide domain subtype. An enveloped virus fusogenic peptide domain subtype can function in substantially the same manner as the reference enveloped virus fusogenic peptide domain on which the enveloped virus fusogenic peptide domain subtype is based, and can be substituted for the reference enveloped virus fusogenic peptide domain in any aspect of the present invention.
As used herein, the term “non-naturally occurring enveloped virus fusogenic peptide domain variant” means any enveloped virus fusogenic peptide domain produced with the aid of human manipulation, including, without limitation, enveloped virus fusogenic peptide domains produced by genetic engineering using random mutagenesis or rational design and enveloped virus fusogenic peptide domains produced by chemical synthesis. Non-limiting examples of non-naturally occurring enveloped virus fusogenic peptide domain variants include, e.g., conservative enveloped virus fusogenic peptide domain variants, non-conservative enveloped virus fusogenic peptide domain variants, enveloped virus fusogenic peptide domain chimeric variants and active enveloped virus fusogenic peptide domain fragments.
As used herein, the term “conservative enveloped virus fusogenic peptide domain variant” means a enveloped virus fusogenic peptide domain that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference enveloped virus fusogenic peptide domain sequence. Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative enveloped virus fusogenic peptide domain variant can function in substantially the same manner as the reference enveloped virus fusogenic peptide domain on which the conservative enveloped virus fusogenic peptide domain variant is based, and can be substituted for the reference enveloped virus fusogenic peptide domain in any aspect of the present invention. A conservative enveloped virus fusogenic peptide domain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids or ten or more amino acids from the reference enveloped virus fusogenic peptide domain on which the conservative enveloped virus fusogenic peptide domain variant is based. A conservative enveloped virus fusogenic peptide domain variant can also substitute at least 2 contiguous amino acids, at least 3 contiguous amino acids, at least 4 contiguous amino acids or at least 5 contiguous amino acids from the reference enveloped virus fusogenic peptide domain on which the conservative enveloped virus fusogenic peptide domain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference enveloped virus fusogenic peptide domain on which the conservative enveloped virus fusogenic peptide domain variant is based. Non-limiting examples of a conservative enveloped virus fusogenic peptide domain variant include, e.g., conservative influenzavirus fusogenic peptide domain variants, conservative alphavirus fusogenic peptide domain variants, conservative vesiculovirus fusogenic peptide domain variants, conservative respirovirus fusogenic peptide domain variants, conservative morbillivirus fusogenic peptide domain variants, conservative avulavirus fusogenic peptide domain variants, conservative henipavirus fusogenic peptide domain variants, conservative metapneumovirus fusogenic peptide domain variants and conservative foamy virus fusogenic peptide domain variants.
As used herein, the term “non-conservative enveloped virus fusogenic peptide domain variant” means a enveloped virus fusogenic peptide domain in which 1) at least one amino acid is deleted from the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based; 2) at least one amino acid added to the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference enveloped virus fusogenic peptide domain sequence. A non-conservative enveloped virus fusogenic peptide domain variant can function in substantially the same manner as the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based, and can be substituted for the reference enveloped virus fusogenic peptide domain in any aspect of the present invention. A non-conservative enveloped virus fusogenic peptide domain variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids or five or more amino acids from the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based. A non-conservative enveloped virus fusogenic peptide domain variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids or five or more amino acids to the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based. A non-conservative enveloped virus fusogenic peptide domain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids or ten or more amino acids from the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based. A non-conservative enveloped virus fusogenic peptide domain variant can also substitute at least 2 contiguous amino acids, at least 3 contiguous amino acids, at least 4 contiguous amino acids or at least 5 contiguous amino acids from the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference enveloped virus fusogenic peptide domain on which the non-conservative enveloped virus fusogenic peptide domain variant is based. Non-limiting examples of a non-conservative enveloped virus fusogenic peptide domain variant include, e.g., non-conservative influenzavirus fusogenic peptide domain variants, non-conservative alphavirus fusogenic peptide domain variants, non-conservative vesiculovirus fusogenic peptide domain variants, non-conservative respirovirus fusogenic peptide domain variants, non-conservative morbillivirus fusogenic peptide domain variants, non-conservative avulavirus fusogenic peptide domain variants, non-conservative henipavirus fusogenic peptide domain variants, non-conservative metapneumovirus fusogenic peptide domain variants and non-conservative foamy virus fusogenic peptide domain variants.
As used herein, the term “enveloped virus fusogenic peptide domain chimeric” means a polypeptide comprising at least a portion of an enveloped virus fusogenic peptide domain and at least a portion of at least one other polypeptide to form an enveloped virus fusogenic peptide domain with at least one property different from the reference enveloped virus fusogenic peptide domain, with the proviso that this enveloped virus fusogenic peptide domain chimeric is still capable of further facilitating the translocation step of the intoxication process where the LC is released from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
As used herein, the term “active enveloped virus fusogenic peptide domain fragment” means any of a variety of enveloped virus fusogenic peptide domain fragments that can further facilitate the translocation step of the intoxication process where the LC is released from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate. Enveloped virus fusogenic peptide domains are approximately 15-30 amino acids in length. Thus, aspects of this embodiment can include a translocation facilitating domain comprising an active enveloped virus fusogenic peptide domain fragment having a length of, e.g., at least 10 amino acids, at least 15 amino acids, at least 20 amino acids and at least 25 amino acids. Other aspects of this embodiment can include a translocation facilitating domain comprising an active enveloped virus fusogenic peptide domain fragment having a length of, e.g., at most 10 amino acids, at most 15 amino acids, at most 20 amino acids and at most 25 amino acids.
Any of a variety of sequence alignment methods can be used to determine percent identity of naturally-occurring enveloped virus fusogenic peptide domain variants and non-naturally-occurring enveloped virus fusogenic peptide domain variants, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises a Clostridial toxin translocation facilitating domain comprising an enveloped virus fusogenic peptide domain. In an aspect of this embodiment, a Clostridial toxin translocation facilitating domain comprises a naturally occurring enveloped virus fusogenic peptide domain variant, such as, e.g., a enveloped virus fusogenic peptide domain isoform or a enveloped virus fusogenic peptide domain subtype. In another aspect of this embodiment, a Clostridial toxin translocation domain comprises a non-naturally occurring enveloped virus fusogenic peptide domain variant, such as, e.g., a conservative enveloped virus fusogenic peptide domain variant, a non-conservative enveloped virus fusogenic peptide domain variant, a enveloped virus fusogenic peptide domain chimeric, an active enveloped virus fusogenic peptide domain fragment, or any combination thereof.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises an influenzavirus fusogenic peptide domain. In another aspect of this embodiment, an influenzavirus fusogenic peptide domain comprises a naturally occurring influenzavirus fusogenic peptide domain variant, such as, e.g., an influenzavirus fusogenic peptide domain isoform or an influenzavirus fusogenic peptide domain subtype. In another aspect of this embodiment, an influenzavirus fusogenic peptide domain comprises a naturally occurring influenzavirus fusogenic peptide domain variant of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, such as, e.g., an influenzavirus fusogenic peptide domain isoform of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91 or an influenzavirus fusogenic peptide domain subtype of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In still another aspect of this embodiment, an influenzavirus fusogenic peptide domain comprises a non-naturally occurring influenzavirus fusogenic peptide domain variant, such as, e.g., a conservative influenzavirus fusogenic peptide domain variant, a non-conservative influenzavirus fusogenic peptide domain variant, an influenzavirus fusogenic peptide domain chimeric, an active influenzavirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, an influenzavirus fusogenic peptide domain comprises amino acids a non-naturally occurring influenzavirus fusogenic peptide domain variant of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, such as, e.g., a conservative influenzavirus fusogenic peptide domain variant of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, a non-conservative influenzavirus fusogenic peptide domain variant of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, an active influenzavirus fusogenic peptide domain fragment of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, or any combination thereof.
In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at least 75% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at least 80% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at least 85% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at least 90% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91 or at least 95% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In yet other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at most 75% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at most 80% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at most 85% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at most 90% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91 or at most 95% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91.
In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In yet other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In still other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91.
In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In yet other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In still other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91. In other aspects of this embodiment, an influenzavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises an alphavirus fusogenic peptide domain. In another aspect of this embodiment, an alphavirus fusogenic peptide domain comprises a naturally occurring alphavirus fusogenic peptide domain variant, such as, e.g., an alphavirus fusogenic peptide domain isoform or an alphavirus fusogenic peptide domain subtype. In another aspect of this embodiment, an alphavirus fusogenic peptide domain comprises a naturally occurring alphavirus fusogenic peptide domain variant of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, such as, e.g., an alphavirus fusogenic peptide domain isoform of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118 or an alphavirus fusogenic peptide domain subtype of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In still another aspect of this embodiment, an alphavirus fusogenic peptide domain comprises a non-naturally occurring alphavirus fusogenic peptide domain variant, such as, e.g., a conservative alphavirus fusogenic peptide domain variant, a non-conservative alphavirus fusogenic peptide domain variant, an alphavirus fusogenic peptide domain chimeric, an active alphavirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, an alphavirus fusogenic peptide domain comprises amino acids a non-naturally occurring alphavirus fusogenic peptide domain variant of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, such as, e.g., a conservative alphavirus fusogenic peptide domain variant of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, a non-conservative alphavirus fusogenic peptide domain variant of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, an active alphavirus fusogenic peptide domain fragment of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, or any combination thereof.
In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at least 75% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at least 80% amino acid identity with SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91, at least 85% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at least 90% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118 or at least 95% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In yet other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at most 75% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at most 80% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at most 85% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118, at most 90% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118 or at most 95% amino acid identity with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118.
In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In yet other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In still other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118.
In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In yet other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In still other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118. In other aspects of this embodiment, an alphavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 118.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises a vesiculovirus fusogenic peptide domain. In another aspect of this embodiment, a vesiculovirus fusogenic peptide domain comprises a naturally occurring vesiculovirus fusogenic peptide domain variant, such as, e.g., a vesiculovirus fusogenic peptide domain isoform or a vesiculovirus fusogenic peptide domain subtype. In another aspect of this embodiment, a vesiculovirus fusogenic peptide domain comprises a naturally occurring vesiculovirus fusogenic peptide domain variant of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, such as, e.g., a vesiculovirus fusogenic peptide domain isoform of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129 or a vesiculovirus fusogenic peptide domain subtype of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In still another aspect of this embodiment, a vesiculovirus fusogenic peptide domain comprises a non-naturally occurring vesiculovirus fusogenic peptide domain variant, such as, e.g., a conservative vesiculovirus fusogenic peptide domain variant, a non-conservative vesiculovirus fusogenic peptide domain variant, a vesiculovirus fusogenic peptide domain chimeric, an active vesiculovirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, a vesiculovirus fusogenic peptide domain comprises amino acids a non-naturally occurring vesiculovirus fusogenic peptide domain variant of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, such as, e.g., a conservative vesiculovirus fusogenic peptide domain variant of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, a non-conservative vesiculovirus fusogenic peptide domain variant of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, an active vesiculovirus fusogenic peptide domain fragment of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, or any combination thereof.
In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at least 75% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at least 80% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at least 85% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at least 90% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129 or at least 95% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In yet other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at most 75% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at most 80% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at most 85% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129, at most 90% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129 or at most 95% amino acid identity with SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.
In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In yet other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In still other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.
In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In yet other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In still other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129. In other aspects of this embodiment, a vesiculovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises a respirovirus fusogenic peptide domain. In another aspect of this embodiment, a respirovirus fusogenic peptide domain comprises a naturally occurring respirovirus fusogenic peptide domain variant, such as, e.g., a respirovirus fusogenic peptide domain isoform or a respirovirus fusogenic peptide domain subtype. In another aspect of this embodiment, a respirovirus fusogenic peptide domain comprises a naturally occurring respirovirus fusogenic peptide domain variant of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, such as, e.g., a respirovirus fusogenic peptide domain isoform of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136 or a respirovirus fusogenic peptide domain subtype of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In still another aspect of this embodiment, a respirovirus fusogenic peptide domain comprises a non-naturally occurring respirovirus fusogenic peptide domain variant, such as, e.g., a conservative respirovirus fusogenic peptide domain variant, a non-conservative respirovirus fusogenic peptide domain variant, a respirovirus fusogenic peptide domain chimeric, an active respirovirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, a respirovirus fusogenic peptide domain comprises amino acids a non-naturally occurring respirovirus fusogenic peptide domain variant of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, such as, e.g., a conservative respirovirus fusogenic peptide domain variant of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, a non-conservative respirovirus fusogenic peptide domain variant of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, an active respirovirus fusogenic peptide domain fragment of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, or any combination thereof.
In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at least 75% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at least 80% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at least 85% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at least 90% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136 or at least 95% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In yet other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at most 75% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at most 80% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at most 85% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136, at most 90% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136 or at most 95% amino acid identity with SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136.
In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In yet other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In still other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136.
In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In yet other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In still other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136. In other aspects of this embodiment, a respirovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 or SEQ ID NO: 136.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises a morbillivirus fusogenic peptide domain. In another aspect of this embodiment, a morbillivirus fusogenic peptide domain comprises a naturally occurring morbillivirus fusogenic peptide domain variant, such as, e.g., a morbillivirus fusogenic peptide domain isoform or a morbillivirus fusogenic peptide domain subtype. In another aspect of this embodiment, a morbillivirus fusogenic peptide domain comprises a naturally occurring morbillivirus fusogenic peptide domain variant of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, such as, e.g., a morbillivirus fusogenic peptide domain isoform of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146 or a morbillivirus fusogenic peptide domain subtype of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In still another aspect of this embodiment, a morbillivirus fusogenic peptide domain comprises a non-naturally occurring morbillivirus fusogenic peptide domain variant, such as, e.g., a conservative morbillivirus fusogenic peptide domain variant, a non-conservative morbillivirus fusogenic peptide domain variant, a morbillivirus fusogenic peptide domain chimeric, an active morbillivirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, a morbillivirus fusogenic peptide domain comprises amino acids a non-naturally occurring morbillivirus fusogenic peptide domain variant of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, such as, e.g., a conservative morbillivirus fusogenic peptide domain variant of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, a non-conservative morbillivirus fusogenic peptide domain variant of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, an active morbillivirus fusogenic peptide domain fragment of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, or any combination thereof.
In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at least 75% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at least 80% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at least 85% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at least 90% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146 or at least 95% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In yet other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at most 75% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at most 80% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at most 85% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146, at most 90% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146 or at most 95% amino acid identity with SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146.
In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In yet other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In still other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146.
In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In yet other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In still other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146. In other aspects of this embodiment, a morbillivirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 or SEQ ID NO: 146.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises an avulavirus fusogenic peptide domain. In another aspect of this embodiment, an avulavirus fusogenic peptide domain comprises a naturally occurring avulavirus fusogenic peptide domain variant, such as, e.g., an avulavirus fusogenic peptide domain isoform or an avulavirus fusogenic peptide domain subtype. In another aspect of this embodiment, an avulavirus fusogenic peptide domain comprises a naturally occurring avulavirus fusogenic peptide domain variant of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, such as, e.g., an avulavirus fusogenic peptide domain isoform of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159 or an avulavirus fusogenic peptide domain subtype of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In still another aspect of this embodiment, an avulavirus fusogenic peptide domain comprises a non-naturally occurring avulavirus fusogenic peptide domain variant, such as, e.g., a conservative avulavirus fusogenic peptide domain variant, a non-conservative avulavirus fusogenic peptide domain variant, an avulavirus fusogenic peptide domain chimeric, an active avulavirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, an avulavirus fusogenic peptide domain comprises amino acids a non-naturally occurring avulavirus fusogenic peptide domain variant of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, such as, e.g., a conservative avulavirus fusogenic peptide domain variant of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, a non-conservative avulavirus fusogenic peptide domain variant of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, an active avulavirus fusogenic peptide domain fragment of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, or any combination thereof.
In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at least 75% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at least 80% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at least 85% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at least 90% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159 or at least 95% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In yet other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at most 75% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at most 80% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at most 85% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159, at most 90% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159 or at most 95% amino acid identity with SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159.
In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In yet other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In still other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159.
In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In yet other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In still other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159. In other aspects of this embodiment, an avulavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 or SEQ ID NO: 159.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises a henipavirus fusogenic peptide domain. In another aspect of this embodiment, a henipavirus fusogenic peptide domain comprises a naturally occurring henipavirus fusogenic peptide domain variant, such as, e.g., a henipavirus fusogenic peptide domain isoform or a henipavirus fusogenic peptide domain subtype. In another aspect of this embodiment, a henipavirus fusogenic peptide domain comprises a naturally occurring henipavirus fusogenic peptide domain variant of SEQ ID NO: 160 or SEQ ID NO: 161, such as, e.g., a henipavirus fusogenic peptide domain isoform of SEQ ID NO: 160 or SEQ ID NO: 161 or a henipavirus fusogenic peptide domain subtype of SEQ ID NO: 160 or SEQ ID NO: 161. In still another aspect of this embodiment, a henipavirus fusogenic peptide domain comprises a non-naturally occurring henipavirus fusogenic peptide domain variant, such as, e.g., a conservative henipavirus fusogenic peptide domain variant, a non-conservative henipavirus fusogenic peptide domain variant, a henipavirus fusogenic peptide domain chimeric, an active henipavirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, a henipavirus fusogenic peptide domain comprises amino acids a non-naturally occurring henipavirus fusogenic peptide domain variant of SEQ ID NO: 160 or SEQ ID NO: 161, such as, e.g., a conservative henipavirus fusogenic peptide domain variant of SEQ ID NO: 160 or SEQ ID NO: 161, a non-conservative henipavirus fusogenic peptide domain variant of SEQ ID NO: 160 or SEQ ID NO: 161, an active henipavirus fusogenic peptide domain fragment of SEQ ID NO: 160 or SEQ ID NO: 161, or any combination thereof.
In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at least 75% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at least 80% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at least 85% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at least 90% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161 or at least 95% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161. In yet other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at most 75% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at most 80% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at most 85% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161, at most 90% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161 or at most 95% amino acid identity with SEQ ID NO: 160 or SEQ ID NO: 161.
In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In yet other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In still other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 160 or SEQ ID NO: 161.
In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In yet other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In still other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 160 or SEQ ID NO: 161. In other aspects of this embodiment, a henipavirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 160 or SEQ ID NO: 161.
In another embodiment, a Clostridial toxin translocation facilitating domain comprises a metapneumovirus fusogenic peptide domain. In another aspect of this embodiment, a metapneumovirus fusogenic peptide domain comprises a naturally occurring metapneumovirus fusogenic peptide domain variant, such as, e.g., a metapneumovirus fusogenic peptide domain isoform or a metapneumovirus fusogenic peptide domain subtype. In another aspect of this embodiment, a metapneumovirus fusogenic peptide domain comprises a naturally occurring metapneumovirus fusogenic peptide domain variant of SEQ ID NO: 162, such as, e.g., a metapneumovirus fusogenic peptide domain isoform of SEQ ID NO: 162 or a metapneumovirus fusogenic peptide domain subtype of SEQ ID NO: 162. In still another aspect of this embodiment, a metapneumovirus fusogenic peptide domain comprises a non-naturally occurring metapneumovirus fusogenic peptide domain variant, such as, e.g., a conservative metapneumovirus fusogenic peptide domain variant, a non-conservative metapneumovirus fusogenic peptide domain variant, a metapneumovirus fusogenic peptide domain chimeric, an active metapneumovirus fusogenic peptide domain fragment, or any combination thereof. In still another aspect of this embodiment, a metapneumovirus fusogenic peptide domain comprises amino acids a non-naturally occurring metapneumovirus fusogenic peptide domain variant of SEQ ID NO: 162, such as, e.g., a conservative metapneumovirus fusogenic peptide domain variant of SEQ ID NO: 162, a non-conservative metapneumovirus fusogenic peptide domain variant of SEQ ID NO: 162, an active metapneumovirus fusogenic peptide domain fragment of SEQ ID NO: 162, or any combination thereof.
In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least 70% amino acid identity with SEQ ID NO: 162, at least 75% amino acid identity with SEQ ID NO: 162, at least 80% amino acid identity with SEQ ID NO: 162, at least 85% amino acid identity with SEQ ID NO: 162, at least 90% amino acid identity with SEQ ID NO: 162 or at least 95% amino acid identity with SEQ ID NO: 162. In yet other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most 70% amino acid identity with SEQ ID NO: 162, at most 75% amino acid identity with SEQ ID NO: 162, at most 80% amino acid identity with SEQ ID NO: 162, at most 85% amino acid identity with SEQ ID NO: 162, at most 90% amino acid identity with SEQ ID NO: 162 or at most 95% amino acid identity with SEQ ID NO: 162.
In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to SEQ ID NO: 162. In yet other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to SEQ ID NO: 162. In still other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to SEQ ID NO: 162.
In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to SEQ ID NO: 162. In yet other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to SEQ ID NO: 162. In still other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 162. In other aspects of this embodiment, a metapneumovirus fusogenic peptide domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to SEQ ID NO: 162.
Aspects of the present invention provide, in part, an altered targeting domain. As used herein, the term “altered targeting domain” means any polypeptide that can selectively bind to a non-Clostridial toxin receptor present on a non-Clostridial toxin target cell and initiate the overall internalization mechanism whereby the modified Clostridial toxin disclosed in the present specification intoxicates a target cell. As used herein, the term “selectively” means having a highly preferred activity or effect. As used herein, the term “selectively bind” means a molecule is able to bind its target receptor under physiological conditions, or in vitro conditions substantially approximating physiological conditions, to a statistically significantly greater degree relative to other, non-target receptors. Thus, with reference to an altered targeting domain of the present specification, there is a discriminatory binding of the altered targeting domain to a non-Clostridial toxin receptor presence in a non-Clostridial toxin target cell.
Aspects of the present invention provide, in part, an enhanced targeting domain. As used herein, the term “enhanced targeting domain” means any polypeptide that can selectively bind to an endogenous Clostridial toxin receptor found on a Clostridial toxin target cell and initiate the overall internalization mechanism whereby the modified Clostridial toxin disclosed in the present specification intoxicates a target cell with the proviso that an enhanced targeting domain is not a naturally-occurring binding domain from a naturally occurring Clostridial toxin. As used herein, the term “selectively” means having a highly preferred activity or effect. As used herein, the term “selectively bind” means a molecule is able to bind its target receptor under physiological conditions, or in vitro conditions substantially approximating physiological conditions, to a statistically significantly greater degree relative to other non-target receptors. Thus, with reference to an enhanced targeting domain of the present specification, there is a discriminatory binding of the enhanced targeting domain to an endogenous Clostridial toxin receptor.
An enhanced targeting domain disclosed in the present specification facilitates the binding activity of the modified Clostridial toxins disclosed in the present specification to an endogenous Clostridial toxin receptor located at the surface of a Clostridial toxin target cell. As used herein, the term “binding activity” means that one molecule is directly or indirectly contacting another molecule via at least one intermolecular or intramolecular force, including, without limitation, a covalent bond, an ionic bond, a metallic bond, a hydrogen bond, a hydrophobic interaction, a van der Waals interaction, and the like, or any combination thereof. “Bound” and “bind” are considered terms for binding.
As used herein, the term “binding affinity” means how strong a molecule's binding activity is for a particular receptor. In general, high binding affinity results from greater intermolecular force between a binding domain and its receptor while low binding affinity involves less intermolecular force between the ligand and its receptor. High binding affinity involves a longer residence time for the binding domain at its receptor binding site than is the case for low binding affinity. As such, a molecule with a high binding affinity means a lower concentration of that molecule is required to maximally occupy the binding sites of a receptor and trigger a physiological response. Conversely, low binding affinity means a relatively high concentration of a molecule is required before the receptor binding sites of a receptor is maximally occupied and the maximum physiological response is achieved. Thus, modified Clostridial toxins with increased binding activity due to high binding affinity will allow administration of reduced doses of the toxin, thereby reducing or preventing unwanted side-effects associated with toxin dispersal into non-targeted areas.
As used herein, the term “binding specificity” means how specific a molecule's binding activity is one particular receptor. In general, high binding specificity results in a more exclusive interaction with one particular receptor or subgroup of receptors while low binding specificity results in a more promiscuous interaction with a larger group of receptors. As such, a molecule with a high binding specificity means that molecule will occupy the binding sites of a particular receptor and trigger a physiological response. Conversely, low binding specificity means a molecule will occupy the binding sites of many receptors and trigger a multitude of physiological responses. Thus, modified Clostridial toxins with increased binding activity due to high binding specificity will only target a subgroup of Clostridial toxin target cells, thereby reducing the side effects associated with the targeting of all Clostridial toxin target cells.
It is envisioned that any and all enhanced targeting domains can be used to practice aspects of the present invention, including, without limitation, an enhanced targeting domain that increases binding affinity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell; and an enhanced targeting domain that increases binding specificity for a subgroup of endogenous Clostridial toxin receptors present on a naturally-occurring Clostridial toxin target cell.
Assays that determine modified Clostridial toxin binding activity or uptake properties can be used to assess whether a modified Clostridial toxin disclosed in the present specification has an enhanced binding activity, such as an increased binding affinity or an increased binding specificity. It is envisioned that heterogeneous assay types, homogeneous assay types and non-separating homogeneous assay types can be used to determine the binding activity of a modified Clostridial toxin with an enhanced targeting domain, see, e.g., Lutea A. A. de Jong et al., Receptor-Binding Assays: Technologies and Applications, 829 J. Chromatogr. B1-25 (2005). It is further envisioned that the binding activity of a modified Clostridial toxin with an enhanced targeting domain can be determined by affinity chromatography using immobilized receptors and interfacial optical assays, such as, e.g., total internal reflection fluorescence (TIRF) and surface plasmon resonance (SPR). Non-limiting examples of these assays include, e.g., FCS using diffusion mediated intensity fluctuations, SPR using a mass-dependent refractive index, TIRF using a mass-independent refractive index, microarrays using optical intensity changes and QAC using retention volume.
As a non-limiting example, cross-linking assays using radio-labeled or non-radio-labeled modified Clostridial toxins can determine whether such a modified toxin has an enhanced targeting activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. Other non-limiting assays include immunocytochemical assays that detect modified toxin binding using labeled or unlabeled antibodies and immunoprecipitation assays that detect bound modified toxin using labeled or unlabeled antibodies. Antibodies useful for these assays include, without limitation, antibodies selected against a portion of a Clostridial toxin heavy chain comprising the HN translocation domain or a portion of a Clostridial toxin light chain; or antibodies selected against the Clostridial toxin receptor. If the antibody is labeled, the binding of the molecule can be detected by various means, including Western blotting, direct microscopic observation of the cellular location of the antibody, measurement of cell or substrate-bound antibody following a wash step, or electrophoresis, employing techniques well-known to those of skill in the art. If the antibody is unlabeled, one may employ a labeled secondary antibody for indirect detection of the bound molecule, and detection can proceed as for a labeled antibody. It is understood that these and similar assays that determine modified Clostridial toxin uptake properties or characteristics can be useful in determining whether a modified toxin disclosed in the present specification has an enhanced targeting activity.
Assays that monitor the release of a molecule after exposure to a modified Clostridial toxin disclosed in the present specification can also be used to assess whether such a modified toxin has enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. In these assays, a greater or faster inhibition of the molecule's release would occur in cells exposed to a modified Clostridial toxin with an enhanced targeting activity after exposure to a modified Clostridial toxin. Well known assays include methods that measure inhibition of radio-labeled catecholamine release from neurons, such as, e.g., [3H] noradrenaline or [3H] dopamine release, see e.g., A Fassio et al., Evidence for calcium-dependent vesicular transmitter release insensitive to tetanus toxin and botulinum toxin type F, 90(3) Neuroscience 893-902 (1999); and Sara Stigliani et al., The sensitivity of catecholamine release to botulinum toxin C1 and E suggests selective targeting of vesicles set into the readily releasable pool, 85(2) J. Neurochem. 409-421 (2003), or measures catecholamine release using a fluorometric procedure, see, e.g., Anton de Paiva et al., A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly, 268(28) J. Biol. Chem. 20838-20844 (1993); Gary W. Lawrence et al., Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-associated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B, 236(3) Eur. J. Biochem. 877-886 (1996); and Patrick Foran et al., Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release, 35(8) Biochemistry 2630-2636 (1996). Other non-limiting examples include assays that measure inhibition of hormone release from endocrine cells, such as, e.g., anterior pituitary cells or ovarian cells. It is understood that these and similar assays for molecule release can be useful in determining whether a modified toxin disclosed in the present specification has an enhanced targeting activity.
Assays that detect the cleavage of a Clostridial toxin substrate after exposure to a modified Clostridial toxin disclosed in the present specification can also be used to assess whether such a modified toxin has enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. In these assays, generation of a Clostridial toxin substrate cleavage-product would be detected in cells expressing a receptor of interest after modified Clostridial toxin treatment. Non-limiting examples of specific Western blotting procedures, as well as well-characterized reagents, conditions and protocols are readily available from commercial vendors that include, without limitation, Amersham Biosciences, Piscataway, N.J.; Bio-Rad Laboratories, Hercules, Calif.; Pierce Biotechnology, Inc., Rockford, Ill.; Promega Corporation, Madison, Wis., and Stratagene, Inc., La Jolla, Calif. It is understood that these and similar assays for Clostridial toxin substrate cleavage can be useful in determining whether a modified toxin disclosed in the present specification has an enhanced targeting activity.
As non-limiting examples, western blot analysis using an antibody that specifically recognizes a BoNT/A substrate cleavage product at the SNAP-25 site can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; western blot analysis using an antibody that specifically recognizes a BoNT/C1 substrate cleavage product at the SNAP-25 site can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; and western blot analysis using an antibody that specifically recognizes a BoNT/E substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. Examples of anti-SNAP-25 antibodies useful for these assays include, without limitation, rabbit polyclonal anti-SNAP25197 antiserum pAb anti-SNAP25197 #1 (Allergan, Inc., Irvine, Calif.), mouse monoclonal anti-SNAP-25 antibody SMI-81 (Sternberger Monoclonals, Lutherville, Md.), mouse monoclonal anti-SNAP-25 antibody CI 71.1 (Synaptic Systems, Goettingen, Germany), mouse monoclonal anti-SNAP-25 antibody CI 71.2 (Synaptic Systems, Goettingen, Germany), mouse monoclonal anti-SNAP-25 antibody SP12 (Abcam, Cambridge, Mass.), rabbit polyclonal anti-SNAP-25 antiserum (Synaptic Systems, Goettingen, Germany), and rabbit polyclonal anti-SNAP-25 antiserum (Abcam, Cambridge, Mass.).
As additional non-limiting examples, western blot analysis using an antibody that specifically recognizes a BoNT/B substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; western blot analysis using an antibody that specifically recognizes a BoNT/D substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; western blot analysis using an antibody that specifically recognizes a BoNT/F substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; western blot analysis using an antibody that specifically recognizes a BoNT/G substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived; and western blot analysis using an antibody that specifically recognizes a TeNT substrate cleaved product can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. Examples of anti-VAMP antibodies useful for these assays include, without limitation, mouse monoclonal anti-VAMP-1 antibody CI 10.1 (Synaptic Systems, Goettingen, Germany), mouse monoclonal anti-VAMP-1 antibody SP10 (Abcam, Cambridge, Mass.), mouse monoclonal anti-VAMP-1 antibody SP11 (Abcam, Cambridge, Mass.), rabbit polyclonal anti-VAMP-1 antiserum (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-VAMP-1 antiserum (Abcam, Cambridge, Mass.), mouse monoclonal anti-VAMP-2 antibody CI 69.1 (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-VAMP-2 antiserum (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-VAMP-2 antiserum (Abcam, Cambridge, Mass.), mouse monoclonal anti-VAMP-3 antibody CI 10.1 (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-VAMP-3 antiserum (Synaptic Systems, Goettingen, Germany) and rabbit polyclonal anti-VAMP-3 antiserum (Abcam, Cambridge, Mass.),
As another non-limiting example, western blot analysis using an antibody that specifically recognizes a BoNT/C1 substrate cleaved product at the Syntaxin site can be used to assay whether a modified toxin has an enhanced binding activity to a Clostridial toxin receptor as compared to the Clostridial toxin from which the modified toxin was derived. Examples of anti-Syntaxin antibodies useful for these assays include, without limitation, mouse monoclonal anti-Syntaxin-1 antibody CI 78.2 (Synaptic Systems, Goettingen, Germany), mouse monoclonal anti-Syntaxin-1A antibody CI 78.3 (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-Syntaxin-1A antiserum (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-Syntaxin-1B antiserum (Synaptic Systems, Goettingen, Germany), rabbit polyclonal anti-Syntaxin antiserum (Abcam, Cambridge, Mass.), rabbit polyclonal anti-Syntaxin-2 antiserum (Abcam, Cambridge, Mass.) and rabbit polyclonal anti-Syntaxin-3 antiserum (Abcam, Cambridge, Mass.),
Thus, in an embodiment, a modified Clostridial toxin with an enhanced targeting activity is a modified Clostridial toxin with an increased binding affinity for a Clostridial toxin receptor. Increased binding affinity for a Clostridial toxin receptor is determined by comparing the binding affinity of the modified Clostridial toxin to that of the binding affinity for the same Clostridial toxin receptor of a Clostridial toxin lacking the enhanced targeting domain modification from which the modified Clostridial toxin is derived. In aspects of this embodiment, a modified Clostridial toxin with an increased binding affinity for a Clostridial toxin receptor exhibits a binding affinity that is, e.g., at least 10% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 20% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 30% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 40% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 50% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 60% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 70% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 80% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 90% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at least 100% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived. In aspects of this embodiment, a modified Clostridial toxin with an increased binding affinity for a Clostridial toxin receptor exhibits a binding affinity that is, e.g., at most 10% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 20% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 30% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 40% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 50% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 60% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 70% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 80% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 90% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at most 100% greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived.
In yet other aspects of this embodiment, a modified Clostridial toxin with an increased binding affinity for a Clostridial toxin receptor exhibits a binding affinity that is, e.g., at least two-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least three-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least four-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least five-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least ten-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at least twenty-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived. In yet other aspects of this embodiment, a modified Clostridial toxin with an increased binding affinity for a Clostridial toxin receptor exhibits a binding affinity that is, e.g., at most two-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most three-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most four-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most five-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most ten-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at most twenty-fold greater than the binding affinity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived.
In another embodiment, a modified Clostridial toxin with an enhanced targeting activity is a modified Clostridial toxin with an increased binding specificity for a Clostridial toxin receptor. Increased binding specificity for a Clostridial toxin receptor is determined by comparing the binding specificity of the modified Clostridial toxin to that of the binding specificity for the same Clostridial toxin receptor of a Clostridial toxin lacking the enhanced targeting domain modification from which the modified Clostridial toxin is derived. In aspects of this embodiment, a modified Clostridial toxin with an increased binding specificity for a Clostridial toxin receptor exhibits a binding specificity that is, e.g., at least 10% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 20% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 30% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 40% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 50% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 60% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 70% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 80% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least 90% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at least 100% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived. In aspects of this embodiment, a modified Clostridial toxin with an increased binding specificity for a Clostridial toxin receptor exhibits a binding specificity that is, e.g., at most 10% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 20% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 30% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 40% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 50% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 60% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 70% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 80% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most 90% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at most 100% greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived.
In yet other aspects of this embodiment, a modified Clostridial toxin with an increased binding specificity for a Clostridial toxin receptor exhibits a binding specificity that is, e.g., at least two-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least three-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least four-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least five-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at least ten-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at least twenty-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived. In yet other aspects of this embodiment, a modified Clostridial toxin with an increased binding specificity for a Clostridial toxin receptor exhibits a binding specificity that is, e.g., at most two-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most three-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most four-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most five-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived, at most ten-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived or at most twenty-fold greater than the binding specificity of the naturally-occurring Clostridial toxin from which the modified Clostridial toxin is derived.
As used herein, the term “Clostridial toxin target cell” means a cell that is a naturally occurring cell that a naturally occurring Clostridial toxin is capable of intoxicating, including, without limitation, motor neurons; sensory neurons; autonomic neurons; such as, e.g., sympathetic neurons and parasympathetic neurons; non-peptidergic neurons, such as, e.g., cholinergic neurons, adrenergic neurons, noradrenergic neurons, serotonergic neurons, GABAergic neurons; and peptidergic neurons, such as, e.g., Substance P neurons, Calcitonin Gene Related Peptide neurons, vasoactive intestinal peptide neurons, Neuropeptide Y neurons, cholecystokinin neurons.
An enhanced targeting domain disclosed in the present specification replaces the binding activity of the Clostridial toxin targeting domain found in naturally occurring Clostridial toxins. As used herein, the term “naturally occurring Clostridial toxin targeting domain” is synonymous with “naturally occurring Clostridial toxin HCC targeting domain” and means any naturally occurring Clostridial toxin polypeptide that can execute the cell binding step of the intoxication process, including, e.g., the binding of the Clostridial toxin to a Clostridial toxin-specific receptor located on the plasma membrane surface of a target cell. It is envisioned that replacement of the binding activity of a naturally occurring Clostridial toxin HCC targeting domain by an enhanced targeting domain can be achieved by, e.g., replacing the entire naturally occurring Clostridial toxin HCC targeting domain with an enhanced targeting domain; replacing a portion of a naturally occurring Clostridial toxin HCC targeting domain with an enhanced targeting domain; and operably-linking an enhanced targeting domain to a naturally occurring Clostridial toxin comprising a Clostridial toxin HCC targeting domain.
An example of an enhanced targeting domain that increases binding activity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell, includes, without limitation, a modified Clostridial toxin HCC targeting domain with enhanced binding activity, such as, e.g., a modified BoNT/A HCC targeting domain with enhanced binding activity, a modified BoNT/B HCC targeting domain with enhanced binding activity, a modified BoNT/C1 HCC targeting domain with enhanced binding activity, a modified BoNT/D HCC targeting domain with enhanced binding activity, a modified BoNT/E HCC targeting domain with enhanced binding activity, a modified BoNT/F HCC targeting domain with enhanced binding activity, a modified BoNT/G HCC targeting domain with enhanced binding activity and a modified TeNT HCC targeting domain with enhanced binding activity. Examples of a modified Clostridial toxin HCC targeting domain that increase binding activity include, e.g., a modified Clostridial toxin HCC targeting domain that increases binding affinity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell and a modified Clostridial toxin HCC targeting domain that increases binding specificity for a subgroup of endogenous Clostridial toxin receptors present on a naturally-occurring Clostridial toxin target cell.
The three-dimensional crystal structures of BoNT/A, BoNT/B and the HC domain of TeNT indicate that the carboxyl-terminal HCC domain comprises a modified β-trefoil domain which forms three distinct carbohydrate binding regions that resembles the carbohydrate binding moiety found in many sugar-binding proteins, such as, e.g., serum amyloid P, sialidase, cryia, insecticidal ∂-endotoxin and lectins. Biochemical studies indicate that the β-trefoil domain structure of the HCC domain appears to mediate the binding to specific carbohydrate containing components of the Clostridial toxin receptor on the cell surface, see, e.g., Krzysztof Ginalski et al., Structure-based Sequence Alignment for the Beta-Trefoil Subdomain of the Clostridial Neurotoxin Family Provides Residue Level Information About the Putative Ganglioside Binding Site, 482(1-2) FEBS Lett. 119-124 (2000).
Proteins containing the structural β-trefoil domain represents a diverse group of proteins, see, e.g., C. A. Orengo et al., Protein Superfamilies and Domain Superfolds, 372 Nature 631-634 (1994). The β-trefoil domain comprises a six-stranded β-barrel closed off at one end by three β-hairpin structures that exhibits a characteristic pseudo-threefold axis symmetry. The monomeric structural unit of this three-fold symmetry is referred to as the β-trefoil fold that contains four β-sheets organized as a pair of antiparallel β-sheets. Dividing each of these β-trefoil folds is a β-hairpin turn. Therefore, in a linear fashion, a β-trefoil domain comprises four β-sheets of the first β-trefoil fold (α-fold), a β-hairpin turn, four β-sheets of the second β-trefoil fold (β-fold), a second β-hairpin turn four β-sheets of the third β-trefoil fold (γ-fold) (see FIG. 2). Because the first hairpin turn is located between the fourth and fifth β-sheets of the β-trefoil domain, it is designated the β4/β5 β-hairpin turn. Likewise, since the second hairpin turn is located between the eight and ninth β-sheets of the β-trefoil domain, it is designated the β8/β9 β-hairpin turn.
Continuing research has elucidated that β4/β5 and β8/β9 β-hairpin turns are important in conferring the proper pseudo-threefold axis symmetry observed in the β-trefoil domain. Additionally, this work has demonstrated that amino acid changes in these two β-hairpin turns can increase the stability of the β-trefoil domain, which in turn results in increased binding activity, see, e.g., Stephen R. Brych et al., Structure and Stability Effects of Mutations Designed to Increase the Primary Sequence Symmetry Within the Core Region of a β-trefoil, 10 Protein Sci. 2587-2599 (2001); Jaewon Kim et al., Alternative Type I and I′ Turn Conformations in the β8/β9 β-hairpin of Human Acidic Fibroblast Growth Factor, 11 Protein Sci. 459-466 (2002); Jaewon Kim et al., Sequence swapping Does Not Result in Conformation Swapping for the β4/β5 and β8/β9 β-hairpin Turns in Human Acidic Fibroblast Growth Factor, 14 Protein Sci. 351-359 (2005). As a non-limiting example, replacement of an amino acid comprising either the β4/β5 hairpin turn or β8/β9 β-hairpin turn with a glycine results in increased stabilization of the β-trefoil domain. Therefore, replacement of amino acids located in the β4/β5 and β8/β9 β-hairpin turns of the β-trefoil domains present in the binding domain of Clostridial toxins will increase binding activity of such a modified Clostridial toxin by increasing the structural stability of the β-trefoil domain. The amino acid sequences comprising the β-trefoil domains found in various Clostridial toxins are shown in Table 2.







TABLE 2







β-trefoil Domains of Clostridial Toxins











Amino Acid Sequence Region of Carbohydrate Binding Moieties
















β4/β5

β8/β9



Protein
SEQ ID NO:
α-fold
β-hairpin turn
β-fold
β-hairpin turn
γ-fold
















BoNT/A
1
1111-1162
1163-1178
1179-1223
1224-1236
1237-1296


BoNT/B
2
1098-1147
1148-1165
1166-1210
1211-1222
1223-1291


BoNT/C1
3
1112-1150
1151-1166
1167-1218
1219-1229
1230-1291


BoNT/D
4
1099-1137
1138-1153
1154-1207
1208-1218
1219-1276


BoNT/E
5
1086-1129
1130-1146
1147-1190
1191-1198
1199-1252


BoNT/F
6
1106-1152
1153-1171
1172-1213
1214-1221
1222-1274


BoNT/G
7
1106-1153
1154-1172
1173-1218
1219-1230
1231-1297


TeNT
8
1128-1177
1178-1194
1195-1240
1241-1254
1255-1315









As is typical for proteins containing a β-trefoil fold, the overall amino acid sequence identity of the HCC domain between Clostridial toxins is low. However, key residues essential for binding activity have been identified by structural analysis and mutagenesis experiments, see, e.g., Krzysztof Ginalski et al., Structure-based Sequence Alignment for the Beta-Trefoil Subdomain of the Clostridial Neurotoxin Family Provides Residue Level Information About the Putative Ganglioside Binding Site, 482(1-2) FEBS Lett. 119-124 (2000). For example, analysis of the HCC domain structure by crystallography identified five highly conserved residues critical for forming a shallow surface pocket of a carbohydrate binding moiety. These polar residues make hydrogen bonds with the carbohydrate ring. In BoNT/A these five polar residues are Glu 1203, Phe 1252, Ser 1264, Tyr 1267 and Gly 1279, while in TeNT, these residues are Asp 1222, Thr 1270, Ser 1287, Tyr 1290 and Gly 1300. Additionally, tyrosine residues forming the hydrophilic wall of this pocket were also important (Trp 1266 of BoNT/A and Trp 1289 of TeNT) and tryptophan fluorescence quenching experiments indicated that Trp 1266 of BoNT/A bound carbohydrate molecules. In another studies, photoaffinity labeling experiments revealed that Gln 1270 of BoNT/A and His 1293 of TeNT were also involved in binding carbohydrate molecules. Mutagenesis experiments designed to assay loss-of-function binding activity mutations confirmed the importance of many of the residues described above for BoNT/A and TeNT and extended this analysis to BoNT/B (Glu 1190, His 1241, Typ 1262, Tyr 1263), see, e.g., Andreas Rummel et al., The HCC-Domain of Botulinum Neurotoxins A and B Exhibits a Singular Ganglioside Binding Site Displaying Serotype Specific Carbohydrate Interaction, 51(3) Mol. Microbiol. 631-643 (2004).
As used herein, the term “Clostridial toxin HCC targeting domain” means any naturally occurring Clostridial toxin polypeptide that can execute the cell binding step of the intoxication process, including, e.g., the selective binding of the Clostridial toxin to a toxin-specific receptor located on the plasma membrane surface of a target cell. As used herein, the term “modified Clostridial toxin HCC targeting domain” means a naturally occurring Clostridial toxin HCC targeting domain modified to enhance its cell binding activity for an endogenous Clostridial toxin receptor, such as, e.g., a binding affinity or a binding specificity, to a statistically significantly degree relative to the unmodified naturally occurring Clostridial toxin HCC targeting domain from which the modified Clostridial toxin HCC targeting domain was derived. By definition, a modified Clostridial toxin HCC targeting domain has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 1) and can be described in percent identity to the corresponding region of that reference sequence.
As another non-limiting examples, a modified BoNT/A HCC targeting domain comprising amino acids 1092-1296 of SEQ ID NO: 1 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1092-1296 of SEQ ID NO: 1; a modified BoNT/B HCC targeting domain comprising amino acids 1079-1291 of SEQ ID NO: 2 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1079-1291 of SEQ ID NO: 2; a modified BoNT/C1 HCC targeting domain comprising amino acids 1093-1291 of SEQ ID NO: 3 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 2093-1291 of SEQ ID NO: 3; a modified BoNT/D HCC targeting domain comprising amino acids 1080-1276 of SEQ ID NO: 4 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1080-1276 of SEQ ID NO: 4; a modified BoNT/E HCC targeting domain comprising amino acids 1067-1252 of SEQ ID NO: 5 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1067-1252 of SEQ ID NO: 5; a modified BoNT/F HCC targeting domain comprising amino acids 1087-1274 of SEQ ID NO: 6 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1087-1274 of SEQ ID NO: 6; a modified BoNT/G HCC targeting domain comprising amino acids 1087-1297 of SEQ ID NO: 7 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1087-1297 of SEQ ID NO: 7; and a modified TeNT HCC targeting domain comprising amino acids 1109-1315 of SEQ ID NO: 8 will have at least one amino acid difference, such as, e.g., an amino acid substitution, deletion or addition, as compared to the amino acid region 1109-1315 of SEQ ID NO: 8.
It is also envisioned that any of a variety of modified Clostridial toxin HCC targeting domain fragments comprising a binding domain with enhanced binding activity can be useful in aspects of the present invention with the proviso that these active fragments can provide enhanced binding activity of the toxin to the receptor located at the surface of the target cell. The HCC targeting domain from the heavy chains of Clostridial toxins are approximately 165-195 amino acids in length and comprise a binding domain (Table 1). Research has shown that the entire length of a HCC targeting domain from a Clostridial toxin heavy chain is not necessary for the binding activity of the binding domain. Thus, aspects of this embodiment can include a Clostridial toxin HCC targeting domain comprising a binding domain having a length of, e.g., at least 150 amino acids, at least 175 amino acids, at least 200 amino acids and at least 225 amino acids. Other aspects of this embodiment can include a Clostridial toxin HCC targeting domain comprising a binding domain having a length of, e.g., at most 150 amino acids, at most 175 amino acids, at most 200 amino acids and at most 225 amino acids.
Any of a variety of sequence alignment methods can be used to determine percent identity of a modified Clostridial toxin HCC targeting domain relative to a naturally-occurring Clostridial toxin HCC targeting domain, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
One general approach well known to one skilled in the art on how to modify a Clostridial toxin HCC targeting domain in order to increase its binding activity for a naturally-occurring Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell involves changing specifically-identified amino acids. As described above, amino acids essential to binding activity have been identified and methods useful for determining which amino acid substitutions will enhance binding activity are known to one skilled in the art. For example, recent advances in computational protein design algorithms have markedly improved capabilities for generating novel proteins with optimized properties, including, enhanced stability, altered substrate specificity, improved binding affinity and optimized pharmacokinetics, see, e.g., Tanja Kortemme et al., Computational redesign of protein-protein interaction specificity, 11(4) Nat. Struct. Mol. Biol. 371-379 (2004); Tanja Kortemme and David Baker, Computational design of protein-protein interactions, 8(1) Curr. Opin. Chem. Biol. 91-97 (2004); Motomu Shimaoka et al., Computational design of an integrin I domain stabilized in the open high affinity conformation, 7(8) Nat. Struct. Biol. 674-678 (2000); Loïc Martin et al., Rational Design of a CD4 Mimic that Inhibits HIV-1 Entry and Exposes Cryptic Neutralization Epitopes, 21(1) Nat. Biotechnol. 71-76 (2003); and Casim A. Sarkar et al., Rational Cytokine Design for Increased Lifetime and Enhanced Potency Using pH-activated “Histidine Switching,”20(9) Nat. Biotechnol. 908-913 (2002).
In addition, methods capable of altering an amino acid present in a Clostridial toxin HCC targeting domain, include, without limitation, site-directed mutagenesis, oligonucleotide-directed mutagenesis and site-specific mutagenesis. Non-limiting examples of specific mutagenesis protocols for making mutations in a Clostridial toxin are described in, e.g., Mutagenesis, pp. 13.1-13.105 (Sambrook and Russell, eds., Molecular Cloning A Laboratory Manual, Vol. 3, 3rd ed. 2001). In addition, non-limiting examples of well-characterized mutagenesis protocols available from commercial vendors include, without limitation, Altered Sites® II in vitro Mutagenesis Systems (Promega Corp., Madison, Wis.); Erase-a-Base® System (Promega, Madison, Wis.); GeneTailorTM Site-Directed Mutagenesis System (Invitrogen, Inc., Carlsbad, Calif.); QuikChange® II Site-Directed Mutagenesis Kits (Stratagene, La Jolla, Calif.); and TransformerTM Site-Directed Mutagenesis Kit (BD-Clontech, Mountain View, Calif.).
Lastly, methods to test the binding activity of modified Clostridial toxins comprising a modified Clostridial toxin HCC targeting domain with altered binding capability are also well known to one skilled in the art, see, e.g., Lutea A. A. de Jong et al., Receptor-Binding Assays: Technologies and Applications, 829 J. Chromatogr. B 1-25 (2005). It is envisioned that heterogeneous assay types, homogeneous assay types and non-separating homogeneous assay types can be used to determine the binding activity of a modified Clostridial toxin with enhanced binding activity disclosed in the present specification. In a heterogeneous assay, the free ligand is separated from the bound ligand by, e.g., filtration, centrifugation or dialysis, before measurement of the binding activity. In a homogeneous assay, no separation of the free ligand from the bound ligand is required before measurement of the binding activity. In non-separating homogeneous assays, either the ligand or the receptor is immobilized on a solid phase support, in addition to the no separation aspect of all homogeneous assay. Non-limiting examples of heterogeneous, homogeneous and non-separating homogeneous assays include, e.g., radioactive heterogeneous assays, such as, e.g., filtration assays using radioactive energy transfer, SPA/flash plate assays using radioactive energy transfer; and non-radioactive heterogeneous assays, such as, e.g., filtration assays using fluorescence, FRET assays using fluorescence energy transfer, FP assays using light polarization, single-cell FMAT assays and flow cytometry. In addition, non-limiting examples of well-characterized receptor binding protocols available from commercial vendors include, without limitation, Homogeneous Time Resolved Fluorescense-based receptor binding assays (HTRF®; Cisbio International, Bedford, Mass.); DELFIA®-based receptor binding assays (PerkinElmer Lifesciences, Boston, Mass.); and AlphaScreenTM-based receptor binding assays (PerkinElmer Lifesciences, Boston, Mass.).
It is further envisioned that the binding activity of a modified Clostridial toxin with altered binding capability disclosed in the present specification can be determined by affinity chromatography using immobilized receptors and interfacial optical assays, such as, e.g., total internal reflection fluorescence (TIRF) and surface plasmon resonance (SPR). Non-limiting examples of these assays include, e.g., FCS using diffusion mediated intensity fluctuations, SPR using a mass-dependent refractive index, TIRF using a mass-independent refractive index, microarrays using optical intensity changes and QAC using retention volume.
As another general approach well known to one skilled in the art on how to modify a Clostridial toxin HCC targeting domain in order to increase its binding activity for a naturally-occurring Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell involves directed-evolution methods, see, e.g., Andre Koltermann et al., Process for Generating Sequence-Specific Proteases by Directed Evolution and Uses Thereof, U.S. Patent Publication 2004/0072276 (Apr. 15, 2004); Lance E. Steward and Kei Roger Aoki, Evolved Clostridial Toxins with Altered Protease Activity, U.S. Patent Publication 2004/0115727 (Jun. 17, 2004); and L Yuan et al., Laboratory-directed protein evolution, 69(3) Microbiol. Mol. Biol. Rev. 373-392 (2005).
Often the first step of directed evolution is error-prone PCR amplification of the gene of interest or gene recombination when a family of related genes is available. In this case, the gene corresponding to full-length Clostridial toxin or the HCC targeting domain alone would be amplified under conditions that yield one to three amino acid substitutions per molecule. The protein would then be expressed and screened for the desired activity (i.e., receptor binding and/or enhanced activity). Any constructs with even a nominal improvement in receptor binding, regardless of the magnitude of the change, would be submitted for additional rounds of evolution. As a result of the random mutagenesis studies, any amino acids displaying improved binding or even dramatically reduced binding could then be submitted to saturation mutagenesis. This is a process in which the codon of interest it completely randomized so that different constructs containing each of the 20 amino acids substituted at the site of interest are generated.
For improvement of receptor binding characteristics, several different screening approaches could be utilized. If the receptor is known the soluble portion of the receptor can be expressed recombinantly for use in SPR binding assays. For example, the soluble portion of the receptor can be expressed as a fusion to streptavidin, polyhistidine tag, etc. and the receptor can then be immobilized on an appropriate sensor chip. Utilizing a SPR instrument, changes in local refractive index as a result of receptor binding are measured as a change in the SPR angle. The rates of change in the SPR angle can then be analyzed to determine association and dissociation phases and therefore equilibrium constants. This type of assay could be measured either with the full-length Clostridial toxin or the HCC targeting domain. Additionally, binding type assays relying on affinity pull-down experiments with affinity tagged receptors acting as a “bait molecule” could be used. The modified Clostridial toxin or HCC targeting domain could then be labeled with radioisotopes for analysis of the amount of target protein associated with the bait. Alternatively, radiolabeled ligands can be competed with Clostridial toxin or HCC targeting domain variants that are not labeled.
If the receptor is not known, variants of full-length Clostridial toxins can be screened using cells that are known to be sensitive to treatment with native the Clostridial toxin. In this case there are several potential readouts for improved receptor binding, including the presence of the Clostridial toxin in the cell, measurement of cleaved SNARE protein by, e.g., Western blot or cell-based FRET activity assay, or inhibition of exocytosis, e.g., a neurotransmitter release assay.
Thus, in an embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified Clostridial toxin HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin HCC targeting domain comprises a modified Clostridial toxin HCC targeting domain with an increased binding affinity or a modified Clostridial toxin HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin binding domain comprises a modified Clostridial toxin HCC targeting domain with an increased binding specificity or a modified Clostridial toxin HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/A HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/A HCC targeting domain with an increased binding affinity or a modified BoNT/A HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/A HCC targeting domain with an increased binding specificity or a modified BoNT/A HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1111-1296 of SEQ ID NO: 1. In another aspect of this embodiment, a modified BoNT/A HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/A HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/A HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/A HCC targeting domain. In another aspect of this embodiment, a modified BoNT/A HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at least 75% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at least 80% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at least 85% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at least 90% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1 or at least 95% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at most 75% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at most 80% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at most 85% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1, at most 90% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1 or at most 95% amino acid identity with amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a 11-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In still other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In still other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1111-1162, amino acids 1179-1223, or amino acids 1237-1296 of SEQ ID NO: 1.
In another embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a modified BoNT/A HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/A HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/A HCC targeting domain. In another aspect of this embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at least 75% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at least 80% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at least 85% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at least 90% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 or at least 95% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at most 75% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at most 80% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at most 85% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1, at most 90% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 or at most 95% amino acid identity with amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In still other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In still other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1163-1178 or amino acids 1224-1236 of SEQ ID NO: 1.
In other aspects of this embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1101, Gly 1102, Leu 1105, Tyr 1111, Tyr 1112, Gly 1158, Ile 1163, Asp 1179, Glu 1203, Phe 1252, Ser 1264, Trp 1266, Tyr 1267, Gln 1270, Gly 1279 or Trp 1282, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/A HCC targeting domain. In other aspects of this embodiment, a modified BoNT/A HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1101, Gly 1102, Leu 1105, Tyr 1111, Tyr 1112, Gly 1158, Ile 1163, Asp 1179, Glu 1203, Phe 1252, Ser 1264, Trp 1266, Tyr 1267, Gln 1270, Gly 1279 or Trp 1282, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/A HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/B HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/B HCC targeting domain with an increased binding affinity or a modified BoNT/B HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/B HCC targeting domain with an increased binding specificity or a modified BoNT/B HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1098-1291 of SEQ ID NO: 2. In another aspect of this embodiment, a modified BoNT/B HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/B HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/B HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/B HCC targeting domain. In another aspect of this embodiment, a modified BoNT/B HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at least 75% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at least 80% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at least 85% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at least 90% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2 or at least 95% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at most 75% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at most 80% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at most 85% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2, at most 90% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2 or at most 95% amino acid identity with amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In still other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a 11-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In still other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1098-1147, amino acids 1166-1210, or amino acids 1223-1291 of SEQ ID NO: 2.
In another embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a modified BoNT/B HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/B HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/B HCC targeting domain. In another aspect of this embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at least 75% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at least 80% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at least 85% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at least 90% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 or at least 95% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at most 75% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at most 80% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at most 85% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2, at most 90% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 or at most 95% amino acid identity with amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In still other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a 11-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In still other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1148-1165 or amino acids 1211-1222 of SEQ ID NO: 2.
In other aspects of this embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1088, Gly 1089, Leu 1092, Tyr 1098, Tyr 1099, Gly 1142, Ile 1147, Asp 1165, Glu 1191, Ile 1240, Ser 1260, Trp 1262, Tyr 1263, Glu 1266, Gly 1277 or Trp 1280, or any combination thereof, the substitution enhancing the binding capability of the modified BoNT/B HCC targeting domain. In other aspects of this embodiment, a modified BoNT/B HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1088, Gly 1089, Leu 1092, Tyr 1098, Tyr 1099, Gly 1142, Ile 1147, Asp 1165, Glu 1191, Ile 1240, Ser 1260, Trp 1262, Tyr 1263, Glu 1266, Gly 1277 or Trp 1280, or any combination thereof, the deletion enhancing the binding capability of the modified BoNT/B HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/C1 HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/C1 HCC targeting domain with an increased binding affinity or a modified BoNT/C1 HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/C1 HCC targeting domain with an increased binding specificity or a modified BoNT/C1 HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1112-1291 of SEQ ID NO: 3. In another aspect of this embodiment, a modified BoNT/C1 HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/C1 HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/C1 HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/C1 HCC targeting domain. In another aspect of this embodiment, a modified BoNT/C1 HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at least 75% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at least 80% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at least 85% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at least 90% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3 or at least 95% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at most 75% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at most 80% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at most 85% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3, at most 90% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3 or at most 95% amino acid identity with amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In still other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In still other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1112-1150, amino acids 1167-1218, or amino acids 1230-1291 of SEQ ID NO: 3.
In another embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a modified BoNT/C1 HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/C1 HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/C1 HCC targeting domain. In another aspect of this embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at least 75% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at least 80% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at least 85% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at least 90% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 or at least 95% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at most 75% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at most 80% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at most 85% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3, at most 90% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 or at most 95% amino acid identity with amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In still other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In still other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1151-1166 or amino acids 1219-1229 of SEQ ID NO: 3.
In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1102, Gly 1103, Leu 1106, Tyr 1112, Tyr 1113, Gly 1145, Ile 1150, Asp 1166, Glu 1196, Ile 1247, Gly 1256, Trp 1258, Tyr 1259, His 1261, Gly 1281 or Trp 1284, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/C1 HCC targeting domain. In other aspects of this embodiment, a modified BoNT/C1 HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1102, Gly 1103, Leu 1106, Tyr 1112, Tyr 1113, Gly 1145, Ile 1150, Asp 1166, Glu 1196, Ile 1247, Gly 1256, Trp 1258, Tyr 1259, His 1261, Gly 1281 or Trp 1284, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/C1 HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/D HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/D HCC targeting domain with an increased binding affinity or a modified BoNT/D HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/D HCC targeting domain with an increased binding specificity or a modified BoNT/D HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1099-1276 of SEQ ID NO: 4. In another aspect of this embodiment, a modified BoNT/D HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/D HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/D HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/D HCC targeting domain. In another aspect of this embodiment, a modified BoNT/D HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at least 75% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at least 80% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at least 85% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at least 90% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4 or at least 95% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at most 75% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at most 80% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at most 85% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4, at most 90% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4 or at most 95% amino acid identity with amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In still other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In still other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1099-1137, amino acids 1154-1207, or amino acids 1219-1276 of SEQ ID NO: 4.
In another embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a modified BoNT/D HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/D HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/D HCC targeting domain. In another aspect of this embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at least 75% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at least 80% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at least 85% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at least 90% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 or at least 95% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at most 75% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at most 80% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at most 85% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4, at most 90% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 or at most 95% amino acid identity with amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In still other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In still other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1138-1153 or amino acids 1208-1218 of SEQ ID NO: 4.
In other aspects of this embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1089, Gly 1090, Leu 1093, Tyr 1099, Tyr 1100, Gly 1132, Ile 1137, Asp 1153, Asn 1186, Lys 1236, Trp 1238, Arg 1239, Phe 1242, Ser 1262 or Trp 1265, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/D HCC targeting domain. In other aspects of this embodiment, a modified BoNT/D HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1089, Gly 1090, Leu 1093, Tyr 1099, Tyr 1100, Gly 1132, Ile 1137, Asp 1153, Asn 1186, Lys 1236, Trp 1238, Arg 1239, Phe 1242, Ser 1262 or Trp 1265, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/D HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/E HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/E HCC targeting domain with an increased binding affinity or a modified BoNT/E HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/E HCC targeting domain with an increased binding specificity or a modified BoNT/E HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1086-1252 of SEQ ID NO: 5. In another aspect of this embodiment, a modified BoNT/E HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/E HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/E HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/E HCC targeting domain. In another aspect of this embodiment, a modified BoNT/E HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at least 75% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at least 80% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at least 85% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at least 90% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5 or at least 95% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at most 75% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at most 80% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at most 85% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5, at most 90% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5 or at most 95% amino acid identity with amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In still other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In still other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1086-1129, amino acids 1147-1190, or amino acids 1199-1252 of SEQ ID NO: 5.
In another embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a modified BoNT/E HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/E HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/E HCC targeting domain. In another aspect of this embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at least 75% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at least 80% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at least 85% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at least 90% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 or at least 95% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at most 75% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at most 80% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at most 85% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5, at most 90% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 or at most 95% amino acid identity with amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In still other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In still other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1130-1146 or amino acids 1191-1198 of SEQ ID NO: 5.
In other aspects of this embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1076, Gly 1077, Leu 1080, Tyr 1086, Tyr 1087, Gly 1124, Ile 1129, Asp 1146, Glu 1172, Phe 1213, Ser 1221, Trp 1223, Tyr 1224, His 1227, Gly 1236 or Trp 1239, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/E HCC targeting domain. In other aspects of this embodiment, a modified BoNT/E HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1076, Gly 1077, Leu 1080, Tyr 1086, Tyr 1087, Gly 1124, Ile 1129, Asp 1146, Glu 1172, Phe 1213, Ser 1221, Trp 1223, Tyr 1224, His 1227, Gly 1236 or Trp 1239, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/E HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/F HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/F HCC targeting domain with an increased binding affinity or a modified BoNT/F HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/F HCC targeting domain with an increased binding specificity or a modified BoNT/F HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1106-1274 of SEQ ID NO: 6. In another aspect of this embodiment, a modified BoNT/F HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/F HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/F HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/F HCC targeting domain. In another aspect of this embodiment, a modified BoNT/F HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at least 75% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at least 80% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at least 85% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at least 90% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6 or at least 95% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at most 75% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at most 80% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at most 85% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6, at most 90% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6 or at most 95% amino acid identity with amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In still other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In still other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1106-1152, amino acids 1172-1213, or amino acids 1222-1274 of SEQ ID NO: 6.
In another embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a modified BoNT/F HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/F HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/F HCC targeting domain. In another aspect of this embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at least 75% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at least 80% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at least 85% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at least 90% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 or at least 95% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at most 75% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at most 80% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at most 85% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6, at most 90% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 or at most 95% amino acid identity with amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In still other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In still other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1153-1171 or amino acids 1214-1221 of SEQ ID NO: 6.
In other aspects of this embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1147, Ile 1152, Asp 1171, Glu 1195, Phe 1237, Ser 1245, Trp 1247, Tyr 1248, Asn 1251, Gly 1260 or Trp 1263, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/F HCC targeting domain. In other aspects of this embodiment, a modified BoNT/F HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1147, Ile 1152, Asp 1171, Glu 1195, Phe 1237, Ser 1245, Trp 1247, Tyr 1248, Asn 1251, Gly 1260 or Trp 1263, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/F HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified BoNT/G HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/G HCC targeting domain with an increased binding affinity or a modified BoNT/G HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified BoNT/G HCC targeting domain with an increased binding specificity or a modified BoNT/G HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1106-1297 of SEQ ID NO: 7. In another aspect of this embodiment, a modified BoNT/G HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a BoNT/G HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a BoNT/G HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a BoNT/G HCC targeting domain. In another aspect of this embodiment, a modified BoNT/G HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at least 75% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at least 80% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at least 85% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at least 90% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7 or at least 95% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at most 75% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at most 80% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at most 85% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7, at most 90% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7 or at most 95% amino acid identity with amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In still other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In still other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1106-1153, amino acids 1173-1218, or amino acids 1231-1297 of SEQ ID NO: 7.
In another embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a modified BoNT/G HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a BoNT/G HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a BoNT/G HCC targeting domain. In another aspect of this embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at least 75% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at least 80% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at least 85% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at least 90% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 or at least 95% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at most 75% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at most 80% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at most 85% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7, at most 90% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 or at most 95% amino acid identity with amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In still other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In still other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1154-1172 or amino acids 1219-1230 of SEQ ID NO: 7.
In other aspects of this embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1148, Ile 1153, Asp 1172, Gln 1198, Ile 1245, Ser 1266, Trp 1268, Tyr 1269, Arg 1272, Gly 1283 or Trp 1285, or any combination thereof, the substitution enhancing the binding activity of the modified BoNT/G HCC targeting domain. In other aspects of this embodiment, a modified BoNT/G HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1148, Ile 1153, Asp 1172, Gln 1198, Ile 1245, Ser 1266, Trp 1268, Tyr 1269, Arg 1272, Gly 1283 or Trp 1285, or any combination thereof, the deletion enhancing the binding activity of the modified BoNT/G HCC targeting domain.
In another embodiment, a modified Clostridial toxin comprising a targeting domain with enhanced binding activity comprises a modified TeNT HCC targeting domain with enhanced binding activity. In an aspect of this embodiment, a modified Clostridial toxin comprises a modified TeNT HCC targeting domain with an increased binding affinity or a modified TeNT HCC targeting domain fragment with an increased binding affinity. In another aspect of this embodiment, a modified Clostridial toxin comprises a modified TeNT HCC targeting domain with an increased binding specificity or a modified TeNT HCC targeting domain fragment with an increased binding specificity.
In another embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1128-1315 of SEQ ID NO: 8. In another aspect of this embodiment, a modified TeNT HCC targeting domain with an altered cell binding capability comprises a modified α-fold motif of a β-trefoil domain of a TeNT HCC targeting domain, a modified β-fold motif of a β-trefoil domain of a TeNT HCC targeting domain, or a modified γ-fold motif of a β-trefoil domain of a TeNT HCC targeting domain. In another aspect of this embodiment, a modified TeNT HCC targeting domain with an altered cell binding capability comprises a modification to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at least 75% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at least 80% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at least 85% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at least 90% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8 or at least 95% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at most 75% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at most 80% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at most 85% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8, at most 90% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8 or at most 95% amino acid identity with amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In still other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In still other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1128-1177, amino acids 1195-1240, or amino acids 1255-1315 of SEQ ID NO: 8.
In another embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a modified TeNT HCC targeting domain with enhanced binding activity of comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a TeNT HCC targeting domain or a β8/β9 hairpin turn of a β-trefoil domain of a TeNT HCC targeting domain. In another aspect of this embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a modification of amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at least 75% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at least 80% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at least 85% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at least 90% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 or at least 95% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at most 75% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at most 80% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at most 85% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8, at most 90% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 or at most 95% amino acid identity with amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid substitutions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid deletions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In still other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 non-contiguous amino acid additions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid substitutions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8 can be replaced with phenylalanine. In yet other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid deletions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In still other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8. In other aspects of this embodiment, a modified TeNT HCC targeting domain comprising a β-trefoil fold domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine or 10 contiguous amino acid additions relative to amino acids 1178-1194 or amino acids 1241-1254 of SEQ ID NO: 8.
In other aspects of this embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a substitution of amino acid Trp 1118, Gly 1119, Leu 1122, Tyr 1128, Tyr 1129, Gly 1172, Ile 1177, Asp 1194, Asp 1222, Thr 1270, Ser 1287, Trp 1289, Tyr 1290, His 1293, Gly 1300 or Trp 1303, or any combination thereof, the substitution enhancing the binding activity of the modified TeNT HCC targeting domain. In other aspects of this embodiment, a modified TeNT HCC targeting domain with enhanced binding activity comprises a deletion of amino acid Trp 1118, Gly 1119, Leu 1122, Tyr 1128, Tyr 1129, Gly 1172, Ile 1177, Asp 1194, Asp 1222, Thr 1270, Ser 1287, Trp 1289, Tyr 1290, His 1293, Gly 1300 or Trp 1303, or any combination thereof, the deletion enhancing the binding activity of the modified TeNT HCC targeting domain.
Another example of an enhanced targeting domain that increases binding activity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell, includes, without limitation, non-toxin associated proteins of Clostridial toxins, such as, e.g., non-toxic non-hemagglutinin (NTNH), hemagglutinin-17 (HA-17), hemagglutinin-33 (HA-33) and hemagglutinin-70 (HA-70). In vivo, Clostridial bacteria produce a toxin complex comprising the approximately 150-kDa Clostridial toxin and other proteins collectively called nontoxin associated proteins (NAPs). Identified NAPs include proteins possessing hemaglutination activity, such, e.g., a hemagglutinin of approximately 17-kDa (HA-17), a hemagglutinin of approximately 33-kDa (HA-33) and a hemagglutinin of approximately 70-kDa (HA-70); as well as non-toxic non-hemagglutinin (NTNH), a protein of approximately 130-kDa, see, e.g., Eric A. Johnson and Marite Bradshaw, Clostridial botulinum and its Neurotoxins: A Metabolic and Cellular Perspective, 39 Toxicon 1703-1722 (2001); and Stephanie Raffestin et al., Organization and Regulation of the Neurotoxin Genes in Clostridium botulinum and Clostridium tetani, 10 Anaerobe 93-100 (2004). The toxin complex is important for the intoxication process because it provides protection from adverse environmental conditions, resistance to protease digestion, and appears to facilitate internalization and activation of the toxin.
Recent crystallography experiments have revealed that HA-17, HA-33 and NTNH from various Clostridial bacteria contain a region comprising β-trefoil domains very similar to the single β-trefoil domain present in the binding domain of Clostridial toxins, see, e.g., Kaoru Inoue et al., Structural Analysis by X-Ray Crystallography and Calorimetry of a Haemagglutinin Component (HA1) of the Progenitor Toxin from Clostridium botulinum, 149 Microbiol. 3361-3370 (2003); and Joseph W. Arndt et al., The Structure of the Neurotoxin-Associated Protein HA33/A from Clostridial botulinum Suggests a Reoccurring β-trefoil Fold in the Progenitor Toxin Complex, 346 J. Mol. Biol. 1083-1093 (2005). For example, HA-33 from Clostridium botulinum serotype A has two β-trefoil domains, each of which consists of three potential carbohydrate binding moieties or β-trefoil folds, designated 1α (amino acids 10-55 of SEQ ID NO: 9), 1β (amino acids 56-102 of SEQ ID NO: 9) and 1γ (amino acids 103-144 of SEQ ID NO: 9) for the first β-trefoil domain and 2a (amino acids 151-197 of SEQ ID NO: 9), 211 (amino acids 198-245 of SEQ ID NO: 9) and 2γ (amino acids 246-293 of SEQ ID NO: 9) for the second β-trefoil domain. Mutations in conserved amino acids of the carbohydrate binding moiety result in a loss of carbohydrate binding, see, e.g., Kaoru Inoue et al., Structural Analysis by X-Ray Crystallography and calorimetry of a Haemagglutinin Component (HA1) of the Progenitor Toxin from Clostridium botulinum, 149 Microbiol. 3361-3370 (2003).
These β-trefoil domains are also found in the HA-33 proteins produced by Clostridium botulinum serotype B, serotype C1 and serotype D and sequence alignments revealed that amino acids essential for overall carbohydrate binding are conserved. The amino acids predicted to be essential for carbohydrate binding are as follows Asp 263, Tyr 265, Gln 268, Gln 276, Phe 278 and Gln 286 of HA-33/A1 of SEQ ID NO: 9, HA-33/A2 of SEQ ID NO: 10, HA-33/A3 of SEQ ID NO: 11, HA-33/A5 of SEQ ID NO: 12 and HA-33/B2 of SEQ ID NO: 15; Asp 264, Tyr 266, Gln 269, Gln 277, Phe 279 and Gln 287 of HA-33/A4 of SEQ ID NO: 12; Asp 262, Tyr 264, Gln 267, Gln 275, Phe 277 and Gln 285 of HA-33/B1 of SEQ ID NO: 14; Asp 255, Val 257, Gly 260, Gln 268, Typ 270 and Gln 278 of HA-33/C1 of SEQ ID NO: 16; and Asp 256, Tyr 258, Gln 261, Ile 269, Asp 271 and Gln 279 of HA-33/C2 of SEQ ID NO: 17 and HA-33/D of SEQ ID NO: 18. Immunoaffinity column chromatography and pull-down assays have shown that HA-33 can bind synaptotagmin II, a putative Clostridial toxin receptor, see, e.g., Yu Zhou et al., Haemagglutinin-33 of Type Q Botulinum Neurotoxin Complex Binds with Synaptotagmin II, 272 FEBS Lett. 2717-2726 (2005). The amino acid sequences comprising the β-trefoil domains found in various Clostridial HA-33 proteins are shown in Tables 3 and 4.







TABLE 3







β-trefoil Domains of Clostridial HA-33 Proteins











Amino Acid Sequence Region of Carbohydrate Binding Moieties














SEQ ID

1β4/β5

1β8/β9



Protein
NO:
1α-fold
β-hairpin turn
1β-fold
β-hairpin turn
1γ-fold
















HA-33/A1
9
10-54
55-59
 60-100
101-104
105-144


HA-33/A2
10
10-54
55-59
 60-100
101-104
105-144


HA-33/A3
11
10-54
55-59
 60-100
101-104
105-144


HA-33/A4
12
10-56
57-61
 62-102
103-106
107-146


HA-33/A5
13
10-54
55-59
 60-100
101-104
105-144


HA-33/B1 
14
10-54
55-59
 60-100
101-104
105-144


HA-33/B2
15
10-56
57-61
 62-102
103-106
107-146


HA-33/C1-1
16
10-54
55-59
60-98
 99-102
103-141


HA-33/C1-2
17
10-54
55-59
60-98
 99-102
103-141


HA-33/D1
18
10-54
55-59
60-98
 99-102
103-141
















TABLE 4







β-trefoil Domains of Clostridial HA-33 Proteins











Amino Acid Sequence Region of Carbohydrate Binding Moieties














SEQ ID

2β4/β5

2β8/β9



Protein
NO:
2α-fold
β-hairpin turn
2β-fold
β-hairpin turn
2γ-fold
















HA-33/A1
9
151-195
196-199
200-242
243-248
249-293


HA-33/A2
10
151-195
196-199
200-242
243-248
249-293


HA-33/A3
11
151-195
196-199
200-242
243-248
249-293


HA-33/A4
12
153-197
198-201
202-243
244-249
250-294


HA-33/A5
13
151-195
196-199
200-242
243-248
249-279


HA-33/B1
14
151-195
196-199
200-241
242-247
248-292


HA-33/B2
15
153-197
198-201
200-242
243-248
249-291


HA-33/C1-1
16
148-190
191-194
195-234
235-240
241-285


HA-33/C1-2
17
148-190
191-194
195-235
236-241
242-286


HA-33/D1
18
148-190
191-194
195-235
236-241
242-286









Further analysis of the β-trefoil domain sequence of HA-33 also identified β-trefoil domains in HA-17 and NTNH, see, e.g., Joseph W. Arndt et al., The Structure of the Neurotoxin-Associated Protein HA33/A from Clostridial botulinum Suggests a Reoccurring β-trefoil Fold in the Progenitor Toxin Complex, 346 J. Mol. Biol. 1083-1093 (2005). The HA-17 comprises a single β-trefoil domain containing three carbohydrate binding moieties or β-trefoil folds. The carbohydrate binding moieties of HA-17 exhibits the greatest sequence similarity with the 2γ carbohydrate binding moiety of HA-33. These β-trefoil domains are also found in the HA-17 proteins produced by Clostridium botulinum serotype B, serotype C1 and serotype D and sequence alignments revealed that amino acids essential for overall carbohydrate binding are conserved. The amino acids predicted to be essential for carbohydrate binding are as follows Tyr 110, Typ 112, Tyr 115, Pro 130, Phe 132 and Asn 138 of HA-17/A of SEQ ID NO: 19, HA-17/B of SEQ ID NO: 20, HA-17/C1 of SEQ ID NO: 21 and HA-17/D of SEQ ID NO: 22. The amino acid sequences comprising the β-trefoil domains found in various Clostridial HA-17 proteins are shown in Table 5.







TABLE 5







β-trefoil Domains of Clostridial HA-17 Proteins











Amino Acid Sequence Region of Carbohydrate Binding Moieties
















β4/β5

β8/β9



Protein
SEQ ID NO:
α-fold
β-hairpin turn
β-fold
β-hairpin turn
γ-fold
















HA-17/A
19
9-50
51-54
55-91
92-94
95-146


HA-17/B
20
9-50
51-54
55-91
92-94
95-146


HA-17/C1
21
9-50
51-54
55-91
92-94
95-146


HA-17/D
22
9-50
51-54
55-91
92-94
95-146









NTNH from various Clostridial bacteria shows significant sequence similarity to the β-trefoil domains present in the cell binding domain of BoNT/A and TeNT. The high degree of structural similarity is interesting in light of the low sequence similarity between NTNH and the Clostridial toxins. Furthermore, since NTNH of the various serotypes have greater sequence similarity than the Clostridial toxins, it is likely that the NTNH produced by other Clostridial strains will also have β-trefoil domains exhibiting high structural similarity with the binding domains of Clostridial toxins. The β-trefoil domains of various Clostridial NTNHs are as follows: amino acids 1050-1193 of NTNH/A1 of SEQ ID NO: 23; amino acids 1050-1198 of NTNH/A2 of SEQ ID NO: 24; amino acids 1050-1193 of NTNH/A3 of SEQ ID NO: 25; amino acids 1049-1197 of NTNH/B of SEQ ID NO: 26; amino acids 1049-1196 of NTNH/C1 of SEQ ID NO: 27; amino acids 1049-1196 of NTNH/D of SEQ ID NO: 28; amino acids 1014-1162 of NTNH/E of SEQ ID NO: 29; amino acids 1016-1159 of NTNH/F1 of SEQ ID NO: 30; amino acids 1017-1165 of NTNH/F2 of SEQ ID NO: 31; and amino acids 1050-1198 of NTNH/G of SEQ ID NO: 32. The amino acid sequences comprising the β-trefoil domains found in various Clostridial NTNH proteins are shown in Table 6.
The β-trefoil domains present in the Clostridial toxin, HA-33, HA-17 and NTNH collectively form nearly half the mass of a Clostridial toxin complex and underlies the apparent importance of carbohydrate binding in the cell binding step of the intoxication process. This observation is further enhanced by the fact that a Clostridial toxin alone is not as effective in intoxicating a cell as the entire toxin complex. One potential explanation for this enhanced binding activity is the presence, both in type and in quantity, of the β-trefoil domains present in HA-33, HA-17 and NTNH. Therefore, the high prediction of structural similarity of the β-trefoil domains present in HA-33, HA-17 and NTNH relative to the β-trefoil domain found in Clostridial toxins provides a potential source of binding domains useful for developing modified Clostridial toxins with enhanced binding activity. As a non-limiting example, a carbohydrate binding moiety or a β-trefoil fold from HA-33, HA-17 or NTNH can be substituted for the naturally occurring carbohydrate binding moiety present in a Clostridial toxin. As another non-limiting example, a carbohydrate binding moiety or a β-trefoil fold from HA-33, HA-17 or NTNH can be added in addition to the naturally occurring carbohydrate binding moiety present in a Clostridial toxin. As yet another non-limiting example, a multiple carbohydrate binding moieties or a β-trefoil folds from HA-33, HA-17 or NTNH can be substituted for the naturally occurring carbohydrate binding moiety present in a Clostridial toxin. As still another non-limiting example, multiple carbohydrate binding moieties or a β-trefoil folds from HA-33, HA-17 or NTNH can be added in addition to the naturally occurring carbohydrate binding moiety present in a Clostridial toxin. As another non-limiting example, multiple carbohydrate binding moieties or a β-trefoil folds from a Clostridial toxin binding domain can be added in addition to the naturally occurring carbohydrate binding moiety present in a Clostridial toxin.







TABLE 6







β-trefoil Domains of Clostridial NTNH Proteins











Amino Acid Sequence Region of Carbohydrate Binding Moieties 
















β4/β5

β8/β9



Protein
SEQ ID NO:
α-fold
β-hairpin turn
β-fold
β-hairpin turn
γ-fold
















NTNH/A1
23
1050-1097
1098-1110
1111-1138
1139-1148
1149-1194


NTNH/A2
24
1050-1097
1098-1110
1111-1139
1140-1148
1149-1199


NTNH/A3
25
1050-1097
1098-1110
1111-1138
1139-1148
1149-1194


NTNH/B
26
1049-1096
1097-1109
1110-1138
1139-1147
1148-1198


NTNH/C1
27
1049-1096
1097-1109
1110-1138
1139-1147
1148-1197


NTNH/D
28
1049-1096
1097-1109
1110-1138
1139-1147
1148-1197


NTNH/E
29
1014-1061
1062-1074
1075-1103
1104-1113
1114-1163


NTNH/F1
30
1016-1063
1064-1076
1077-1104
1105-1114
1115-1160


NTNH/F2
31
1017-1064
1065-1077
1078-1106
1107-1116
1117-1166


NTNH/G
32
1050-1097
1098-1110
1111-1139
1140-1149
1150-1199









As used herein, the term “Non-toxin Associated Protein” is synonymous with “NAP” and means a Clostridial NAP with selective binding activity, such as, e.g., a binding affinity or a binding specificity, for an endogenous Clostridial toxin receptor. It is envisioned that both naturally occurring NAPs as well as NAPs with enhanced binding activity can be used to practice aspects of the present invention. As used herein, the term “NAP with enhanced binding activity” means a Clostridial NAP with enhanced binding activity for an endogenous Clostridial toxin receptor, such as, e.g., a binding affinity or a binding specificity, to a statistically significantly degree relative to an unmodified naturally occurring Clostridial toxin binding domain from a Clostridial toxin. By definition, a NAP with enhanced binding activity has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 3-6) and can be described in percent identity to the corresponding region of that reference sequence.
Any of a variety of sequence alignment methods can be used to determine percent identity of a modified Clostridial NAP relative to a naturally-occurring Clostridial NAP, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Approaches well known to one skilled in the art on how to modify a Clostridial NAP in order to increase its binding activity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell. As described above, one approach involves identifying amino acids using computational protein design algorithms; changing specifically-identified amino acids using, without limitation, site-directed mutagenesis, oligonucleotide-directed mutagenesis and site-specific mutagenesis; and testing the binding activity of modified Clostridial toxins comprising a modified Clostridial NAP with enhanced binding activity using, e.g., heterogeneous assays, homogeneous assays and non-separating homogeneous assays. It is further envisioned that the binding activity of a modified Clostridial toxin with enhanced binding activity disclosed in the present specification can be determined by affinity chromatography using immobilized receptors and interfacial optical assays. In another approach described above, a binding activity of a modified Clostridial NAP for a naturally-occurring Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell can be achieved using directed-evolution methods.
A Clostridial NAP includes, without limitation, naturally occurring Clostridial NAP variants, such as, e.g., Clostridial NAP isoforms and Clostridial NAP subtypes; non-naturally occurring Clostridial NAP variants, such as, e.g., conservative Clostridial NAP variants, non-conservative Clostridial NAP variants, Clostridial NAP chimerics, active Clostridial NAP fragments thereof, or any combination thereof.
As used herein, the term “Clostridial NAP variant,” whether naturally-occurring or non-naturally-occurring, means a Clostridial NAP that has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Tables 3-6) and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all Clostridial NAP variants disclosed in the present specification are capable of executing the cell binding step of the intoxication process.
It is recognized by those of skill in the art that within each Clostridial bacterium there can be naturally occurring Clostridial NAP variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, there are presently five Clostridial botulinum serotype A HA-33 variants, HA-33/A1, HA-33/A2, HA-33/A3, HA-33/A4 and HA-33/A5 (Tables 3 and 4), with specific HA-33 variants showing various degrees of amino acid divergence when compared to another HA-33 variant. As another example, there are presently three Clostridial botulinum serotype A NTNH-33 variants, NTNH/A1, NTNH/A2 and NTNH/A3 (Table 6), with specific NTNH variant showing various degrees of amino acid divergence when compared to another NTNH variant. As used herein, the term “naturally occurring Clostridial NAP variant” means any Clostridial NAP produced by a naturally-occurring process, including, without limitation, Clostridial NAP isoforms produced from alternatively-spliced transcripts, Clostridial NAP isoforms produced by spontaneous mutation and Clostridial NAP subtypes. A naturally occurring Clostridial NAP variant can function in substantially the same manner as the reference Clostridial NAP on which the naturally occurring Clostridial NAP variant is based, and can be substituted for the reference Clostridial NAP in any aspect of the present invention. A naturally occurring Clostridial NAP variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial NAP on which the naturally occurring Clostridial NAP variant is based. A naturally occurring Clostridial NAP variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial NAP on which the naturally occurring Clostridial NAP variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial NAP on which the naturally occurring Clostridial NAP variant is based.
A non-limiting examples of a naturally occurring Clostridial NAP variant is a Clostridial NAP isoform such as, e.g., a Clostridial botulinum serotype A HA-33 isoform, a Clostridial botulinum serotype B HA-33 isoform, a Clostridial botulinum serotype C1 HA-33 isoform, a Clostridial botulinum serotype D HA-33 isoform, a Clostridial botulinum serotype A HA-17 isoform, a Clostridial botulinum serotype B HA-17 isoform, a Clostridial botulinum serotype C1 HA-17 isoform, a Clostridial botulinum serotype D HA-17 isoform, a Clostridial botulinum serotype A NTNH isoform, a Clostridial botulinum serotype B NTNH isoform, a Clostridial botulinum serotype C1 NTNH isoform, a Clostridial botulinum serotype D NTNH isoform, a Clostridial botulinum serotype E NTNH isoform, a Clostridial botulinum serotype F NTNH isoform and a Clostridial botulinum serotype G NTNH isoform. A Clostridial NAP isoform can function in substantially the same manner as the reference Clostridial NAP on which the Clostridial NAP isoform is based, and can be substituted for the reference Clostridial NAP in any aspect of the present invention.
Another non-limiting examples of a naturally occurring Clostridial NAP variant is a Clostridial NAP subtype such as, e.g., a Clostridial botulinum serotype A HA-33 subtype, a Clostridial botulinum serotype B HA-33 subtype, a Clostridial botulinum serotype C1 HA-33 subtype, a Clostridial botulinum serotype D HA-33 subtype, a Clostridial botulinum serotype A HA-17 subtype, a Clostridial botulinum serotype B HA-17 subtype, a Clostridial botulinum serotype C1 HA-17 subtype, a Clostridial botulinum serotype D HA-17 subtype, a Clostridial botulinum serotype A NTNH subtype, a Clostridial botulinum serotype B NTNH subtype, a Clostridial botulinum serotype C1 NTNH subtype, a Clostridial botulinum serotype D NTNH subtype, a Clostridial botulinum serotype E NTNH subtype, a Clostridial botulinum serotype F NTNH subtype and a Clostridial botulinum serotype G NTNH subtype. A Clostridial NAP subtype can function in substantially the same manner as the reference Clostridial NAP on which the Clostridial NAP subtype is based, and can be substituted for the reference Clostridial NAP in any aspect of the present invention.
As used herein, the term “non-naturally occurring Clostridial NAP variant” means any Clostridial NAP produced with the aid of human manipulation, including, without limitation, Clostridial NAPs produced by genetic engineering using random mutagenesis or rational design and Clostridial NAPs produced by chemical synthesis. Non-limiting examples of non-naturally occurring Clostridial NAP variants include, e.g., conservative Clostridial NAP variants, non-conservative Clostridial NAP variants, Clostridial NAP chimeric variants and active Clostridial NAP fragments.
As used herein, the term “conservative Clostridial NAP variant” means a Clostridial NAP that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference Clostridial NAP sequence (see Tables 3-6). Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative Clostridial NAP variant can function in substantially the same manner as the reference Clostridial NAP on which the conservative Clostridial NAP variant is based, and can be substituted for the reference Clostridial NAP in any aspect of the present invention. A conservative Clostridial NAP variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids or 50 or more amino acids from the reference Clostridial NAP on which the conservative Clostridial NAP variant is based. A conservative Clostridial NAP variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial NAP on which the conservative Clostridial NAP variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial NAP on which the conservative Clostridial NAP variant is based. Non-limiting examples of a conservative Clostridial NAP variant include, e.g., a conservative Clostridial botulinum serotype A HA-33 variant, a conservative Clostridial botulinum serotype B HA-33 variant, a conservative Clostridial botulinum serotype C1 HA-33 variant, a conservative Clostridial botulinum serotype D HA-33 variant, a conservative Clostridial botulinum serotype A HA-17 variant, a conservative Clostridial botulinum serotype B HA-17 variant, a conservative Clostridial botulinum serotype C1 HA-17 variant, a conservative Clostridial botulinum serotype D HA-17 variant, a conservative Clostridial botulinum serotype A NTNH variant, a conservative Clostridial botulinum serotype B NTNH variant, a conservative Clostridial botulinum serotype C1 NTNH variant, a conservative Clostridial botulinum serotype D NTNH variant, a conservative Clostridial botulinum serotype E NTNH variant, a conservative Clostridial botulinum serotype F NTNH variant and a conservative Clostridial botulinum serotype G NTNH variant.
As used herein, the term “non-conservative Clostridial NAP variant” means a Clostridial NAP in which 1) at least one amino acid is deleted from the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based; 2) at least one amino acid added to the reference Clostridial NAP on which the non-conservative Clostridial NAP is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference Clostridial NAP sequence (see Tables 3-6). A non-conservative Clostridial NAP variant can function in substantially the same manner as the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based, and can be substituted for the reference Clostridial NAP in any aspect of the present invention. A non-conservative Clostridial NAP variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids from the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based. A non-conservative Clostridial NAP variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids to the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based. A non-conservative Clostridial NAP variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids or 50 or more amino acids from the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based. A non-conservative Clostridial NAP variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial NAP on which the non-conservative Clostridial NAP variant is based. Non-limiting examples of a non-conservative Clostridial NAP variant include, e.g., a non-conservative Clostridial botulinum serotype A HA-33 variant, a non-conservative Clostridial botulinum serotype B HA-33 variant, a non-conservative Clostridial botulinum serotype C1 HA-33 variant, a non-conservative Clostridial botulinum serotype D HA-33 variant, a non-conservative Clostridial botulinum serotype A HA-17 variant, a non-conservative Clostridial botulinum serotype B HA-17 variant, a non-conservative Clostridial botulinum serotype C1 HA-17 variant, a non-conservative Clostridial botulinum serotype D HA-17 variant, a non-conservative Clostridial botulinum serotype A NTNH variant, a non-conservative Clostridial botulinum serotype B NTNH variant, a non-conservative Clostridial botulinum serotype C1 NTNH variant, a non-conservative Clostridial botulinum serotype D NTNH variant, a non-conservative Clostridial botulinum serotype E NTNH variant, a non-conservative Clostridial botulinum serotype F NTNH variant and a non-conservative Clostridial botulinum serotype G NTNH variant.
As used herein, the term “Clostridial NAP chimeric” means a polypeptide comprising at least a portion of a Clostridial NAP and at least a portion of at least one other polypeptide to form an enhanced targeting domain with at least one property different from the reference Clostridial NAP (see Tables 3-6), with the proviso that this Clostridial NAP chimeric can specifically bind to a Clostridial toxin receptor present in a Clostridial toxin target cell, and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
As used herein, the term “active Clostridial NAP fragment” means any of a variety of Clostridial NAP fragments comprising the enhanced targeting domain can be useful in aspects of the present invention with the proviso that these NAP fragments can specifically bind to a Clostridial toxin receptor present in a Clostridial toxin target cell, and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain derived from a NAP. In another embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain with enhanced binding activity derived from a NAP.
In another embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain derived from a Clostridial HA-33. In an aspect of this embodiment, a β-trefoil domain derived from a Clostridial HA-33 comprises, e.g., a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 or a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33.
In another embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-33. In an aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-33 comprises, e.g., a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 or a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at least 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at least 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at least 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at least 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at most 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at most 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at most 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9, at most 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 9.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 9. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modification of amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at least 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at least 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at least 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at least 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 or at least 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at most 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at most 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at most 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9, at most 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 or at most 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 9.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at least 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at least 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at least 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at least 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at most 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at most 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at most 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10, at most 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 10.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 10. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modification of amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at least 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at least 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at least 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at least 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 or at least 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at most 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at most 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at most 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10, at most 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 or at most 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 10.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at least 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at least 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at least 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at least 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at most 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at most 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at most 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11, at most 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 11.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 11. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modification of amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at least 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at least 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at least 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at least 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 or at least 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at most 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at most 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at most 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11, at most 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 or at most 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 11.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-146 or amino acids 153-294 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-146 or amino acids 153-294 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at least 75% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at least 80% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at least 85% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at least 90% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12 or at least 95% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at most 75% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at most 80% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at most 85% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12, at most 90% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12 or at most 95% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 202-243, or amino acids 250-294 of SEQ ID NO: 12.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 12. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modification of amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at least 75% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at least 80% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at least 85% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at least 90% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 or at least 95% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at most 75% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at most 80% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at most 85% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12, at most 90% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 or at most 95% amino acid identity with amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 57-61, amino acids 103-106, amino acids 198-201, or amino acids 244-249 of SEQ ID NO: 12.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 13.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-144 or amino acids 151-293 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-242, or amino acids 249-293 of SEQ ID NO: 13.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at least 75% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at least 80% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at least 85% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at least 90% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13 or at least 95% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at most 75% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at most 80% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at most 85% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13, at most 90% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13 or at most 95% amino acid identity with amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-55, amino acids 56-102, amino acids 103-144, amino acids 151-197, amino acids 198-245, or amino acids 246-279 of SEQ ID NO: 13.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-33 comprises amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-33 of SEQ ID NO: 13. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a modification of amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at least 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at least 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at least 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at least 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 or at least 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at most 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at most 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at most 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13, at most 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 or at most 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 243-248 of SEQ ID NO: 13.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 10-144 or amino acids 151-292 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 10-144 or amino acids 151-292 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at least 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at least 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at least 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at least 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at most 75% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at most 80% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at most 85% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14, at most 90% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-100, amino acids 105-144, amino acids 151-195, amino acids 200-241, or amino acids 248-292 of SEQ ID NO: 14.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 14. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a modification of amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at least 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at least 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at least 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at least 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 or at least 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at most 75% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at most 80% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at most 85% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14, at most 90% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 or at most 95% amino acid identity with amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 101-104, amino acids 196-199, or amino acids 242-247 of SEQ ID NO: 14.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 15. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at least 75% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at least 80% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at least 85% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at least 90% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15 or at least 95% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at most 75% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at most 80% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at most 85% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15, at most 90% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15 or at most 95% amino acid identity with amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-56, amino acids 62-102, amino acids 107-146, amino acids 153-197, amino acids 200-242, or amino acids 249-291 of SEQ ID NO: 15.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 15. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-33 comprises amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-33 of SEQ ID NO: 15. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a modification of amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at least 75% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at least 80% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at least 85% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at least 90% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 or at least 95% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at most 75% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at most 80% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at most 85% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15, at most 90% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 or at most 95% amino acid identity with amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 56-61, amino acids 103-106, amino acids 198-201, or amino acids 243-248 of SEQ ID NO: 15.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-141 or amino acids 148-285 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-141 or amino acids 148-285 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at least 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at least 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at least 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at least 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at most 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at most 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at most 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16, at most 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-234, or amino acids 241-285 of SEQ ID NO: 16.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 or a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 16. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modification of amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at least 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at least 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at least 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at least 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 or at least 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at most 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at most 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at most 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16, at most 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 or at most 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 235-240 of SEQ ID NO: 16.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-141 or amino acids 148-286 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-141 or amino acids 148-286 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at least 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at least 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at least 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at least 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at most 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at most 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at most 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17, at most 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 17.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-33 comprises amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-33 of SEQ ID NO: 17. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a modification of amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at least 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at least 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at least 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at least 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 or at least 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at most 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at most 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at most 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17, at most 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 or at most 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 17.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises amino acids 10-141 or amino acids 148-286 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises a 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, or a 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises amino acids 10-141 or amino acids 148-286 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a modified 1α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 1β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 1γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 2α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 2β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, or a modified 2γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at least 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at least 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at least 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at least 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18 or at least 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at most 75% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at most 80% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at most 85% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18, at most 90% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18 or at most 95% amino acid identity with amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In still other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In still other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-33 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 10-54, amino acids 60-98, amino acids 103-141, amino acids 148-190, amino acids 195-235, or amino acids 242-286 of SEQ ID NO: 18.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises a 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 or a 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-33 comprises amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a modified 1β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 1β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33, a modified 2β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 or a modified 2β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-33 of SEQ ID NO: 18. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a modification of amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at least 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at least 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at least 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at least 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 or at least 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at most 75% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at most 80% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at most 85% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18, at most 90% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 or at most 95% amino acid identity with amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-33 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 55-59, amino acids 99-102, amino acids 191-194, or amino acids 236-241 of SEQ ID NO: 18.
In an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain derived from a Clostridial HA-17. In an aspect of this embodiment, a β-trefoil domain derived from a Clostridial HA-17 comprises, e.g., a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 or a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial HA-17 comprises a α-fold motif of a β-trefoil domain of a Clostridial HA-17, a β-fold motif of a β-trefoil domain of a Clostridial HA-17 or a γ-fold motif of a β-trefoil domain of a Clostridial HA-17.
In an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-17. In an aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-17 comprises, e.g., a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 or a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial HA-17 comprises a modified α-fold motif of a β-trefoil domain of a Clostridial HA-17, a modified β-fold motif of a β-trefoil domain of a Clostridial HA-17 or a modified γ-fold motif of a β-trefoil domain of a Clostridial HA-17.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises amino acids 9-146 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises amino acids 9-146 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at least 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at least 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at least 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at least 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19 or at least 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at most 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at most 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at most 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19, at most 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19 or at most 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19.
In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In yet other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In still other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19. In other aspects of this embodiment, a Clostridial botulinum serotype A HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 19.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A HA-17 comprises amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A HA-17 of SEQ ID NO: 19. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a modification of amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at least 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at least 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at least 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at least 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 or at least 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at most 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at most 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at most 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19, at most 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 or at most 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 19.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises amino acids 9-146 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises amino acids 9-146 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at least 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at least 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at least 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at least 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20 or at least 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at most 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at most 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at most 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20, at most 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20 or at most 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20.
In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In yet other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In still other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20. In other aspects of this embodiment, a Clostridial botulinum serotype B HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 20.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B HA-17 comprises amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B HA-17 of SEQ ID NO: 20. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a modification of amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at least 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at least 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at least 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at least 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 or at least 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at most 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at most 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at most 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20, at most 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 or at most 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 20.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises amino acids 9-146 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises amino acids 9-146 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at least 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at least 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at least 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at least 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21 or at least 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at most 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at most 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at most 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21, at most 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21 or at most 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21. In other aspects of this embodiment, a Clostridial botulinum serotype C1 HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 21.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 HA-17 comprises amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 HA-17 of SEQ ID NO: 21. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a modification of amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at least 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at least 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at least 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at least 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 or at least 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at most 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at most 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at most 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21, at most 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 or at most 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 21.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises amino acids 9-146 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises amino acids 9-146 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at least 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at least 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at least 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at least 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22 or at least 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at most 75% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at most 80% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at most 85% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22, at most 90% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22 or at most 95% amino acid identity with amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In still other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22.
In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In yet other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In still other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22. In other aspects of this embodiment, a Clostridial botulinum serotype D HA-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 9-50, amino acids 55-91, or amino acids 95-146 of SEQ ID NO: 22.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D HA-17 comprises amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D HA-17 of SEQ ID NO: 22. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a modification of amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at least 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at least 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at least 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at least 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 or at least 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at most 75% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at most 80% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at most 85% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22, at most 90% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 or at most 95% amino acid identity with amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D HA-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 51-54 or amino acids 92-94 of SEQ ID NO: 22.
In an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain derived from a Clostridial NTNH. In an aspect of this embodiment, a β-trefoil domain derived from a Clostridial NTNH comprises, e.g., a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH or a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial NTNH, a β-fold motif of a β-trefoil domain of a Clostridial NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial NTNH.
In an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain with enhanced binding activity derived from a Clostridial NTNH. In an aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial NTNH comprises, e.g., a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH or, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial NTNH.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at least 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at least 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at least 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at least 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23 or at least 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at most 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at most 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at most 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23, at most 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23 or at most 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 23.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 23. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modification of amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at least 75% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at least 80% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at least 85% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at least 90% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 or at least 95% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at most 75% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at most 80% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at most 85% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23, at most 90% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 or at most 95% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 23.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at least 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at least 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at least 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at least 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24 or at least 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at most 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at most 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at most 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24, at most 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24 or at most 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1149-1199 of SEQ ID NO: 24.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 24. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modification of amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at least 75% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at least 80% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at least 85% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at least 90% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 or at least 95% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at most 75% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at most 80% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at most 85% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24, at most 90% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 or at most 95% amino acid identity with amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1148 of SEQ ID NO: 24.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1194 of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at least 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at least 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at least 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at least 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25 or at least 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at most 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at most 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at most 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25, at most 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25 or at most 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25.
In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In yet other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In still other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25. In other aspects of this embodiment, a Clostridial botulinum serotype A NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1138, or amino acids 1149-1194 of SEQ ID NO: 25.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype A NTNH comprises amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype A NTNH of SEQ ID NO: 25. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a modification of amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at least 75% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at least 80% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at least 85% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at least 90% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 or at least 95% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at most 75% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at most 80% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at most 85% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25, at most 90% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 or at most 95% amino acid identity with amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype A NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1139-1148 of SEQ ID NO: 25.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises amino acids 1049-1198 of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises amino acids 1049-1198 of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26.
In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at least 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at least 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at least 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at least 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26 or at least 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In yet other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at most 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at most 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at most 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26, at most 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26 or at most 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26.
In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In yet other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In still other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26.
In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In yet other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In still other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26. In other aspects of this embodiment, a Clostridial botulinum serotype B NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1198 of SEQ ID NO: 26.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype B NTNH comprises amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype B NTNH of SEQ ID NO: 26. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a modification of amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at least 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at least 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at least 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at least 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 or at least 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at most 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at most 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at most 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26, at most 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 or at most 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype B NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 26.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises amino acids 1049-1197 of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises amino acids 1049-1197 of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at least 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at least 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at least 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at least 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27 or at least 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at most 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at most 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at most 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27, at most 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27 or at most 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27.
In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In yet other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In still other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27. In other aspects of this embodiment, a Clostridial botulinum serotype C1 NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 27.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype C1 NTNH comprises amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype C1 NTNH of SEQ ID NO: 27. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a modification of amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at least 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at least 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at least 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at least 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 or at least 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at most 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at most 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at most 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27, at most 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 or at most 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype C1 NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 27.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises amino acids 1049-1197 of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises amino acids 1049-1197 of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28.
In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at least 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at least 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at least 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at least 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28 or at least 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In yet other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at most 75% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at most 80% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at most 85% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28, at most 90% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28 or at most 95% amino acid identity with amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28.
In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In yet other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In still other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28.
In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In yet other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In still other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28. In other aspects of this embodiment, a Clostridial botulinum serotype D NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1049-1096, amino acids 1110-1138, or amino acids 1148-1197 of SEQ ID NO: 28.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype D NTNH comprises amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype D NTNH of SEQ ID NO: 28. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a modification of amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at least 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at least 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at least 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at least 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 or at least 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at most 75% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at most 80% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at most 85% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28, at most 90% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 or at most 95% amino acid identity with amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype D NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1097-1109 or amino acids 1139-1147 of SEQ ID NO: 28.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises amino acids 1014-1163 of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises amino acids 1014-1163 of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29.
In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at least 75% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at least 80% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at least 85% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at least 90% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29 or at least 95% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In yet other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at most 75% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at most 80% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at most 85% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29, at most 90% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29 or at most 95% amino acid identity with amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29.
In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In yet other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In still other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29.
In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In yet other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In still other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29. In other aspects of this embodiment, a Clostridial botulinum serotype E NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1014-1061, amino acids 1075-1103, or amino acids 1114-1163 of SEQ ID NO: 29.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype E NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype E NTNH comprises amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype E NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype E NTNH of SEQ ID NO: 29. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a modification of amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at least 75% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at least 80% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at least 85% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at least 90% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 or at least 95% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at most 75% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at most 80% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at most 85% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29, at most 90% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 or at most 95% amino acid identity with amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype E NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1062-1074 or amino acids 1104-1113 of SEQ ID NO: 29.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1016-1160 of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1016-1160 of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at least 75% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at least 80% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at least 85% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at least 90% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30 or at least 95% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at most 75% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at most 80% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at most 85% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30, at most 90% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30 or at most 95% amino acid identity with amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In still other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In still other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1016-1063, amino acids 1077-1104, or amino acids 1115-1160 of SEQ ID NO: 30.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 30. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modification of amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at least 75% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at least 80% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at least 85% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at least 90% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 or at least 95% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at most 75% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at most 80% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at most 85% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30, at most 90% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 or at most 95% amino acid identity with amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1064-1076 or amino acids 1105-1114 of SEQ ID NO: 30.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1017-1166 of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1017-1166 of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at least 75% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at least 80% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at least 85% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at least 90% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31 or at least 95% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at most 75% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at most 80% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at most 85% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31, at most 90% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31 or at most 95% amino acid identity with amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In still other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31.
In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In yet other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In still other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31. In other aspects of this embodiment, a Clostridial botulinum serotype F NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1017-1064, amino acids 1078-1106, or amino acids 1117-1166 of SEQ ID NO: 31.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype F NTNH comprises amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype F NTNH of SEQ ID NO: 31. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a modification of amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at least 75% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at least 80% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at least 85% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at least 90% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 or at least 95% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at most 75% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at most 80% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at most 85% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31, at most 90% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 or at most 95% amino acid identity with amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype F NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1065-1077 or amino acids 1107-1116 of SEQ ID NO: 31.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises amino acids 1050-1199 of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises a α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH, a β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH or a γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises amino acids 1050-1199 of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a modified α-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH, a modified β-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH or a modified γ-fold motif of a β-trefoil domain of a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32.
In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at least 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at least 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at least 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at least 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32 or at least 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In yet other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at most 75% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at most 80% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at most 85% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32, at most 90% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32 or at most 95% amino acid identity with amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32.
In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In yet other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In still other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32.
In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In yet other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In still other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32. In other aspects of this embodiment, a Clostridial botulinum serotype G NTNH comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 1050-1097, amino acids 1111-1139, or amino acids 1150-1199 of SEQ ID NO: 32.
In another embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises a β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype G NTNH or a β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain derived from a Clostridial botulinum serotype G NTNH comprises amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype G NTNH or a modified β8/β9 hairpin turn of a β-trefoil domain of a Clostridial botulinum serotype G NTNH of SEQ ID NO: 32. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a modification of amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at least 75% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at least 80% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at least 85% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at least 90% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 or at least 95% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at most 75% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at most 80% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at most 85% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32, at most 90% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 or at most 95% amino acid identity with amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a Clostridial botulinum serotype G NTNH comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 1098-1110 or amino acids 1140-1149 of SEQ ID NO: 32.
Another example of an enhanced targeting domain that increases binding activity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell, includes, without limitation, ligands that bind the same receptors as naturally-occurring Clostridial toxins. Recent studies are revealing components of the endogenous receptors used by a Clostridial toxin during the intoxication process. As a non-limiting example, fibroblast growth factor 3 receptor (FGFR3) serves as a BoNT/A receptor, see, e.g., Ester Fernandez-Salas et al., Botulinum Toxin Screening Assays, PCT Patent Application No. 2005/006421 (Sep., 9, 2005). As another non-limiting example, synaptotagmin I serves as a BoNT/B receptor and as a BoNT/G receptor, see, e.g., Min Dong et al., Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells, 162(7) J. Cell Biol. 1293-1303 (2003); and Andreas Rummel et al., Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G, 279(29) J. Biol. Chem. 30865-30870 (2004). As yet another non-limiting example, synaptotagmin II serves as a BoNT/B receptor and as a BoNT/G receptor, see, e.g., Min Dong et al., supra, (2003); and Andreas Rummel et al., supra, (2004). The selection of a ligand domain as an enhanced binding region will depend on the Clostridial toxin being modified. As non-limiting examples, ligands that selectively bind to a FGFR3 could be used as an enhanced targeting domain for a modified BoNT/A, whereas ligands that selectively bind a Synaptotagmin I or Synaptotagmin II could be used as an enhanced targeting domain for a modified BoNT/B or a modified BoNT/G.
In addition to its enhanced targeting activity, replacement of a naturally-occurring targeting domain with an FGF ligand has an added advantage of reducing the likelihood of the modified toxin from eliciting an immunogenic response. Regions found in the HCC targeting domain are bound by neutralizing anti-BoNT/A antibodies, see, e.g., M. Zouhair Atassi et al., Mapping of the Antibody-binding Regions on Botulinum Neurotoxin H-chain Domain 855-1296 with Anti-toxin Antibodies from Three Host Species, 15 J. PROT. CHEM. 691-700, (1996); M. Zouhair Atassi & Behzod Z. Dolimbek, Mapping of the Antibody-binding Profile on Botulinum Neurotoxin A HN-domain (residues 449-859) with Anti-toxin Antibodies from Four Host Species. Antigenic Profile of the Entire H-chain of Botulinum Neurotoxin A, 23(1) PROTEIN J. 39-52, (2004). Therefore, elimination of this targeting domain will reduce the likelihood of an immunogenic response because 1) the Clostridial toxin HCC targeting domain is absent; 2) a human FGF targeting domain will most likely not elicit an immunogenic response in a patient because it is a human polypeptide.
Fibroblast growth factors (FGF) participate in many developmental, differentiation and growth and repair processes of cells through complex combinatorial signaling pathways. Presently, at least 23 ligands (FGF1-23) are known to signal through a family of five transmembrane tyrosine kinase FGF receptors (FGFR1-5). Affinity of FGFRs for their ligands is highly diverse with different affinities for each family member of growth factors, see, e.g., C. J. Powers et al., Fibroblast growth factors, their receptors and signaling, 7(3) Endocr. Relat. Cancer. 165-197 (2000). This diversity is achieved in part by the generation of alternatively spliced variants encoding distinct receptor isoforms, see, e.g., Bernhard Reuss & Oliver von Bohlen and Halbach, Fibroblast growth factors and their receptors in the central nervous system, 313(2) Cell Tissue Res. 139-157 (2003). The protein region that appears to have the highest influence on ligand binding selectivity is a portion of the IgIII domain, for which isoforms encoded by three different splice variants have been identified. These three isoforms, designated IgIIIa, IgIIIb and IgIIIc, have relative binding affinities for different FGFR family members. Alternative splicing in the FGFR ligand binding domain, designated a and b, generates additional receptor isoforms with novel ligand affinities. Isoforms for IgIIIa, IgIIIb and IgIIIc have been identified for both FGFR1 and FGFR2. Thus far, the IgIIIa isoform of FGFR3 and the IgIIIa and IgIIIb isoforms of FGFR4 and FGFR5 have not been reported.
Currently, several FGFs have been shown to selectively bind FGFR3, such as, e.g., FGF-1, FGF-2, FGF-4, FGF-8, FGF-9, FGF-17 and FGF-18, see, e.g., Hecht et al., 1995; Ornitz et al., 1996; and Xu et al., 2000. Additional studies have revealed that FGF-1 and FGF9 preferentially bind FGFR3IIIb, whereas FGF-1 FGF-2, FGF-4, FGF-8, and FGF9 preferentially bind FGFR3IIIc. Studies have shown that each of these ligands is present in various vertebrate species with a high degree of sequence identity which suggests functional equivalence or similarity. As a non-limiting example, FGF-8 is found in fish, birds and mammals and each of these FGF-8 ligands have over 80% amino acid sequence identity. As another non-limiting example, FGF-18 is found in fish, birds and mammals and each of these FGF-18 ligands have over 70% amino acid sequence identity. Crystallographic studies have revealed that all FGFs are structurally organized into a β-trefoil domain. The amino acid sequences comprising the β-trefoil domains found in various FGF ligands that bind FGFR3 are shown in Table 7.







TABLE 7







β-trefoil Domains of FGFs











Amino Acid Sequence Region of Carbohydrate Binding Moieties
















β4/β5

β8/β9



Ligand
SEQ ID NQ:
α-fold
β-hairpin turn
β-fold
β-hairpin turn
γ-fold
















FGF-1
33
26-64
65-67
 68-105
106-108
109-155


FGF-2
34
29-67
68-70
 71-111
112-114
115-155


FGF-4
35
 83-121
122-124
125-162
163-165
166-206


FGF-8
36
43-80
81-83
 84-123
124-126
127-172


FGF-9
37
 63-100
101-103
104-144
145-147
148-196


FGF-17
38
55-91
92-94
 95-134
135-137
138-183


FGF-18
39
54-91
92-94
 95-134
135-137
138-183









As used herein, the term “Fibroblast Growth Factor” is synonymous with “FGF” and means a polypeptide with selective binding activity, such as, e.g., a binding affinity or a binding specificity, for a receptor, including endogenous Clostridial toxin receptors such as, e.g., a receptor comprising FGFR3. It is envisioned that both naturally occurring FGFs as well as FGFs with enhanced binding activity can be used to practice aspects of the present invention. As used herein, the term “FGF with enhanced binding activity” means a FGF with enhanced binding activity for an endogenous Clostridial toxin receptor, such as, e.g., a binding affinity or a binding specificity, to a statistically significantly degree relative to an unmodified naturally occurring Clostridial toxin binding domain from a Clostridial toxin. By definition, a FGF with enhanced binding activity has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Table 7) and can be described in percent identity to the corresponding region of that reference sequence.
Any of a variety of sequence alignment methods can be used to determine percent identity of a modified FGF relative to a naturally-occurring FGF, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art and from the teaching herein.
Approaches well known to one skilled in the art on how to modify a FGF in order to increase its binding activity for an endogenous Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell. As described above, one approach involves identifying amino acids using computational protein design algorithms; changing specifically-identified amino acids using, without limitation, site-directed mutagenesis, oligonucleotide-directed mutagenesis and site-specific mutagenesis; and testing the binding activity of modified Clostridial toxins comprising a modified FGF with enhanced binding activity using, e.g., heterogeneous assays, homogeneous assays and non-separating homogeneous assays. It is further envisioned that the binding activity of a modified Clostridial toxin with enhanced binding activity disclosed in the present specification can be determined by affinity chromatography using immobilized receptors and interfacial optical assays. In another approach described above, a binding activity of a modified FGF for a naturally-occurring Clostridial toxin receptor present on a naturally-occurring Clostridial toxin target cell can be achieved using directed-evolution methods.
A FGF includes, without limitation, naturally occurring FGF variants, such as, e.g., FGF isoforms and FGF subtypes; non-naturally occurring FGF variants, such as, e.g., conservative FGF variants, non-conservative FGF variants, FGF chimerics, active FGF fragments thereof, or any combination thereof.
As used herein, the term “FGF variant,” whether naturally-occurring or non-naturally-occurring, means a FGF that has at least one amino acid change from the corresponding region of the disclosed reference sequences (see Tables 7) and can be described in percent identity to the corresponding region of that reference sequence. Unless expressly indicated, all FGF variants disclosed in the present specification are capable of executing the cell binding step of the intoxication process.
It is recognized by those of skill in the art that within each Clostridial bacterium there can be naturally occurring FGF variants that differ somewhat in their amino acid sequence, and also in the nucleic acids encoding these proteins. For example, there are presently at least four FGF-8 variants, FGF-8A, FGF-8A, FGF-8B, FGF-8E and FGF-8F, with specific FGF-8 variants showing various degrees of amino acid divergence when compared to another FGF-8 variant. As another example, there are presently at least two FGF-2 variants, FGF-2-1 and FGF-2-1, with the FGF-2-1 variant showing an amino acid divergence when compared to the FGF-2-2 variant. As used herein, the term “naturally occurring FGF variant” means any FGF produced by a naturally-occurring process, including, without limitation, FGF isoforms produced from alternatively-spliced transcripts, FGF isoforms produced by spontaneous mutation and FGF subtypes. A naturally occurring FGF variant can function in substantially the same manner as the reference FGF on which the naturally occurring FGF variant is based, and can be substituted for the reference FGF in any aspect of the present invention. A naturally occurring FGF variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference FGF on which the naturally occurring FGF variant is based. A naturally occurring FGF variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference FGF on which the naturally occurring FGF variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference FGF on which the naturally occurring FGF variant is based.
A non-limiting examples of a naturally occurring FGF variant is a FGF isoform such as, e.g., a FGF-1 isoform, a FGF-2 isoform, a FGF-4 isoform, a FGF-8 isoform, a FGF-9 isoform, a FGF-17 isoform and a FGF-18 isoform. A FGF isoform can function in substantially the same manner as the reference FGF on which the FGF isoform is based, and can be substituted for the reference FGF in any aspect of the present invention.
Another non-limiting examples of a naturally occurring FGF variant is a FGF subtype such as, e.g., a FGF-1 subtype, a FGF-2 subtype, a FGF-4 subtype, a FGF-8 subtype, a FGF-9 subtype, a FGF-17 subtype and a FGF-18 subtype. A FGF subtype can function in substantially the same manner as the reference FGF on which the FGF subtype is based, and can be substituted for the reference FGF in any aspect of the present invention.
As used herein, the term “non-naturally occurring FGF variant” means any FGF produced with the aid of human manipulation, including, without limitation, FGFs produced by genetic engineering using random mutagenesis or rational design and FGFs produced by chemical synthesis. Non-limiting examples of non-naturally occurring FGF variants include, e.g., conservative FGF variants, non-conservative FGF variants, FGF chimeric variants and active FGF fragments.
As used herein, the term “conservative FGF variant” means a FGF that has at least one amino acid substituted by another amino acid or an amino acid analog that has at least one property similar to that of the original amino acid from the reference FGF sequence (see Table 7). Examples of properties include, without limitation, similar size, topography, charge, hydrophobicity, hydrophilicity, lipophilicity, covalent-bonding capacity, hydrogen-bonding capacity, a physicochemical property, of the like, or any combination thereof. A conservative FGF variant can function in substantially the same manner as the reference FGF on which the conservative FGF variant is based, and can be substituted for the reference FGF in any aspect of the present invention. A conservative FGF variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids or 50 or more amino acids from the reference FGF on which the conservative FGF variant is based. A conservative FGF variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference FGF on which the conservative FGF variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference FGF on which the conservative FGF variant is based. Non-limiting examples of a conservative FGF variant include, e.g., a conservative FGF-1 variant, a conservative FGF-2 variant, a conservative FGF-4 variant, a conservative FGF-8 variant, a conservative FGF-9 variant, a conservative FGF-17 variant and a conservative FGF-18 variant.
As used herein, the term “non-conservative FGF variant” means a FGF in which 1) at least one amino acid is deleted from the reference FGF on which the non-conservative FGF variant is based; 2) at least one amino acid added to the reference FGF on which the non-conservative FGF is based; or 3) at least one amino acid is substituted by another amino acid or an amino acid analog that does not share any property similar to that of the original amino acid from the reference FGF sequence (see Table 7). A non-conservative FGF variant can function in substantially the same manner as the reference FGF on which the non-conservative FGF variant is based, and can be substituted for the reference FGF in any aspect of the present invention. A non-conservative FGF variant can delete one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids from the reference FGF on which the non-conservative FGF variant is based. A non-conservative FGF variant can add one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, and ten or more amino acids to the reference FGF on which the non-conservative FGF variant is based. A non-conservative FGF variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids or 50 or more amino acids from the reference FGF on which the non-conservative FGF variant is based. A non-conservative FGF variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference FGF on which the non-conservative FGF variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference FGF on which the non-conservative FGF variant is based. Non-limiting examples of a non-conservative FGF variant include, e.g., a non-conservative FGF-1 variant, a non-conservative FGF-2 variant, a non-conservative FGF-4 variant, a non-conservative FGF-8 variant, a non-conservative FGF-9 variant, a non-conservative FGF-17 variant and a non-conservative FGF-18 variant.
As used herein, the term “FGF chimeric” means a polypeptide comprising at least a portion of a FGF and at least a portion of at least one other polypeptide to form an enhanced targeting domain with at least one property different from the reference FGF (see Tables 7), with the proviso that this FGF chimeric can specifically bind to an endogenous Clostridial toxin receptor present in a Clostridial toxin target cell, and thus participate in executing the overall cellular mechanism whereby a Clostridial toxin proteolytically cleaves a substrate.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain derived from a FGF. In an aspect of this embodiment, a β-trefoil domain derived from a FGF comprises, e.g., a β-trefoil domain derived from a FGF-1, a β-trefoil domain derived from a FGF-2, a β-trefoil domain derived from FGF-4, a β-trefoil domain derived from a FGF-8, a β-trefoil domain derived from a FGF-9, a β-trefoil domain derived from a FGF-17 or a β-trefoil domain derived from a FGF-18. In another aspect of this embodiment, a β-trefoil domain derived from a FGF comprises a α-fold motif of a β-trefoil domain of a FGF, a β-fold motif of a β-trefoil domain of a FGF or a γ-fold motif of a β-trefoil domain of a FGF.
In an embodiment, a modified Clostridial toxin disclosed in the present specification comprises an enhanced targeting domain comprising a β-trefoil domain with enhanced binding activity derived from a FGF. In an aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF comprises, e.g., a β-trefoil domain with enhanced binding activity derived from a FGF-1, a β-trefoil domain with enhanced binding activity derived from a FGF-2, a β-trefoil domain with enhanced binding activity derived from a FGF-4, a β-trefoil domain with enhanced binding activity derived from a FGF-8, a β-trefoil domain with enhanced binding activity derived from a FGF-9, a β-trefoil domain with enhanced binding activity derived from a FGF-17 or a β-trefoil domain with enhanced binding activity derived from a FGF-18. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF comprises a modified α-fold motif of a β-trefoil domain of a FGF, a modified β-fold motif of a β-trefoil domain of a FGF or a modified γ-fold motif of a β-trefoil domain of a FGF.
In another embodiment, a β-trefoil domain derived from a FGF-1 comprises a β-trefoil domain derived from a FGF-1 of SEQ ID NO: 33. In another embodiment, a β-trefoil domain derived from a FGF-1 comprises amino acids 26-155 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-1 comprises a α-fold motif of a β-trefoil domain of a FGF-1, a β-fold motif of a β-trefoil domain of a FGF-1 or a γ-fold motif of a β-trefoil domain of a FGF-1 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-1 comprises amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-1 of SEQ ID NO: 33. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises amino acids 26-155 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a modified α-fold motif of a β-trefoil domain of a FGF-1, a modified β-fold motif of a β-trefoil domain of a FGF-1 or a modified γ-fold motif of a β-trefoil domain of a FGF-1 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33.
In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at least 75% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at least 80% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at least 85% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at least 90% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33 or at least 95% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In yet other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at most 75% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at most 80% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at most 85% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33, at most 90% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33 or at most 95% amino acid identity with amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33.
In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In yet other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In still other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33.
In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In yet other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In still other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33. In other aspects of this embodiment, a FGF-1 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 26-64, amino acids 68-105, or amino acids 109-155 of SEQ ID NO: 33.
In another embodiment, a β-trefoil domain derived from a FGF-1 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-1 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-1 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-1 comprises amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-1 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-1 of SEQ ID NO: 33. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a modification of amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at least 75% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at least 80% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at least 85% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at least 90% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 or at least 95% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at most 75% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at most 80% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at most 85% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33, at most 90% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 or at most 95% amino acid identity with amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-1 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 65-67 or amino acids 106-108 of SEQ ID NO: 33.
In another embodiment, a β-trefoil domain derived from a FGF-2 comprises a β-trefoil domain derived from a FGF-2 of SEQ ID NO: 34. In another embodiment, a β-trefoil domain derived from a FGF-2 comprises amino acids 29-155 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-2 comprises a α-fold motif of a β-trefoil domain of a FGF-2, a β-fold motif of a β-trefoil domain of a FGF-2 or a γ-fold motif of a β-trefoil domain of a FGF-2 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-2 comprises amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-2 of SEQ ID NO: 34. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises amino acids 29-155 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a modified α-fold motif of a β-trefoil domain of a FGF-2, a modified β-fold motif of a β-trefoil domain of a FGF-2 or a modified γ-fold motif of a β-trefoil domain of a FGF-2 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34.
In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at least 75% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at least 80% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at least 85% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at least 90% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34 or at least 95% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In yet other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at most 75% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at most 80% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at most 85% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34, at most 90% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34 or at most 95% amino acid identity with amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34.
In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In yet other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In still other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34.
In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In yet other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In still other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34. In other aspects of this embodiment, a FGF-2 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 29-67, amino acids 71-111, or amino acids 115-155 of SEQ ID NO: 34.
In another embodiment, a β-trefoil domain derived from a FGF-2 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-2 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-2 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-2 comprises amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-2 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-2 of SEQ ID NO: 34. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a modification of amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at least 75% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at least 80% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at least 85% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at least 90% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 or at least 95% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at most 75% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at most 80% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at most 85% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34, at most 90% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 or at most 95% amino acid identity with amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-2 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 68-70 or amino acids 112-114 of SEQ ID NO: 34.
In another embodiment, a β-trefoil domain derived from a FGF-4 comprises a β-trefoil domain derived from a FGF-4 of SEQ ID NO: 35. In another embodiment, a β-trefoil domain derived from a FGF-4 comprises amino acids 83-206 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-4 comprises a α-fold motif of a β-trefoil domain of a FGF-4, a β-fold motif of a β-trefoil domain of a FGF-4 or a γ-fold motif of a β-trefoil domain of a FGF-4 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-4 comprises amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-4 of SEQ ID NO: 35. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises amino acids 83-206 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a modified α-fold motif of a β-trefoil domain of a FGF-4, a modified β-fold motif of a β-trefoil domain of a FGF-4 or a modified γ-fold motif of a β-trefoil domain of a FGF-4 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35.
In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at least 75% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at least 80% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at least 85% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at least 90% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35 or at least 95% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In yet other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at most 75% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at most 80% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at most 85% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35, at most 90% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35 or at most 95% amino acid identity with amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35.
In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In yet other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In still other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35.
In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In yet other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In still other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35. In other aspects of this embodiment, a FGF-4 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 83-121, amino acids 125-162, or amino acids 166-206 of SEQ ID NO: 35.
In another embodiment, a β-trefoil domain derived from a FGF-4 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-4 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-4 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-4 comprises amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-4 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-4 of SEQ ID NO: 35. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a modification of amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at least 75% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at least 80% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at least 85% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at least 90% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 or at least 95% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at most 75% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at most 80% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at most 85% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35, at most 90% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 or at most 95% amino acid identity with amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-4 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 122-124 or amino acids 163-165 of SEQ ID NO: 35.
In another embodiment, a β-trefoil domain derived from a FGF-8 comprises a β-trefoil domain derived from a FGF-8 of SEQ ID NO: 36. In another embodiment, a β-trefoil domain derived from a FGF-8 comprises amino acids 43-172 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-8 comprises a α-fold motif of a β-trefoil domain of a FGF-8, a β-fold motif of a β-trefoil domain of a FGF-8 or a γ-fold motif of a β-trefoil domain of a FGF-8 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-8 comprises amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-8 of SEQ ID NO: 36. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises amino acids 43-172 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a modified α-fold motif of a β-trefoil domain of a FGF-8, a modified β-fold motif of a β-trefoil domain of a FGF-8 or a modified γ-fold motif of a β-trefoil domain of a FGF-8 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36.
In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at least 75% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at least 80% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at least 85% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at least 90% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36 or at least 95% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In yet other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at most 75% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at most 80% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at most 85% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36, at most 90% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36 or at most 95% amino acid identity with amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36.
In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In yet other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In still other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36.
In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In yet other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In still other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36. In other aspects of this embodiment, a FGF-8 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 43-80, amino acids 84-123, or amino acids 127-172 of SEQ ID NO: 36.
In another embodiment, a β-trefoil domain derived from a FGF-8 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-8 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-8 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-8 comprises amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-8 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-8 of SEQ ID NO: 36. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a modification of amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at least 75% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at least 80% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at least 85% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at least 90% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 or at least 95% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at most 75% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at most 80% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at most 85% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36, at most 90% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 or at most 95% amino acid identity with amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-8 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 81-83 or amino acids 124-126 of SEQ ID NO: 36.
In another embodiment, a β-trefoil domain derived from a FGF-9 comprises a β-trefoil domain derived from a FGF-9 of SEQ ID NO: 37. In another embodiment, a β-trefoil domain derived from a FGF-9 comprises amino acids 63-196 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-9 comprises a α-fold motif of a β-trefoil domain of a FGF-9, a β-fold motif of a β-trefoil domain of a FGF-9 or a γ-fold motif of a β-trefoil domain of a FGF-9 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-9 comprises amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-9 of SEQ ID NO: 37. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises amino acids 63-196 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a modified α-fold motif of a β-trefoil domain of a FGF-9, a modified β-fold motif of a β-trefoil domain of a FGF-9 or a modified γ-fold motif of a β-trefoil domain of a FGF-9 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37.
In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at least 75% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at least 80% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at least 85% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at least 90% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37 or at least 95% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In yet other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at most 75% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at most 80% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at most 85% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37, at most 90% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37 or at most 95% amino acid identity with amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37.
In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In yet other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In still other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37.
In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In yet other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In still other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37. In other aspects of this embodiment, a FGF-9 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 63-100, amino acids 104-144, or amino acids 148-196 of SEQ ID NO: 37.
In another embodiment, a β-trefoil domain derived from a FGF-9 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-9 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-9 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-9 comprises amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-9 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-9 of SEQ ID NO: 37. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a modification of amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at least 75% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at least 80% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at least 85% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at least 90% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 or at least 95% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at most 75% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at most 80% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at most 85% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37, at most 90% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 or at most 95% amino acid identity with amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-9 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 101-103 or amino acids 145-147 of SEQ ID NO: 37.
In another embodiment, a β-trefoil domain derived from a FGF-17 comprises a β-trefoil domain derived from a FGF-17 of SEQ ID NO: 38. In another embodiment, a β-trefoil domain derived from a FGF-17 comprises amino acids 55-183 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-17 comprises a α-fold motif of a β-trefoil domain of a FGF-17, a β-fold motif of a β-trefoil domain of a FGF-17 or a γ-fold motif of a β-trefoil domain of a FGF-17 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-17 comprises amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-17 of SEQ ID NO: 38. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises amino acids 55-183 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a modified α-fold motif of a β-trefoil domain of a FGF-17, a modified β-fold motif of a β-trefoil domain of a FGF-17 or a modified γ-fold motif of a β-trefoil domain of a FGF-17 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38.
In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at least 75% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at least 80% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at least 85% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at least 90% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38 or at least 95% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In yet other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at most 75% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at most 80% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at most 85% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38, at most 90% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38 or at most 95% amino acid identity with amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38.
In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In yet other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In still other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38.
In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In yet other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In still other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38. In other aspects of this embodiment, a FGF-17 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 55-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 38.
In another embodiment, a β-trefoil domain derived from a FGF-17 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-17 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-17 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-17 comprises amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-17 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-17 of SEQ ID NO: 38. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a modification of amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at least 75% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at least 80% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at least 85% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at least 90% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 or at least 95% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at most 75% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at most 80% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at most 85% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38, at most 90% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 or at most 95% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-17 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 38.
In another embodiment, a β-trefoil domain derived from a FGF-18 comprises a β-trefoil domain derived from a FGF-18 of SEQ ID NO: 39. In another embodiment, a β-trefoil domain derived from a FGF-18 comprises amino acids 54-183 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-18 comprises a α-fold motif of a β-trefoil domain of a FGF-18, a β-fold motif of a β-trefoil domain of a FGF-18 or a γ-fold motif of a β-trefoil domain of a FGF-18 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-18 comprises amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a β-trefoil domain with enhanced binding activity derived from a FGF-18 of SEQ ID NO: 39. In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises amino acids 54-183 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a modified α-fold motif of a β-trefoil domain of a FGF-18, a modified β-fold motif of a β-trefoil domain of a FGF-18 or a modified γ-fold motif of a β-trefoil domain of a FGF-18 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39.
In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at least 75% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at least 80% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at least 85% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at least 90% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39 or at least 95% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In yet other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at most 75% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at most 80% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at most 85% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39, at most 90% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39 or at most 95% amino acid identity with amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39.
In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid substitutions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In yet other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid deletions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In still other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 non-contiguous amino acid additions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39.
In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid substitutions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In yet other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid deletions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In still other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at most one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39. In other aspects of this embodiment, a FGF-18 comprising a β-trefoil domain with enhanced binding activity comprises a polypeptide having, e.g., at least one, two, three, four, five, six, seven, eight, nine, 10 or 20 contiguous amino acid additions relative to amino acids 54-91, amino acids 95-134, or amino acids 138-183 of SEQ ID NO: 39.
In another embodiment, a β-trefoil domain derived from a FGF-18 comprises a β4/β5 hairpin turn of a β-trefoil domain of a FGF-18 or a β8/β9 hairpin turn of a β-trefoil domain of a FGF-18 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain derived from a FGF-18 comprises amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39.
In another embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a modified β4/β5 hairpin turn of a β-trefoil domain of a FGF-18 or a modified β8/β9 hairpin turn of a β-trefoil domain of a FGF-18 of SEQ ID NO: 39. In another aspect of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a modification of amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least 70% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at least 75% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at least 80% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at least 85% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at least 90% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 or at least 95% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most 70% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at most 75% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at most 80% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at most 85% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39, at most 90% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 or at most 95% amino acid identity with amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a non-contiguous amino acid substitution of any amino acid from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 can be replaced with glycine. In other aspects of this embodiment, a non-contiguous amino acid substitution of any hydrophobic amino acid from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four non-contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four non-contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39.
In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid substitutions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, contiguous amino acid substitutions of amino acids from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 can be replaced with glycine. In other aspects of this embodiment, contiguous amino acid substitutions of hydrophobic amino acids from amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39 can be replaced with phenylalanine. In yet other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid deletions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In still other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at most one, two, three or four contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39. In other aspects of this embodiment, a β-trefoil domain with enhanced binding activity derived from a FGF-18 comprises a polypeptide having, e.g., at least one, two, three or four contiguous amino acid additions relative to amino acids 92-94 or amino acids 135-137 of SEQ ID NO: 39.
Because of the modular nature of the β-trefoil domain, it is envisioned that any combination of α-folds, β-folds, γ-folds, β4/β5 β-hairpin turns, β8/β9 β-hairpin turns, or any combination thereof from a β-trefoil domain of a Clostridial toxin binding domain, a β-trefoil domain of a modified Clostridial toxin binding domain, a β-trefoil domain of a NAP or a β-trefoil domain, a β-trefoil domain of a modified NAP, a β-trefoil domain of an FGF ligand, a β-trefoil domain of a modified FGF ligand, or any combination thereof, can be used to practice aspect of the present invention. As a non-limiting example, a modified Clostridial toxin disclosed in the present specification can comprise an enhanced targeting domain comprising a α-fold from a BoNT/A binding domain, a β-fold from a FGF-18 and a 2γ-fold from a Clostridial botulinum serotype A HA-33. As another non-limiting example, a modified Clostridial toxin disclosed in the present specification can comprise an enhanced targeting domain comprising a α-fold from a Clostridial botulinum serotype A HA-17, a β-fold from a Clostridial botulinum serotype E NTNH and a γ-fold from a modified BoNT/C1 binding domain with enhanced binding activity.
In another aspect of the invention, a modified Clostridial toxin with enhanced binding activity comprises, in part, a protease cleavage site is located within a di-chain loop region. As used herein, the term “di-chain loop region” means the amino acid sequence of a Clostridial toxin containing a protease cleavage site used to convert the single-chain form of a Clostridial toxin into the di-chain form. Non-limiting examples of a Clostridial toxin di-chain loop region, include, a di-chain loop region of BoNT/A comprising amino acids 430-454 of SEQ ID NO: 1; a di-chain loop region of BoNT/B comprising amino acids 437-446 of SEQ ID NO: 2; a di-chain loop region of BoNT/C1 comprising amino acids 437-453 of SEQ ID NO: 3; a di-chain loop region of BoNT/D comprising amino acids 437-450 of SEQ ID NO: 4; a di-chain loop region of BoNT/E comprising amino acids 412-426 of SEQ ID NO: 5; a di-chain loop region of BoNT/F comprising amino acids 429-445 of SEQ ID NO: 6; a di-chain loop region of BoNT/G comprising amino acids 436-450 of SEQ ID NO: 7; and a di-chain loop region of TeNT comprising amino acids 439-467 of SEQ ID NO: 8 (Table 8).







TABLE 8







Di-chain Loop Region of Clostridial Toxins












SEQ 

Di-chain Loop Region Containing the 




ID
Light Chain
Naturally-occurring Protease
Heavy Chain


Toxin
NO:
Region
Cleavage Site
Region





BoNT/A
1
NMNFTKLKNFTGLFEFYKLL
CVRGIITSKTKSLDKGYNK*----ALNDLC
IKVNNWDL


BoNT/B
2
KQAYEEISKEHLAVYKIQM
CKSVK*-------------------APGIC
IDVDNEDL


BoNT/C1
3
PALRKVNPENMLYLFTKF
CHKAIDGRSLYNK*------------TLDC
RELLVKNTDL


BoNT/D
4
PALQKLSSESVVDLFTKV
CLRLTKNSR*---------------DDSTC
IKVKNNRL


BoNT/E
5
IITPITGRGLVKKIIRF
CKNIVSVKGIR*--------------KSIC
IEINNGEL


BoNT/F
6
IIDSIPDKGLVEKIVKF
CKSVIPRKGTK*------------APPRLC
IRVNNSEL


BoNT/G
7
KEAYEEISLEHLVIYRIAM
CKPVMYKNTGK*--------------SEQC
IIVNNEDL


TeNT
8
TNAFRNVDGSGLVSKLIGL
CKKIIPPTNIRENLYNRTA*SLTDLGGELC
IKIKNEDL





The amino acid sequence displayed are as follows: BoNT/A, residues 325-462 of SEQ ID No: 1; BoNT/B, residues 332-454 of SEQ ID No: 2; BoNT/C1, residues 334-463 of SEQ ID No: 3; BoNT/D, residues 334-458 of SEQ ID No: 4; BoNT/E, residues 311-434 of SEQ ID No: 5; BoNT/F, residues 328-453 of SEQ ID No: 6; BoNT/G, residues 331-458 of SEQ ID No: 7; and TeNT, residues 334-474 of SEQ ID No: 8. An asterisks (*) indicates a peptide bond that is cleaved by a Clostridial toxin protease.






In is envisioned that any and all protease cleavage sites can be used to convert the single-chain polypeptide form of a Clostridial toxin into the di-chain form, including, without limitation, endogenous di-chain loop protease cleavage sites and exogenous protease cleavage sites. The location and kind of protease cleavage site may be critical because certain targeting domains require a free amino-terminal or carboxyl-terminal amino acid. For example, when a targeting domain is placed between two other domains, e.g., see FIG. 5, a criteria for selection of a protease cleavage site could be whether the protease that cleaves its site leaves a flush cut, exposing the free amino-terminal or carboxyl-terminal of the altered targeting domain necessary for selective binding of the targeting domain to its receptor. The selection and placement of a protease cleavage site is well known in the art.
As used herein, the term “endogenous di-chain loop protease cleavage site” is synonymous with a “naturally occurring di-chain loop protease cleavage site” and means a naturally occurring protease cleavage site found within the di-chain loop region of a naturally occurring Clostridial toxin and includes, without limitation, naturally occurring Clostridial toxin di-chain loop protease cleavage site variants, such as, e.g., Clostridial toxin di-chain loop protease cleavage site isoforms and Clostridial toxin di-chain loop protease cleavage site subtypes. Non-limiting examples of an endogenous protease cleavage site, include, e.g., a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site and a TeNT di-chain loop protease cleavage site.
As mentioned above, Clostridial toxins are translated as a single-chain polypeptide of approximately 150 kDa that is subsequently cleaved by proteolytic scission within a disulfide loop by a naturally-occurring protease. This posttranslational processing yields a di-chain molecule comprising an approximately 50 kDa light chain (LC) and an approximately 100 kDa heavy chain (HC) held together by a single disulphide bond and noncovalent interactions. While the identity of the protease is currently unknown, the di-chain loop protease cleavage site for many Clostridial toxins has been proposed. In BoNTs, cleavage at K448-A449 converts the single polypeptide form of BoNT/A into the di-chain form; cleavage at K441-A442 converts the single polypeptide form of BoNT/B into the di-chain form; cleavage at K449-T450 converts the single polypeptide form of BoNT/C1 into the di-chain form; cleavage at R445-D446 converts the single polypeptide form of BoNT/D into the di-chain form; cleavage at R422-K423 converts the single polypeptide form of BoNT/E into the di-chain form; cleavage at K439-A440 converts the single polypeptide form of BoNT/F into the di-chain form; and cleavage at K446-5447 converts the single polypeptide form of BoNT/G into the di-chain form. Proteolytic cleavage of the single polypeptide form of TeNT at A457-5458 results in the di-chain form. Such a di-chain loop protease cleavage site is operably-linked in-frame to a modified Clostridial toxin as a fusion protein.
However, it should also be noted that additional cleavage sites within the di-chain loop also appear to be cleaved resulting in the generation of a small peptide fragment being lost. As a non-limiting example, BoNT/A single-chain polypeptide cleave ultimately results in the loss of a ten amino acid fragment within the di-chain loop. Thus, in BoNTs, cleavage at S441-L442 converts the single polypeptide form of BoNT/A into the di-chain form; cleavage at G444-I445 converts the single polypeptide form of BoNT/B into the di-chain form; cleavage at S445-L446 converts the single polypeptide form of BoNT/C1 into the di-chain form; cleavage at K442-N443 converts the single polypeptide form of BoNT/D into the di-chain form; cleavage at K419-G420 converts the single polypeptide form of BoNT/E into the di-chain form; cleavage at K423-S424 converts the single polypeptide form of BoNT/E into the di-chain form; cleavage at K436-G437 converts the single polypeptide form of BoNT/F into the di-chain form; cleavage at T444-G445 converts the single polypeptide form of BoNT/G into the di-chain form; and cleavage at E448-Q449 converts the single polypeptide form of BoNT/G into the di-chain form.
Thus, in an embodiment, a protease cleavage site comprising an endogenous Clostridial toxin di-chain loop protease cleavage site is used to convert the single-chain toxin into the di-chain form. In aspects of this embodiment, conversion into the di-chain form by proteolytic cleavage occurs from a site comprising, e.g., a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site or a TeNT di-chain loop protease cleavage site.
In other aspects of this embodiment, conversion into the di-chain form by proteolytic cleavage occurs from a site comprising, e.g., a di-chain loop region of BoNT/A comprising amino acids 430-454 of SEQ ID NO: 1; a di-chain loop region of BoNT/B comprising amino acids 437-446 of SEQ ID NO: 2; a di-chain loop region of BoNT/C1 comprising amino acids 437-453 of SEQ ID NO: 3; a di-chain loop region of BoNT/D comprising amino acids 437-450 of SEQ ID NO: 4; a di-chain loop region of BoNT/E comprising amino acids 412-426 of SEQ ID NO: 5; a di-chain loop region of BoNT/F comprising amino acids 429-445 of SEQ ID NO: 6; a di-chain loop region of BoNT/G comprising amino acids 436-450 of SEQ ID NO: 7; or a di-chain loop region of TeNT comprising amino acids 439-467 of SEQ ID NO: 8.
It is also envisioned that an exogenous protease cleavage site can be used to convert the single-chain polypeptide form of a modified Clostridial toxin disclosed in the present specification into the di-chain form. As used herein, the term “exogenous protease cleavage site” is synonymous with a “non-naturally occurring protease cleavage site” and means a protease cleavage site that is not normally present in a di-chain loop region from a naturally occurring Clostridial toxin. Non-limiting examples of exogenous protease cleavage sites include, e.g., an enterokinase cleavage site (Table 9); a Thrombin cleavage site (Table 9); a Factor Xa cleavage site (Table 9); a human rhinovirus 3C protease cleavage site (Table 9); a tobacco etch virus (TEV) protease cleavage site (Table 9); a dipeptidyl aminopeptidase cleavage site; a small ubiquitin-like modifier (SUMO)/ubiquitin-like protein-1(ULP-1) protease cleavage site, such as, e.g., MADSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGK EMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGG (SEQ ID. NO: 57); and a Clostridial toxin substrate cleavage site.







TABLE 9







Exogenous Protease Cleavage Sites










Protease 

Non-limiting
SEQ ID


Cleavage Site
Consensus Sequence
Examples
NO:





Bovine 
DDDDK*
DDDDK*
40


enterokinase





Tobacco 
E P5 P4YP2Q*(G/S),
ENLYFQ*G
41


Etch Virus
where P2, P4 and P5 can 
ENLYFQ*S
42


(TEV)
be any amino acid
ENIYTQ*G
43




ENIYTQ*S
44




ENIYLQ*G
45




ENVYFQ*G
47




ENVYSQ*S
48




ENVYSQ*G
49




ENVYSQ*S
50


Human 
P5P4LFQ*GP
EALFQ*GP
51


Rhinovirus 3C
where P4 is G, A, V, L, 
EVLFQ*GP
52



I, M, S or T and P5 can any 
ELLFQ*GP
53



amino acid, with D or 
DALFQ*GP
54



E preferred.
DVLFQ*GP
55




DLLFQ*GP
56


SUMO/ULP-1
Tertiary structure
polypeptide-G*
57


Thrombin
P3P2(R/K)P1′,
GVR*G
58



where P3 is any amino acid 
SAR*G
59



and P2 or P1′ is G with the 
SLR*G
60



other position being any 
DGR*I
61



amino acid
QGK*I
62


Thrombin
P4P3P(R/K)*P1′ P2′
LVPR*GS
63



where P1′ and P2′ can be 
LVPK*GS
64



any amino acid except for
FIPR*TF
65



acidic amino acids like 
VLPR*SF
66



D or E; and P3 and P4 are
IVPR*SF
67



hydrophobic amino acids 
IVPR*GY
68



like F, L, I, Y, W, V, M, P,
WPR*GV
69



C or A
VLPR*LI
70




VMPR*SL
71




MFPR*SL
72


Coagulation 
I(E/D)GR*
IDGR*
73


Factor Xa

IEGR*
74





An asterisks (*) indicates the peptide bond that is cleaved by the indicated protease.






As mentioned above, a Clostridial toxin is converted from a single polypeptide form into a di-chain molecule by proteolytic cleavage. While the naturally-occurring protease is currently not known, cleavage occurs within the di-chain loop region between the two cysteine residues that form the disulfide bridge (see Table 8). Replacement of an endogenous protease cleavage site with an exogenous protease cleavage site will enable cleavage of a modified Clostridial toxin disclosed in the present specification when expressed in an organism that does not produce the naturally-occurring protease used to cleave the di-chain loop region of a toxin. Similarly, an addition of an exogenous protease cleavage site in the di-chain loop region will also enable cleavage of a modified Clostridial toxin disclosed in the present specification when expressed in an organism that does not produce the naturally-occurring protease used to cleave the di-chain loop region of a toxin.
It is envisioned that an exogenous protease cleavage site of any and all lengths can be useful in aspects of the present invention with the proviso that the exogenous protease cleavage site is capable of being cleaved by its respective protease. Thus, in aspects of this embodiment, an exogenous protease cleavage site can be, e.g., at least 6 amino acids in length, at least 7 amino acids in length, at least 8 amino acids in length, at least 9 amino acids in length, at least 10 amino acids in length, at least 15 amino acids in length, at least 20 amino acids in length, at least 25 amino acids in length, at least 30 amino acids in length, at least 40 amino acids in length, at least 50 amino acids in length or at least 60 amino acids in length. In other aspects of this embodiment, an exogenous protease cleavage site can be, e.g., at most 6 amino acids in length, at most 7 amino acids in length, at most 8 amino acids in length, at most 9 amino acids in length, at most 10 amino acids in length, at most 15 amino acids in length, at most 20 amino acids in length, at most 25 amino acids in length, at most 30 amino acids in length, at most 40 amino acids in length, at most 50 amino acids in length or at most 60 amino acids in length.
In aspects of this embodiment, a di-chain loop region can be modified to substitute a naturally-occurring protease cleavage site for an exogenous protease cleavage site. In this type of modification, the naturally-occurring protease cleavage site is made inoperable and thus can not be cleaved by its protease. Only the exogenous protease cleavage site can be cleaved by its corresponding exogenous protease. In this type of modification, the exogenous protease site is operably-linked in-frame to a modified Clostridial toxin as a fusion protein and the site can be cleaved by its respective exogenous protease. As a non-limiting example, a single-chain modified BoNT/A comprising an exogenous protease cleavage site in the di-chain loop region can be cleaved by its respective exogenous protease to produce the di-chain form of the toxin.
In other aspects of this embodiment, a di-chain loop region can be modified to include an exogenous protease cleavage site in addition to the naturally-occurring protease cleavage site. In this type of modification, both cleavage sites are operably-linked in-frame to a modified Clostridial toxin as a fusion protein and both sites can be cleaved by their respective proteases. As a non-limiting example, a single-chain modified BoNT/A that comprises a di-chain loop containing both the naturally-occurring BoNT/A di-chain loop protease cleavage site and an exogenous protease cleavage site can be cleaved by either the naturally occurring di-chain loop protease or by the appropriate exogenous protease to produce the di-chain form of the toxin.
A naturally-occurring protease cleavage site can be made inoperable by altering at least the two amino acids flanking the peptide bond cleaved by the naturally-occurring di-chain loop protease. More extensive alterations can be made, with the proviso that the two cysteine residues of the di-chain loop region remain intact and can still form the disulfide bridge. Non-limiting examples of an amino acid alteration include deletion of an amino acid or replacement of the original amino acid with a different amino acid. Thus, in one embodiment, a naturally-occurring protease cleavage site is made inoperable by altering the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease. In other aspects of this embodiment, a naturally-occurring protease cleavage site is made inoperable by altering, e.g., at least three amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least four amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least five amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least six amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least seven amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least eight amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least nine amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least ten amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at least 15 amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; or at least 20 amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease.
In still other aspects of this embodiment, a naturally-occurring di-chain protease cleavage site is made inoperable by altering, e.g., at most three amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most four amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most five amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most six amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most seven amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most eight amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most nine amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most ten amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; at most 15 amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease; or at most 20 amino acids including the two amino acids flanking the peptide bond cleaved by a naturally-occurring protease.
In an embodiment, an exogenous protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In aspects of this embodiment, a modified Clostridial toxin comprises an exogenous protease cleavage site comprises, e.g., a bovine enterokinase protease cleavage site, a Tobacco Etch Virus protease cleavage site, a Human Rhinovirus 3C protease cleavage site, a SUMO/ULP-1 protease cleavage site, a Thrombin protease cleavage site or a Factor Xa protease cleavage site. In other aspects of this embodiment, an exogenous protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In an aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a bovine enterokinase cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a bovine enterokinase protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 40. Is still other aspects of this embodiment, a bovine enterokinase protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In another aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a Tobacco Etch Virus protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a Tobacco Etch Virus protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50. Is still other aspects of this embodiment, a Tobacco Etch Virus protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In still another aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a Human Rhinovirus 3C protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a Human Rhinovirus 3C protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 or SEQ ID NO: 56. Is still other aspects of this embodiment, a Human Rhinovirus 3C protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In yet another aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a SUMO/ULP-1 protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a SUMO/ULP-1 protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 57. Is still other aspects of this embodiment, a SUMO/ULP-1 protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In a further aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a Thrombin protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a Thrombin protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71 or SEQ ID NO: 72. Is still other aspects of this embodiment, a Thrombin protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In another aspect of this embodiment, an exogenous protease cleavage site can be, e.g., a Coagulation Factor Xa protease cleavage site is located within the di-chain loop of a modified Clostridial toxin. In other aspects of the embodiment, an exogenous protease cleavage site can be, e.g., a Coagulation Factor Xa protease cleavage site located within the di-chain loop of a modified Clostridial toxin comprises SEQ ID NO: 73 or SEQ ID NO: 74. Is still other aspects of this embodiment, a Coagulation Factor Xa protease cleavage site is located within the di-chain loop of, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
In another embodiment, an exogenous protease site comprises a Clostridial toxin substrate cleavage site. As used herein, the term “Clostridial toxin substrate cleavage site” means a scissile bond together with adjacent or non-adjacent recognition elements, or both, sufficient for detectable proteolysis at the scissile bond by a Clostridial toxin under conditions suitable for Clostridial toxin protease activity. By definition, a Clostridial toxin substrate cleavage site is susceptible to cleavage by at least one Clostridial toxin under conditions suitable for Clostridial toxin protease activity. Non-limiting examples of Clostridial toxin substrate cleavage site are disclosed in, e.g., Steward, L. E. et al., Self-Activating Clostridial Toxins, U.S. Patent Application 60/718,616 (Sep., 19, 2005).
It is understood that a modified Clostridial toxin disclosed in the present specification can optionally include one or more additional components. As a non-limiting example of an optional component, a modified Clostridial toxin can further comprise a flexible region comprising a flexible spacer. Non-limiting examples of a flexible spacer include, e.g., a G-spacer GGGGS (SEQ ID NO: 75) or an A-spacer EAAAK (SEQ ID NO: 76). A flexible region comprising flexible spacers can be used to adjust the length of a polypeptide region in order to optimize a characteristic, attribute or property of a polypeptide. Such a flexible region is operably-linked in-frame to the modified Clostridial toxin as a fusion protein. As a non-limiting example, a polypeptide region comprising one or more flexible spacers in tandem can be use to better expose a protease cleavage site thereby facilitating cleavage of that site by a protease. As another non-limiting example, a polypeptide region comprising one or more flexible spacers in tandem can be use to better present an enhanced targeting domain, thereby facilitating the binding of that enhanced targeting domain to its receptor.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification can further comprise a flexible region comprising a flexible spacer. In another embodiment, a modified Clostridial toxin disclosed in the present specification can further comprise flexible region comprising a plurality of flexible spacers in tandem. In aspects of this embodiment, a flexible region can comprise in tandem, e.g., at least 1 G-spacer, at least 2 G-spacers, at least 3 G-spacers, at least 4 G-spacers or at least 5 G-spacers. In other aspects of this embodiment, a flexible region can comprise in tandem, e.g., at most 1 G-spacer, at most 2 G-spacers, at most 3 G-spacers, at most 4 G-spacers or at most 5 G-spacers. In still other aspects of this embodiment, a flexible region can comprise in tandem, e.g., at least 1 A-spacer, at least 2 A-spacers, at least 3 A-spacers, at least 4 A-spacers or at least 5 A-spacers. In still other aspects of this embodiment, a flexible region can comprise in tandem, e.g., at most 1 A-spacer, at most 2 A-spacers, at most 3 A-spacers, at most 4 A-spacers or at most 5 A-spacers. In another aspect of this embodiment, a modified Clostridial toxin can comprise a flexible region comprising one or more copies of the same flexible spacers, one or more copies of different flexible-spacer regions, or any combination thereof.
In aspects of this embodiment, a modified Clostridial toxin comprising a flexible spacer can be, e.g., a modified BoNT/A, a modified BoNT/B, a modified BoNT/C1, a modified BoNT/D, a modified BoNT/E, a modified BoNT/F, a modified BoNT/G or a modified TeNT.
It is envisioned that a modified Clostridial toxin disclosed in the present specification can comprise a flexible spacer in any and all locations with the proviso that modified Clostridial toxin is capable of performing the intoxication process. In aspects of this embodiment, a flexible spacer is positioned between, e.g., an enzymatic domain and a translocation domain, an enzymatic domain and an enhanced targeting domain, an enzymatic domain and a protease cleavage site. In other aspects of this embodiment, a G-spacer is positioned between, e.g., an enzymatic domain and a translocation domain, an enzymatic domain and an enhanced targeting domain, an enzymatic domain and a protease cleavage site. In other aspects of this embodiment, a A-spacer is positioned between, e.g., an enzymatic domain and a translocation domain, an enzymatic domain and an enhanced targeting domain, an enzymatic domain and a protease cleavage site.
In other aspects of this embodiment, a flexible spacer is positioned between, e.g., an enhanced targeting domain and a translocation domain, an enhanced targeting domain and an enzymatic domain, an enhanced targeting domain and a protease cleavage site. In other aspects of this embodiment, a G-spacer is positioned between, e.g., an enhanced targeting domain and a translocation domain, an enhanced targeting domain and an enzymatic domain, an enhanced targeting domain and a protease cleavage site. In other aspects of this embodiment, a A-spacer is positioned between, e.g., an enhanced targeting domain and a translocation domain, an enhanced targeting domain and an enzymatic domain, an enhanced targeting domain and a protease cleavage site.
In yet other aspects of this embodiment, a flexible spacer is positioned between, e.g., a translocation domain and an enzymatic domain, an translocation domain and an enhanced targeting domain, an translocation domain and a protease cleavage site. In other aspects of this embodiment, a G-spacer is positioned between, e.g., a translocation domain and an enzymatic domain, an translocation domain and an enhanced targeting domain, an translocation domain and a protease cleavage site. In other aspects of this embodiment, a A-spacer is positioned between, e.g., a translocation domain and an enzymatic domain, an translocation domain and an enhanced targeting domain, a translocation domain and a protease cleavage site.
As another non-limiting example of an optional component, a modified Clostridial toxin can further comprise an epitope-binding region. An epitope-binding region can be used in a wide variety of procedures involving, e.g., protein purification and protein visualization. Such an epitope-binding region is operably-linked in-frame to a modified Clostridial toxin as a fusion protein. Non-limiting examples of an epitope-binding region include, e.g., FLAG, ExpressTM (SEQ ID NO: 77), human Influenza virus hemagluttinin (HA) (SEQ ID NO: 78), human p62c-Myc protein (c-MYC) (SEQ ID NO: 79), Vesicular Stomatitis Virus Glycoprotein (VSV-G) (SEQ ID NO: 80), Substance P (SEQ ID NO: 81), glycoprotein-D precursor of Herpes simplex virus (HSV) (SEQ ID NO: 82), V5 (SEQ ID NO: 83), AU1 (SEQ ID NO: 84) and AU5 (SEQ ID NO: 85); affinity-binding, such as. e.g., polyhistidine (HIS) (SEQ ID NO: 86), streptavidin binding peptide (strep), and biotin or a biotinylation sequence; peptide-binding regions, such as. e.g., the glutathione binding domain of glutathione-S-transferase, the calmodulin binding domain of the calmodulin binding protein, and the maltose binding domain of the maltose binding protein. Non-limiting examples of specific protocols for selecting, making and using an appropriate binding peptide are described in, e.g., Epitope Tagging, pp. 17.90-17.93 (Sambrook and Russell, eds., Molecular Cloning A Laboratory Manual, Vol. 3, 3rd ed. 2001); Antibodies: A Laboratory Manual (Edward Harlow & David Lane, eds., Cold Spring Harbor Laboratory Press, 2nd ed. 1998); and Using Antibodies: A Laboratory Manual: Portable Protocol No. I (Edward Harlow & David Lane, Cold Spring Harbor Laboratory Press, 1998). In addition, non-limiting examples of binding peptides as well as well-characterized reagents, conditions and protocols are readily available from commercial vendors that include, without limitation, BD Biosciences-Clontech, Palo Alto, Calif.; BD Biosciences Pharmingen, San Diego, Calif.; Invitrogen, Inc, Carlsbad, Calif.; QIAGEN, Inc., Valencia, Calif.; and Stratagene, La Jolla, Calif. These protocols are routine procedures well within the scope of one skilled in the art and from the teaching herein.
Thus, in an embodiment, a modified Clostridial toxin disclosed in the present specification can further comprise an epitope-binding region. In another embodiment, a modified Clostridial toxin disclosed in the present specification can further comprises a plurality of epitope-binding regions. In aspects of this embodiment, a modified Clostridial toxin can comprise, e.g., at least 1 epitope-binding region, at least 2 epitope-binding regions, at least 3 epitope-binding regions, at least 4 epitope-binding regions or at least 5 epitope-binding regions. In other aspects of this embodiment, a modified Clostridial toxin can comprise, e.g., at most 1 epitope-binding region, at most 2 epitope-binding regions, at most 3 epitope-binding regions, at most 4 epitope-binding regions or at most 5 epitope-binding regions. In another aspect of this embodiment, a modified Clostridial toxin can comprise one or more copies of the same epitope-binding region, one or more copies of different epitope-binding regions, or any combination thereof.
The location of an epitope-binding region can be in various positions, including, without limitation, at the amino terminus of a modified Clostridial toxin, within a modified Clostridial toxin, or at the carboxyl terminus of a modified Clostridial toxin. Thus, in an embodiment, an epitope-binding region is located at the amino-terminus of a modified Clostridial toxin. In such a location, a start methionine should be placed in front of the epitope-binding region. In addition, it is known in the art that when adding a polypeptide that is operationally-linked to the amino terminus of another polypeptide comprising the start methionine that the original methionine residue can be deleted. This is due to the fact that the added polypeptide will contain a new start methionine and that the original start methionine may reduce optimal expression of the fusion protein. In aspects of this embodiment, an epitope-binding region located at the amino-terminus of a modified Clostridial toxin disclosed in the present specification can be, e.g., a FLAG, ExpressTM epitope-binding region, a human Influenza virus hemagluttinin (HA) epitope-binding region, a human p62c-Myc protein (c-MYC) epitope-binding region, a Vesicular Stomatitis Virus Glycoprotein (VSV-G) epitope-binding region, a Substance P epitope-binding region, a glycoprotein-D precursor of Herpes simplex virus (HSV) epitope-binding region, a V5 epitope-binding region, a AU1 epitope-binding region, a AU5 epitope-binding region, a polyhistidine epitope-binding region, a streptavidin binding peptide epitope-binding region, a biotin epitope-binding region, a biotinylation epitope-binding region, a glutathione binding domain of glutathione-S-transferase, a calmodulin binding domain of the calmodulin binding protein or a maltose binding domain of the maltose binding protein.
In another embodiment, an epitope-binding region is located at the carboxyl-terminus of a modified Clostridial toxin. In aspects of this embodiment, an epitope-binding region located at the carboxyl-terminus of a modified Clostridial toxin disclosed in the present specification can be, e.g., a FLAG, ExpressTM epitope-binding region, a human Influenza virus hemagluttinin (HA) epitope-binding region, a human p62c-Myc protein (c-MYC) epitope-binding region, a Vesicular Stomatitis Virus Glycoprotein (VSV-G) epitope-binding region, a Substance P epitope-binding region, a glycoprotein-D precursor of Herpes simplex virus (HSV) epitope-binding region, a V5 epitope-binding region, a AU1 epitope-binding region, a AU5 epitope-binding region, a polyhistidine epitope-binding region, a streptavidin binding peptide epitope-binding region, a biotin epitope-binding region, a biotinylation epitope-binding region, a glutathione binding domain of glutathione-S-transferase, a calmodulin binding domain of the calmodulin binding protein or a maltose binding domain of the maltose binding protein.
It is envisioned that a modified Clostridial toxin disclosed in the present specification can comprise an enhance targeting domain in any and all locations with the proviso that modified Clostridial toxin is capable of performing the intoxication process. Non-limiting examples include, locating an enhance targeting domain at the amino terminus of a modified Clostridial toxin (see FIG. 4); locating an enhance targeting domain between a Clostridial toxin enzymatic domain and a Clostridial toxin translocation domain of a modified Clostridial toxin (see FIG. 5); and locating an enhance targeting domain at the carboxyl terminus of a modified Clostridial toxin (see FIG. 6). The enzymatic domain of naturally-occurring Clostridial toxins contains the native start methionine. Thus, in domain organizations where the enzymatic domain is not in the amino-terminal location an amino acid sequence comprising the start methionine should be placed in front of the amino-terminal domain. Likewise, where the enhanced targeting domain is in the amino-terminal position, an amino acid sequence comprising a start methionine and a protease cleavage site may be operably-linked in situations in which the enhanced targeting domain requires a free amino terminus, see, e.g., Shengwen Li et al., Degradable Clostridial Toxins, International Patent Application Publication WO 2006/026780 (Mar. 9, 2006). In addition, it is known in the art that when adding a polypeptide that is operably-linked to the amino terminus of another polypeptide comprising the start methionine that the original methionine residue can be deleted.
Thus, in an embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain and an enhanced targeting domain. In an aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, a protease cleavage site, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain and an enhanced targeting domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, an endogenous protease cleavage site, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain and an enhanced targeting domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, an exogenous protease cleavage site, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain and an enhanced targeting domain.
In another embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, an enhanced targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In an aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, a protease cleavage site, an enhanced targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, an endogenous protease cleavage site, an enhanced targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin enzymatic domain, an exogenous protease cleavage site, an enhanced targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain.
In another embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain and a Clostridial toxin enzymatic domain. In an aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, a protease cleavage site and a Clostridial toxin enzymatic domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, an endogenous protease cleavage site and a Clostridial toxin enzymatic domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, an exogenous protease cleavage site and a Clostridial toxin enzymatic domain.
In another embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In an aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin enzymatic domain, a protease cleavage site, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin enzymatic domain, an endogenous protease cleavage site, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising an enhanced targeting domain, a Clostridial toxin enzymatic domain, an exogenous protease cleavage site, a Clostridial toxin translocation domain and a Clostridial toxin translocation facilitating domain.
In another embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, a Clostridial toxin enzymatic domain and an enhanced targeting domain. In an aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, a protease cleavage site, a Clostridial toxin enzymatic domain and an enhanced targeting domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, an endogenous protease cleavage site, a Clostridial toxin enzymatic domain and an enhanced targeting domain. In another aspect of this embodiment, a modified Clostridial toxin can comprise an amino to carboxyl single polypeptide linear order comprising a Clostridial toxin translocation domain, a Clostridial toxin translocation facilitating domain, an exogenous protease cleavage site, a Clostridial toxin enzymatic domain and an enhanced targeting domain.
Aspects of the present invention provide, in part modified Clostridial toxins. Non-limiting examples of Clostridial toxin modifications disclosed in the present specification include, e.g., addition of an enhanced targeting domain, addition of a protease cleavage site, rearrangement of the enzymatic, translocation and binding domains and addition of a spacer region. It is understood that all such modifications do not substantially affect the ability of a modified Clostridial toxin to intoxicate a cell. As used herein, the term “do not substantially affect” means a modified Clostridial toxin can still execute the overall cellular mechanism whereby a Clostridial toxin enters a neuron and inhibits neurotransmitter release and encompasses the binding of a Clostridial toxin to a low or high affinity receptor complex, the internalization of the toxin/receptor complex, the translocation of the Clostridial toxin light chain into the cytoplasm and the enzymatic modification of a Clostridial toxin substrate. In aspects of this embodiment, the modified Clostridial toxin is, e.g., at least 10% as toxic as a naturally-occurring Clostridial toxin, at least 20% as toxic as a naturally-occurring Clostridial toxin, at least 30% as toxic as a naturally-occurring Clostridial toxin, at least 40% as toxic as a naturally-occurring Clostridial toxin, at least 50% as toxic as a naturally-occurring Clostridial toxin, at least 60% as toxic as a naturally-occurring Clostridial toxin, at least 70% as toxic as a naturally-occurring Clostridial toxin, at least 80% as toxic as a naturally-occurring Clostridial toxin, at least 90% as toxic as a naturally-occurring Clostridial toxin or at least 95% as toxic as a naturally-occurring Clostridial toxin. In aspects of this embodiment, the modified Clostridial toxin is, e.g., at most 10% as toxic as a naturally-occurring Clostridial toxin, at most 20% as toxic as a naturally-occurring Clostridial toxin, at most 30% as toxic as a naturally-occurring Clostridial toxin, at most 40% as toxic as a naturally-occurring Clostridial toxin, at most 50% as toxic as a naturally-occurring Clostridial toxin, at most 60% as toxic as a naturally-occurring Clostridial toxin, at most 70% as toxic as a naturally-occurring Clostridial toxin, at most 80% as toxic as a naturally-occurring Clostridial toxin, at most 90% as toxic as a naturally-occurring Clostridial toxin or at most 95% as toxic as a naturally-occurring Clostridial toxin.
Another aspect of the present invention provides polynucleotide molecules encoding modified Clostridial toxins disclosed in the present specification. It is envisioned that any and all modified Clostridial toxin disclosed in the present specification can be encoded by a polynucleotide molecule.
Aspects of the present invention provide, in part polynucleotide molecules. As used herein, the term “polynucleotide molecule” is synonymous with “nucleic acid molecule” and means a polymeric form of nucleotides, such as, e.g., ribonucleotides and deoxyribonucleotides, of any length. It is envisioned that any and all polynucleotide molecules that can encode a modified Clostridial toxin disclosed in the present specification can be useful, including, without limitation naturally-occurring and non-naturally-occurring DNA molecules and naturally-occurring and non-naturally-occurring RNA molecules. Non-limiting examples of naturally-occurring and non-naturally-occurring DNA molecules include single-stranded DNA molecules, double-stranded DNA molecules, genomic DNA molecules, cDNA molecules, vector constructs, such as, e.g., plasmid constructs, phagmid constructs, bacteriophage constructs, retroviral constructs and artificial chromosome constructs. Non-limiting examples of naturally-occurring and non-naturally-occurring RNA molecules include single-stranded RNA, double stranded RNA and mRNA.
Thus, in an embodiment, a polynucleotide molecule encodes a modified Clostridial toxin disclosed in the present specification.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising a Clostridial toxin enzymatic domain disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a modified Clostridial toxin enzymatic domain comprises a naturally occurring Clostridial toxin enzymatic domain variant, such as, e.g., a Clostridial toxin enzymatic domain isoform or a Clostridial toxin enzymatic domain subtype. In another aspect of this embodiment, a polynucleotide molecule encoding a Clostridial toxin enzymatic domain comprises a non-naturally occurring Clostridial toxin enzymatic domain variant, such as, e.g., a conservative Clostridial toxin enzymatic domain variant, a non-conservative Clostridial toxin enzymatic domain variant or an active Clostridial toxin enzymatic domain fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial toxin enzymatic domain comprises a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain, a TeNT enzymatic domain, or active fragment thereof.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising a Clostridial toxin translocation domain disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a modified Clostridial toxin translocation domain comprises a naturally occurring Clostridial toxin translocation domain variant, such as, e.g., a Clostridial toxin translocation domain isoform or a Clostridial toxin translocation domain subtype. In another aspect of this embodiment, a polynucleotide molecule encoding a Clostridial toxin translocation domain comprises a non-naturally occurring Clostridial toxin translocation domain variant, such as, e.g., a conservative Clostridial toxin translocation domain variant, a non-conservative Clostridial toxin translocation domain variant or an active Clostridial toxin translocation domain fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial toxin translocation domain comprises a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain, a TeNT translocation domain, or active fragment thereof.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising a translocation facilitating domain disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a translocation facilitating domain comprises a naturally occurring Clostridial toxin translocation facilitating domain variant, such as, e.g., a Clostridial toxin translocation facilitating domain isoform or a Clostridial toxin translocation facilitating domain subtype. In another aspect of this embodiment, a polynucleotide molecule encoding a translocation facilitating domain comprises a non-naturally occurring Clostridial toxin translocation facilitating domain variant, such as, e.g., a conservative Clostridial toxin translocation facilitating domain variant, a non-conservative Clostridial toxin translocation facilitating domain variant or an active Clostridial toxin translocation facilitating domain fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial toxin translocation facilitating domain comprises a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation facilitating domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain, a TeNT translocation facilitating domain, or active fragment thereof. In yet another aspect of this embodiment, a polynucleotide molecule encoding a translocation domain comprises a naturally occurring enveloped virus fusogenic peptide domain variant, such as, e.g., an enveloped virus fusogenic peptide domain isoform or an enveloped virus fusogenic peptide domain subtype. In another aspect of this embodiment, a polynucleotide molecule encoding a translocation domain comprises a non-naturally occurring enveloped virus fusogenic peptide domain variant, such as, e.g., a conservative enveloped virus fusogenic peptide domain variant, a non-conservative enveloped virus fusogenic peptide domain variant or an active enveloped virus fusogenic peptide domain fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding an enveloped virus fusogenic peptide domain comprises an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain, a foamy virus fusogenic peptide domain, or active fragment thereof.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising an enhanced targeting domain disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding an enhanced targeting domain comprises a modified Clostridial toxin targeting domain with enhanced binding activity disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a modified Clostridial toxin targeting domain with enhanced binding activity comprises a non-naturally occurring Clostridial toxin targeting domain variant with enhanced binding activity, such as, e.g., a conservative Clostridial toxin targeting domain variant with enhanced binding activity, a non-conservative Clostridial toxin targeting domain variant with enhanced binding activity or an active Clostridial toxin targeting domain fragment with enhanced binding activity, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial toxin targeting domain with enhanced binding activity comprises a BoNT/A targeting domain with enhanced binding activity, a BoNT/B targeting domain with enhanced binding activity, a BoNT/C1 targeting domain with enhanced binding activity, a BoNT/D targeting domain with enhanced binding activity, a BoNT/E targeting domain with enhanced binding activity, a BoNT/F targeting domain with enhanced binding activity, a BoNT/G targeting domain with enhanced binding activity, a TeNT targeting domain with enhanced binding activity, or active fragment thereof.
In an aspect of this embodiment, an enhanced targeting domain comprises a Clostridial NAP disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a Clostridial NAP comprises a naturally occurring Clostridial NAP variant, such as, e.g., a Clostridial NAP isoform or a Clostridial NAP subtype. In an aspect of this embodiment, a polynucleotide molecule encoding a NAP comprises a non-naturally occurring Clostridial NAP variant, such as, e.g., a conservative Clostridial NAP variant, a non-conservative Clostridial NAP variant or an active Clostridial NAP fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial NAP comprises a Clostridial botulinum serotype A HA-33, a Clostridial botulinum serotype B HA-33, a Clostridial botulinum serotype C1 HA-33, a Clostridial botulinum serotype D HA-33, a Clostridial botulinum serotype A HA-17, a Clostridial botulinum serotype B HA-17, a Clostridial botulinum serotype C1 HA-17, a Clostridial botulinum serotype D HA-17, a Clostridial botulinum serotype A NTNH, a Clostridial botulinum serotype B NTNH, a Clostridial botulinum serotype C1 NTNH, a Clostridial botulinum serotype D NTNH, a Clostridial botulinum serotype E NTNH, a Clostridial botulinum serotype F NTNH and a Clostridial botulinum serotype G NTNH.
In an aspect of this embodiment, an enhanced targeting domain comprises a Clostridial NAP with enhanced binding activity disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a NAP with enhanced binding activity comprises a non-naturally occurring Clostridial NAP variant with enhanced binding activity, such as, e.g., a conservative Clostridial NAP variant with enhanced binding activity, a non-conservative Clostridial NAP variant with enhanced binding activity or an active Clostridial NAP fragment with enhanced binding activity, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a Clostridial NAP comprises a Clostridial botulinum serotype A HA-33 with enhanced binding activity, a Clostridial botulinum serotype B HA-33 with enhanced binding activity, a Clostridial botulinum serotype C1 HA-33 with enhanced binding activity, a Clostridial botulinum serotype D HA-33 with enhanced binding activity, a Clostridial botulinum serotype A HA-17 with enhanced binding activity, a Clostridial botulinum serotype B HA-17 with enhanced binding activity, a Clostridial botulinum serotype C1 HA-17 with enhanced binding activity, a Clostridial botulinum serotype D HA-17 with enhanced binding activity, a Clostridial botulinum serotype A NTNH with enhanced binding activity, a Clostridial botulinum serotype B NTNH with enhanced binding activity, a Clostridial botulinum serotype C1 NTNH with enhanced binding activity, a Clostridial botulinum serotype D NTNH with enhanced binding activity, a Clostridial botulinum serotype E NTNH with enhanced binding activity, a Clostridial botulinum serotype F NTNH with enhanced binding activity and a Clostridial botulinum serotype G NTNH with enhanced binding activity.
In an aspect of this embodiment, an enhanced targeting domain comprises a FGF disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a FGF comprises a naturally occurring FGF variant, such as, e.g., a FGF isoform or a FGF subtype. In an aspect of this embodiment, a polynucleotide molecule encoding a FGF comprises a non-naturally occurring FGF variant, such as, e.g., a conservative FGF variant, a non-conservative FGF variant or an active FGF fragment, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a FGF comprises a FGF-1, a FGF-2, a FGF-4, a FGF-8, a FGF-9, a FGF-17 and a FGF-18.
In an aspect of this embodiment, an enhanced targeting domain comprises a FGF with enhanced binding activity disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a FGF with enhanced binding activity comprises a non-naturally occurring FGF variant with enhanced binding activity, such as, e.g., a conservative FGF variant with enhanced binding activity, a non-conservative FGF variant with enhanced binding activity or an active FGF fragment with enhanced binding activity, or any combination thereof. In other aspects of this embodiment, a polynucleotide molecule encoding a FGF with enhanced binding activity comprises a FGF-1 with enhanced binding activity, a FGF-2 with enhanced binding activity, a FGF-4 with enhanced binding activity, a FGF-8 with enhanced binding activity, a FGF-9 with enhanced binding activity, a FGF-17 with enhanced binding activity and a FGF-18 with enhanced binding activity.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising a protease cleavage site disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a protease cleavage site comprises an endogenous Clostridial toxin protease site. In aspects of this embodiment, a polynucleotide molecule encoding an endogenous Clostridial toxin protease site can be, e.g., a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site or a TeNT di-chain loop protease cleavage site. In another aspect of this embodiment, a polynucleotide molecule encoding a protease cleavage site comprises an exogenous Clostridial toxin protease site. In aspects of this embodiment, a polynucleotide molecule encoding an exogenous Clostridial toxin protease site can be, e.g., a bovine enterokinase protease cleavage site, a Tobacco Etch Virus protease cleavage site, a Human Rhinovirus 3C protease cleavage site, a SUMO/ULP-1 protease cleavage site, a Thrombin protease cleavage site, a Coagulation Factor Xa protease cleavage site or a Clostridial toxin substrate cleavage site, such as, e.g., a BoNT/A substrate cleavage site, a BoNT/B substrate cleavage site, a BoNT/C1 substrate cleavage site, a BoNT/D substrate cleavage site, a BoNT/E substrate cleavage site, a BoNT/F substrate cleavage site, a BoNT/G substrate cleavage site or a TeNT substrate cleavage site.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising a flexible spacer disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding a flexible spacer can comprise a G-spacer, a A-spacer or any combination thereof.
In another embodiment, a polynucleotide molecule encodes, in part, a modified Clostridial toxin comprising an epitope-binding region disclosed in the present specification. In an aspect of this embodiment, a polynucleotide molecule encoding an epitope-binding region can comprise a FLAG, ExpressTM, a human Influenza virus hemagluttinin (HA), a human p62c-Myc protein (c-MYC), a Vesicular Stomatitis Virus Glycoprotein (VSV-G), a Substance P, a glycoprotein-D precursor of Herpes simplex virus (HSV), a V5, a AU1, a AU5 (SEQ ID NO: 85), a polyhistidine (HIS), or any combination thereof.
Well-established molecular biology techniques that may be necessary to make a polynucleotide molecule encoding a modified Clostridial toxin disclosed in the present specification including, but not limited to, procedures involving polymerase chain reaction (PCR) amplification, restriction enzyme reactions, agarose gel electrophoresis, nucleic acid ligation, bacterial transformation, nucleic acid purification, nucleic acid sequencing and recombination-based techniques are routine procedures well within the scope of one skilled in the art and from the teaching herein. Non-limiting examples of specific protocols necessary to make a polynucleotide molecule encoding a modified Clostridial toxin are described in e.g., MOLECULAR CLONING A LABORATORY MANUAL, supra, (2001); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Frederick M. Ausubel et al., eds. John Wiley & Sons, 2004). Additionally, a variety of commercially available products useful for making a polynucleotide molecule encoding a modified Clostridial toxin are widely available. These protocols are routine procedures well within the scope of one skilled in the art and from the teaching herein.
Another aspect of the present invention provides a method of producing a modified Clostridial toxin disclosed in the present specification, such method comprising the step of expressing a polynucleotide molecule encoding a modified Clostridial toxin in a cell. Another aspect of the present invention provides a method of producing a modified Clostridial toxin disclosed in the present specification, such method comprising the steps of introducing an expression construct comprising a polynucleotide molecule encoding a modified Clostridial toxin into a cell and expressing the expression construct in the cell.
The methods disclosed in the present specification include, in part, a modified Clostridial toxin. It is envisioned that any and all modified Clostridial toxins disclosed in the present specification can be produced using the methods disclosed in the present specification. It is also envisioned that any and all polynucleotide molecules encoding a modified Clostridial toxins disclosed in the present specification can be useful in producing a modified Clostridial toxins disclosed in the present specification using the methods disclosed in the present specification.
The methods disclosed in the present specification include, in part, an expression construct. An expression construct comprises a polynucleotide molecule disclosed in the present specification operably-linked to an expression vector useful for expressing the polynucleotide molecule in a cell or cell-free extract. A wide variety of expression vectors can be employed for expressing a polynucleotide molecule encoding a modified Clostridial toxin, including, without limitation, a viral expression vector; a prokaryotic expression vector; eukaryotic expression vectors, such as, e.g., a yeast expression vector, an insect expression vector and a mammalian expression vector; and a cell-free extract expression vector. It is further understood that expression vectors useful to practice aspects of these methods may include those which express a modified Clostridial toxin under control of a constitutive, tissue-specific, cell-specific or inducible promoter element, enhancer element or both. Non-limiting examples of expression vectors, along with well-established reagents and conditions for making and using an expression construct from such expression vectors are readily available from commercial vendors that include, without limitation, BD Biosciences-Clontech, Palo Alto, Calif.; BD Biosciences Pharmingen, San Diego, Calif.; Invitrogen, Inc, Carlsbad, Calif.; EMD Biosciences-Novagen, Madison, Wis.; QIAGEN, Inc., Valencia, Calif.; and Stratagene, La Jolla, Calif. The selection, making and use of an appropriate expression vector are routine procedures well within the scope of one skilled in the art and from the teachings herein.
Thus, aspects of this embodiment include, without limitation, a viral expression vector operably-linked to a polynucleotide molecule encoding a modified Clostridial toxin; a prokaryotic expression vector operably-linked to a polynucleotide molecule encoding a modified Clostridial toxin; a yeast expression vector operably-linked to a polynucleotide molecule encoding a modified Clostridial toxin; an insect expression vector operably-linked to a polynucleotide molecule encoding a modified Clostridial toxin; and a mammalian expression vector operably-linked to a polynucleotide molecule encoding a modified Clostridial toxin. Other aspects of this embodiment include, without limitation, expression constructs suitable for expressing a modified Clostridial toxin disclosed in the present specification using a cell-free extract comprising a cell-free extract expression vector operably linked to a polynucleotide molecule encoding a modified Clostridial toxin. Other aspects of this embodiment include, without limitation, expression constructs comprising polynucleotide molecules comprising any one of SEQ ID NO: 109 through SEQ ID NO: 132 and SEQ ID NO: 136 through SEQ ID NO: 159. Other aspects of this embodiment include, without limitation, expression constructs comprising polynucleotide molecules encoding a modified Clostridial toxin comprising any one of SEQ ID NO: 85 through SEQ ID NO: 108.
The methods disclosed in the present specification include, in part, a cell. It is envisioned that any and all cells can be used. Thus, aspects of this embodiment include, without limitation, prokaryotic cells including, without limitation, strains of aerobic, microaerophilic, capnophilic, facultative, anaerobic, gram-negative and gram-positive bacterial cells such as those derived from, e.g., Escherichia coli, Bacillus subtilis, Bacillus licheniformis, Bacteroides fragilis, Clostridia perfringens, Clostridia difficile, Caulobacter crescentus, Lactococcus lactis, Methylobacterium extorquens, Neisseria meningirulls, Neisseria meningitidis, Pseudomonas fluorescens and Salmonella typhimurium; and eukaryotic cells including, without limitation, yeast strains, such as, e.g., those derived from Pichia pastoris, Pichia methanolica, Pichia angusta, Schizosaccharomyces pombe, Saccharomyces cerevisiae and Yarrowia lipolytica; insect cells and cell lines derived from insects, such as, e.g., those derived from Spodoptera frugiperda, Trichoplusia ni, Drosophila melanogaster and Manduca sexta; and mammalian cells and cell lines derived from mammalian cells, such as, e.g., those derived from mouse, rat, hamster, porcine, bovine, equine, primate and human. Cell lines may be obtained from the American Type Culture Collection, European Collection of Cell Cultures and the German Collection of Microorganisms and Cell Cultures. Non-limiting examples of specific protocols for selecting, making and using an appropriate cell line are described in e.g., INSECT CELL CULTURE ENGINEERING (Mattheus F. A. Goosen et al. eds., Marcel Dekker, 1993); INSECT CELL CULTURES: FUNDAMENTAL AND APPLIED ASPECTS (J. M. Vlak et al. eds., Kluwer Academic Publishers, 1996); Maureen A. Harrison & Ian F. Rae, GENERAL TECHNIQUES OF CELL CULTURE (Cambridge University Press, 1997); CELL AND TISSUE CULTURE: LABORATORY PROCEDURES (Alan Doyle et al eds., John Wiley and Sons, 1998); R. Ian Freshney, CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC TECHNIQUE (Wiley-Liss, 4th ed. 2000); ANIMAL CELL CULTURE: A PRACTICAL APPROACH (John R. W. Masters ed., Oxford University Press, 3rd ed. 2000); MOLECULAR CLONING A LABORATORY MANUAL, supra, (2001); BASIC CELL CULTURE: A PRACTICAL APPROACH (John M. Davis, Oxford Press, 2nd ed. 2002); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, supra, (2004). These protocols are routine procedures within the scope of one skilled in the art and from the teaching herein.
The methods disclosed in the present specification include, in part, introducing into a cell a polynucleotide molecule. A polynucleotide molecule introduced into a cell can be transiently or stably maintained by that cell. Stably-maintained polynucleotide molecules may be extra-chromosomal and replicate autonomously, or they may be integrated into the chromosomal material of the cell and replicate non-autonomously. It is envisioned that any and all methods for introducing a polynucleotide molecule disclosed in the present specification into a cell can be used. Methods useful for introducing a nucleic acid molecule into a cell include, without limitation, chemical-mediated transfection such as, e.g., calcium phosphate-mediated, diethyl-aminoethyl (DEAE) dextran-mediated, lipid-mediated, polyethyleneimine (PEI)-mediated, polylysine-mediated and polybrene-mediated; physical-mediated transfection, such as, e.g., biolistic particle delivery, microinjection, protoplast fusion and electroporation; and viral-mediated transfection, such as, e.g., retroviral-mediated transfection, see, e.g., Introducing Cloned Genes into Cultured Mammalian Cells, pp. 16.1-16.62 (Sambrook & Russell, eds., Molecular Cloning A Laboratory Manual, Vol. 3, 3rd ed. 2001). One skilled in the art understands that selection of a specific method to introduce an expression construct into a cell will depend, in part, on whether the cell will transiently contain an expression construct or whether the cell will stably contain an expression construct. These protocols are routine procedures within the scope of one skilled in the art and from the teaching herein.
In an aspect of this embodiment, a chemical-mediated method, termed transfection, is used to introduce a polynucleotide molecule encoding a modified Clostridial toxin into a cell. In chemical-mediated methods of transfection the chemical reagent forms a complex with the nucleic acid that facilitates its uptake into the cells. Such chemical reagents include, without limitation, calcium phosphate-mediated, see, e.g., Martin Jordan & Florian Worm, Transfection of adherent and suspended cells by calcium phosphate, 33(2) Methods 136-143 (2004); diethyl-aminoethyl (DEAE) dextran-mediated, lipid-mediated, cationic polymer-mediated like polyethyleneimine (PEI)-mediated and polylysine-mediated and polybrene-mediated, see, e.g., Chun Zhang et al., Polyethylenimine strategies for plasmid delivery to brain-derived cells, 33(2) Methods 144-150 (2004). Such chemical-mediated delivery systems can be prepared by standard methods and are commercially available, see, e.g., CellPhect Transfection Kit (Amersham Biosciences, Piscataway, N.J.); Mammalian Transfection Kit, Calcium phosphate and DEAE Dextran, (Stratagene, Inc., La Jolla, Calif.); LipofectamineTM Transfection Reagent (Invitrogen, Inc., Carlsbad, Calif.); ExGen 500 Transfection kit (Fermentas, Inc., Hanover, Md.), and SuperFect and Effectene Transfection Kits (Qiagen, Inc., Valencia, Calif.).
In another aspect of this embodiment, a physical-mediated method is used to introduce a polynucleotide molecule encoding a modified Clostridial toxin into a cell. Physical techniques include, without limitation, electroporation, biolistic and microinjection. Biolistics and microinjection techniques perforate the cell wall in order to introduce the nucleic acid molecule into the cell, see, e.g., Jeike E. Biewenga et al., Plasmid-mediated gene transfer in neurons using the biolistics technique, 71(1) J. Neurosci. Methods. 67-75 (1997); and John O'Brien & Sarah C. R. Lummis, Biolistic and diolistic transfection: using the gene gun to deliver DNA and lipophilic dyes into mammalian cells, 33(2) Methods 121-125 (2004). Electroporation, also termed electropermeabilization, uses brief, high-voltage, electrical pulses to create transient pores in the membrane through which the nucleic acid molecules enter and can be used effectively for stable and transient transfections of all cell types, see, e.g., M. Golzio et al., In vitro and in vivo electric field-mediated permeabilization, gene transfer, and expression, 33(2) Methods 126-135 (2004); and Oliver Gresch et al., New non-viral method for gene transfer into primary cells, 33(2) Methods 151-163 (2004).
In another aspect of this embodiment, a viral-mediated method, termed transduction, is used to introduce a polynucleotide molecule encoding a modified Clostridial toxin into a cell. In viral-mediated methods of transient transduction, the process by which viral particles infect and replicate in a host cell has been manipulated in order to use this mechanism to introduce a nucleic acid molecule into the cell. Viral-mediated methods have been developed from a wide variety of viruses including, without limitation, retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, picornaviruses, alphaviruses and baculoviruses, see, e.g., Armin Blesch, Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer, 33(2) Methods 164-172 (2004); and Maurizio Federico, From lentiviruses to lentivirus vectors, 229 Methods Mol. Biol. 3-15 (2003); E. M. Poeschla, Non-primate lentiviral vectors, 5(5) Curr. Opin. Mol. Ther. 529-540 (2003); Karim Benihoud et al, Adenovirus vectors for gene delivery, 10(5) Curr. Opin. Biotechnol. 440-447 (1999); H. Bueler, Adeno-associated viral vectors for gene transfer and gene therapy, 380(6) Biol. Chem. 613-622 (1999); Chooi M. Lai et al., Adenovirus and adeno-associated virus vectors, 21(12) DNA Cell Biol. 895-913 (2002); Edward A. Burton et al., Gene delivery using herpes simplex virus vectors, 21(12) DNA Cell Biol. 915-936 (2002); Paola Grandi et al., Targeting HSV amplicon vectors, 33(2) Methods 179-186 (2004); Ilya Frolov et al., Alphavirus-based expression vectors: strategies and applications, 93(21) Proc. Natl. Acad. Sci. U.S.A. 11371-11377 (1996); Markus U. Ehrengruber, Alphaviral gene transfer in neurobiology, 59(1) Brain Res. Bull. 13-22 (2002); Thomas A. Kost & J. Patrick Condreay, Recombinant baculoviruses as mammalian cell gene-delivery vectors, 20(4) Trends Biotechnol. 173-180 (2002); and A. Huser & C. Hofmann, Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications, 3(1) Am. J. Pharmacogenomics 53-63 (2003).
Adenoviruses, which are non-enveloped, double-stranded DNA viruses, are often selected for mammalian cell transduction because adenoviruses handle relatively large polynucleotide molecules of about 36 kb, are produced at high titer, and can efficiently infect a wide variety of both dividing and non-dividing cells, see, e.g., Wim T. J. M. C. Hermens et al., Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS, 71(1) J. Neurosci. Methods 85-98 (1997); and Hiroyuki Mizuguchi et al., Approaches for generating recombinant adenovirus vectors, 52(3) Adv. Drug Deliv. Rev. 165-176 (2001). Transduction using adenoviral-based system do not support prolonged protein expression because the nucleic acid molecule is carried from an episome in the cell nucleus, rather than being integrated into the host cell chromosome. Adenoviral vector systems and specific protocols for how to use such vectors are disclosed in, e.g., ViraPowerTM Adenoviral Expression System (Invitrogen, Inc., Carlsbad, Calif.) and ViraPowerTM Adenoviral Expression System Instruction Manual 25-0543 version A, Invitrogen, Inc., (Jul. 15, 2002); and AdEasyTM Adenoviral Vector System (Stratagene, Inc., La Jolla, Calif.) and AdEasyTM Adenoviral Vector System Instruction Manual 064004f, Stratagene, Inc.
Nucleic acid molecule delivery can also use single-stranded RNA retroviruses, such as, e.g., oncoretroviruses and lentiviruses. Retroviral-mediated transduction often produce transduction efficiencies close to 100%, can easily control the proviral copy number by varying the multiplicity of infection (MOI), and can be used to either transiently or stably transduce cells, see, e.g., Tiziana Tonini et al., Transient production of retroviral- and lentiviral-based vectors for the transduction of Mammalian cells, 285 Methods Mol. Biol. 141-148 (2004); Armin Blesch, Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer, 33(2) Methods 164-172 (2004); Félix Recillas-Targa, Gene transfer and expression in mammalian cell lines and transgenic animals, 267 Methods Mol. Biol. 417-433 (2004); and Roland Wolkowicz et al., Lentiviral vectors for the delivery of DNA into mammalian cells, 246 Methods Mol. Biol. 391-411 (2004). Retroviral particles consist of an RNA genome packaged in a protein capsid, surrounded by a lipid envelope. The retrovirus infects a host cell by injecting its RNA into the cytoplasm along with the reverse transcriptase enzyme. The RNA template is then reverse transcribed into a linear, double stranded cDNA that replicates itself by integrating into the host cell genome. Viral particles are spread both vertically (from parent cell to daughter cells via the provirus) as well as horizontally (from cell to cell via virions). This replication strategy enables long-term persistent expression since the nucleic acid molecules of interest are stably integrated into a chromosome of the host cell, thereby enabling long-term expression of the protein. For instance, animal studies have shown that lentiviral vectors injected into a variety of tissues produced sustained protein expression for more than 1 year, see, e.g., Luigi Naldini et al., In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector, 272(5259) Science 263-267 (1996). The Oncoretroviruses-derived vector systems, such as, e.g., Moloney murine leukemia virus (MoMLV), are widely used and infect many different non-dividing cells. Lentiviruses can also infect many different cell types, including dividing and non-dividing cells and possess complex envelope proteins, which allows for highly specific cellular targeting.
Retroviral vectors and specific protocols for how to use such vectors are disclosed in, e.g., U.S. Patent Nos. Manfred Gossen & Hermann Bujard, Tight control of gene expression in eukaryotic cells by tetracycline-responsive promoters, U.S. Pat. No. 5,464,758 (Nov. 7, 1995) and Hermann Bujard & Manfred Gossen, Methods for regulating gene expression, U.S. Pat. No. 5,814,618 (Sep. 29, 1998) David S. Hogness, Polynucleotides encoding insect steroid hormone receptor polypeptides and cells transformed with same, U.S. Pat. No. 5,514,578 (May 7, 1996) and David S. Hogness, Polynucleotide encoding insect ecdysone receptor, U.S. Pat. No. 6,245,531 (Jun. 12, 2001); Elisabetta Vegeto et al., Progesterone receptor having C. terminal hormone binding domain truncations, U.S. Pat. No. 5,364,791 (Nov. 15, 1994), Elisabetta Vegeto et al., Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy, U.S. Pat. No. 5,874,534 (Feb. 23, 1999) and Elisabetta Vegeto et al., Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy, U.S. Pat. No. 5,935,934 (Aug. 10, 1999). Furthermore, such viral delivery systems can be prepared by standard methods and are commercially available, see, e.g., BDTM Tet-Off and Tet-On Gene Expression Systems (BD Biosciences-Clonetech, Palo Alto, Calif.) and BDTM Tet-Off and Tet-On Gene Expression Systems User Manual, PT3001-1, BD Biosciences Clonetech, (Mar. 14, 2003), GeneSwitchTM System (Invitrogen, Inc., Carlsbad, Calif.) and GeneSwitchTM System A Mifepristone-Regulated Expression System for Mammalian Cells version D, 25-0313, Invitrogen, Inc., (Nov. 4, 2002); ViraPowerTM Lentiviral Expression System (Invitrogen, Inc., Carlsbad, Calif.) and ViraPowerTM Lentiviral Expression System Instruction Manual 25-0501 version E, Invitrogen, Inc., (Dec. 8, 2003); and Complete Control® Retroviral Inducible Mammalian Expression System (Stratagene, La Jolla, Calif.) and Complete Control® Retroviral Inducible Mammalian Expression System Instruction Manual, 064005e.
The methods disclosed in the present specification include, in part, expressing a modified Clostridial toxin from a polynucleotide molecule. It is envisioned that any of a variety of expression systems may be useful for expressing a modified Clostridial toxin from a polynucleotide molecule disclosed in the present specification, including, without limitation, cell-based systems and cell-free expression systems. Cell-based systems include, without limitation, viral expression systems, prokaryotic expression systems, yeast expression systems, baculoviral expression systems, insect expression systems and mammalian expression systems. Cell-free systems include, without limitation, wheat germ extracts, rabbit reticulocyte extracts and E. coli extracts and generally are equivalent to the method disclosed herein. Expression of a polynucleotide molecule using an expression system can include any of a variety of characteristics including, without limitation, inducible expression, non-inducible expression, constitutive expression, viral-mediated expression, stably-integrated expression, and transient expression. Expression systems that include well-characterized vectors, reagents, conditions and cells are well-established and are readily available from commercial vendors that include, without limitation, Ambion, Inc. Austin, Tex.; BD Biosciences-Clontech, Palo Alto, Calif.; BD Biosciences Pharmingen, San Diego, Calif.; Invitrogen, Inc, Carlsbad, Calif.; QIAGEN, Inc., Valencia, Calif.; Roche Applied Science, Indianapolis, Ind.; and Stratagene, La Jolla, Calif. Non-limiting examples on the selection and use of appropriate heterologous expression systems are described in e.g., PROTEIN EXPRESSION. A PRACTICAL APPROACH(S. J. Higgins and B. David Hames eds., Oxford University Press, 1999); Joseph M. Fernandez & James P. Hoeffler, GENE EXPRESSION SYSTEMS. USING NATURE FOR THE ART OF EXPRESSION (Academic Press, 1999); and Meena Rai & Harish Padh, Expression Systems for Production of Heterologous Proteins, 80(9) CURRENT SCIENCE 1121-1128, (2001). These protocols are routine procedures well within the scope of one skilled in the art and from the teaching herein.
A variety of cell-based expression procedures are useful for expressing a modified Clostridial toxin encoded by polynucleotide molecule disclosed in the present specification. Examples included, without limitation, viral expression systems, prokaryotic expression systems, yeast expression systems, baculoviral expression systems, insect expression systems and mammalian expression systems. Viral expression systems include, without limitation, the ViraPowerTM Lentiviral (Invitrogen, Inc., Carlsbad, Calif.), the Adenoviral Expression Systems (Invitrogen, Inc., Carlsbad, Calif.), the AdEasyTM XL Adenoviral Vector System (Stratagene, La Jolla, Calif.) and the ViraPort® Retroviral Gene Expression System (Stratagene, La Jolla, Calif.). Non-limiting examples of prokaryotic expression systems include the ChampionTM pET Expression System (EMD Biosciences-Novagen, Madison, Wis.), the TriExTM Bacterial Expression System (EMD Biosciences-Novagen, Madison, Wis.), the QIAexpress® Expression System (QIAGEN, Inc.), and the Affinity® Protein Expression and Purification System (Stratagene, La Jolla, Calif.). Yeast expression systems include, without limitation, the EasySelectTM Pichia Expression Kit (Invitrogen, Inc., Carlsbad, Calif.), the YES-EchoTM Expression Vector Kits (Invitrogen, Inc., Carlsbad, Calif.) and the SpECTRATM S. pombe Expression System (Invitrogen, Inc., Carlsbad, Calif.). Non-limiting examples of baculoviral expression systems include the BaculoDirectTM (Invitrogen, Inc., Carlsbad, Calif.), the Bac-to-Bac® (Invitrogen, Inc., Carlsbad, Calif.), and the BD BaculoGoldTM (BD Biosciences-Pharmigen, San Diego, Calif.). Insect expression systems include, without limitation, the Drosophila Expression System (DES®) (Invitrogen, Inc., Carlsbad, Calif.), InsectSelectTM System (Invitrogen, Inc., Carlsbad, Calif.) and InsectDirectTM System (EMD Biosciences-Novagen, Madison, Wis.). Non-limiting examples of mammalian expression systems include the T-RExTM (Tetracycline-Regulated Expression) System (Invitrogen, Inc., Carlsbad, Calif.), the Flp-InTM T-RExTM System (Invitrogen, Inc., Carlsbad, Calif.), the pcDNATM system (Invitrogen, Inc., Carlsbad, Calif.), the pSecTag2 system (Invitrogen, Inc., Carlsbad, Calif.), the Exchanger® System, InterPlayTM Mammalian TAP System (Stratagene, La Jolla, Calif.), Complete Control® Inducible Mammalian Expression System (Stratagene, La Jolla, Calif.) and LacSwitch® II Inducible Mammalian Expression System (Stratagene, La Jolla, Calif.).
Another procedure of expressing a modified Clostridial toxin encoded by polynucleotide molecule disclosed in the present specification employs a cell-free expression system such as, without limitation, prokaryotic extracts and eukaryotic extracts. Non-limiting examples of prokaryotic cell extracts include the RTS 100 E. coli HY Kit (Roche Applied Science, Indianapolis, Ind.), the ActivePro In Vitro Translation Kit (Ambion, Inc., Austin, Tex.), the EcoProTM System (EMD Biosciences-Novagen, Madison, Wis.) and the ExpresswayTM Plus Expression System (Invitrogen, Inc., Carlsbad, Calif.). Eukaryotic cell extract include, without limitation, the RTS 100 Wheat Germ CECF Kit (Roche Applied Science, Indianapolis, Ind.), the TnT® Coupled Wheat Germ Extract Systems (Promega Corp., Madison, Wis.), the Wheat Germ IVTTM Kit (Ambion, Inc., Austin, Tex.), the Retic Lysate IVTTM Kit (Ambion, Inc., Austin, Tex.), the PROTEINscript® II System (Ambion, Inc., Austin, Tex.) and the TnT® Coupled Reticulocyte Lysate Systems (Promega Corp., Madison, Wis.).
Aspects of the present invention can also be described as follows:

    1. A modified Clostridial toxin comprising:
    
        a) a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) an enhanced targeting domain comprising a modified Clostridial HCC targeting domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a protease cleavage site;
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form; and
        wherein the modified Clostridial HCC targeting domain exhibits enhanced binding activity for an endogenous Clostridial toxin receptor relative to the binding activity of a naturally-occurring Clostridial HCC targeting domain from which the modified Clostridial HCC targeting domain is derived.
    
    
    2. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain, the translocation facilitating domain and the enhanced targeting domain.
    3. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the enhanced targeting domain, the Clostridial toxin translocation domain and the translocation facilitating domain.
    4. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site and the Clostridial toxin enzymatic domain.
    5. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain and the translocation facilitating domain.
    6. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the Clostridial toxin enzymatic domain and the enhanced targeting domain.
    7. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the enhanced targeting domain and the Clostridial toxin enzymatic domain.
    8. The modified Clostridial toxin according to 1, wherein the Clostridial toxin enzymatic domain is selected from the group consisting of a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    9. The modified Clostridial toxin according to 1, wherein the Clostridial toxin translocation domain is selected from the group consisting of a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    10. The modified Clostridial toxin according to 1, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    11. The modified Clostridial toxin according to 10, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    12. The modified Clostridial toxin according to 10, wherein the Clostridial toxin translocation facilitating domain comprises an amino acid sequence selected from the group consisting of amino acids 874-1110 of SEQ ID NO: 1, amino acids 861-1097 of SEQ ID NO: 2, amino acids 869-1111 of SEQ ID NO: 3, amino acids 865-1098 of SEQ ID NO: 4, amino acids 848-1085 of SEQ ID NO: 5, amino acids 867-1105 of SEQ ID NO: 6, amino acids 866-1105 of SEQ ID NO: 7 and amino acid 882-1127 of SEQ ID NO: 8.
    13. The modified Clostridial toxin according to 1, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    14. The modified Clostridial toxin according to 13, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    15. The modified Clostridial toxin according to 14, wherein the influenzavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 and SEQ ID NO: 91.
    16. The modified Clostridial toxin according to 14, wherein the alphavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 and SEQ ID NO: 118.
    17. The modified Clostridial toxin according to 14, wherein the vesiculovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129.
    18. The modified Clostridial toxin according to 14, wherein the respirovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 and SEQ ID NO: 136.
    19. The modified Clostridial toxin according to 14, wherein the morbillivirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 and SEQ ID NO: 146.
    20. The modified Clostridial toxin according to 14, wherein the avulavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 and SEQ ID NO: 159.
    21. The modified Clostridial toxin according to 14, wherein the henipavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 160 and SEQ ID NO: 161.
    22. The modified Clostridial toxin according to 14, wherein the metapneumovirus fusogenic peptide domain is SEQ ID NO: 162.
    23. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain is selected from the group consisting of a modified BoNT/A HCC targeting domain, a modified BoNT/B HCC targeting domain, a modified BoNT/C1 HCC targeting domain, a modified BoNT/D HCC targeting domain, a modified BoNT/E HCC targeting domain, a modified BoNT/F HCC targeting domain, a modified BoNT/G HCC targeting domain and a modified TeNT HCC targeting domain.
    24. The modified Clostridial toxin according to 23, wherein the modified BoNT/A HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1101, Gly 1102, Leu 1105, Tyr 1111, Tyr 1112, Gly 1158, Ile 1163, Asp 1179, Glu 1203, Phe 1252, Ser 1264, Trp 1266, Tyr 1267, Gln 1270, Gly 1279 and Trp 1282 of SEQ ID NO: 1, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/A HCC targeting domain for a BoNT/A receptor.
    
    
    25. The modified Clostridial toxin according to 23, wherein the modified BoNT/B HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1088, Gly 1089, Leu 1092, Tyr 1098, Tyr 1099, Gly 1142, Ile 1147, Asp 1165, Glu 1191, Ile 1240, Ser 1260, Trp 1262, Tyr 1263, Glu 1266, Gly 1277 and Trp 1280 of SEQ ID NO: 2, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/B HCC targeting domain for a BoNT/B receptor.
    
    
    26. The modified Clostridial toxin according to 23, wherein the modified BoNT/C1 HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1102, Gly 1103, Leu 1106, Tyr 1112, Tyr 1113, Gly 1145, Ile 1150, Asp 1166, Glu 1196, Ile 1247, Gly 1256, Trp 1258, Tyr 1259, His 1261, Gly 1281 and Trp 1284 of SEQ ID NO: 3, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/C1 HCC targeting domain for a BoNT/C1 receptor.
    
    
    27. The modified Clostridial toxin according to 23, wherein the modified BoNT/D HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1089, Gly 1090, Leu 1093, Tyr 1099, Tyr 1100, Gly 1132, Ile 1137, Asp 1153, Asn 1186, Lys 1236, Trp 1238, Arg 1239, Phe 1242, Ser 1262 and Trp 1265 of SEQ ID NO: 4, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/D HCC targeting domain for a BoNT/D receptor.
    
    
    28. The modified Clostridial toxin according to 23, wherein the modified BoNT/E HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1076, Gly 1077, Leu 1080, Tyr 1086, Tyr 1087, Gly 1124, Ile 1129, Asp 1146, Glu 1172, Phe 1213, Ser 1221, Trp 1223, Tyr 1224, His 1227, Gly 1236 and Trp 1239 of SEQ ID NO: 5, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/E HCC targeting domain for a BoNT/E receptor.
    
    
    29. The modified Clostridial toxin according to 23, wherein the modified BoNT/F HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1147, Ile 1152, Asp 1171, Glu 1195, Phe 1237, Ser 1245, Trp 1247, Tyr 1248, Asn 1251, Gly 1260 and Trp 1263 of SEQ ID NO: 6, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/F HCC targeting domain for a BoNT/F receptor.
    
    
    30. The modified Clostridial toxin according to 23, wherein the modified BoNT/G HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1096, Gly 1097, Leu 1100, Tyr 1106, Tyr 1107, Gly 1148, Ile 1153, Asp 1172, Gln 1198, Ile 1245, Ser 1266, Trp 1268, Tyr 1269, Arg 1272, Gly 1283 and Trp 1285 of SEQ ID NO: 7, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified BoNT/G HCC targeting domain for a BoNT/G receptor.
    
    
    31. The modified Clostridial toxin according to 23, wherein the modified TeNT HCC targeting domain comprises an amino acid substitution at a position selected from the group consisting of Trp 1118, Gly 1119, Leu 1122, Tyr 1128, Tyr 1129, Gly 1172, Ile 1177, Asp 1194, Asp 1222, Thr 1270, Ser 1287, Trp 1289, Tyr 1290, His 1293, Gly 1300 and Trp 1303 of SEQ ID NO: 8, and any combination thereof;
    
        wherein the amino acid substitution enhances the binding activity of the modified TeNT HCC targeting domain for a TeNT receptor.
    
    
    32. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises at least one amino acid substitution in a β-trefoil domain.
    33. The modified Clostridial toxin according to 31, wherein the amino acid substitution is located within an α-fold, a β-fold or a γ-fold of the β-trefoil domain.
    34. The modified Clostridial toxin according to 31, wherein the amino acid substitution is located within a β4/β5 β-hairpin turn or a β8/β9 β-hairpin turn of the β-trefoil domain.
    35. The modified Clostridial toxin according to 33, wherein the amino acid substitution is a glycine or a phenylalanine.
    36. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises a substitution of a Clostridial toxin HCC targeting domain α-fold for an α-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1α-fold, a Clostridial botulinum serotype B HA-33 1α-fold, a Clostridial botulinum serotype C1 HA-33 1α-fold, a Clostridial botulinum serotype D HA-33 1α-fold, a Clostridial botulinum serotype A HA-33 2α-fold, a Clostridial botulinum serotype B HA-33 2α-fold, a Clostridial botulinum serotype C1 HA-33 2α-fold, a Clostridial botulinum serotype D HA-33 2α-fold, a Clostridial botulinum serotype A HA-17 α-fold, a Clostridial botulinum serotype B HA-17 α-fold, a Clostridial botulinum serotype C1 HA-17 α-fold, a Clostridial botulinum serotype D HA-17 α-fold, a Clostridial botulinum serotype A NTNH α-fold, a Clostridial botulinum serotype B NTNH α-fold, a Clostridial botulinum serotype C1 NTNH α-fold, a Clostridial botulinum serotype D NTNH α-fold, a Clostridial botulinum serotype E NTNH α-fold, a Clostridial botulinum serotype F NTNH α-fold, a Clostridial botulinum serotype G NTNH α-fold, a FGF-1α-fold, a FGF-2 α-fold, a FGF-4 α-fold, a FGF-8 α-fold, a FGF-9 α-fold, a FGF-17 α-fold and a FGF-18 α-fold.
    37. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises a substitution of a Clostridial toxin HCC targeting domain β-fold for a β-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1β-fold, a Clostridial botulinum serotype B HA-33 1β-fold, a Clostridial botulinum serotype C1 HA-33 1β-fold, a Clostridial botulinum serotype D HA-33 1β-fold, a Clostridial botulinum serotype A HA-33 2β-fold, a Clostridial botulinum serotype B HA-33 2β-fold, a Clostridial botulinum serotype C1 HA-33 2β-fold, a Clostridial botulinum serotype D HA-33 2β-fold, a Clostridial botulinum serotype A HA-17 β-fold, a Clostridial botulinum serotype B HA-17 β-fold, a Clostridial botulinum serotype C1 HA-17 β-fold, a Clostridial botulinum serotype D HA-17 β-fold, a Clostridial botulinum serotype A NTNH β-fold, a Clostridial botulinum serotype B NTNH β-fold, a Clostridial botulinum serotype C1 NTNH β-fold, a Clostridial botulinum serotype D NTNH β-fold, a Clostridial botulinum serotype E NTNH β-fold, a Clostridial botulinum serotype F NTNH β-fold, a Clostridial botulinum serotype G NTNH β-fold, a FGF-1 β-fold, a FGF-2 β-fold, a FGF-4 β-fold, a FGF-8 β-fold, a FGF-9 β-fold, a FGF-17 β-fold and a FGF-18 β-fold.
    38. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises a substitution of a Clostridial toxin HCC targeting domain γ-fold for a γ-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1γ-fold, a Clostridial botulinum serotype B HA-33 1γ-fold, a Clostridial botulinum serotype C1 HA-33 1γ-fold, a Clostridial botulinum serotype D HA-33 1γ-fold, a Clostridial botulinum serotype A HA-33 2γ-fold, a Clostridial botulinum serotype B HA-33 2γ-fold, a Clostridial botulinum serotype C1 HA-33 2γ-fold, a Clostridial botulinum serotype D HA-33 2γ-fold, a Clostridial botulinum serotype A HA-17 γ-fold, a Clostridial botulinum serotype B HA-17 γ-fold, a Clostridial botulinum serotype C1 HA-17 γ-fold, a Clostridial botulinum serotype D HA-17 γ-fold, a Clostridial botulinum serotype A NTNH γ-fold, a Clostridial botulinum serotype B NTNH γ-fold, a Clostridial botulinum serotype C1 NTNH γ-fold, a Clostridial botulinum serotype D NTNH γ-fold, a Clostridial botulinum serotype E NTNH γ-fold, a Clostridial botulinum serotype F NTNH γ-fold, a Clostridial botulinum serotype G NTNH γ-fold, a FGF-1 γ-fold, a FGF-2γ-fold, a FGF-4 γ-fold, a FGF-8 γ-fold, a FGF-9 γ-fold, a FGF-17 γ-fold and a FGF-18 γ-fold.
    39. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises a substitution of a Clostridial toxin HCC targeting domain β4/β5 β-hairpin turn for a β4/β5 β-hairpin turn selected from the group consisting of a Clostridial botulinum serotype A HA-33 β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype A HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype A HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype A NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype B NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype D NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype E NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype F NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype G NTNH β4/β5 β-hairpin turn, a FGF-1 β4/β5 β-hairpin turn, a FGF-2 β4/β5 β-hairpin turn, a FGF-4 β4/β5 β-hairpin turn, a FGF-8 β4/β5 β-hairpin turn, a FGF-9 β4/β5 β-hairpin turn, a FGF-17 β4/β5 β-hairpin turn and a FGF-18 β4/β5 β-hairpin turn.
    40. The modified Clostridial toxin according to 1, wherein the modified Clostridial toxin HCC targeting domain comprises a substitution of a Clostridial toxin HCC targeting domain β8/β9 β-hairpin turn for a β8/β9 β-hairpin turn selected from the group consisting of a Clostridial botulinum serotype A HA-33 β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype A HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype A HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype A NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype B NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype D NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype E NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype F NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype G NTNH β8/β9 β-hairpin turn, a FGF-1 β8/β9 β-hairpin turn, a FGF-2 β8/β9 β-hairpin turn, a FGF-4 β8/β9 β-hairpin turn, a FGF-8 β8/β9 β-hairpin turn, a FGF-9 β8/β9 β-hairpin turn, a FGF-17 β8/β9 β-hairpin turn and a FGF-18 β8/β9 β-hairpin turn.
    41. The modified Clostridial toxin according to 1, wherein the protease cleavage site is an endogenous Clostridial toxin di-chain loop protease cleavage site or an exogenous cleavage site.
    42. The modified Clostridial toxin according to 41, wherein the endogenous Clostridial toxin di-chain loop protease cleavage site is selected from the group consisting of a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site and a TeNT di-chain loop protease cleavage site.
    43. The modified Clostridial toxin according to 41, wherein the exogenous protease cleavage site is selected from the group consisting of an enterokinase cleavage site, a Thrombin cleavage site, a Factor Xa cleavage site, a human rhinovirus 3C protease cleavage site, a tobacco etch virus protease cleavage site, a dipeptidyl aminopeptidase cleavage site, a small ubiquitin-like modifier (SUMO)/ubiquitin-like protein-1(ULP-1) protease cleavage site, and a Clostridial toxin substrate cleavage site.
    44. The modified Clostridial toxin according to 43, wherein the Clostridial toxin substrate cleavage site is selected from the group consisting of a BoNT/A substrate cleavage site, a BoNT/B substrate cleavage site, a BoNT/C1 substrate cleavage site, a BoNT/D substrate cleavage site, a BoNT/E substrate cleavage site, a BoNT/F substrate cleavage site, a BoNT/G substrate cleavage site and a TeNT substrate cleavage site.
    45. A modified Clostridial toxin comprising:
    
        a) a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) an enhanced targeting domain comprising a Clostridial non-toxin associated protein β-trefoil domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    46. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain, the translocation facilitating domain and the enhanced targeting domain.
    47. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the enhanced targeting domain, the Clostridial toxin translocation domain and the translocation facilitating domain.
    48. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site and the Clostridial toxin enzymatic domain.
    49. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain and the translocation facilitating domain.
    50. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the Clostridial toxin enzymatic domain and the enhanced targeting domain.
    51. The modified Clostridial toxin according to 45, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the enhanced targeting domain and the Clostridial toxin enzymatic domain.
    52. The modified Clostridial toxin according to 45, wherein the Clostridial toxin enzymatic domain is selected from the group consisting of a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    53. The modified Clostridial toxin according to 45, wherein the Clostridial toxin translocation domain is selected from the group consisting of a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    54. The modified Clostridial toxin according to 45, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    55. The modified Clostridial toxin according to 54, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    56. The modified Clostridial toxin according to 54, wherein the Clostridial toxin translocation facilitating domain comprises an amino acid sequence selected from the group consisting of amino acids 874-1110 of SEQ ID NO: 1, amino acids 861-1097 of SEQ ID NO: 2, amino acids 869-1111 of SEQ ID NO: 3, amino acids 865-1098 of SEQ ID NO: 4, amino acids 848-1085 of SEQ ID NO: 5, amino acids 867-1105 of SEQ ID NO: 6, amino acids 866-1105 of SEQ ID NO: 7 and amino acid 882-1127 of SEQ ID NO: 8. 57. The modified Clostridial toxin according to 45, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    58. The modified Clostridial toxin according to 57, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    59. The modified Clostridial toxin according to 58, wherein the influenzavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 and SEQ ID NO: 91.
    60. The modified Clostridial toxin according to 58, wherein the alphavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 and SEQ ID NO: 118.
    61. The modified Clostridial toxin according to 58, wherein the vesiculovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129.
    62. The modified Clostridial toxin according to 58, wherein the respirovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 and SEQ ID NO: 136.
    63. The modified Clostridial toxin according to 58, wherein the morbillivirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 and SEQ ID NO: 146.
    64. The modified Clostridial toxin according to 58, wherein the avulavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 and SEQ ID NO: 159.
    65. The modified Clostridial toxin according to 58, wherein the henipavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 160 and SEQ ID NO: 161.
    66. The modified Clostridial toxin according to 58, wherein the metapneumovirus fusogenic peptide domain is SEQ ID NO: 162.
    67. The modified Clostridial toxin according to 45, wherein the Clostridial non-toxin associated protein β-trefoil domain is selected from the group consisting of a Clostridial botulinum serotype A HA-33 β-trefoil domain, a Clostridial botulinum serotype B HA-33 β-trefoil domain, a Clostridial botulinum serotype C1 HA-33 β-trefoil domain, a Clostridial botulinum serotype D HA-33 β-trefoil domain, a Clostridial botulinum serotype A HA-17 β-trefoil domain, a Clostridial botulinum serotype B HA-17 β-trefoil domain, a Clostridial botulinum serotype C1 HA-17 β-trefoil domain, a Clostridial botulinum serotype D HA-17 β-trefoil domain, a Clostridial botulinum serotype A NTNH β-trefoil domain, a Clostridial botulinum serotype B NTNH β-trefoil domain, a Clostridial botulinum serotype C1 NTNH β-trefoil domain, a Clostridial botulinum serotype D NTNH β-trefoil domain, a Clostridial botulinum serotype E NTNH β-trefoil domain, a Clostridial botulinum serotype F NTNH β-trefoil domain and a Clostridial botulinum serotype G NTNH β-trefoil domain.
    68. The modified Clostridial toxin according to 45, wherein the Clostridial non-toxin associated protein β-trefoil domain is selected from the group consisting of amino acids 10-144 of SEQ ID NO: 9, amino acids 151-293 of SEQ ID NO: 9, amino acids 10-144 of SEQ ID NO: 10, amino acids 151-293 of SEQ ID NO: 10, amino acids 10-144 of SEQ ID NO: 11, amino acids 151-293 of SEQ ID NO: 11, amino acids 10-146 of SEQ ID NO: 12, amino acids 153-294 of SEQ ID NO: 12, amino acids 10-144 of SEQ ID NO: 13, amino acids 151-279 of SEQ ID NO: 13, amino acids 10-144 of SEQ ID NO: 14, amino acids 151-292 of SEQ ID NO: 14, amino acids 10-146 of SEQ ID NO: 15, amino acids 153-291 of SEQ ID NO: 15, amino acids 10-141 of SEQ ID NO: 16, amino acids 148-285 of SEQ ID NO: 15, amino acids 10-141 of SEQ ID NO: 16, amino acids 148-285 of SEQ ID NO: 16, amino acids 10-141 of SEQ ID NO: 17, amino acids 148-286 of SEQ ID NO: 17, amino acids 10-141 of SEQ ID NO: 18, amino acids 148-286 of SEQ ID NO: 18, amino acids 9-146 of SEQ ID NO: 19, amino acids 9-146 of SEQ ID NO: 20, amino acids 9-146 of SEQ ID NO: 21, amino acids 9-146 of SEQ ID NO: 22, amino acids 1050-1194 of SEQ ID NO: 23, amino acids 1050-1199 of SEQ ID NO: 24, amino acids 1050-1194 of SEQ ID NO: 25, amino acids 1049-1198 of SEQ ID NO: 26, amino acids 1049-1197 of SEQ ID NO: 27, amino acids 1049-1197 of SEQ ID NO: 28, amino acids 1014-1163 of SEQ ID NO: 29, amino acids 1016-1160 of SEQ ID NO: 30, amino acids 1017-1166 of SEQ ID NO: 31 and amino acids 1050-1197 of SEQ ID NO: 1199.
    69. The modified Clostridial toxin according to 45, wherein the protease cleavage site is an endogenous Clostridial toxin di-chain loop protease cleavage site or an exogenous cleavage site.
    70. The modified Clostridial toxin according to 69, wherein the endogenous Clostridial toxin di-chain loop protease cleavage site is selected from the group consisting of a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site and a TeNT di-chain loop protease cleavage site.
    71. The modified Clostridial toxin according to 69, wherein the exogenous protease cleavage site is selected from the group consisting of an enterokinase cleavage site, a Thrombin cleavage site, a Factor Xa cleavage site, a human rhinovirus 3C protease cleavage site, a tobacco etch virus protease cleavage site, a dipeptidyl aminopeptidase cleavage site, a small ubiquitin-like modifier (SUMO)/ubiquitin-like protein-1(ULP-1) protease cleavage site, and a Clostridial toxin substrate cleavage site.
    72. The modified Clostridial toxin according to 71, wherein the Clostridial toxin substrate cleavage site is selected from the group consisting of a BoNT/A substrate cleavage site, a BoNT/B substrate cleavage site, a BoNT/C1 substrate cleavage site, a BoNT/D substrate cleavage site, a BoNT/E substrate cleavage site, a BoNT/F substrate cleavage site, a BoNT/G substrate cleavage site and a TeNT substrate cleavage site.
    73. A modified Clostridial toxin comprising:
    
        a) a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) an enhanced targeting domain comprising a FGF β-trefoil domain capable of selectively binding an FGFR3; and
        e) a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    74. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain, the translocation facilitating domain and the enhanced targeting domain.
    75. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin enzymatic domain, the protease cleavage site, the enhanced targeting domain, the Clostridial toxin translocation domain and the translocation facilitating domain.
    76. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site and the Clostridial toxin enzymatic domain.
    77. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the enhanced targeting domain, the Clostridial toxin enzymatic domain, the protease cleavage site, the Clostridial toxin translocation domain and the translocation facilitating domain.
    78. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the Clostridial toxin enzymatic domain and the enhanced targeting domain.
    79. The modified Clostridial toxin according to 73, wherein the modified Clostridial toxin comprises, in a linear amino-to-carboxyl single polypeptide order, the Clostridial toxin translocation domain, the translocation facilitating domain, the protease cleavage site, the enhanced targeting domain and the Clostridial toxin enzymatic domain.
    80. The modified Clostridial toxin according to 73, wherein the Clostridial toxin enzymatic domain is selected from the group consisting of a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    81. The modified Clostridial toxin according to 73, wherein the Clostridial toxin translocation domain is selected from the group consisting of a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    82. The modified Clostridial toxin according to 73, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    83. The modified Clostridial toxin according to 82, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    84. The modified Clostridial toxin according to 82, wherein the Clostridial toxin translocation facilitating domain comprises an amino acid sequence selected from the group consisting of amino acids 874-1110 of SEQ ID NO: 1, amino acids 861-1097 of SEQ ID NO: 2, amino acids 869-1111 of SEQ ID NO: 3, amino acids 865-1098 of SEQ ID NO: 4, amino acids 848-1085 of SEQ ID NO: 5, amino acids 867-1105 of SEQ ID NO: 6, amino acids 866-1105 of SEQ ID NO: 7 and amino acid 882-1127 of SEQ ID NO: 8.
    85. The modified Clostridial toxin according to 73, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    86. The modified Clostridial toxin according to 85, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    87. The modified Clostridial toxin according to 86, wherein the influenzavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 and SEQ ID NO: 91.
    88. The modified Clostridial toxin according to 86, wherein the alphavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 and SEQ ID NO: 118.
    89. The modified Clostridial toxin according to 86, wherein the vesiculovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129.
    90. The modified Clostridial toxin according to 86, wherein the respirovirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135 and SEQ ID NO: 136.
    91. The modified Clostridial toxin according to 86, wherein the morbillivirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145 and SEQ ID NO: 146.
    92. The modified Clostridial toxin according to 86, wherein the avulavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158 and SEQ ID NO: 159.
    93. The modified Clostridial toxin according to 86, wherein the henipavirus fusogenic peptide domain is selected from the group consisting of SEQ ID NO: 160 and SEQ ID NO: 161.
    94. The modified Clostridial toxin according to 86, wherein the metapneumovirus fusogenic peptide domain is SEQ ID NO: 162.
    95. The modified Clostridial toxin according to 73, wherein the FGF β-trefoil domain is selected from the group consisting of a FGF-1 β-trefoil domain, a FGF-2 β-trefoil domain, a FGF-4 β-trefoil domain, a FGF-8 β-trefoil domain, a FGF-9 β-trefoil domain, a FGF-17 β-trefoil domain and a FGF-18 β-trefoil domain.
    96. The modified Clostridial toxin according to 73, wherein the FGF β-trefoil domain is selected from the group consisting of amino acids 26-155 of SEQ ID NO: 33, amino acids 29-155 of SEQ ID NO: 34, amino acids 83-206 of SEQ ID NO: 35, amino acids 43-172 of SEQ ID NO: 36, amino acids 63-196 of SEQ ID NO: 37, amino acids 55-183 of SEQ ID NO: 38 and amino acids 54-183 of SEQ ID NO: 39.
    97. The modified Clostridial toxin according to 73, wherein the protease cleavage site is an endogenous Clostridial toxin di-chain loop protease cleavage site or an exogenous cleavage site.
    98. The modified Clostridial toxin according to 97, wherein the endogenous Clostridial toxin di-chain loop protease cleavage site is selected from the group consisting of a BoNT/A di-chain loop protease cleavage site, a BoNT/B di-chain loop protease cleavage site, a BoNT/C1 di-chain loop protease cleavage site, a BoNT/D di-chain loop protease cleavage site, a BoNT/E di-chain loop protease cleavage site, a BoNT/F di-chain loop protease cleavage site, a BoNT/G di-chain loop protease cleavage site and a TeNT di-chain loop protease cleavage site.
    99. The modified Clostridial toxin according to 97, wherein the exogenous protease cleavage site is selected from the group consisting of an enterokinase cleavage site, a Thrombin cleavage site, a Factor Xa cleavage site, a human rhinovirus 3C protease cleavage site, a tobacco etch virus protease cleavage site, a dipeptidyl aminopeptidase cleavage site, a small ubiquitin-like modifier (SUMO)/ubiquitin-like protein-1(ULP-1) protease cleavage site, and a Clostridial toxin substrate cleavage site.
    100. The modified Clostridial toxin according to 99, wherein the Clostridial toxin substrate cleavage site is selected from the group consisting of a BoNT/A substrate cleavage site, a BoNT/B substrate cleavage site, a BoNT/C1 substrate cleavage site, a BoNT/D substrate cleavage site, a BoNT/E substrate cleavage site, a BoNT/F substrate cleavage site, a BoNT/G substrate cleavage site and a TeNT substrate cleavage site.
    101. A polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a modified Clostridial HCC targeting domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form; and
        wherein the modified Clostridial HCC targeting domain exhibits enhanced binding activity for an endogenous Clostridial toxin receptor relative to the binding activity of a naturally-occurring Clostridial HCC targeting domain from which the modified Clostridial HCC targeting domain is derived.
    
    
    102. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encodes the modified Clostridial toxin of any one of Claims 1-7.
    103. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a Clostridial toxin enzymatic domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    104. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a Clostridial toxin translocation domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    105. The polynucleotide molecule according to 101, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    106. The polynucleotide molecule according to 105, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    107. The polynucleotide molecule according to 101, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    108. The polynucleotide molecule according to 107, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    109. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain is selected from the group consisting of a polynucleotide molecule encoding a modified BoNT/A HCC targeting domain, a modified BoNT/B HCC targeting domain, a modified BoNT/C1 HCC targeting domain, a modified BoNT/D HCC targeting domain, a modified BoNT/E HCC targeting domain, a modified BoNT/F HCC targeting domain, a modified BoNT/G HCC targeting domain and a modified TeNT HCC targeting domain.
    110. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain comprises a polynucleotide molecule encoding a substitution of a Clostridial toxin HCC targeting domain α-fold for an α-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1α-fold, a Clostridial botulinum serotype B HA-33 1α-fold, a Clostridial botulinum serotype C1 HA-33 1α-fold, a Clostridial botulinum serotype D HA-33 1α-fold, a Clostridial botulinum serotype A HA-33 2α-fold, a Clostridial botulinum serotype B HA-33 2α-fold, a Clostridial botulinum serotype C1 HA-33 2α-fold, a Clostridial botulinum serotype D HA-33 2α-fold, a Clostridial botulinum serotype A HA-17 α-fold, a Clostridial botulinum serotype B HA-17 α-fold, a Clostridial botulinum serotype C1 HA-17 α-fold, a Clostridial botulinum serotype D HA-17 α-fold, a Clostridial botulinum serotype A NTNH α-fold, a Clostridial botulinum serotype B NTNH α-fold, a Clostridial botulinum serotype C1 NTNH α-fold, a Clostridial botulinum serotype D NTNH α-fold, a Clostridial botulinum serotype E NTNH α-fold, a Clostridial botulinum serotype F NTNH α-fold, a Clostridial botulinum serotype G NTNH α-fold, a FGF-1 α-fold, a FGF-2 α-fold, a FGF-4 α-fold, a FGF-8 α-fold, a FGF-9 α-fold, a FGF-17 α-fold and a FGF-18 α-fold.
    111. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain comprises a polynucleotide molecule encoding a substitution of a Clostridial toxin HCC targeting domain β-fold for a β-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1β-fold, a Clostridial botulinum serotype B HA-33 1β-fold, a Clostridial botulinum serotype C1 HA-33 1β-fold, a Clostridial botulinum serotype D HA-33 1β-fold, a Clostridial botulinum serotype A HA-33 2β-fold, a Clostridial botulinum serotype B HA-33 2β-fold, a Clostridial botulinum serotype C1 HA-33 2β-fold, a Clostridial botulinum serotype D HA-33 2β-fold, a Clostridial botulinum serotype A HA-17 β-fold, a Clostridial botulinum serotype B HA-17 β-fold, a Clostridial botulinum serotype C1 HA-17 β-fold, a Clostridial botulinum serotype D HA-17 β-fold, a Clostridial botulinum serotype A NTNH β-fold, a Clostridial botulinum serotype B NTNH β-fold, a Clostridial botulinum serotype C1 NTNH β-fold, a Clostridial botulinum serotype D NTNH β-fold, a Clostridial botulinum serotype E NTNH β-fold, a Clostridial botulinum serotype F NTNH β-fold, a Clostridial botulinum serotype G NTNH β-fold, a FGF-1 β-fold, a FGF-2 β-fold, a FGF-4 β-fold, a FGF-8 β-fold, a FGF-9 β-fold, a FGF-17β-fold and a FGF-18 β-fold.
    112. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain comprises a polynucleotide molecule encoding a substitution of a Clostridial toxin HCC targeting domain γ-fold for a γ-fold selected from the group consisting of a Clostridial botulinum serotype A HA-33 1γ-fold, a Clostridial botulinum serotype B HA-33 1γ-fold, a Clostridial botulinum serotype C1 HA-33 1γ-fold, a Clostridial botulinum serotype D HA-33 1γ-fold, a Clostridial botulinum serotype A HA-33 2γ-fold, a Clostridial botulinum serotype B HA-33 2γ-fold, a Clostridial botulinum serotype C1 HA-33 2γ-fold, a Clostridial botulinum serotype D HA-33 2γ-fold, a Clostridial botulinum serotype A HA-17 γ-fold, a Clostridial botulinum serotype B HA-17 γ-fold, a Clostridial botulinum serotype C1 HA-17 γ-fold, a Clostridial botulinum serotype D HA-17 γ-fold, a Clostridial botulinum serotype A NTNH γ-fold, a Clostridial botulinum serotype B NTNH γ-fold, a Clostridial botulinum serotype C1 NTNH γ-fold, a Clostridial botulinum serotype D NTNH γ-fold, a Clostridial botulinum serotype E NTNH γ-fold, a Clostridial botulinum serotype F NTNH γ-fold, a Clostridial botulinum serotype G NTNH γ-fold, a FGF-1 γ-fold, a FGF-2 γ-fold, a FGF-4 γ-fold, a FGF-8 γ-fold, a FGF-9 γ-fold, a FGF-17 γ-fold and a FGF-18 γ-fold.
    113. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain comprises a polynucleotide molecule encoding a substitution of a Clostridial toxin HCC targeting domain β4/β5 β-hairpin turn for a β4/β5 β-hairpin turn selected from the group consisting of a Clostridial botulinum serotype A HA-33 β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-33 1β4/β5 β-hairpin turn, a Clostridial botulinum serotype A HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-33 2β4/β5 β-hairpin turn, a Clostridial botulinum serotype A HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype B HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype D HA-17 β4/β5 β-hairpin turn, a Clostridial botulinum serotype A NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype B NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype C1 NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype D NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype E NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype F NTNH β4/β5 β-hairpin turn, a Clostridial botulinum serotype G NTNH β4/β5 β-hairpin turn, a FGF-1 β4/β5 β-hairpin turn, a FGF-2 β4/β5 β-hairpin turn, a FGF-4 β4/β5 β-hairpin turn, a FGF-8 β4/β5 β-hairpin turn, a FGF-9 β4/β5 β-hairpin turn, a FGF-17 β4/β5 β-hairpin turn and a FGF-18 β4/β5 β-hairpin turn.
    114. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding a modified Clostridial toxin HCC targeting domain comprises a polynucleotide molecule encoding a substitution of a Clostridial toxin HCC targeting domain β8/β9 β-hairpin turn for a β8/β9 β-hairpin turn selected from the group consisting of a Clostridial botulinum serotype A HA-33 β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-33 1β8/β9 β-hairpin turn, a Clostridial botulinum serotype A HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-33 2β8/β9 β-hairpin turn, a Clostridial botulinum serotype A HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype B HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype D HA-17 β8/β9 β-hairpin turn, a Clostridial botulinum serotype A NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype B NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype C1 NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype D NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype E NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype F NTNH β8/β9 β-hairpin turn, a Clostridial botulinum serotype G NTNH β8/β9 β-hairpin turn, a FGF-1 β8/β9 β-hairpin turn, a FGF-2 β8/β9 β-hairpin turn, a FGF-4 β8/β9 β-hairpin turn, a FGF-8 β8/β9 β-hairpin turn, a FGF-9 β8/β9 β-hairpin turn, a FGF-17 β8/β9 β-hairpin turn and a FGF-18 β8/β9 β-hairpin turn.
    115. The polynucleotide molecule according to 101, wherein the polynucleotide molecule encoding the protease cleavage site is a polynucleotide molecule encoding an endogenous Clostridial toxin di-chain loop protease cleavage site or a polynucleotide molecule encoding an exogenous cleavage site.
    116. The polynucleotide molecule according to 101, wherein the polynucleotide molecule comprises an expression vector.
    117. A polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a Clostridial non-toxin associated protein β-trefoil domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    118. The polynucleotide molecule according to 115, wherein the polynucleotide molecule encodes a modified Clostridial toxin of any one of Claims 45-51.
    119. The polynucleotide molecule according to 117, wherein the polynucleotide molecule encoding a Clostridial toxin enzymatic domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    120. The polynucleotide molecule according to 117, wherein the polynucleotide molecule encoding a Clostridial toxin translocation domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    121. The polynucleotide molecule according to 117, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    122. The polynucleotide molecule according to 121, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    123. The polynucleotide molecule according to 117, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    124. The polynucleotide molecule according to 123, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    125. The polynucleotide molecule according to 117, wherein the polynucleotide molecule encoding a Clostridial non-toxin associated protein β-trefoil domain selected from the group consisting of a polynucleotide molecule encoding a Clostridial botulinum serotype A HA-33 β-trefoil domain, a Clostridial botulinum serotype B HA-33 β-trefoil domain, a Clostridial botulinum serotype C1 HA-33 β-trefoil domain, a Clostridial botulinum serotype D HA-33 β-trefoil domain, a Clostridial botulinum serotype A HA-17 β-trefoil domain, a Clostridial botulinum serotype B HA-17 β-trefoil domain, a Clostridial botulinum serotype C1 HA-17 β-trefoil domain, a Clostridial botulinum serotype D HA-17 β-trefoil domain, a Clostridial botulinum serotype A NTNH β-trefoil domain, a Clostridial botulinum serotype B NTNH β-trefoil domain, a Clostridial botulinum serotype C1 NTNH β-trefoil domain, a Clostridial botulinum serotype D NTNH β-trefoil domain, a Clostridial botulinum serotype E NTNH β-trefoil domain, a Clostridial botulinum serotype F NTNH β-trefoil domain and a Clostridial botulinum serotype G NTNH β-trefoil domain.
    126. The polynucleotide molecule according to 117, wherein the polynucleotide molecule encoding the protease cleavage site is a polynucleotide molecule encoding an endogenous Clostridial toxin di-chain loop protease cleavage site or a polynucleotide molecule encoding an exogenous cleavage site.
    127. The polynucleotide molecule according to 117, wherein the polynucleotide molecule comprises an expression vector.
    128. A polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a Clostridial toxin translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a FGF β-trefoil domain capable of selectively binding an FGFR3; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    129. The polynucleotide molecule according to 128, wherein the polynucleotide molecule encodes a modified Clostridial toxin of any one of Claims 73-79.
    130. The polynucleotide molecule according to 128, wherein the polynucleotide molecule encoding a Clostridial toxin enzymatic domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain and a TeNT enzymatic domain.
    131. The polynucleotide molecule according to 128, wherein the polynucleotide molecule encoding a Clostridial toxin translocation domain is selected from the group consisting of a polynucleotide molecule encoding a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain and a TeNT translocation domain.
    132. The polynucleotide molecule according to 128, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain.
    133. The polynucleotide molecule according to 132, wherein the Clostridial toxin translocation facilitating domain is selected from the group consisting of a BoNT/A translocation facilitating domain, a BoNT/B translocation facilitating domain, a BoNT/C1 translocation facilitating domain, a BoNT/D translocation domain, a BoNT/E translocation facilitating domain, a BoNT/F translocation facilitating domain, a BoNT/G translocation facilitating domain and a TeNT translocation facilitating domain.
    134. The polynucleotide molecule according to 128, wherein the translocation facilitating domain is an enveloped virus fusogenic peptide domain.
    135. The polynucleotide molecule according to 134, wherein the enveloped virus fusogenic peptide domain is selected from the group consisting of an influenzavirus fusogenic peptide domain, an alphavirus fusogenic peptide domain, a vesiculovirus fusogenic peptide domain, a respirovirus fusogenic peptide domain, a morbillivirus fusogenic peptide domain, an avulavirus fusogenic peptide domain, a henipavirus fusogenic peptide domain, a metapneumovirus fusogenic peptide domain and a foamy virus fusogenic peptide domain.
    136. The polynucleotide molecule according to 128, wherein the polynucleotide molecule encoding a FGF β-trefoil domain is selected from the group consisting of a polynucleotide molecule encoding a FGF-1 β-trefoil domain, a FGF-2 β-trefoil domain, a FGF-4 β-trefoil domain, a FGF-8 β-trefoil domain, a FGF-9 β-trefoil domain, a FGF-17 β-trefoil domain and a FGF-18 β-trefoil domain.
    137. The polynucleotide molecule according to 128, wherein the polynucleotide molecule encoding the protease cleavage site is a polynucleotide molecule encoding an endogenous Clostridial toxin di-chain loop protease cleavage site or a polynucleotide molecule encoding an exogenous cleavage site.
    138. The polynucleotide molecule according to 128, wherein the polynucleotide molecule comprises an expression vector.
    139. A method of producing a modified Clostridial toxin comprising the step of expressing a polynucleotide molecule encoding a modified Clostridial toxin in a cell, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a modified Clostridial HCC targeting domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form; and
        wherein the modified Clostridial HCC targeting domain exhibits enhanced binding activity for an endogenous Clostridial toxin receptor relative to the binding activity of a naturally-occurring Clostridial HCC targeting domain from which the modified Clostridial binding HCC targeting is derived.
    
    
    140. The method according to 139, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 102.
    141. A method of producing a modified Clostridial toxin comprising the step of expressing a polynucleotide molecule encoding a modified Clostridial toxin in a cell, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a Clostridial non-toxin associated protein β-trefoil domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    142. The method according to 141, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 118.
    143. A method of producing a modified Clostridial toxin comprising the step of expressing a polynucleotide molecule encoding a modified Clostridial toxin in a cell, the polynucleotide molecule comprising:
    
        a) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
        b) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
        c) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
        d) a polynucleotide molecule encoding an enhanced targeting domain comprising a FGF β-trefoil domain capable of selectively binding an FGFR3; and
        e) a polynucleotide molecule encoding a protease cleavage site
        wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
    
    
    144. The method according to 143, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 129.
    145. A method of producing a modified Clostridial toxin comprising the steps of:
    
        a) introducing into a cell a polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
        
            i) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
            ii) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
            iii) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
            iv) a polynucleotide molecule encoding an enhanced targeting domain comprising a modified Clostridial HCC targeting domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
            v) a polynucleotide molecule encoding a protease cleavage site
            wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form; and
            wherein the modified Clostridial HCC targeting domain exhibits enhanced binding activity for an endogenous Clostridial toxin receptor relative to the binding activity of a naturally-occurring Clostridial HCC targeting domain from which the modified Clostridial HCC targeting domain is derived.
        
        
        b) expressing the modified Clostridial toxin encoded by the polynucleotide molecule.
    
    
    146. The method according to 145, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 102.
    147. A method of producing a modified Clostridial toxin comprising the steps of:
    
        a) introducing into a cell a polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
        
            i) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
            ii) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
            iii) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
            iv) a polynucleotide molecule encoding an enhanced targeting domain comprising a Clostridial non-toxin associated protein β-trefoil domain capable of executing a cell binding step of a Clostridial toxin intoxication process; and
            v) a polynucleotide molecule encoding a protease cleavage site
            wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
        
        
        b) expressing the modified Clostridial toxin encoded by the polynucleotide molecule.
    
    
    148. The method according to 147, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 118.
    149. A method of producing a modified Clostridial toxin comprising the steps of:
    
        a) introducing into a cell a polynucleotide molecule encoding a modified Clostridial toxin, the polynucleotide molecule comprising:
        
            i) a polynucleotide molecule encoding a Clostridial toxin enzymatic domain capable of executing an enzymatic target modification step of a Clostridial toxin intoxication process;
            ii) a polynucleotide molecule encoding a Clostridial toxin translocation domain capable of executing a translocation step of a Clostridial toxin intoxication process;
            iii) a polynucleotide molecule encoding a translocation facilitating domain capable of facilitating a translocation step of a Clostridial toxin intoxication process;
            iv) a polynucleotide molecule encoding an enhanced targeting domain comprising a FGF β-trefoil domain capable of selectively binding an FGFR3; and
            v) a polynucleotide molecule encoding a protease cleavage site
            wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
        
        
        b) expressing the modified Clostridial toxin encoded by the polynucleotide molecule.
    
    
    150. The method according to 149, wherein the polynucleotide molecule is any one of the polynucleotide molecules of 129.


EXAMPLES
The following non-limiting examples are provided for illustrative purposes only in order to facilitate a more complete understanding of disclosed embodiments and are in no way intended to limit any of the embodiments disclosed in the present specification.
Example 1
Construction of a Modified Clostridial Toxin Comprising a Translocation Facilitating Domain and a Modified Clostridial Toxin Targeting Domain with Enhanced Binding Activity
This example illustrates how to make a modified Clostridial toxin comprising a translocation facilitating domain and a modified Clostridial toxin binding domain with enhanced binding activity using site-directed mutagenesis.
A polynucleotide molecule encoding BoNT/A (SEQ ID NO: 1) is synthesized using standard procedures (BlueHeron® Biotechnology, Bothell, Wash.). Oligonucleotides of 20 to 50 bases in length are synthesized using standard phosphoramidite synthesis. These oligonucleotides are hybridized into double stranded duplexes that are ligated together to assemble the full-length polynucleotide molecule. This polynucleotide molecule is cloned using standard molecular biology methods into a pUCBHB1 vector at the SmaI site to generate pUCBHB1/BoNT/A. The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.).
If desired, an expression optimized polynucleotide molecule encoding BoNT/A (SEQ ID NO: 1) can be synthesized in order to improve expression in an Escherichia coli strain. The polynucleotide molecule encoding the BoNT/A can be modified to 1) contain synonymous codons typically present in native polynucleotide molecules of an Escherichia coli strain; 2) contain a G+C content that more closely matches the average G+C content of native polynucleotide molecules found in an Escherichia coli strain; 3) reduce polymononucleotide regions found within the polynucleotide molecule; and/or 4) eliminate internal regulatory or structural sites found within the polynucleotide molecule, see, e.g., Lance E. Steward et al. Optimizing Expression of Active Botulinum Toxin Type E, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); Lance E. Steward et al. Optimizing Expression of Active Botulinum Toxin Type A, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005). Once sequence optimization is complete, oligonucleotides of 20 to 50 bases in length are synthesized using standard phosphoramidite synthesis. These oligonucleotides are hybridized into double stranded duplexes that are ligated together to assemble the full-length polynucleotide molecule. This polynucleotide molecule is cloned using standard molecular biology methods into a pUCBHB1 vector at the SmaI site to generate pUCBHB1/BoNT/A. The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.). Is so desired, optimization to a different organism, such as, e.g., a yeast strain, an insect cell-line or a mammalian cell line, can be done, see, e.g., Steward, supra, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); and Steward, supra, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005).
A similar cloning strategy is used to make pUCBHB1 cloning constructs comprising a polynucleotide molecule encoding BoNT/B of SEQ ID NO: 2; a polynucleotide molecule encoding BoNT/C1 of SEQ ID NO: 3; a polynucleotide molecule encoding BoNT/D of SEQ ID NO: 4; a polynucleotide molecule encoding BoNT/E of SEQ ID NO: 5; a polynucleotide molecule encoding BoNT/F of SEQ ID NO: 6; a polynucleotide molecule encoding BoNT/G of SEQ ID NO: 7; and a polynucleotide molecule encoding TeNT of SEQ ID NO: 8. In addition, one skilled in the art can modify Clostridial toxins, such as, e.g., to include an exogenous protease cleavage site within the di-chain loop region, or flexible spacer regions.
To construct pET29/BoNT/A, a pUCBHB1/BoNT/A construct is digested with restriction endonucleases that 1) excise the insert comprising the open reading frame of SEQ ID NO: 1 encoding BoNT/A; and 2) enable this insert to be operably-linked to a pET29 vector (EMD Biosciences-Novagen, Madison, Wis.). This insert is subcloned using a T4 DNA ligase procedure into a pET29 vector that is digested with appropriate restriction endonucleases to yield pET29/BoNT/A. The ligation mixture is transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin, and placed in a 37° C. incubator for overnight growth. Bacteria containing expression constructs are identified as Kanamycin resistant colonies. Candidate constructs are isolated using an alkaline lysis plasmid mini-preparation procedure and analyzed by restriction endonuclease digest mapping to determine the presence and orientation of the insert. This cloning strategy yielded a pET29 expression construct comprising the polynucleotide molecule encoding the BoNT/A of SEQ ID NO: 1 operably-linked to a carboxyl terminal polyhistidine affinity binding peptide.
A similar cloning strategy is used to make pET29 expression constructs comprising a polynucleotide molecule encoding BoNT/B of SEQ ID NO: 2; a polynucleotide molecule encoding BoNT/C1 of SEQ ID NO: 3; a polynucleotide molecule encoding BoNT/D of SEQ ID NO: 4; a polynucleotide molecule encoding BoNT/E of SEQ ID NO: 5; a polynucleotide molecule encoding BoNT/F of SEQ ID NO: 6; a polynucleotide molecule encoding BoNT/G of SEQ ID NO: 7; and a polynucleotide molecule encoding TeNT of SEQ ID NO: 8.
To construct a modified BoNT/A comprising a modified HCC targeting domain with enhanced binding activity, specific amino acids influencing binding activity will be changed. It is already known that amino acids Trp 1101, Gly 1102, Leu 1105, Tyr 1111, Tyr 1112, Gly 1158, Ile 1163, Asp 1179, Glu 1203, Phe 1252, Ser 1264, Trp 1266, Tyr 1267, Gln 1270, Gly 1279 and Trp 1282 of SEQ ID NO: 1 are important for function. To determine which amino acid substitutions could enhance the binding activity of a BoNT/A binding domain, computational protein design algorithms will generate novel proteins with optimized properties. The crystal structure of a BoNT/A binding domain will be used as the starting template for computational calculations. Potential amino acid candidates will be identified using a combined output from Protein Design Automation® (PDA®) and Sequence Prediction AlgorithmTM (SPATM) calculations. For PDA calculations, the conformations of amino acids at variable positions will be represented as a set of backbone-independent side chain rotamers derived from the rotamer library. The energies of all possible combinations of the considered amino acids at the chosen variable positions will be calculated using a force field containing terms describing van der Waals, solvation, electrostatic, and hydrogen bond interactions. The optimal (ground state) sequence will be determined using a Dead End Elimination (DEE) algorithm, and a Monte Carlo (MC) algorithm will be used to evaluate the energies of similar sequences around the predicted ground state. SPA calculations utilize a genetic algorithm to screen for low energy sequences, with energies being calculated during each round of “evolution” for those sequences being sampled. The conformations of amino acids will be represented as a set of side chain rotamers derived from a backbone-independent rotamer library using a flexible rotamer model. SPA calculations will generate sequences which will be subsequently clustered computationally into groups of similar sequences using a nearest neighbor single linkage hierarchical clustering algorithm. Critical contact amino acids will be fixed in both sequence and conformation and calculations will be carried out to evaluate single and combinatorial substitutions at variable amino acids. All amino acids in contact with these residues will be floated, that is the amino acid conformation but not the amino acid identity will be allowed to vary to allow for conformational adjustments. Final experimental substitutions will be chosen based on their predicted energies relative to the naturally occurring BoNT/A binding domain and their occupancy, that is the number times the substitution occurred in the set of 1000 MC or genetic algorithm sequences. Two sets of design calculations will be carried out using Rosetta to identify substitutions predicted to stabilize the BoNT/A binding domain. In the first round, only single amino acid substitutions will be modeled. In a second round, interface amino acids will be allowed to change to all 20 naturally occurring amino acids including the native amino acid type, but excluding cysteine, simultaneously. In each case, amino acid side chains contacting the substituted amino acid side chains will be repacked (allowing all rotamers of the native amino acid type). Sequences and conformations with low energies will be selected using a Monte-Carlo simulated annealing procedure. All resulting protein complex models will be rescored by computing a predicted binding energy. Final sequences were selected for the lowest binding energy
Identified candidate amino acids will be changed using site-directed in vitro mutagenesis. A 50 μL reaction will be assembled using pET29/BoNT/A as a template, sense and antisense oligonucleotides encoding the desired amino acid change identified above, and reagents included with the QuickChange® II XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, Calif.). The polymerase chain reaction (PCR) mix will contain 5 μL of 10× Buffer, 1 μL of deoxyribonucleotides (dNTPs), 1 μL of PfuUltraTM High Fidelity DNA polymerase (2.5 units/μL), 125 ng of each primer, 100 ng of template DNA, and nuclease-free water to a final volume of 50 μL. The thermocycler conditions will be: one cycle of 95° C. for 60 seconds; 16 cycles of 95° C. for 30 seconds, 55° C. for 60 seconds, and 72° C. for 10 minutes; one cycle of 72° C. for 5 minutes; and 4° C. to hold. Following thermocycling, 1 μL of DpnI restriction enzyme (Stratagene, La Jolla, Calif.) will be added to the reaction and will be incubated for 1 hour at 37° C. to digest the template DNA. The reaction will be purified by QIAquick kit (QIAGEN, Inc., Valencia, Calif.) and will be analysis by agarose gel electrophoresis to determine that the reaction produced full-length plasmid. The mutagenesis products will be transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 100 μg/mL of Ampicillin, and will be placed in a 37° C. incubator for overnight growth. Candidate mutagenesis constructs will be isolated as Ampicillin resistant colonies and will be analyzed using an alkaline lysis plasmid mini-preparation procedure to isolate the expression construct and restriction endonuclease digests to determine the presence of the insert. The incorporation of the point mutation will be determined by sequence analysis of candidate plasmid constructs.
To test the binding activity of modified BoNT/A candidates with enhanced binding activity, the soluble portion of FGFR3 will be expressed recombinantly for use in surface plasmon resonance (SPR) binding assays, e.g., Biacore® (Biacore Inc., Piscataway, N.J.). The soluble portion of FGFR3 will be expressed as a fusion to streptavidin and the receptor will then be immobilized on an appropriate sensor chip. Utilizing a Biacore® instrument, changes in local refractive index as a result of receptor binding will be measured as a change in the SPR angle. The rates of change in the SPR angle will then be analyzed to determine association rate (Kon), dissociation rate (Koff) and the dissociation equilibrium constant (KD=Koff/Kon). Modified BoNT/A candidates with enhanced binding activity will exhibit either an increased association rate, a decreased dissociation rate, both an increased association rate and a decreased dissociation rate, or a decreased dissociation equilibrium constant relative to the measurements obtained from the naturally occurring BoNT/A from which the modified BoNT/A with enhanced binding activity was derived.
To construct a modified BoNT/A described above that replaces the BoNT/A translocation facilitating domain with another Clostridial toxin translocation facilitating domain, a translocation facilitating domain of BoNT/B will be introduced into the modified BoNT/A described above using a Splicing by Overlapping ends polymerase chain reaction (SOE-PCR) procedure, see, e.g., R. M. Horton et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlapping extension, 77(1) Gene 61-68 (1989); and R. M. Horton, PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes, 3(2) Mol. Biotechnol. 93-99 (1995). A nucleic acid fragment comprising a region encoding amino acids 859 to 1097 of BoNT/B (SEQ ID NO: 2) will be operably-linked by SOE-PCR to replace the region corresponding to the BoNT/A translocation facilitating domain of amino acids 874-1110 of SEQ ID NO: 1 of the modified BoNT/A described above and will be subcloned into a pCR2.1 vector using the TOPO® TA cloning method (Invitrogen, Inc, Carlsbad, Calif.). The forward and reverse oligonucleotide primers used for these reactions are designed to include unique restriction enzyme sites useful for subsequent subcloning steps. The resulting construct is digested with restriction enzymes that 1) excise the insert containing the entire open reading frame encoding the modified BoNT/A; and 2) enable this insert to be operably-linked to a pQBI-25A vector (Qbiogene, Inc., Carlsbad, Calif.). The resulting restriction fragment will be purified by the QIAquick Gel Extraction Kit (QIAGEN, Inc., Valencia, Calif.), and will be subcloned using a T4 DNA ligase procedure into a pQBI-25A vector (Qbiogene, Inc., Irvine, Calif.). This cloning strategy yielded a pQBI-25 expression construct encoding a modified BoNT/A comprising a BoNT/B translocation facilitating domain and a modified HCC targeting domain with enhanced binding activity.
A similar cloning strategy is used to make pQBI-25 expression constructs comprising a polynucleotide molecule encoding a modified BoNT/A comprising a modified targeting domain with enhanced binding activity that includes, e.g., a translocation facilitating domain comprising amino acids 869-1111 of BoNT/C1 of SEQ ID NO: 3; a translocation facilitating domain comprising amino acids 865-1098 of BoNT/D of SEQ ID NO: 4; a translocation facilitating domain comprising amino acids 846-1058 of BoNT/E of SEQ ID NO: 5; a translocation facilitating domain comprising amino acids 867-1105 of BoNT/F of SEQ ID NO: 6; a translocation facilitating domain comprising amino acids 866-1105 of BoNT/G of SEQ ID NO: 7; or a translocation facilitating domain comprising amino acids 882-1127 of TeNT of SEQ ID NO: 8.
Example 2
Construction of a Modified Clostridial Toxin Comprising a Translocation Facilitating Domain and a Non-Toxin Associated Protein
The following example illustrates how to make a modified Clostridial toxin comprising a translocation facilitating domain and an enhanced targeting domain comprising a non-toxin associated protein.
A polynucleotide molecule encoding BoNT/A-33/A is synthesized using standard procedures (BlueHeron® Biotechnology, Bothell, Wash.), as described in Example 1. BoNT/A-33/A is a BoNT/A modified to replace amino acids 1111-1296 of SEQ ID NO: 1, a BoNT/A β-trefoil domain, with amino acids 151 to 293 of SEQ ID NO: 9, a HA-33 β-trefoil domain from a Clostridial botulinum serotype A strain. If desired, an expression optimized polynucleotide molecule encoding BoNT/A-33/A can be synthesized in order to improve expression in to a different organism, such as, e.g., an Escherichia coli strain, a yeast strain, an insect cell-line or a mammalian cell line, can be done, see, e.g., Steward, supra, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); and Steward, supra, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005). The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.).
A similar cloning strategy is used to make pUCBHB1 cloning constructs for BoNT/B-33/A, a modified BoNT/B where amino acids 1098-1291 of SEQ ID NO: 2 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; BoNT/C1-33/A, a modified BoNT/C1 where amino acids 1112-1291 of SEQ ID NO: 3 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; BoNT/D-33/A, a modified BoNT/D where amino acids 1099-1276 of SEQ ID NO: 4 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; BoNT/E-33/A, a modified BoNT/E where amino acids 1086-1252 of SEQ ID NO: 5 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; BoNT/F-33/A, a modified BoNT/F where amino acids 1106-1274 of SEQ ID NO: 6 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; BoNT/G-33/A, a modified BoNT/G where amino acids 1106-1297 of SEQ ID NO: 7 are replaced with amino acids 151 to 293 of SEQ ID NO: 9; and TeNT-33/A, a modified TeNT where amino acids 1128-1315 of SEQ ID NO: 8 are replaced with amino acids 151 to 293 of SEQ ID NO: 9. Similarly, the β-trefoil domain from a Clostridial toxin indicated above can be replaced with a non-toxin associated protein β-trefoil domain comprising amino acids 10-144 of SEQ ID NO: 9; amino acids 10-144 of SEQ ID NO: 10; amino acids 10-144 of SEQ ID NO: 11; amino acids 10-146 of SEQ ID NO: 12; amino acids 10-144 of SEQ ID NO: 13; amino acids 10-144 of SEQ ID NO: 14; amino acids 10-146 of SEQ ID NO: 15; amino acids 10-141 of SEQ ID NO: 16; amino acids 10-141 of SEQ ID NO: 17; amino acids 10-141 of SEQ ID NO: 18; amino acids 151-293 of SEQ ID NO: 10; amino acids 151-293 of SEQ ID NO: 11; amino acids 153-294 of SEQ ID NO: 12; amino acids 151-279 of SEQ ID NO: 13; amino acids 151-292 of SEQ ID NO: 14; amino acids 153-291 of SEQ ID NO: 15; amino acids 148-285 of SEQ ID NO: 16; amino acids 148-286 of SEQ ID NO: 17; amino acids 148-286 of SEQ ID NO: 18; amino acids 9-146 of SEQ ID NO: 19; amino acids 9-146 of SEQ ID NO: 20; amino acids 9-146 of SEQ ID NO: 21; amino acids 9-146 of SEQ ID NO: 22; amino acids 1050-1194 of SEQ ID NO: 23; amino acids 1050-1199 of SEQ ID NO: 24; amino acids 1050-1194 of SEQ ID NO: 25; amino acids 1049-1198 of SEQ ID NO: 26; amino acids 1049-1197 of SEQ ID NO: 27; amino acids 1049-1197 of SEQ ID NO: 28; amino acids 1014-1163 of SEQ ID NO: 29; amino acids 1016-1160 of SEQ ID NO: 30; amino acids 1017-1166 of SEQ ID NO: 31; and amino acids 1050-1199 of SEQ ID NO: 32.
To construct pET29/BoNT/A-33/A, a pUCBHB1/BoNT/A-33/A construct is digested with restriction endonucleases that 1) excise the insert comprising the open reading frame encoding BoNT/A-33/A; and 2) enable this insert to be operably-linked to a pET29 vector (EMD Biosciences-Novagen, Madison, Wis.). This insert is subcloned using a T4 DNA ligase procedure into a pET29 vector that is digested with appropriate restriction endonucleases to yield pET29/BoNT/A-33/A. The ligation mixture is transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin, and placed in a 37° C. incubator for overnight growth. Bacteria containing expression constructs are identified as Kanamycin resistant colonies. Candidate constructs are isolated using an alkaline lysis plasmid mini-preparation procedure and analyzed by restriction endonuclease digest mapping to determine the presence and orientation of the insert. This cloning strategy yielded a pET29 expression construct comprising the polynucleotide molecule encoding BoNT/A-33/A operably-linked to a carboxyl terminal polyhistidine affinity binding peptide.
A similar cloning strategy is used to make pET29 expression constructs comprising a polynucleotide molecule encoding for BoNT/B-33/A, BoNT/C1-33/A, BoNT/D-33/A, BoNT/E-33/A, BoNT/F-33/A, BoNT/G-33/A, TeNT-33/A, as well as the modified Clostridial toxin indicated above comprising amino acids 10-144 of SEQ ID NO: 9; amino acids 10-144 of SEQ ID NO: 10; amino acids 10-144 of SEQ ID NO: 11; amino acids 10-146 of SEQ ID NO: 12; amino acids 10-144 of SEQ ID NO: 13; amino acids 10-144 of SEQ ID NO: 14; amino acids 10-146 of SEQ ID NO: 15; amino acids 10-141 of SEQ ID NO: 16; amino acids 10-141 of SEQ ID NO: 17; amino acids 10-141 of SEQ ID NO: 18; amino acids 151-293 of SEQ ID NO: 10; amino acids 151-293 of SEQ ID NO: 11; amino acids 153-294 of SEQ ID NO: 12; amino acids 151-279 of SEQ ID NO: 13; amino acids 151-292 of SEQ ID NO: 14; amino acids 153-291 of SEQ ID NO: 15; amino acids 148-285 of SEQ ID NO: 16; amino acids 148-286 of SEQ ID NO: 17; amino acids 148-286 of SEQ ID NO: 18; amino acids 9-146 of SEQ ID NO: 19; amino acids 9-146 of SEQ ID NO: 20; amino acids 9-146 of SEQ ID NO: 21; amino acids 9-146 of SEQ ID NO: 22; amino acids 1050-1194 of SEQ ID NO: 23; amino acids 1050-1199 of SEQ ID NO: 24; amino acids 1050-1194 of SEQ ID NO: 25; amino acids 1049-1198 of SEQ ID NO: 26; amino acids 1049-1197 of SEQ ID NO: 27; amino acids 1049-1197 of SEQ ID NO: 28; amino acids 1014-1163 of SEQ ID NO: 29; amino acids 1016-1160 of SEQ ID NO: 30; amino acids 1017-1166 of SEQ ID NO: 31; and amino acids 1050-1199 of SEQ ID NO: 32.
To construct a BoNT/A-33/A that replaces the BoNT/A translocation facilitating domain with another Clostridial toxin translocation facilitating domain, a translocation facilitating domain of BoNT/B will be introduced into the BoNT/A-33/A as described above using a Splicing by Overlapping ends polymerase chain reaction (SOE-PCR) procedure, see, e.g., R. M. Horton et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlapping extension, 77(1) Gene 61-68 (1989); and R. M. Horton, PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes, 3(2) Mol. Biotechnol. 93-99 (1995). A nucleic acid fragment comprising a region encoding amino acids 859 to 1097 of BoNT/B (SEQ ID NO: 2) will be operably-linked by SOE-PCR to replace the region corresponding to the BoNT/A translocation facilitating domain comprising amino acids 874-1110 of SEQ ID NO: 1 of the BoNT/A-33/A and will be subcloned into a pCR2.1 vector using the TOPO® TA cloning method (Invitrogen, Inc, Carlsbad, Calif.). The forward and reverse oligonucleotide primers used for these reactions are designed to include unique restriction enzyme sites useful for subsequent subcloning steps. The resulting construct is digested with restriction enzymes that 1) excise the insert containing the entire open reading frame encoding the modified BoNT/A-33/A; and 2) enable this insert to be operably-linked to a pQBI-25A vector (Qbiogene, Inc., Carlsbad, Calif.). The resulting restriction fragment will be purified by the QIAquick Gel Extraction Kit (QIAGEN, Inc., Valencia, Calif.), and will be subcloned using a T4 DNA ligase procedure into a pQBI-25A vector (Qbiogene, Inc., Irvine, Calif.). This cloning strategy yielded a pQBI-25 expression construct encoding a BoNT/A-33/A comprising a BoNT/B translocation facilitating domain.
A similar cloning strategy is used to make pQBI-25 expression constructs comprising a polynucleotide molecule encoding a BoNT/A-33/A that includes, e.g., a translocation facilitating domain comprising amino acids 869-1111 of BoNT/C1 of SEQ ID NO: 3; a translocation facilitating domain comprising amino acids 865-1098 of BoNT/D of SEQ ID NO: 4; a translocation facilitating domain comprising amino acids 846-1058 of BoNT/E of SEQ ID NO: 5; a translocation facilitating domain comprising amino acids 867-1105 of BoNT/F of SEQ ID NO: 6; a translocation facilitating domain comprising amino acids 866-1105 of BoNT/G of SEQ ID NO: 7; or a translocation facilitating domain comprising amino acids 882-1127 of TeNT of SEQ ID NO: 8, as well as the modified Clostridial toxin indicated above comprising amino acids 10-144 of SEQ ID NO: 9; amino acids 10-144 of SEQ ID NO: 10; amino acids 10-144 of SEQ ID NO: 11; amino acids 10-146 of SEQ ID NO: 12; amino acids 10-144 of SEQ ID NO: 13; amino acids 10-144 of SEQ ID NO: 14; amino acids 10-146 of SEQ ID NO: 15; amino acids 10-141 of SEQ ID NO: 16; amino acids 10-141 of SEQ ID NO: 17; amino acids 10-141 of SEQ ID NO: 18; amino acids 151-293 of SEQ ID NO: 10; amino acids 151-293 of SEQ ID NO: 11; amino acids 153-294 of SEQ ID NO: 12; amino acids 151-279 of SEQ ID NO: 13; amino acids 151-292 of SEQ ID NO: 14; amino acids 153-291 of SEQ ID NO: 15; amino acids 148-285 of SEQ ID NO: 16; amino acids 148-286 of SEQ ID NO: 17; amino acids 148-286 of SEQ ID NO: 18; amino acids 9-146 of SEQ ID NO: 19; amino acids 9-146 of SEQ ID NO: 20; amino acids 9-146 of SEQ ID NO: 21; amino acids 9-146 of SEQ ID NO: 22; amino acids 1050-1194 of SEQ ID NO: 23; amino acids 1050-1199 of SEQ ID NO: 24; amino acids 1050-1194 of SEQ ID NO: 25; amino acids 1049-1198 of SEQ ID NO: 26; amino acids 1049-1197 of SEQ ID NO: 27; amino acids 1049-1197 of SEQ ID NO: 28; amino acids 1014-1163 of SEQ ID NO: 29; amino acids 1016-1160 of SEQ ID NO: 30; amino acids 1017-1166 of SEQ ID NO: 31; and amino acids 1050-1199 of SEQ ID NO: 32.
Example 3
Construction of a Modified Clostridial Toxin Comprising a Translocation Facilitating Domain and a Non-Toxin Associated Protein Fold
The following example illustrates how to make a modified Clostridial toxin comprising a translocation facilitating domain and an enhanced targeting domain comprising a non-toxin associated protein fold.
A polynucleotide molecule encoding BoNT/A-17γ/A is synthesized using standard procedures (BlueHeron® Biotechnology, Bothell, Wash.), as described in Example 1. BoNT/A-17γ/A is a BoNT/A modified to replace amino acids 1237-1296 of SEQ ID NO: 1, a γ-fold from a BoNT/A β-trefoil domain, with amino acids 95 to 146 of SEQ ID NO: 19, a γ-fold from a HA-17 β-trefoil domain from a Clostridial botulinum serotype A strain. If desired, an expression optimized polynucleotide molecule encoding BoNT/A-17γ/A can be synthesized in order to improve expression in to a different organism, such as, e.g., an Escherichia coli strain, a yeast strain, an insect cell-line or a mammalian cell line, can be done, see, e.g., Steward, supra, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); and Steward, supra, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005). The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.).
A similar cloning strategy is used to make pUCBHB1 cloning constructs for BoNT/B-17γ/A, a modified BoNT/B where amino acids 1223-1291 of SEQ ID NO: 2 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; BoNT/C1-F18γ, a modified BoNT/C1 where amino acids 1230-1291 of SEQ ID NO: 3 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; BoNT/D-17γ/A, a modified BoNT/D where amino acids 1219-1276 of SEQ ID NO: 4 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; BoNT/E-17γ/A, a modified BoNT/E where amino acids 1199-1252 of SEQ ID NO: 5 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; BoNT/F-17γ/A, a modified BoNT/F where amino acids 1222-1274 of SEQ ID NO: 6 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; BoNT/G-17γ/A, a modified BoNT/G where amino acids 1231-1297 of SEQ ID NO: 7 are replaced with amino acids 95 to 146 of SEQ ID NO: 19; and TeNT-17γ/A, a modified TeNT where amino acids 1255-1315 of SEQ ID NO: 8 are replaced with amino acids 95 to 146 of SEQ ID NO: 19.
Similarly, the γ-fold from a HA-17/A β-trefoil domain can replace amino acids 1111-1162 of SEQ ID NO: 1, an α-fold from a BoNT/A β-trefoil domain; amino acids 1098-1147 of SEQ ID NO: 2, an α-fold from a BoNT/B β-trefoil domain; amino acids 1112-1150 of SEQ ID NO: 3, an α-fold from a BoNT/C1 β-trefoil domain; amino acids 1099-1137 of SEQ ID NO: 4, an α-fold from a BoNT/D β-trefoil domain; amino acids 1086-1129 of SEQ ID NO: 5, an α-fold from a BoNT/E β-trefoil domain; amino acids 1106-1152 of SEQ ID NO: 6, an α-fold from a BoNT/F β-trefoil domain; amino acids 1106-1153 of SEQ ID NO: 7, an α-fold from a BoNT/G β-trefoil domain; or amino acids 1128-1177 of SEQ ID NO: 8, an α-fold from a TeNT β-trefoil domain. Similarly, the γ-fold from a HA-17/A β-trefoil domain can replace amino acids 1179-1223 of SEQ ID NO: 1, a β-fold from a BoNT/A β-trefoil domain; amino acids 1166-1210 of SEQ ID NO: 2, a β-fold from a BoNT/B β-trefoil domain; amino acids 1167-1218 of SEQ ID NO: 3, a β-fold from a BoNT/C1 β-trefoil domain; amino acids 1154-1207 of SEQ ID NO: 4, a β-fold from a BoNT/D β-trefoil domain; amino acids 1147-1190 of SEQ ID NO: 5, a β-fold from a BoNT/E β-trefoil domain; amino acids 1172-1213 of SEQ ID NO: 6, a β-fold from a BoNT/F β-trefoil domain; amino acids 1173-1218 of SEQ ID NO: 7, a β-fold from a BoNT/G β-trefoil domain; or amino acids 1195-1240 of SEQ ID NO: 8, a β-fold from a TeNT β-trefoil domain.
Similarly, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a HA-17γ-fold comprising amino acids 95-146 of SEQ ID NO: 20, amino acids 95-146 of SEQ ID NO: 21, or amino acids 95-146 of SEQ ID NO: 22; a HA-33γ-fold comprising amino acids 105-144 of SEQ ID NO: 9, amino acids 105-144 of SEQ ID NO: 10, amino acids 105-144 of SEQ ID NO: 11, amino acids 107-146 of SEQ ID NO: 12, amino acids 105-144 of SEQ ID NO: 13, amino acids 105-144 of SEQ ID NO: 14, amino acids 107-146 of SEQ ID NO: 15, amino acids 103-141 of SEQ ID NO: 16, amino acids 103-141 of SEQ ID NO: 17, amino acids 103-141 of SEQ ID NO: 18, amino acids 249-293 of SEQ ID NO: 9, amino acids 249-293 of SEQ ID NO: 10, amino acids 249-293 of SEQ ID NO: 11, amino acids 250-294 of SEQ ID NO: 12, amino acids 249-279 of SEQ ID NO: 13, amino acids 248-292 of SEQ ID NO: 14, amino acids 249-291 of SEQ ID NO: 15, amino acids 241-285 of SEQ ID NO: 16, amino acids 242-286 of SEQ ID NO: 17, or amino acids 242-286 of SEQ ID NO: 18; or a NTNH γ-fold comprising amino acids 1149-1194 of SEQ ID NO: 23, amino acids 1149-1199 of SEQ ID NO: 24, amino acids 1149-1194 of SEQ ID NO: 25, amino acids 1148-1198 of SEQ ID NO: 26, amino acids 1148-1197 of SEQ ID NO: 27, amino acids 1148-1197 of SEQ ID NO: 28, amino acids 1114-1163 of SEQ ID NO: 29, amino acids 1115-1160 of SEQ ID NO: 30, amino acids 1117-1166 of SEQ ID NO: 31, or amino acids 1150-1199 of SEQ ID NO: 32.
Likewise, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a HA-17 α-fold comprising amino acids 9-50 of SEQ ID NO: 19, amino acids 9-50 of SEQ ID NO: 20, amino acids 9-50 of SEQ ID NO: 21, or amino acids 9-50 of SEQ ID NO: 22; a HA-33 α-fold comprising amino acids 10-54 of SEQ ID NO: 9, amino acids 10-54 of SEQ ID NO: 10, amino acids 10-54 of SEQ ID NO: 11, amino acids 10-56 of SEQ ID NO: 12, amino acids 10-54 of SEQ ID NO: 13, amino acids 10-54 of SEQ ID NO: 14, amino acids 10-56 of SEQ ID NO: 15, amino acids 10-54 of SEQ ID NO: 16, amino acids 10-54 of SEQ ID NO: 17, amino acids 10-54 of SEQ ID NO: 18, amino acids 151-195 of SEQ ID NO: 9, amino acids 151-195 of SEQ ID NO: 10, amino acids 151-195 of SEQ ID NO: 11, amino acids 153-197 of SEQ ID NO: 12, amino acids 151-195 of SEQ ID NO: 13, amino acids 151-195 of SEQ ID NO: 14, amino acids 153-197 of SEQ ID NO: 15, amino acids 148-190 of SEQ ID NO: 16, amino acids 148-190 of SEQ ID NO: 17, or amino acids 148-190 of SEQ ID NO: 18; or a NTNH α-fold comprising amino acids 1050-1097 of SEQ ID NO: 23, amino acids 1050-1097 of SEQ ID NO: 24, amino acids 1050-1097 of SEQ ID NO: 25, amino acids 1049-1096 of SEQ ID NO: 26, amino acids 1049-1096 of SEQ ID NO: 27, amino acids 1049-1096 of SEQ ID NO: 28, amino acids 1014-1061 of SEQ ID NO: 29, amino acids 1016-1063 of SEQ ID NO: 30, amino acids 1017-1064 of SEQ ID NO: 31, or amino acids 1050-1097 of SEQ ID NO: 32.
Further, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a HA-17 β-fold comprising amino acids 55-91 of SEQ ID NO: 19, amino acids 55-91 of SEQ ID NO: 20, amino acids 55-91 of SEQ ID NO: 21, or amino acids 55-91 of SEQ ID NO: 22; a HA-33 β-fold comprising amino acids 60-100 of SEQ ID NO: 9, amino acids 60-100 of SEQ ID NO: 10, amino acids 60-100 of SEQ ID NO: 11, amino acids 62-102 of SEQ ID NO: 12, amino acids 60-100 of SEQ ID NO: 13, amino acids 60-100 of SEQ ID NO: 14, amino acids 62-102 of SEQ ID NO: 15, amino acids 60-98 of SEQ ID NO: 16, amino acids 60-98 of SEQ ID NO: 17, amino acids 60-98 of SEQ ID NO: 18, amino acids 200-242 of SEQ ID NO: 9, amino acids 200-242 of SEQ ID NO: 10, amino acids 200-242 of SEQ ID NO: 11, amino acids 202-243 of SEQ ID NO: 12, amino acids 200-242 of SEQ ID NO: 13, amino acids 200-241 of SEQ ID NO: 14, amino acids 200-242 of SEQ ID NO: 15, amino acids 195-234 of SEQ ID NO: 16, amino acids 195-235 of SEQ ID NO: 17, or amino acids 195-235 of SEQ ID NO: 18; or a NTNH β-fold comprising amino acids 1111-1138 of SEQ ID NO: 23, amino acids 1111-1139 of SEQ ID NO: 24, amino acids 1111-1138 of SEQ ID NO: 25, amino acids 1110-1138 of SEQ ID NO: 26, amino acids 1110-1138 of SEQ ID NO: 27, amino acids 1110-1138 of SEQ ID NO: 28, amino acids 1075-1103 of SEQ ID NO: 29, amino acids 1077-1104 of SEQ ID NO: 30, amino acids 1078-1106 of SEQ ID NO: 31, or amino acids 1111-1139 of SEQ ID NO: 32.
To construct pET29/BoNT/A-17γ/A, a pUCBHB1/BoNT/A-17γ/A construct is digested with restriction endonucleases that 1) excise the insert comprising the open reading frame encoding BoNT/A-17γ/A; and 2) enable this insert to be operably-linked to a pET29 vector (EMD Biosciences-Novagen, Madison, Wis.). This insert is subcloned using a T4 DNA ligase procedure into a pET29 vector that is digested with appropriate restriction endonucleases to yield pET29/BoNT/A-17γ/A. The ligation mixture is transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin, and placed in a 37° C. incubator for overnight growth. Bacteria containing expression constructs are identified as Kanamycin resistant colonies. Candidate constructs are isolated using an alkaline lysis plasmid mini-preparation procedure and analyzed by restriction endonuclease digest mapping to determine the presence and orientation of the insert. This cloning strategy yielded a pET29 expression construct comprising the polynucleotide molecule encoding BoNT/A-17γ/A operably-linked to a carboxyl terminal polyhistidine affinity binding peptide.
A similar cloning strategy is used to make pET29 expression constructs comprising a polynucleotide molecule encoding BoNT/B-17γ/A, BoNT/C1-17γ/A, BoNT/D-17γ/A, BoNT/E-17γ/A, BoNT/F-17γ/A, BoNT/G-17γ/A, TeNT-17γ/A, BoNT/A-33-1γ/A, BoNT/B-33-1γ/A, BoNT/C1-33-1γ/A, BoNT/D-33-1γ/A, BoNT/E-33-1γ/A, BoNT/F-33-1γ/A, BoNT/G-33-1γ/A, TeNT-33-1γ/A, BoNT/A-33-2γ/A, BoNT/B-33-2γ/A, BoNT/C1-33-2γ/A, BoNT/D-33-2γ/A, BoNT/E-33-2γ/A, BoNT/F-33-2γ/A, BoNT/G-33-2γ/A, TeNT-33-2γ/A, BoNT/B-NTNHγ/A, BoNT/B-NTNHγ/A, BoNT/C1-NTNHγ/A, BoNT/D-NTNHγ/A, BoNT/E-NTNHγ/A, BoNT/F-NTNHγ/A, BoNT/G-NTNHγ/A, TeNT-NTNHγ/A, BoNT/A-17α/A, BoNT/B-17α/A, BoNT/C1-17α/A, BoNT/D-17α/A, BoNT/E-17α/A, BoNT/F-17α/A, BoNT/G-17α/A, TeNT-17α/A, BoNT/A-33-1α/A, BoNT/B-33-1α/A, BoNT/C1-33-1α/A, BoNT/D-33-1α/A, BoNT/E-33-1α/A, BoNT/F-33-1α/A, BoNT/G-33-1α/A, TeNT-33-1α/A, BoNT/A-33-2α/A, BoNT/B-33-2α/A, BoNT/C1-33-2α/A, BoNT/D-33-2α/A, BoNT/E-33-2α/A, BoNT/F-33-2α/A, BoNT/G-33-2α/A, TeNT-33-2α/A, BoNT/B-NTNHα/A, BoNT/B-NTNHα/A, BoNT/C1-NTNHα/A, BoNT/D-NTNHα/A, BoNT/E-NTNHα/A, BoNT/F-NTNHα/A, BoNT/G-NTNHα/A, TeNT-NTNHα, BoNT/A-17β/A, BoNT/B-17β/A, BoNT/C1-17β/A, BoNT/D-17β/A, BoNT/E-17β/A, BoNT/F-17β/A, BoNT/G-17β/A, TeNT-17β/A, BoNT/A-33-1β/A, BoNT/B-33-1β/A, BoNT/C1-33-1β/A, BoNT/D-33-1β/A, BoNT/E-33-1β/A, BoNT/F-33-1β/A, BoNT/G-33-1β/A, TeNT-33-1β/A, BoNT/A-33-2β/A, BoNT/B-33-2β/A, BoNT/C1-33-2β/A, BoNT/D-33-2β/A, BoNT/E-33-2β/A, BoNT/F-33-2β/A, BoNT/G-33-2β/A, TeNT-33-2β/A, BoNT/B-NTNHβ/A, BoNT/B-NTNHβ/A, BoNT/C1-NTNHβ/A, BoNT/D-NTNHβ/A, BoNT/E-NTNHβ/A, BoNT/F-NTNHβ/A, BoNT/G-NTNHβ/A, TeNT-NTNHβ.
A similar cloning strategy is also used to make pET29 expression constructs comprising a polynucleotide molecule encoding a modified Clostridial toxin indicated above that has its α-fold or β-fold replaced by amino acids comprising a HA-17 α-fold, β-fold or γ-fold; amino acids comprising a HA-33 1α-fold, 1β-fold, 1γ-fold, 2α-fold, 2β-fold, or 2γ-fold; or amino acids comprising a NTNH α-fold, β-fold or γ-fold.
To construct a BoNT/A-17γ/A that replaces the BoNT/A translocation facilitating domain with another Clostridial toxin translocation facilitating domain, a translocation facilitating domain of BoNT/B will be introduced into the BoNT/A-17γ/A as described above using a Splicing by Overlapping ends polymerase chain reaction (SOE-PCR) procedure, see, e.g., R. M. Horton et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlapping extension, 77(1) Gene 61-68 (1989); and R. M. Horton, PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes, 3(2) Mol. Biotechnol. 93-99 (1995). A nucleic acid fragment comprising a region encoding amino acids 859 to 1097 of BoNT/B (SEQ ID NO: 2) will be operably-linked by SOE-PCR to replace the region corresponding to the BoNT/A translocation facilitating domain comprising amino acids 874-1110 of SEQ ID NO: 1 of the BoNT/A-17γ/A and will be subcloned into a pCR2.1 vector using the TOPO® TA cloning method (Invitrogen, Inc, Carlsbad, Calif.). The forward and reverse oligonucleotide primers used for these reactions are designed to include unique restriction enzyme sites useful for subsequent subcloning steps. The resulting construct is digested with restriction enzymes that 1) excise the insert containing the entire open reading frame encoding the modified BoNT/A-17γ/A; and 2) enable this insert to be operably-linked to a pQBI-25A vector (Qbiogene, Inc., Carlsbad, Calif.). The resulting restriction fragment will be purified by the QIAquick Gel Extraction Kit (QIAGEN, Inc., Valencia, Calif.), and will be subcloned using a T4 DNA ligase procedure into a pQBI-25A vector (Qbiogene, Inc., Irvine, Calif.). This cloning strategy yielded a pQBI-25 expression construct encoding a BoNT/A-17γ/A comprising a BoNT/B translocation facilitating domain.
A similar cloning strategy is used to make pQBI-25 expression constructs comprising a polynucleotide molecule encoding a BoNT/A-17γ/A that includes, e.g., a translocation facilitating domain comprising amino acids 869-1111 of BoNT/C1 of SEQ ID NO: 3; a translocation facilitating domain comprising amino acids 865-1098 of BoNT/D of SEQ ID NO: 4; a translocation facilitating domain comprising amino acids 846-1058 of BoNT/E of SEQ ID NO: 5; a translocation facilitating domain comprising amino acids 867-1105 of BoNT/F of SEQ ID NO: 6; a translocation facilitating domain comprising amino acids 866-1105 of BoNT/G of SEQ ID NO: 7; or a translocation facilitating domain comprising amino acids 882-1127 of TeNT of SEQ ID NO: 8.
Likewise, as well as, a polynucleotide molecule encoding a Clostridial translocation facilitating domain as described above can be introduced into a polynucleotide molecule encoding BoNT/B-17γ/A, BoNT/C1-17γ/A, BoNT/D-17γ/A, BoNT/E-17γ/A, BoNT/F-17γ/A, BoNT/G-17γ/A, TeNT-17γ/A, BoNT/A-33-1γ/A, BoNT/B-33-1γ/A, BoNT/C1-33-1γ/A, BoNT/D-33-1γ/A, BoNT/E-33-1γ/A, BoNT/F-33-1γ/A, BoNT/G-33-1γ/A, TeNT-33-1γ/A, BoNT/A-33-2γ/A, BoNT/B-33-2γ/A, BoNT/C1-33-2γ/A, BoNT/D-33-2γ/A, BoNT/E-33-2γ/A, BoNT/F-33-2γ/A, BoNT/G-33-2γ/A, TeNT-33-2γ/A, BoNT/B-NTNHγ/A, BoNT/B-NTNHγ/A, BoNT/C1-NTNHγ/A, BoNT/D-NTNHγ/A, BoNT/E-NTNHγ/A, BoNT/F-NTNHγ/A, BoNT/G-NTNHγ/A, TeNT-NTNHγ/A, BoNT/A-17α/A, BoNT/B-17α/A, BoNT/C1-17α/A, BoNT/D-17α/A, BoNT/E-17α/A, BoNT/F-17α/A, BoNT/G-17α/A, TeNT-17α/A, BoNT/A-33-1α/A, BoNT/B-33-1α/A, BoNT/C1-33-1α/A, BoNT/D-33-1α/A, BoNT/E-33-1α/A, BoNT/F-33-1α/A, BoNT/G-33-1α/A, TeNT-33-1α/A, BoNT/A-33-2α/A, BoNT/B-33-2α/A, BoNT/C1-33-2α/A, BoNT/D-33-2α/A, BoNT/E-33-2α/A, BoNT/F-33-2α/A, BoNT/G-33-2α/A, TeNT-33-2α/A, BoNT/B-NTNHα/A, BoNT/B-NTNHα/A, BoNT/C1-NTNHα/A, BoNT/D-NTNHα/A, BoNT/E-NTNHα/A, BoNT/F-NTNHα/A, BoNT/G-NTNHα/A, TeNT-NTNHα, BoNT/A-17β/A, BoNT/B-17β/A, BoNT/C1-17β/A, BoNT/D-17β/A, BoNT/E-17β/A, BoNT/F-17β/A, BoNT/G-17β/A, TeNT-17β/A, BoNT/A-33-1β/A, BoNT/B-33-1β/A, BoNT/C1-33-1β/A, BoNT/D-33-1β/A, BoNT/E-33-1β/A, BoNT/F-33-1β/A, BoNT/G-33-1β/A, TeNT-33-1β/A, BoNT/A-33-2β/A, BoNT/B-33-2β/A, BoNT/C1-33-2β/A, BoNT/D-33-2β/A, BoNT/E-33-2β/A, BoNT/F-33-2β/A, BoNT/G-33-2β/A, TeNT-33-2β/A, BoNT/B-NTNHβ/A, BoNT/B-NTNHβ/A, BoNT/C1-NTNHβ/A, BoNT/D-NTNHβ/A, BoNT/E-NTNHβ/A, BoNT/F-NTNHβ/A, BoNT/G-NTNHβ/A, TeNT-NTNHβ.
Example 4
Construction of a Modified Clostridial Toxin Comprising a Translocation Facilitating Domain and a FGF that Selectively Binds to a FGFR3
The following example illustrates how to make a modified Clostridial toxin comprising a translocation facilitating domain and an enhanced targeting domain comprising a FGF that selectively binds to a FGFR3.
A polynucleotide molecule encoding BoNT/A-F18 is synthesized using standard procedures (BlueHeron® Biotechnology, Bothell, Wash.), as described in Example 1. BoNT/A-F18 is a BoNT/A modified to replace amino acids 1111-1296 of SEQ ID NO: 1, a BoNT/A β-trefoil domain, with amino acids 54 to 183 of SEQ ID NO: 39, a FGF-18 β-trefoil domain. If desired, an expression optimized polynucleotide molecule encoding BoNT/A-F18 can be synthesized in order to improve expression in to a different organism, such as, e.g., an Escherichia coli strain, a yeast strain, an insect cell-line or a mammalian cell line, can be done, see, e.g., Steward, supra, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); and Steward, supra, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005). The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.).
A similar cloning strategy is used to make pUCBHB1 cloning constructs for BoNT/B-F18, a modified BoNT/B where amino acids 1098-1291 of SEQ ID NO: 2 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; BoNT/C1-F18, a modified BoNT/C1 where amino acids 1112-1291 of SEQ ID NO: 3 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; BoNT/D-F18, a modified BoNT/D where amino acids 1099-1276 of SEQ ID NO: 4 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; BoNT/E-F18, a modified BoNT/E where amino acids 1086-1252 of SEQ ID NO: 5 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; BoNT/F-F18, a modified BoNT/F where amino acids 1106-1274 of SEQ ID NO: 6 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; BoNT/G-F18, a modified BoNT/G where amino acids 1106-1297 of SEQ ID NO: 7 are replaced with amino acids 54 to 183 of SEQ ID NO: 39; and TeNT-F18, a modified TeNT where amino acids 1128-1315 of SEQ ID NO: 8 are replaced with amino acids 54 to 183 of SEQ ID NO: 39. Similarly, the β-trefoil domain from a Clostridial toxin indicated above can be replaced with a FGF β-trefoil domain comprising amino acids 26-155 of SEQ ID NO: 33; amino acids 29-155 of SEQ ID NO: 34; amino acids 83-206 of SEQ ID NO: 35; amino acids 43-172 of SEQ ID NO: 36; amino acids 63-196 of SEQ ID NO: 37; amino acids 55-183 of SEQ ID NO: 38; and amino acids 54-183 of SEQ ID NO: 39.
To construct pET29/BoNT/A-F18, a pUCBHB1/BoNT/A-F18 construct is digested with restriction endonucleases that 1) excise the insert comprising the open reading frame encoding BoNT/A-F18; and 2) enable this insert to be operably-linked to a pET29 vector (EMD Biosciences-Novagen, Madison, Wis.). This insert is subcloned using a T4 DNA ligase procedure into a pET29 vector that is digested with appropriate restriction endonucleases to yield pET29/BoNT/A-F18. The ligation mixture is transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin, and placed in a 37° C. incubator for overnight growth. Bacteria containing expression constructs are identified as Kanamycin resistant colonies. Candidate constructs are isolated using an alkaline lysis plasmid mini-preparation procedure and analyzed by restriction endonuclease digest mapping to determine the presence and orientation of the insert. This cloning strategy yielded a pET29 expression construct comprising the polynucleotide molecule encoding BoNT/A-F18 operably-linked to a carboxyl terminal polyhistidine affinity binding peptide.
A similar cloning strategy is used to make pET29 expression constructs comprising a polynucleotide molecule encoding for BoNT/B-F18, BoNT/C1-F18, BoNT/D-F18, BoNT/E-F18, BoNT/F-F18, BoNT/G-F18, TeNT-F18, as well as the modified Clostridial toxin indicated above comprising amino acids 26-155 of SEQ ID NO: 33; amino acids 29-155 of SEQ ID NO: 34; amino acids 83-206 of SEQ ID NO: 35; amino acids 43-172 of SEQ ID NO: 36; amino acids 63-196 of SEQ ID NO: 37; amino acids 55-183 of SEQ ID NO: 38; and amino acids 54-183 of SEQ ID NO: 39.
To construct a BoNT/A-F18 that replaces the BoNT/A translocation facilitating domain with another Clostridial toxin translocation facilitating domain, a translocation facilitating domain of BoNT/B will be introduced into the BoNT/A-F18 as described above using a Splicing by Overlapping ends polymerase chain reaction (SOE-PCR) procedure, see, e.g., R. M. Horton et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlapping extension, 77(1) Gene 61-68 (1989); and R. M. Horton, PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes, 3(2) Mol. Biotechnol. 93-99 (1995). A nucleic acid fragment comprising a region encoding amino acids 859 to 1097 of BoNT/B (SEQ ID NO: 2) will be operably-linked by SOE-PCR to replace the region corresponding to the BoNT/A translocation facilitating domain comprising amino acids 874-1110 of SEQ ID NO: 1 of the BoNT/A-F18 and will be subcloned into a pCR2.1 vector using the TOPO® TA cloning method (Invitrogen, Inc, Carlsbad, Calif.). The forward and reverse oligonucleotide primers used for these reactions are designed to include unique restriction enzyme sites useful for subsequent subcloning steps. The resulting construct is digested with restriction enzymes that 1) excise the insert containing the entire open reading frame encoding the modified BoNT/A-F18; and 2) enable this insert to be operably-linked to a pQBI-25A vector (Qbiogene, Inc., Carlsbad, Calif.). The resulting restriction fragment will be purified by the QIAquick Gel Extraction Kit (QIAGEN, Inc., Valencia, Calif.), and will be subcloned using a T4 DNA ligase procedure into a pQBI-25A vector (Qbiogene, Inc., Irvine, Calif.). This cloning strategy yielded a pQBI-25 expression construct encoding a BoNT/A-F18 comprising a BoNT/B translocation facilitating domain.
A similar cloning strategy is used to make pQBI-25 expression constructs comprising a polynucleotide molecule encoding a BoNT/A-F18 that includes, e.g., a translocation facilitating domain comprising amino acids 869-1111 of BoNT/C1 of SEQ ID NO: 3; a translocation facilitating domain comprising amino acids 865-1098 of BoNT/D of SEQ ID NO: 4; a translocation facilitating domain comprising amino acids 846-1058 of BoNT/E of SEQ ID NO: 5; a translocation facilitating domain comprising amino acids 867-1105 of BoNT/F of SEQ ID NO: 6; a translocation facilitating domain comprising amino acids 866-1105 of BoNT/G of SEQ ID NO: 7; or a translocation facilitating domain comprising amino acids 882-1127 of TeNT of SEQ ID NO: 8.
Likewise, as well as, a polynucleotide molecule encoding a Clostridial translocation facilitating domain as described above can be introduced into a polynucleotide molecule encoding BoNT/B-F18, BoNT/C1-F18, BoNT/D-F18, BoNT/E-F18, BoNT/F-F18, BoNT/G-F18, TeNT-F18, as well as the modified Clostridial toxin indicated above comprising amino acids 26-155 of SEQ ID NO: 33; amino acids 29-155 of SEQ ID NO: 34; amino acids 83-206 of SEQ ID NO: 35; amino acids 43-172 of SEQ ID NO: 36; amino acids 63-196 of SEQ ID NO: 37; amino acids 55-183 of SEQ ID NO: 38; and amino acids 54-183 of SEQ ID NO: 39.
Example 5
Construction of a Modified Clostridial Toxin Comprising a Translocation Facilitating Domain and a FGF Fold that Selectively Binds to a FGFR3
The following example illustrates how to make a modified Clostridial toxin comprising a translocation facilitating domain and an enhanced targeting domain comprising a FGF fold that selectively binds to a FGFR3.
A polynucleotide molecule encoding BoNT/A-F18γ is synthesized using standard procedures (BlueHeron® Biotechnology, Bothell, Wash.), as described in Example 1. BoNT/A-F18γ is a BoNT/A modified to replace amino acids 1237-1296 of SEQ ID NO: 1, a γ-fold from a BoNT/A β-trefoil domain, with amino acids 138 to 183 of SEQ ID NO: 39, a γ-fold from a FGF-18 β-trefoil domain. If desired, an expression optimized polynucleotide molecule encoding BoNT/A-F18γ can be synthesized in order to improve expression in to a different organism, such as, e.g., an Escherichia coli strain, a yeast strain, an insect cell-line or a mammalian cell line, can be done, see, e.g., Steward, supra, PCT Patent Serial No. 2005/020578 (Jun. 9, 2005); and Steward, supra, PCT Patent Serial No. 2005/027917 (Aug. 3, 2005). The synthesized polynucleotide molecule is verified by sequencing using Big Dye TerminatorTM Chemistry 3.1 (Applied Biosystems, Foster City, Calif.) and an ABI 3100 sequencer (Applied Biosystems, Foster City, Calif.).
A similar cloning strategy is used to make pUCBHB1 cloning constructs for BoNT/B-F18γ, a modified BoNT/B where amino acids 1223-1291 of SEQ ID NO: 2 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; BoNT/C1-F18γ, a modified BoNT/C1 where amino acids 1230-1291 of SEQ ID NO: 3 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; BoNT/D-F18γ, a modified BoNT/D where amino acids 1219-1276 of SEQ ID NO: 4 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; BoNT/E-F18γ, a modified BoNT/E where amino acids 1199-1252 of SEQ ID NO: 5 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; BoNT/F-F18γ, a modified BoNT/F where amino acids 1222-1274 of SEQ ID NO: 6 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; BoNT/G-F18γ, a modified BoNT/G where amino acids 1231-1297 of SEQ ID NO: 7 are replaced with amino acids 138 to 183 of SEQ ID NO: 39; and TeNT-F18γ, a modified TeNT where amino acids 1255-1315 of SEQ ID NO: 8 are replaced with amino acids 138 to 183 of SEQ ID NO: 39. Similarly, the γ-fold from a FGF-18 β-trefoil domain can replace amino acids 1111-1162 of SEQ ID NO: 1, an α-fold from a BoNT/A β-trefoil domain; amino acids 1098-1147 of SEQ ID NO: 2, an α-fold from a BoNT/B β-trefoil domain; amino acids 1112-1150 of SEQ ID NO: 3, an α-fold from a BoNT/C1 β-trefoil domain; amino acids 1099-1137 of SEQ ID NO: 4, an α-fold from a BoNT/D β-trefoil domain; amino acids 1086-1129 of SEQ ID NO: 5, an α-fold from a BoNT/E β-trefoil domain; amino acids 1106-1152 of SEQ ID NO: 6, an α-fold from a BoNT/F β-trefoil domain; amino acids 1106-1153 of SEQ ID NO: 7, an α-fold from a BoNT/G β-trefoil domain; or amino acids 1128-1177 of SEQ ID NO: 8, an α-fold from a TeNT β-trefoil domain. Similarly, the γ-fold from a FGF-18 β-trefoil domain can replace amino acids 1179-1223 of SEQ ID NO: 1, a β-fold from a BoNT/A β-trefoil domain; amino acids 1166-1210 of SEQ ID NO: 2, a β-fold from a BoNT/B β-trefoil domain; amino acids 1167-1218 of SEQ ID NO: 3, a β-fold from a BoNT/C1 β-trefoil domain; amino acids 1154-1207 of SEQ ID NO: 4, a β-fold from a BoNT/D β-trefoil domain; amino acids 1147-1190 of SEQ ID NO: 5, a β-fold from a BoNT/E β-trefoil domain; amino acids 1172-1213 of SEQ ID NO: 6, a β-fold from a BoNT/F β-trefoil domain; amino acids 1173-1218 of SEQ ID NO: 7, a β-fold from a BoNT/G β-trefoil domain; or amino acids 1195-1240 of SEQ ID NO: 8, a β-fold from a TeNT β-trefoil domain.
Similarly, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a FGF γ-fold comprising amino acids 109-155 of SEQ ID NO: 33; amino acids 115-155 of SEQ ID NO: 34; amino acids 166-206 of SEQ ID NO: 35; amino acids 127-172 of SEQ ID NO: 36; amino acids 148-196 of SEQ ID NO: 37; or amino acids 138-183 of SEQ ID NO: 38. Likewise, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a FGF α-fold comprising amino acids 26-64 of SEQ ID NO: 33; amino acids 29-67 of SEQ ID NO: 34; amino acids 83-121 of SEQ ID NO: 35; amino acids 43-80 of SEQ ID NO: 36; amino acids 63-100 of SEQ ID NO: 37; amino acids 55-91 of SEQ ID NO: 38; or amino acids 54-91 of SEQ ID NO: 39. Further, an α-fold, β-fold or γ-fold from a β-trefoil domain from a Clostridial toxin indicated above can be replaced with a FGF β-fold comprising amino acids 68-105 of SEQ ID NO: 33; amino acids 71-111 of SEQ ID NO: 34; amino acids 125-162 of SEQ ID NO: 35; amino acids 84-123 of SEQ ID NO: 36; amino acids 104-144 of SEQ ID NO: 37; amino acids 95-134 of SEQ ID NO: 38; or amino acids 95-134 of SEQ ID NO: 39.
To construct pET29/BoNT/A-F18, a pUCBHB1/BoNT/A-F18γ construct is digested with restriction endonucleases that 1) excise the insert comprising the open reading frame encoding BoNT/A-F18γ; and 2) enable this insert to be operably-linked to a pET29 vector (EMD Biosciences-Novagen, Madison, Wis.). This insert is subcloned using a T4 DNA ligase procedure into a pET29 vector that is digested with appropriate restriction endonucleases to yield pET29/BoNT/A-F18γ. The ligation mixture is transformed into chemically competent E. coli DH5α cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat shock method, plated on 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin, and placed in a 37° C. incubator for overnight growth. Bacteria containing expression constructs are identified as Kanamycin resistant colonies. Candidate constructs are isolated using an alkaline lysis plasmid mini-preparation procedure and analyzed by restriction endonuclease digest mapping to determine the presence and orientation of the insert. This cloning strategy yielded a pET29 expression construct comprising the polynucleotide molecule encoding BoNT/A-F18γ operably-linked to a carboxyl terminal polyhistidine affinity binding peptide.
A similar cloning strategy is used to make pET29 expression constructs comprising a polynucleotide molecule encoding for BoNT/B-F18γ, BoNT/C1-F18γ, BoNT/D-F18γ, BoNT/E-F18γ, BoNT/F-F18γ, BoNT/G-F18γ, TeNT-F18γ, BoNT/A-F18α, BoNT/B-F18α, BoNT/C1-F18α, BoNT/D-F18α, BoNT/E-F18α, BoNT/F-F18α, BoNT/G-F18α, TeNT-F18α, BoNT/A-F18β, BoNT/B-F18β, BoNT/C1-F18β, BoNT/D-F18β, BoNT/E-F18β, BoNT/F-F18β, BoNT/G-F18β, or TeNT-F18β, as well as the modified Clostridial toxin indicated above comprising amino acids 109-155 of SEQ ID NO: 33; amino acids 115-155 of SEQ ID NO: 34; amino acids 166-206 of SEQ ID NO: 35; amino acids 127-172 of SEQ ID NO: 36; amino acids 148-196 of SEQ ID NO: 37; amino acids 138-183 of SEQ ID NO: 38; amino acids 26-64 of SEQ ID NO: 33; amino acids 29-67 of SEQ ID NO: 34; amino acids 83-121 of SEQ ID NO: 35; amino acids 43-80 of SEQ ID NO: 36; amino acids 63-100 of SEQ ID NO: 37; amino acids 55-91 of SEQ ID NO: 38; amino acids 54-91 of SEQ ID NO: 39; amino acids 68-105 of SEQ ID NO: 33; amino acids 71-111 of SEQ ID NO: 34; amino acids 125-162 of SEQ ID NO: 35; amino acids 84-123 of SEQ ID NO: 36; amino acids 104-144 of SEQ ID NO: 37; amino acids 95-134 of SEQ ID NO: 38; or amino acids 95-134 of SEQ ID NO: 39.
To construct a BoNT/A-F18γ that replaces the BoNT/A translocation facilitating domain with another Clostridial toxin translocation facilitating domain, a translocation facilitating domain of BoNT/B will be introduced into the BoNT/A-F18γ as described above using a Splicing by Overlapping ends polymerase chain reaction (SOE-PCR) procedure, see, e.g., R. M. Horton et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlapping extension, 77(1) Gene 61-68 (1989); and R. M. Horton, PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes, 3(2) Mol. Biotechnol. 93-99 (1995). A nucleic acid fragment comprising a region encoding amino acids 859 to 1097 of BoNT/B (SEQ ID NO: 2) will be operably-linked by SOE-PCR to replace the region corresponding to the BoNT/A translocation facilitating domain comprising amino acids 874-1110 of SEQ ID NO: 1 of the BoNT/A-F18γ and will be subcloned into a pCR2.1 vector using the TOPO® TA cloning method (Invitrogen, Inc, Carlsbad, Calif.). The forward and reverse oligonucleotide primers used for these reactions are designed to include unique restriction enzyme sites useful for subsequent subcloning steps. The resulting construct is digested with restriction enzymes that 1) excise the insert containing the entire open reading frame encoding the modified BoNT/A-F18γ; and 2) enable this insert to be operably-linked to a pQBI-25A vector (Qbiogene, Inc., Carlsbad, Calif.). The resulting restriction fragment will be purified by the QIAquick Gel Extraction Kit (QIAGEN, Inc., Valencia, Calif.), and will be subcloned using a T4 DNA ligase procedure into a pQBI-25A vector (Qbiogene, Inc., Irvine, Calif.). This cloning strategy yielded a pQBI-25 expression construct encoding a BoNT/A-F18γ comprising a BoNT/B translocation facilitating domain.
A similar cloning strategy is used to make pQBI-25 expression constructs comprising a polynucleotide molecule encoding a BoNT/A-F18γ that includes, e.g., a translocation facilitating domain comprising amino acids 869-1111 of BoNT/C1 of SEQ ID NO: 3; a translocation facilitating domain comprising amino acids 865-1098 of BoNT/D of SEQ ID NO: 4; a translocation facilitating domain comprising amino acids 846-1058 of BoNT/E of SEQ ID NO: 5; a translocation facilitating domain comprising amino acids 867-1105 of BoNT/F of SEQ ID NO: 6; a translocation facilitating domain comprising amino acids 866-1105 of BoNT/G of SEQ ID NO: 7; or a translocation facilitating domain comprising amino acids 882-1127 of TeNT of SEQ ID NO: 8.
Likewise, as well as, a polynucleotide molecule encoding a Clostridial translocation facilitating domain as described above can be introduced into a polynucleotide molecule encoding BoNT/B-F18γ, BoNT/C1-F18γ, BoNT/D-F18γ, BoNT/E-F18γ, BoNT/F-F18γ, BoNT/G-F18γ, TeNT-F18γ, BoNT/A-F18α, BoNT/B-F18α, BoNT/C1-F18α, BoNT/D-F18α, BoNT/E-F18α, BoNT/F-F18α, BoNT/G-F18α, TeNT-F18α, BoNT/A-F18β, BoNT/B-F18β, BoNT/C1-F18β, BoNT/D-F18β, BoNT/E-F18β, BoNT/F-F18β, BoNT/G-F18β, or TeNT-F18β, as well as the modified Clostridial toxin indicated above comprising amino acids 109-155 of SEQ ID NO: 33; amino acids 115-155 of SEQ ID NO: 34; amino acids 166-206 of SEQ ID NO: 35; amino acids 127-172 of SEQ ID NO: 36; amino acids 148-196 of SEQ ID NO: 37; amino acids 138-183 of SEQ ID NO: 38; amino acids 26-64 of SEQ ID NO: 33; amino acids 29-67 of SEQ ID NO: 34; amino acids 83-121 of SEQ ID NO: 35; amino acids 43-80 of SEQ ID NO: 36; amino acids 63-100 of SEQ ID NO: 37; amino acids 55-91 of SEQ ID NO: 38; amino acids 54-91 of SEQ ID NO: 39; amino acids 68-105 of SEQ ID NO: 33; amino acids 71-111 of SEQ ID NO: 34; amino acids 125-162 of SEQ ID NO: 35; amino acids 84-123 of SEQ ID NO: 36; amino acids 104-144 of SEQ ID NO: 37; amino acids 95-134 of SEQ ID NO: 38; or amino acids 95-134 of SEQ ID NO: 39.
Example 6
Expression of Modified Clostridial Toxins in a Bacterial Cell
The following example illustrates a procedure useful for expressing any of the modified Clostridial toxins disclosed in the present specification in a bacterial cell.
An expression construct, such as, e.g., any of the expression constructs in Examples 1-5, is introduced into chemically competent E. coli BL21 (DE3) cells (Invitrogen, Inc, Carlsbad, Calif.) using a heat-shock transformation protocol. The heat-shock reaction is plated onto 1.5% Luria-Bertani agar plates (pH 7.0) containing 50 μg/mL of Kanamycin and is placed in a 37° C. incubator for overnight growth. Kanamycin-resistant colonies of transformed E. coli containing the expression construct are used to inoculate a baffled flask containing 3.0 mL of PA-0.5G media containing 50 μg/mL of Kanamycin which is then placed in a 37° C. incubator, shaking at 250 rpm, for overnight growth. The resulting overnight starter culture is in turn used to inoculate a 3 L baffled flask containing ZYP-5052 autoinducing media containing 50 μg/mL of Kanamycin at a dilution of 1:1000. Culture volumes ranged from about 600 mL (20% flask volume) to about 750 mL (25% flask volume). These cultures are grown in a 37° C. incubator shaking at 250 rpm for approximately 5.5 hours and are then transferred to a 16° C. incubator shaking at 250 rpm for overnight expression. Cells are harvested by centrifugation (4,000 rpm at 4° C. for 20-30 minutes) and are used immediately, or stored dry at −80° C. until needed.
Example 7
Purification and Quantification of Modified Clostridial Toxins
The following example illustrates methods useful for purification and quantification of any modified Clostridial toxins disclosed in the present specification.
For immobilized metal affinity chromatography (IMAC) protein purification, E. coli BL21 (DE3) cell pellets used to express a modified Clostridial toxin, as described in Example 7, are resuspended in Column Binding Buffer (25 mM N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), pH 7.8; 500 mM sodium chloride; 10 mM imidazole; 2× Protease Inhibitor Cocktail Set III (EMD Biosciences-Calbiochem, San Diego Calif.); 5 units/mL of Benzonase (EMD Biosciences-Novagen, Madison, Wis.); 0.1% (v/v) Triton-X® 100, 4-octylphenol polyethoxylate; 10% (v/v) glycerol), and then are transferred to a cold Oakridge centrifuge tube. The cell suspension is sonicated on ice (10-12 pulses of 10 seconds at 40% amplitude with 60 seconds cooling intervals on a Branson Digital Sonifier) in order to lyse the cells and then is centrifuged (16,000 rpm at 4° C. for 20 minutes) to clarify the lysate. An immobilized metal affinity chromatography column is prepared using a 20 mL Econo-Pac column support (Bio-Rad Laboratories, Hercules, Calif.) packed with 2.5-5.0 mL of TALONTM SuperFlow Co2+ affinity resin (BD Biosciences-Clontech, Palo Alto, Calif.), which is then equilibrated by rinsing with 5 column volumes of deionized, distilled water, followed by 5 column volumes of Column Binding Buffer. The clarified lysate is applied slowly to the equilibrated column by gravity flow (approximately 0.25-0.3 mL/minute). The column is then washed with 5 column volumes of Column Wash Buffer (N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), pH 7.8; 500 mM sodium chloride; 10 mM imidazole; 0.1% (v/v) Triton-X® 100, 4-octylphenol polyethoxylate; 10% (v/v) glycerol). The modified Clostridial toxin is eluted with 20-30 mL of Column Elution Buffer (25 mM N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), pH 7.8; 500 mM sodium chloride; 500 mM imidazole; 0.1% (v/v) Triton-X® 100, 4-octylphenol polyethoxylate; 10% (v/v) glycerol) and is collected in approximately twelve 1 mL fractions. The amount of modified Clostridial toxin contained in each elution fraction is determined by a Bradford dye assay. In this procedure, 20 μL aliquots of each 1.0 mL fraction is combined with 200 μL of Bio-Rad Protein Reagent (Bio-Rad Laboratories, Hercules, Calif.), diluted 1 to 4 with deionized, distilled water, and then the intensity of the colorimetric signal is measured using a spectrophotometer. The five fractions with the strongest signal are considered the elution peak and are combined together. Total protein yield is determined by estimating the total protein concentration of the pooled peak elution fractions using bovine gamma globulin as a standard (Bio-Rad Laboratories, Hercules, Calif.).
For purification of a modified Clostridial toxin using a FPLC desalting column, a HiPrepTM 26/10 size exclusion column (Amersham Biosciences, Piscataway, N.J.) is pre-equilibrated with 80 mL of 4° C. Column Buffer (50 mM sodium phosphate, pH 6.5). After the column is equilibrated, a modified Clostridial toxin sample is applied to the size exclusion column with an isocratic mobile phase of 4° C. Column Buffer and at a flow rate of 10 mL/minute using a BioLogic DuoFlow chromatography system (Bio-Rad Laboratories, Hercules, Calif.). The desalted modified Clostridial toxin sample is collected as a single fraction of approximately 7-12 mL.
For purification of a modified Clostridial toxin using a FPLC ion exchange column, a modified Clostridial toxin sample that has been desalted following elution from an IMAC column is applied to a 1 mL Q1TM anion exchange column (Bio-Rad Laboratories, Hercules, Calif.) using a BioLogic DuoFlow chromatography system (Bio-Rad Laboratories, Hercules, Calif.). The sample is applied to the column in 4° C. Column Buffer (50 mM sodium phosphate, pH 6.5) and is eluted by linear gradient with 4° C. Elution Buffer (50 mM sodium phosphate, 1 M sodium chloride, pH 6.5) as follows: step 1, 5.0 mL of 5% Elution Buffer at a flow rate of 1 mL/minute; step 2, 20.0 mL of 5-30% Elution Buffer at a flow rate of 1 mL/minute; step 3, 2.0 mL of 50% Elution Buffer at a flow rate of 1.0 mL/minute; step 4, 4.0 mL of 100% Elution Buffer at a flow rate of 1.0 mL/minute; and step 5, 5.0 mL of 0% Elution Buffer at a flow rate of 1.0 mL/minute. Elution of modified Clostridial toxin from the column is monitored at 280, 260, and 214 nm, and peaks absorbing above a minimum threshold (0.01 au) at 280 nm are collected. Most of the modified Clostridial toxin will elute at a sodium chloride concentration of approximately 100 to 200 mM. Average total yields of modified Clostridial toxin will be determined by a Bradford assay.
Expression of a modified Clostridial toxin is analyzed by polyacrylamide gel electrophoresis. Samples purified using the procedure described above are added to 2×LDS Sample Buffer (Invitrogen, Inc, Carlsbad, Calif.) and are separated by MOPS polyacrylamide gel electrophoresis using NuPAGE® Novex 4-12% Bis-Tris precast polyacrylamide gels (Invitrogen, Inc, Carlsbad, Calif.) under denaturing, reducing conditions. Gels are stained with SYPRO® Ruby (Bio-Rad Laboratories, Hercules, Calif.) and the separated polypeptides are imaged using a Fluor-S MAX Multilmager (Bio-Rad Laboratories, Hercules, Calif.) for quantification of modified Clostridial toxin expression levels. The size and amount of modified Clostridial toxin is determined by comparison to MagicMarkTM protein molecular weight standards (Invitrogen, Inc, Carlsbad, Calif.).
Expression of modified Clostridial toxin is also analyzed by Western blot analysis. Protein samples purified using the procedure described above are added to 2×LDS Sample Buffer (Invitrogen, Inc, Carlsbad, Calif.) and are separated by MOPS polyacrylamide gel electrophoresis using NuPAGE® Novex 4-12% Bis-Tris precast polyacrylamide gels (Invitrogen, Inc, Carlsbad, Calif.) under denaturing, reducing conditions. Separated polypeptides are transferred from the gel onto polyvinylidene fluoride (PVDF) membranes (Invitrogen, Inc, Carlsbad, Calif.) by Western blotting using a Trans-Blot® SD semi-dry electrophoretic transfer cell apparatus (Bio-Rad Laboratories, Hercules, Calif.). PVDF membranes are blocked by incubating at room temperature for 2 hours in a solution containing 25 mM Tris-Buffered Saline (25 mM 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloric acid (Tris-HCl) (pH 7.4), 137 mM sodium chloride, 2.7 mM potassium chloride), 0.1% TWEEN-20®, polyoxyethylene (20) sorbitan monolaureate, 2% bovine serum albumin, 5% nonfat dry milk. Blocked membranes are incubated at 4° C. for overnight in Tris-Buffered Saline TWEEN-20® (25 mM Tris-Buffered Saline, 0.1% TWEEN-20®, polyoxyethylene (20) sorbitan monolaureate) containing appropriate primary antibodies as a probe. Primary antibody probed blots are washed three times for 15 minutes each time in Tris-Buffered Saline TWEEN-20®. Washed membranes are incubated at room temperature for 2 hours in Tris-Buffered Saline TWEEN-20® containing an appropriate immunoglobulin G antibody conjugated to horseradish peroxidase as a secondary antibody. Secondary antibody-probed blots are washed three times for 15 minutes each time in Tris-Buffered Saline TWEEN-20®. Signal detection of the labeled modified Clostridial toxin are visualized using the ECL PIusTM Western Blot Detection System (Amersham Biosciences, Piscataway, N.J.) and are imaged with a Typhoon 9410 Variable Mode Imager (Amersham Biosciences, Piscataway, N.J.) for quantification of modified Clostridial toxin expression levels.
Although aspects of the present invention have been described with reference to the disclosed embodiments, one skilled in the art will readily appreciate that the specific examples disclosed are only illustrative of these aspects and in no way limit the present invention. Various modifications can be made without departing from the spirit of the present invention.

## Claims

1. A modified Clostridial botulinum toxin comprising:
a) a Clostridial botulinum toxin type A enzymatic domain;
b) a Clostridial botulinum toxin type A translocation domain;
c) a translocation facilitating domain comprising an enveloped virus fusogenic peptide domain capable of facilitating a translocation step of a Clostridial toxin intoxication process; and,
d) an enhanced targeting domain consisting essentially of a modified Clostridial botulinum HCC targeting domain capable of executing a cell binding step of a Clostridial botulinum toxin intoxication process;
wherein the modified Clostridial botulinum toxin comprises a linear amino-to-carboxyl order of the Clostridial botulinum toxin enzymatic domain, the Clostridial botulinum toxin translocation domain, the translocation facilitating domain and the enhanced targeting domain, and
wherein the modified Clostridial botulinum HCC targeting domain comprises a Clostridial botulinum serotype A NTNH β-fold and exhibits enhanced binding activity for an endogenous Clostridial botulinum toxin receptor relative to the binding activity of a naturally-occurring Clostridial botulinum serotype A HCC targeting domain.